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Abstract
The thesis discusses the regulation of foodstuffs and medicines, and particularly the regulation 
of functional foods. Legal systems investigated are the EU and China. Both are members of the 
WTO and Codex Alimentarius, which binds European and Chinese rules together. The study 
uses three Chinese berries as case examples of how product development faces regulation in 
practice. The berries have traditional uses as herbal medicines. Europe and China have similar 
nutrition problems to be resolved, such as obesity, cardiovascular disease, and diabetes. The 
three berries might be suitable raw materials for functional foods. Consumer products with 
health-enhancing functions, such as lowering blood pressure, might legally be classifi ed either 
as foodstuffs or medicines. The classifi cation will depend on functions and presentation of 
the product. In our opinion, food and medicine regulation should come closer together so the 
classifi cation issue would no longer be an issue.
Safety of both foodstuffs and medicines is strictly regulated. With medicines, safety is a 
more relative concept, where benefi ts of the product are compared to side-effects in thorough 
scientifi c tests and trials. Foods, on the other hand, are not allowed to have side-effects. 
Hygiene rules and rules on the use of chemicals apply. In China, food safety is currently at 
focus as China has had several severe food scandals. Newly developed foods are called novel 
foods, and are specifi cally regulated. The current European novel food regulation from 1997 
treats traditional third country products as novel. The Chinese regulation of 2007 also defi nes 
novel foods as something unfamiliar to a Chinese consumer. The concepts of novel food thus 
serve a protectionist purpose.
As regards marketing, foods are allowed to bear health claims, whereas medicines bear 
medicinal claims. The separation is legally strict: foods are not to be presented as having 
medicinal functions. European nutrition and health claim regulation exists since 2006. China 
also has its regulation on health foods, listing the permitted claims and how to substantiate 
them. Health claims are allowed only on health foods. The European rules on medicines include 
separate categories for herbal medicines, traditional herbal medicines, and homeopathic 
medicines, where there are differing requirements for scientifi c substantiation. The scientifi c 
and political grounds for the separate categories provoke criticism.
At surface, the Chinese legal system seems similar to the European one. To facilitate 
trade, China has enacted modern laws. Laws are needed as the country moves from planned 
economy to market economy: ‘rule of law’ needs to replace ‘rule of man’. Instead of being 
citizens, Chinese people long were subordinates to the Emperor. Confucius himself advised 
to avoid confl ict. Still, Chinese people do not and cannot always trust the legal system, as 
laws are enforced in an inconsistent manner, and courts are weak. In China, there have been 
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problems with confl icting national and local laws. In Europe, the competence of the EU vs. the 
competence of the Member States is still not resolved, even though the European Commission 
often states that free trade requires harmonisation.
Food and medicine regulation is created by international organisations, food and medicine 
control agencies, standards agencies, companies and their organisations. Regulation can be 
divided in ‘hard law’ and ‘soft law’. One might claim that hard law is in crisis, as soft law 
is gaining importance. If law is out of fashion, regulation certainly isn’t. In the future, ‘law’ 
might mean a process where rules and incentives are created by states, NGOs, companies, 
consumers, and other stakeholders. ‘Law’ might thus refer to a constant negotiation between 
public and private actors. Legal principles such as transparency, equal treatment, and the right 
to be heard would still be important.
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1 INTRODUCTION
1.1 The Role of Functional Foods in Modern Diets
Today, many people are voluntarily engaging in unhealthy diets consisting of too much energy, 
fat, salt, and sugar. This, together with insuffi cient physical exercise, is causing a profusion of diet-
related illnesses, which in turn cause much human suffering and signifi cant expenditure. Europe 
and China face similar problems in this respect. Because these problems are continually discussed 
in the media, consumers are increasingly aware of the diet-health relationship.1 In the past, dietary 
advice has often focused on what not to eat. Currently, the focus is on what should be eaten more. 
There is an abundance of foods on the market that are consumed in order to improve one’s health 
in general or in a particular manner.
‘Functional foods’ is the term used for foods with special health effects.2 Interest in 
functional foods is stimulated by several factors. There is a market push from food companies 
looking for products with higher margins. A plethora of private research resources are invested 
in functional foods. Clinical studies are being performed world-wide to show effects of new 
foods or food ingredients. Functional attributes of many traditional foods are being discovered, 
and new products are being developed with benefi cial components3. Market pull is created by 
aging, affl uent populations of health conscious consumers.4
In addition to companies and consumers, functional foods are interesting also from 
a governments’ perspective. The main severe health challenges in Western countries are 
obesity, cardiovascular disease, diabetes, and cancer. Healthcare costs are increasing, and the 
prevalence of all of these diseases can be affected by dietary choices. Heart conditions and 
diabetes, along with the acceptance of Western-like diets have also become more common in 
Asia. This means the diet-related health problems are largely the same all over the world and 
different governments are faced with the almost identical task of promoting the same kind 
of dietary change. Public research funds are liberally invested in functional foods to support 
private research efforts.
1  This awareness as such is nothing new. For example Hippocrates said in 337 BC “Let food be your medicine 
and medicine be your food”. This wisdom is now being rediscovered in the West.
2  There are different defi nitions of the term ’functional food’, and related terms referring to similar products. 
In chapter 1.3., we present the different defi nitions and defi ne the term ‘functional food’ for our purposes.
3  International Food Information Council. Functional Foods. Backgrounder. November 2007. 
4  Katan 1999, 1.
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1.2 Law on Functional Foods
Legislation on functional foods has not developed as quickly as functional foods. It is typical 
that legal development follows scientifi c development. Compared to discussing the legal 
defi nitions, scientists are more interested in developing effective products, and marketers 
more interested in fi nding attractive marketing messages. Consumers need time to become 
acquainted with new types of products. 5 It has been acknowledged that legal defi nitions 
and rules on product safety and effi cacy are needed for consumers to trust the products and 
the markets to develop. New legislation has been shown to be necessary. The wrong type 
of legislation, confusing legislation or non-existing legislation might discourage fi rms from 
investing in safety assessment and research.6 This could lead to a situation where:
 the food industry lacks innovative and successful products to compete with, –
 consumers do not get the product selection they are willing to pay for, and–
 populations are not as healthy as they could be.– 7
Currently no legal defi nitions exist for functional foods. Health claim legislation can be seen 
as indirectly defi ning functional foods, though. According to Heasman and Mellentin, the 
exceptional speed of internationally agreeing on the need of health claim legislation shows 
the power of the functional food concept8. For example, United States, Japanese, and Chinese 
legislation developed quite quickly after the functional food business started to grow. Health 
claim standards were developed by Codex Alimentarius already in the beginning of the 21st 
century. Similarly, some European states like Sweden, the Netherlands, and the UK, regulated 
functional foods and health claims early on. States in southern Europe, conversely, were in no 
rush to regulate. The European disagreement on the need, purpose, and content of common 
legislation led to lengthy negotiations, before nutrition and health claim legislation fi nally 
came into effect in 2007.
The basic legal question with functional foods is the division between foodstuffs and medicinal 
products. In Europe, foods and medicines were traditionally separate legal categories. Food safety 
fundamentally signifi ed hygiene rules and safety evaluations concerning the use of chemicals. It 
was not a problem that marketing claims relating to diseases were prohibited on foodstuffs. In the 
Eastern countries infl uenced by Chinese culture, food and medicines have traditionally been thought 
of as materials from the same source, not something separate. For example, a plant can be used as 
food for healthy people and as medicine for people who are sick. It is thus not a Western invention 
5  See also Kwak – Jukes 2000a, 101.
6  Salminen – Mykkänen 2002, 33. See also Kotler 2002, 174-175. The legal issues are something a food 
marketer wants to consider already at the product development phase. It is not clever to develop a product 
with a focus on a certain planned marketing strategy only to fi nd out that such a product is not even allowed, 
or that the planned marketing claim is prohibited.
7  According to Brookes, this is exactly what has happened with regard to novel foods and their regulation 
in Europe. R&D expenditure on food products tends to be lower in the EU compared to average levels in 
other countries. As a result, improved products are not available to EU consumers. Levels of income and 
employment generation in the EU are, according to Brookes, “probably” lower than in more “innovation-
friendly” regulatory environments. Brookes 2007, 6.
8  Heasman – Mellentin 2001, 104.
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and not simply a current phenomenon that the categories of food and drugs can sometimes overlap; 
merely functional foods make this overlap more obvious.
Regulating safety and effi cacy of consumer products is basic consumer protection law. 
Consumer protection law can be divided into product safety, contract terms, marketing, and 
product liability9. Here we deal with two of these areas: product safety and marketing. Product 
safety is defi ned as physical safety, protecting the consumer’s body. Safety is a relative term 
referring to absence of negative health effects. Effi cacy is used as a term related to marketing 
claims of the product. Effi cacy means that the product delivers the health-benefi t it promises. 
The basic goal of marketing regulation is economic safety - protecting the consumer’s purse10. 
This means marketing rules may also be seen as part of product safety.
The regulation of medicines and the regulation of foods have important features in common. 
Both groups of products are used in a way that leads to a potential risk to consumers11. Costs 
of inadequate information are severe, and yet the markets do not accord information its full 
value12. Consumers usually cannot see the ingredients, qualities, or functions of a foodstuff or 
a medicine just by looking at the product. Even if all the scientifi c information was available 
to consumers, they still could not determine the potential risks or benefi ts for their health. 
This signifi cant information asymmetry creates the need for regulation13. With foodstuffs 
and medicines, consumer protection laws are widely accepted because of these information 
diffi culties14. However, even if we agree on the necessity to regulate food and medicine 
businesses, particular policies are still not free from controversy15. For example, insistence 
on safe medicines and functional foods may prevent useful but slightly risky substances from 
reaching the market16.
Procedural rules are also important as they defi ne how substantial rules are implemented 
in practice. When implementing safety and effi cacy requirements, the legislator must decide 
whether to rely on pre-market control or post-market control. Pre-market authorisation is 
often preferred today. Innovative functional foods must be authorised in both the EU and 
China before being marketed to consumers.
Legislators must also resolve the appropriate level and type of regulations. When discussing 
the level of regulation, all of the above-mentioned issues can be resolved either on local or global 
level. Both the European Community and China are members of WTO and other international 
organisations where food and drug law issues are discussed. On one hand, global agreements guide 
legislative actions of their parties. On the other hand, through global negotiations it is possible for 
the EU and China to affect global legal development. In the EU, Community level legislation is 
9  Wilhelmsson (1991) divides consumer protection into protection against: dangerous products (product 
safety and product liability), unreasonable contract terms, inappropriate marketing and unconsidered decision-
making. Kivivuori et al. (1978) divide consumer policy into four areas according to stages of the product life 
cycle: production, marketing, trade, and consumption. 
10  Besides consumer protection, marketing regulation is particularly important also from competitor point 
of view.
11  Krapohl 2004, 519. 
12  Asch 1988, 55.
13  Krapohl 2004, 521. According to Määttä, information asymmetry is one of the basic reasons for consumer 
protection laws. Määttä 2006, 22. 
14  Asch 1988, 55.
15  Asch 1988, 55. 
16  Asch 1988, 56.
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today often preferred to legislation on Member State level. Likewise in China, national laws are 
preferred to local laws.
With regard to the types of regulation, the issues can be resolved either by legally binding 
or non-binding instruments. Governments need to consider their role in relation to other 
regulators such as governmental and non-governmental organisations. Soft law has many 
defi nitions, but it essentially means regulations that are not laws17. The binding nature of soft 
law materials will be an unresolved issue. These guideline-type norms are often considered 
suitable for regulating foodstuffs and medicines. This is due to the amount of scientifi c issues, 
the need for complex procedures, the need for rapid changes, and the need for some fl exibility 
in interpreting these complex issues. Soft law is mainly created by food and medicine control 
agencies. This means implementing the law actually includes creating the law. Also self-
regulation by enterprises themselves has its limited space.
1.3 Basic Defi nitions Used in this Study
Legally, the defi nitions of ‘foodstuff’ and ‘medicine’ exclude one another. If a product is a 
medicine, it is not a food.
‘Foodstuff’ or ‘food’ means any edible product suitable for people in general or for a certain 
group of people. This includes foods in food form and in other forms such as pills, capsules, 
powders, etc.
‘Medicine’ is synonymous with drug18. It means a product that is used to treat, prevent, or 
cure a disease. This includes modern medicines (pharmaceuticals), and traditional medicines, 
which in practice are often herbal medicines.
The third signifi cant term used in this study, ‘functional food’, is more diffi cult to defi ne. As 
the laws do not defi ne the concept, we have to use our own defi nition to suit our purposes.
Globally, there are many different defi nitions of the term ‘functional food’. ‘Functional 
food’ often refers to products that are in food form, whereas the term ‘nutraceutical’ often 
refers to products isolated or purifi ed from foods.19 Both are generally understood as products 
demonstrated to have physiological benefi ts and/or to reduce the risk of chronic disease 
beyond basic nutritional functions. Functional foods can be understood either as fi nished food 
products or health-enhancing dietary components or ingredients.
It is not clear what ‘beyond basic nutrition’ means. According to Agriculture and agri-
food Canada, this means that there are so-called “bioactive compounds” involved20. Bioactive 
compounds are “naturally occurring chemical compounds contained in, or derived from, a 
plant, animal or marine source”, that exert the desired health/wellness benefi t. They mention 
omega-3 fatty acids in fi sh oils and beta-glucan in oats and barley. According to Kris-Etherton 
et al, bioactive compounds are extranutritional constituents that typically occur in small 
17  Tala 2005a. Korkea-aho 2005.
18  ‘Drug’ could also be defi ned to mean any chemical other than food that affects living processes. By this 
defi nition, a drug could either be a ‘medicine’ or a ‘poison’. University of Elmhurst web page.
19  The term ‘medicinal food’ is also used, often to include food-form and pill-form foods. See for example 
Journal of Medicinal Foods.
20  Agriculture and agri-food Canada. What are Functional Foods and Nutraceuticals? 
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quantities in foods21. They mention for example phenolic compounds, including fl avonoids as 
their subcategory, and recommend consuming foods rich in bioactive compounds.
Different layers of functional foods can be identifi ed. There are fresh foods such as carrot 
and tomato that have functional effects22 basic processed foods such as rye bread, oat bran 
cereal, and yogurt that have functional effects23and fortifi ed foods where certain nutritional 
ingredients are added24. In addition there are foods traditionally propagated or genetically 
engineered to have more of a functional component25.26 Heasman and Mellentin27 use the 
defi nition ‘any modifi ed food or food ingredient that may provide a health benefi t beyond 
the traditional nutrients it contains’. They do not include ‘natural’ functional foods in their 
defi nition.
Diplock et al.28 proposed, as a working defi nition, that a food can be regarded as ‘functional’, 
“if it is satisfactorily demonstrated to affect benefi cially one or more target functions in the body, 
beyond adequate nutritional effects, in a way that is relevant to either an improved state of health 
and well-being and/or reduction of risk of disease.” It is also required that functional foods:
remain as foodsa) 29,
demonstrate their effects in amounts that can normally be expected to be consumed in b) 
the diet, and
are consumed as part of a normal food pattern.c) 
Because functional food is not a legal term in the EU or China, the aforementioned defi nitions 
have no legal relevance. The legal rules on products are based on other concepts such as ‘food’, 
‘health food’, ‘novel food’, ‘medicine’, ‘herbal medicine’, ‘traditional herbal medicine’, and 
‘traditional Chinese medicine’. The defi nition of functional foods by Diplock et al. seems to 
have transferred into principles that are used in health claim legislation.
In this study, we use the term functional food to describe a certain type of product, the legal 
treatment of which we are interested:
 A functional food is  – a fi nal product in any digestible form (food, pill, capsule, powder, etc.)
 A functional food might be –  fortifi ed (unfamiliar ingredients added), possibly with novel 
ingredients, possibly genetically engineered.
 A functional food has  – benefi cial health effects, which are either traditionally or 
scientifi cally established.
21  Kris-Etherton et al. 2002. 
22  Carrots have carotene. Tomatoes have lycopene.
23  Oats has beta-glucan (fi bre). Rye has lignans (fi bre). Yogurt has benefi cial bacteria such as lactic acid 
bacteria.
24  Vitamins and minerals such as calcium or magnesium are commonly added to several foods. For example 
plant sterols (phytosterols), plant stanols (phytostanols) and probiotics are also commonly added to foods 
where they normally are not present. 
25  For example tomatoes with higher levels of lycopene.
26  Categories by Agriculture and agri-food Canada. The Leatherhead Functional food report from 2006 
identifi es two basic layers of functional foods from the marketing perspective, the health claim being the 
factor that separates ‘actual’ functional foods from ‘healthy foods’ merely perceived as functional.
27  Heasman – Mellentin 2001, 5.
28  Diplock et al. 1999, S6.
29  This means food supplements do not go under this defi nition of functional foods.
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Even though our concept ‘functional food’ includes the term ‘food’, we do not presuppose 
that a functional food is legally a foodstuff. Instead, we investigate the conditions on which a 
hypothetical product is legally a food and on which a medicine. The legal category will depend 
on product functions and on marketing claims used. We are particularly interested in the legal 
evaluation of healthy products made of three Chinese berries, which might in Europe be 
classifi ed as ordinary foods, foods for particular nutritional use, or herbal medicines. In China, 
the products could possibly be registered as health foods or traditional Chinese medicines. The 
determination of legal category will affect the evidence required on safety and effi cacy, and 
the marketing claims available.
1.4 Comparative Law: EU and China as Objects of Research
Comparative law means the study of legal systems by comparison with each other. According 
to editors of Electronic Journal of Comparative Law, “substantive comparative ... law topics 
will have to discuss and compare at least two legal systems”30. The idea of the comparative 
approach is to collect information on several legal systems simultaneously, crossing national 
borders31. This is the simple and practical view to comparative law: if there are at least two 
legal systems under discussion, it is comparative law.
According to Aarnio, comparative law is interested in the norm itself: it is about describing 
the structure and content of norms in a foreign legal order32. Mikkola sees comparative law 
more as understanding legal frameworks, structures, and principles rather than concrete rules. 
Rules are important, but only in their connection.33 Husa sees comparative legal research as 
explaining and evaluating solutions to certain problems within societies, and the reasons for 
differences in these solutions34. Also according to Watson, comparative law does not mean 
merely defi ning what is similar and what is different between two or more legal systems: it 
is about understanding the nature and development of legal systems. This includes analysing 
why certain institutions have been created in a legal system, and understanding the historical 
connections between legal systems and legal rules.35 Comparative law can also be seen as 
having various ambition levels. A researcher can merely describe foreign law as curiosity, or 
try to understand it as a phenomenon.36
In recent years, comparative law has gained in practical importance. According to 
Norman37, there are two reasons for this. The fi rst is the increased globalisation of world trade, 
which involves the need to do business in unfamiliar legal systems. The second is the move 
towards global or regional harmonisation of laws. Before laws are harmonised, they have to be 
compared. Along with the trend, we have reached the comparative approach because of global 
trade. More particularly, we are interested in global trade of functional foods, and therefore 
30  In addition to substantive topics, methodological aspects of comparative law are discussed under 
comparative law. Electronic Journal of Comparative Law. About EJCL. 
31  Husa 2009, 123.
32  Aarnio 1988, 50.
33  Mikkola 2001, 2.
34  Husa 1998, 15-16.
35  Watson 1974, 6-7.
36  See Huhtamäki 1993, 20.
37  Norman 2007. 
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need to understand global rules and rules outside our own legal system. As Husa suggests, we 
try to examine, explain, and evaluate different legal solutions to the reasonably wide issue of 
how to regulate functional foods.
The legal systems investigated here are the European Union legal system and the Chinese 
legal system. Generally, results of comparative legal research can be used in legal policy 
and lawmaking, in jurisdiction, and in creating legal theories. Regardless of how results are 
used, comparative law widens knowledge base. 38 We primarily aim at providing information 
for two audiences: businesses and regulators39. Initially, we will study existing and planned 
regulations as they interest a business operating in 2009. In addition, we will look at the law 
from a regulator’s perspective, focusing on how regulation should be formulated in the future. 
This study is not comparative law in the history-oriented sense. We will only briefl y discuss 
the issue of how and why the European and Chinese legal systems have developed so far. We 
will, however, consider the fundamental differences of the two legal systems as they affect our 
conclusions both from business viewpoint and from the regulator’s viewpoint.
The practical reason for choosing the EU as object of research is because of our residency in 
the EU. The practical reason for choosing China is due to the University of Turku maintaining 
close connections with Chinese universities and researchers. In particular, the University of 
Turku40 has a project with the University of Beijing where we ultimately aim to bring new 
functional food products to European and Chinese markets. We have chosen the three berries 
(hawthorn, barbaric wolfberry, and emblic leaffl ower) because they are objects of interest in 
this project. We are aware that for a European lawyer, the Chinese part of this study is the more 
diffi cult one. Hence, the goals need to be somewhat different regarding European vs. Chinese 
law. With Chinese law, the aim is to achieve an understanding, and with European law, the aim 
is to add to the understanding.
Legal systems can be divided in Western and non-Western systems, where Western 
systems are individual-centred and non-Western systems are community-centred. Westerns 
systems can be further divided in common law and Romano-Germanic civil law. Non-Western 
legal systems can be divided in religious (Islamic, Jewish, and Hindu law) and non-religious 
systems. Non-religious systems include Asian law and traditional law. Asian law relies on the 
Confucian principle of mediation and avoiding disputes, which means that courts and lawyers 
are not in a central role. Traditional law, which is typical of aboriginal people and tribes, 
relies on spiritual and supernatural forces.41 In this division, Chinese law is a member of the 
Asian family. There are also other classifi cations: some writers, for example, separate between 
Roman, German, and Scandinavian law.
Today, Chinese law shares many of the characteristics of the Romano-Germanic system. 
The legislation refl ects a structural similarity to countries in the civil law family, and Chinese 
jurists value legal doctrines and hold written law in esteem. Concrete judicial decisions are not 
offi cially considered as a source of law.42 However, the Supreme People’s Court is particularly 
38  Husa 1998, 14.
39  Instead of legislator, we use the term regulator here to include bodies other than governments. These are 
the WTO, international standards bodies, administrative agencies, self-regulation associations, etc.
40  Department of Biochemistry and Food Chemistry.
41  Husa 2009, 126-127. 
42  This can be attributed to the Europeanization in China in the end of the 19th century and the beginning of 
the 20th century, and is also based on Chinese tradition: statutes or codes were highly valued already by the 
Qin Dynasty in 221-207 BC. Liu 2000.
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infl uential in practice. Its decisions are factually used as a guideline in the practice of lower 
courts when the provision of law is obscure.43 According to Jones, China has succumbed 
to Western arguments and built a European-style legal system, but has never been entirely 
convinced44. The Chinese legal system is closely linked to the economy: China is still 
balancing between market economy and socialism. The need to balance market effi ciency and 
social stability has left administrators considerable discretion, which has resulted in legal and 
practical uncertainty as regards the roles of government vs. markets45.
In China, the statutes and institutions involved in food and medicine law are rather similar 
to the European ones. Superfi cially, the Chinese legal system thus seems similar to ours; however, 
China is still heavily infl uenced by tradition. The most important trace of Chinese history is in the 
close connection between strong central government (previously headed by the Emperor) and the 
administration46. Historically, the Emperor had all the power. Each dynasty had its own legal code. 
There could be no discussion on separation of powers: local offi cials carried out all governmental 
functions at the bottom level47. Separation between legislation, its execution, and adjudication is 
still unfamiliar to the Chinese.
Turning from the legal orders to business reality, European and Chinese food markets 
and food consumption patterns still differ greatly. This means the forms of business action 
regulated by food law differ in the EU as opposed to China. China faces the dual problem of 
malnutrition and over-eating. Use of milk and dairy products has been almost non-existent 
but is currently growing in China. The Europeans consume twice as much meat and fruit 
as the Chinese. In contrast, the Chinese consume twice as many vegetables. Only fi sh and 
seafood consumption fi gures are similar in the EU-15 and China.48 With regard to medicines, 
consumption of Western medicines is growing faster than consumption in general in China49.
In China, functional foods could be used to allow malnourished citizens to have an 
adequate daily nutrient intake. This potential side of functional foods is not at focus here. 
Instead we focus on nutritional problems that are common to Europe and China. In Europe, 
diet-related diseases are very common. Health is an important driver for food innovation50, 
and the European market for functional foods is growing. Likewise, the Chinese market for 
functional foods is growing fast51 and in China the nutrition-related diseases are becoming 
more common, and consumers are acquiring affl uence.52.
European and Chinese legislators are dealing with functional foods in their own ways. 
Chinese legal solutions concerning functional foods should be interesting to Western lawmakers 
43  Liu 2000.
44  Jones 2003, 8.
45  Peerenboom 2008 a, 3.
46  Jones 2003, 8-9. This system of government developed over 2000 years ago and remained similar until 
the 20th century.
47  Jones 2000, 9.
48  Data and Trends of the European Food and Drink Industry 2006. CIAA report. Figures are from 2003.
49  Li & Fung 2003.
50  Data and Trends of the European Food and Drink Industry 2006. CIAA report.
51  Yeaman 2002. 
52  The ratio of health products in the total expenditure of Chinese consumers is currently reaching that 
of Japanese or Western consumers China Health Products Association according to Functional Ingredients 
March 2005, China News. 
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because of thousands of years of Chinese tradition in treating diseases with nutrition53. 
Knowledge of Chinese legislation is also important for Western companies, because the 
market potential in China is great due to the size of the market54. Conversely, European legal 
solutions might be interesting for the Chinese. Currently, the EU is the largest food exporter in 
the world while China is fourth after the U.S. and Brazil55. However, the EU’s share of exports 
is shrinking in favour of Brazil and China.56
Simultaneously to product markets, the European and Chinese legal systems are becoming 
analogous. For the past 30 years, the Chinese have put focus on “socialist justice” and legality. 
A lot of legislative work has been done, particularly economic reforms including modern 
legislation.57 That is why differences between European and Chinese legislation are no longer 
considerable, at least superfi cially. A comparative research approach should be neutral in a 
sense that it does not presume one legal order superior to others58. We try to avoid seeing 
European legal order as the inevitable endpoint for China, and look at both legal orders 
neutrally through a critical lens.
Donald C. Clarke has described methods for comparing Chinese law to Western, particularly 
American law. First, the naive ignorance approach, which needs to be avoided, views the two 
legal systems as similar and looks only at legal texts. We could also compare Chinese reality to 
“Ideal Western Legal Order”.59 An alternative would be to see the “errors” as normal features 
of the Chinese legal system60. A “disciplinary model” might be fruitful in understanding the 
Chinese legal system as the model is based on the assumption of state as Emperor. According 
to Clarke, no single model for describing Chinese law is perfect, and different models might 
be suitable for different fi elds of law or the same fi eld at different times61.
1.5 Consumer Protection vs. Food Law and Medical Law
In this study, we discuss regulation of foodstuffs and medicines regarding the relationship 
between sellers and buyers. Guaranteeing safety and effi cacy are responsibilities of the seller, 
and typical issues of consumer protection.62 We could thus say this study discusses consumer 
53  In the Chinese culture, it is deemed better to avoid illness by eating the right food at the right time, than 
curing it with medicine. There are even ‘medicinal restaurants’ in China, where one can order food on the 
basis of one’s ailments. Giract China news March 2006. 
54  China has a huge emerging middle class with high discretionary spending power. The middle class 
comprises of around 125 million people in 2005, and over 300 million by 2010. Doering 2005, 20. According 
to Doering, one of the main sectors that can benefi t from the explosion of consumer demand is processed 
foods. 
55  China is followed by Canada, Australia, Thailand, Argentina, New Zealand, and Malaysia.
56  CIAA: Data and Trends of the European Food and Drink Industry 2006.
57  Huotari – Seppälä 2005, 132-133.
58  Pöyhönen 1997, 247.
59  A sophisticated researcher with this approach will notice features of the Chinese legal system that do not 
fi t the Western model, but still see them as errors. If we try to understand Chinese law and where it is going, 
we cannot simply presume it is going towards Ideal Western Legal Order. Clarke 2003, 99-100.
60  Clarke 2003, 100.
61  Clarke 2003, 102.
62  For example Leonard 2005 discusses food and medicine regulations under European consumer law, 
acknowledging both the health and safety aspect and economic interest aspect. Pages 227-229.
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protection. The two viewpoints of consumer protection are the seller’s perspective and the 
legislator’s perspective.
However, regulation of foodstuffs and regulation of medicines are wider concepts than 
what is included in consumer protection. Safety and accurate marketing (in the case of 
functional foods: effi cacy) of foods is only one of food law areas. Similarly, safety and effi cacy 
of medicines is only one of medical law tasks.
According to Zhang, the concept of food security encompasses:
 adequacy of food supply or availability; –
 stability of supply, without fl uctuations from year to year or from season to season; –
 accessibility of food or affordability; and –
 quality and safety of food. – 63
First, there must be food before the regulation of its qualities has relevance. Food security is 
“the right to food”, and is thus a human rights issue64. Second, because food is one of the main 
commodities of international trade65, food is a trade issue. This viewpoint relates to agricultural 
policies including subsidies, customs policies, and creating free trade areas. Harmonising 
consumer laws can be seen as one part of this international trade law regime. Third, as food 
production has wide consequences to the environment, food is also an environmental issue. 
At times food law is in fact classifi ed under environmental law, as it is in Finland. ‘Food law’ 
is a concept that could be used to cover all of the above-mentioned legal perspectives on the 
agri-food business. As previously stated, we only deal with the consumer protection portion 
of food law.
Medical law is a rather young discipline and academic topic, but is gaining more interest. 
For example the Uppsala University in Sweden introduced a chair in this discipline in 2003. 
Their defi nition of medical law is the following: “Medical law deals with legal aspects of 
emerging scientifi c developments, concerning for example stem cell research, genetic 
diagnosis, reproduction technology or new e-health applications. Studies in this area of law 
can also include the regulation of pharmaceuticals and forensic medicine, as well as the 
organisation and supervision of health care and research, obligations and liability, the status 
and rights of patients and research subjects, etcetera.” Medical law “transcends traditional 
divisions, since it involves a number of legal areas such as public law, private law, criminal 
law and international law, as well as the relationship between law and ethics”.66 As stated 
above, here we only deal with the consumer-protection -part of medical law.
1.6 Purpose of this Study: the Research Questions
From a typical lawyer’s viewpoint, food and medicine law is unremarkable. For example, 
Jääskinen sees constitutional law, civil law, general administrative law, criminal law, and 
procedural law as legal system core. This leaves business law, such as the regulation of 
63  Zhang 2004, 566. 
64  Zhang 2004, 567.
65  Zhang 2004, 567.
66  Uppsala Universitet. Centre for Research Ethics and Bioethics. 
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foodstuffs and medicines, as periphery. Jääskinen compares laws on pig slaughtering vs. 
extradition of citizens, and sees them as “different things”.67 By Tuori’s theory, we could also 
see principles of civil law, criminal law, etc. as part of the legal culture, and business law as a 
more labile surface-level phenomenon affected by changing market situations.
We see the “legal system core” as an area of law where lawyers have less competition from 
other sciences. Lawyers see that part of the legal system as more personalised. As business law 
is typically affected by economic considerations, and food and medicine law additionally by 
natural science, it is not seen as much as “law”. This means that even though periphery might 
be important in practice, it is less interesting for lawyers. According to Jääskinen, resistance to 
change is smaller in normative periphery that is outside “general” law68. In other words, “real” 
law is more profound and stable than setting “technical” requirements on consumer goods that 
happen to be on the market this century. Historical perspective thus affects what is considered 
valuable legal research. We see this research as less traditional in this sense.
The aim of this thesis is, from business law perspective, to evaluate the somewhat 
complicated fi eld of law that lies between food law and medicine law in the EU and China. 
We will focus on the law that typically affects functional foods as defi ned above, but will also 
discuss other relevant legislation. The reasons for the comparative approach were already 
discussed above. Primarily, businesses need to know of different rules that apply in different 
market areas. In addition, regulators might have something to learn from one another.
Foundations of food law and medicine law are discussed in chapter 2. This means mapping 
out the global framework and principles behind European and Chinese rules, and explaining 
how regulation on foodstuffs and medicines is drafted and implemented. In chapter 3, the 
borderline between the two categories of foodstuffs and medicines is discussed, focusing 
particularly on the question of how functional foods fi t into these categories. Safety of 
foodstuffs vs. medicines is the topic of chapter 4, and effi cacy and marketing of foodstuffs vs. 
medicines is the topic of chapter 5.
In chapters 6 and 7, the aforementioned legal issues will be summarised and conclusions 
will be drawn. This will be done separately from the entrepreneur’s perspective (chapter 6) 
and regulator’s perspective (chapter 7). ‘Entrepreneur’ here refers to a developer of functional 
foods, which refers to a certain type of product defi ned above.
From the entrepreneur’s position, the main legal questions to be answered are:
What are the rules affecting my business?1) 
Where is the line between foodstuffs and medicines?2) 
How safe must my product be? What is the procedure to prove safety?3) 
How can I market my product? What is the procedure to prove effi cacy?4) 
An integral part of this viewpoint is a case study, included in chapter 6. Three Chinese berries 
(hawthorn fruit, emblic leaffl ower fruit, and barbary wolfberry) have been selected as test 
cases on how functional food legislation works. The three berries or their fractions could 
be used as raw material in different types of functional food products. The aim of the case 
study is to make the legislation more concrete and to fi nd out how product development faces 
regulation in practice.
67  Jääskinen 2008, 43.
68  Jääskinen 2008, 43.
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The berries were chosen as objects of research in the above-mentioned project between 
the universities of Turku and Beijing, because the berries have scientifi cally proven benefi cial 
effects on metabolic syndrome69. Metabolic syndrome is a suitable test case, as it is a globally 
common medical condition, and treating it is expensive. The berries are suitable test cases also 
because they are legally evaluated very differently due to differences in their traditional uses.
From a regulator’s perspective, the main legal questions to be answered are:
Whether and where to draw the line between foodstuffs and medicines?1) 
How to defi ne safety requirements for foodstuffs vs. medicines?2) 
How to regulate effi cacy and marketing of foodstuffs vs. medicines?3) 
When implementing safety and effi cacy requirements, whether to rely on pre-market 4) 
or post-market control?
Whether to resolve the above-mentioned legal issues locally (EU member state, Chinese 5) 
province or city) or centrally (European Union, the People’s Republic of China)?
Whether to resolve the above-mentioned legal issues by binding or non-binding 6) 
instruments (hard law or soft law)?
The ultimate aims of regulating functional foods are presumably consumer protection and 
health promotion. This is also the goal of legislation on functional foods as defi ned above. 
Our presumption is that legislation is needed to promote research and development of new raw 
materials and products, to ensure the consumer’s right to buy safe and effective products and 
to make informed decisions, and possibly to fi nancially support healthy choices. Here we need 
to discuss whether food law, medicine law, and functional food law in particular are fulfi lling 
their goals, and put functional food legislation into its societal context.
1.7 Materials for this Study
The basic materials for this study are the statutes and soft law documents on foodstuffs and 
medicines, including their preparatory and explanatory materials. A literature study has been 
made on European and Chinese food law and medicine law. The literature concerns legal 
rules on safety, effi cacy and marketing of different types of health-related consumer products. 
Focus is on legal rules on functional foods. The literature used is mainly European, Chinese, 
and American.
European Community legislation has been viewed at EU web pages www.europa.eu, 
and national law on national legal web pages. With European laws, the offi cial legal texts 
have been used. With Chinese legislation, we have had to rely on translations into English. 
Offi cial translations are not available. The translations used are by various translators: Chinese 
ministries, ChinaLawWeb by the University of Maryland, United States Department of 
Agriculture Foreign Agricultural Service, law fi rms situated in Europe, China or the United 
States, or by Miao Qing at University of Turku. For some laws, there have been several 
translations available. In these cases, selection of translation was based on perceived expertise 
of the translator.
69  Encompassing obesity, type 2 diabetes, and cardiovascular disease.
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The local laws of EU Member States and Chinese provinces and cities are not studied 
in detail. Local rules or procedures are mentioned or discussed when they are considered 
particularly important in legally evaluating functional foods, as is the case with the European 
food vs. medicine issue. The general trend in both Europe and China is towards harmonisation. 
This means European food and medicine laws are often given at Community level, and Chinese 
laws at national level70.
As we have focused on legislation, discussion on administrative practice and court cases is 
limited in this study. We see food and medicine law as constant negotiation between authorities 
and entrepreneurs, where the role of courts is typically not important. Administrative guidelines 
as soft law will be discussed in connection with hard law. Instead of cases, we use these 
guidelines as proof on how legislation is implemented and interpreted in practice. This is 
a defi ciency, particularly with regard to China, where the role of administrative practice is 
important, and would deserve further study.
70  The question of central vs. local legislation will be discussed below.
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2 LEGAL FOUNDATIONS
In this chapter, we discuss the very basic foundations of European and Chinese law on foodstuffs 
and medicines71 by mapping out the global background, the legal institutions involved, and the 
sources of law. The question of ‘hard law’ vs. ‘soft law’ is integral here. Drafting the law and 
implementing the law cannot always be distinguished, as the regulatory agencies have their 
role in both.
2.1 Global Background
Before we turn to EU and Chinese law, we will briefl y discuss the global harmonisation of 
food and medicine laws, as it creates the framework in which the EU and China operate.
2.1.1 WTO Agreements
The World Trade Organization was established in 1994 after the Uruguay round of GATT 
negotiations. The WTO consists of negotiations, agreements, and dispute resolution. The most 
important agreements from our perspective are the Technical Barriers to Trade Agreement (TBT 
Agreement) and the Agreement on Sanitary and Phytosanitary Measures (SPS Agreement). 
The TBT Agreement covers all mandatory and voluntary technical regulations and standards, 
including testing and certifi cation procedures. The aim of the agreement is that these technical 
measures do not create unnecessary obstacles to trade.72 The SPS Agreement defi nes the rights 
and obligations of members with respect to application of sanitary and phytosanitary measures 
meaning laws and standards on food safety, animal health and plant health. Basically, the SPS 
agreement defi nes how food is to be regulated in order to maintain TBT agreement goals73.
71  From consumer protection perspective as described above.
72  Wanhua 2002, 316. 
73  Hollo 2008, 26.
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The GATT agreement established the fundamental principles of international trade: the 
most-favoured-nation treatment74, and national treatment.75 Most-favoured-nation treatment 
means that if a Member grants an advantage to a product from another country, the same 
advantage shall be granted to similar products of all other Members. Likewise, restrictive 
practices must be applied in a universal fashion76. National treatment means that Members 
apply equal taxation and regulation to imports compared to domestically produced or supplied 
goods.77 The GATT agreement was incorporated into the WTO. The principles of non-
discrimination are also included in GATS (services) and TRIPs (intellectual property rights) 
agreements, the TBT agreement78, and the SPS agreement79.
In law, there are always exceptions to rules. Wilkinson distinguishes eight instances in the GATT 
agreement which allow Members to engage in discriminatory practices against each other. For 
example, free trade areas among certain members are allowed, new Members can be discriminated 
against, and infant industries can be protected80. The most interesting exception category is the 
‘general exceptions’ that include a wide range of criteria including “the protection of human, 
animal or plant life or health”. The GATT, the TBT, and the SPS Agreement allow Members to 
adopt exceptions on these grounds81. This means a country may, for example, prohibit imports of 
foods from a certain Member country. According to the TBT Agreement, risks must be assessed 
based on available scientifi c and technical information82. Sanitary and phytosanitary measures 
have to be based on scientifi c evidence83. Measures shall not constitute arbitrary or unjustifi able 
discrimination or disguised restrictions on international trade84.
China joined the WTO in 200185. China is expected to comply with the WTO agreements 
and develop into a “more responsible member of the international community”86. Foreign 
businesses expected to benefi t from a more transparent and predictable business environment87. 
The worst possible scenario was that China would disrupt the whole WTO process that is 
74  “Any advantage, favour, privilege or immunity granted by any contracting party to any product originating in or 
destined for any other country shall be accorded immediately and unconditionally to the like product originating in 
or destined for the territories of all other contracting parties.” GATT 1994, Article I, paragraph 1. 
75  “The products of the territory of any contracting party imported into the territory of any other contracting 
party shall not be subject, directly or indirectly, to internal taxes or other internal charges of any kind in excess 
of those applied, directly or indirectly, to like domestic products.” GATT 1994, Article III, paragraph 2.
76  “The exports of a Member must not be prohibited or encounter restriction into domestic markets, unless 
the importation of the like product of all third countries is similarly prohibited or restricted.” GATT 1994, 
Article XIII, paragraph 1. 
77  Wilkinson 2000, 81-82.
78  Article 2 paragraph 1.
79  Article 2 paragraph 3.
80  In addition, the WTO does not say anything about discriminating against non-Members. Wilkinson 2000, 85.
81  GATT Article XX, TBT Article 2 paragraph 2, SPS Article 2. Other grounds for these safeguard measures 
include ensuring the quality of the country’s exports, protection of environment and prevention of deceptive 
practices. Wanhua 2002, 316.
82  Article 2 paragraph 2.
83  Article 2 paragraph 2.
84  TBT preamble, SPS Agreement Article 2 paragraph 3.
85  This happened after lengthy discussions with the most important trading partners. As a non-member, 
China’s exports were often the subject of discriminatory treatment in overseas markets. By adjoining, China 
gained new market access opportunities and new legal protections against discrimination. Gong 2005.
86  Kobayashi 2008, 1.
87  Qingjiang 2002, v.
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based on consensus88. According to US-China Business Council in 2008, China has gone a 
long way in fulfi lling its WTO obligations, but there are still problems related to the principle 
of national treatment in particular. This means that foreign companies experience adverse 
treatment compared to Chinese companies. Discrimination comes in the form of stricter 
regulations and enforcement, more stringent, time consuming, or costly application and 
licence approval processes, exclusion from the standards setting process, and bias towards 
domestic goods in government procurement.89 According to Peerenboom, some of the areas 
listed by foreign investors are actually required of China by the WTO, while others are just 
wishful thinking seeking to further foreign interests90. Besides factors related to the Chinese 
legal culture, employment and income levels of the Chinese people will determine whether 
China will fulfi l its WTO obligations91.
Disputes arise when trade restrictions are justifi ed by somewhat ambiguous goals such as 
human health. The most famous food disputes resolved by the WTO Dispute Settlement Body 
are the ‘hormones in beef case’92 of 1998 and the ‘sardine case’93 of 2002. The EC banning 
beef hormones was not justifi ed according to the SPS agreement, nor was the EC restriction 
of the use of the term ‘sardine’ justifi ed according to the TBT agreement, because neither was 
based on Codex. Here we see the connection between Codex standards and WTO disputes. 
With regard to China, absence of disputes against China is seen as a sign of China’s reasonably 
effective implementation of the WTO rules94. Lack of disputes could also be a sign of lack of 
confi dence on the WTO system. Jackson is of the view that WTO members do trust the dispute 
settlement procedures, and sees dispute resolution as the heart of the WTO95.
If WTO law is breached, the primary obligation is to bring the unlawful measure into 
conformity with WTO law. If a state does not implement the ruling of the Dispute Settlement 
Body, the WTO agreements provide for remedies: compensation or countermeasures. Both 
are temporary, emphasising that the primary obligation is to remove the unlawfulness. 
Compensation is preferred to countermeasures, but as compensation must be agreed between 
the parties of the dispute, countermeasures are often the only alternative in practice.96
Trade sanctions, which proved to be ineffi cient against large trade powers97, are anticipated 
to be inadequate against China. The WTO mechanisms generally resolve whether certain 
national legislation contravenes WTO agreements. The WTO does not resolve issues such as 
hierarchy of norms, competences of authorities, resources for implementation, or enforcement 
of judgments.98 These general legal issues remain the important factors of legal risk management 
that foreign businesses must face in China.
88  Qingjian 2002, vi.
89  US-China Business Council 2008, 10.
90  Peerenboom 2008 b, 8.
91  Qingjiang 2002, 308.
92  EC measures concerning meat and meat products (Hormones), WT/DS48/AB/R of 16 January 1998. (AB-
1997-4).
93  WT/DS231/R of 29 May 2002.
94  Mertha 2008, 1.
95  Jackson 1998, 59.
96  Nordblad 2003, 88.
97  See Lindblad analysis of the Bananas case and the Hormones case, Lindblad 2003, 99.
98  Seppänen 2005, 587.
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The EC and China are simultaneously recipients and makers of international standards. 
There are several parties involved in making these standards, the United States among them. 
This makes international food law a constant negotiation and a series of compromises. 
Every state pursues individual ideas on how the law should be developed. Lately Codex 
Alimentarius Commission has paid more attention to horizontal standards applicable to all 
foods. Emphasis has been placed on principles of scientifi c risk assessment, the precautionary 
principle, traceability, and views from consumers and NGOs. Besides plain natural science, 
other legitimate factors are considered, such as economics and characteristics of different 
regions and countries.99
The precautionary principle and the need to consider factors other than science in 
determining food standards are something the EU has demanded, and the United States 
have resisted100. The EU earlier argued in the above-mentioned EU – Hormones case that 
the precautionary principle is a customary rule of international law or at least a general 
principle of international law. The EU had prohibited import of beef hormones. According to 
the precautionary principle, WTO member states are allowed to take precautionary measures 
in the absence of full scientifi c certainty. According to Wanhua, the EU lost the hormone case 
because the precautionary principle was still considered to await authoritative formulation.101 
The Cartagena Protocol on Biosafety entered into force in 2003, and clearly embraces the 
precautionary principle. The Cartagena Protocol refers to the Rio Declaration on Environment 
and Development 1992 in this issue, and the Rio Declaration was already written in 1992. It 
seems that those in favour of the precautionary principle see it emerging in the 1990s at the 
latest, and those against it still resist its existence.
The role of the WTO in building international legal principles is under discussion. The 
WTO can either focus on resolving disputes in a bilateral and practical case-to-case approach, 
or it can build international rule of law. Consistency and abiding by the rules is integral for 
the credibility of the Dispute Settlement Body102. Nordblad is of the view that the WTO needs 
stronger remedies to be able to achieve rule-oriented dispute settlement. He is also of the 
view that effective remedies are those that repair damage and induce compliance, and thus 
compensation and countermeasures are both needed. Compensation and countermeasures 
should be considered separate issues. Rule integrity would be enhanced by the situation where 
countermeasures were free of the compensatory element.103
2.1.2 Global Standards
2.1.2.1 ISO Standards
The TBT Agreement requires that technical regulations and international standards are 
developed and implemented in a non- discriminatory manner, and without creating unnecessary 
99  Kan – Zhang 2002.
100  Poli 2004, 614. The European Community applied for full membership of Codex so that it could better 
pursue its goals, which often clash with US goals.
101  Wanhua 2002. 
102  See Palmujoki 2003, 719, as regards the role of the WTO dispute resolution body in evaluating the 
acceptability of national environmental legislation.
103  Nordblad 2003, 103.
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obstacles to trade. The TBT Agreement also recommends the recourse to international standards 
wherever possible while drafting technical regulations.104 ISO/IEC105 standards are particularly 
referred to in the TBT Agreement106. ISO is the International Organisation for Standardisation, 
and has published several standards related to the food industry. For example the International 
Standard ISO 22000:2005 is promoted in the following manner: “food safety management 
system meeting the requirements of the Standard could be the entry ticket to increased business 
in the global market and participation in cross-border food supply chains”107.108.
ISO is a non-governmental organisation “forming a bridge between the public and private 
sectors”, and a network of the national standards institutes of its 157 member countries. Many 
of the member institutes are part of the governmental structure of their countries, while others 
have been set up by national partnerships of industry associations.109 Legally describing ISO 
standards is diffi cult. They are not agreements between states as Codex standards, and they 
are not self-regulating because governments are involved. They are followed voluntarily, 
although abiding by a standard might be required in practice. In any case, ISO standards can 
be defi ned as soft law.
The EU sees international standards as a positive phenomenon. According to the European 
Commission, it will, in co-operation with the European Standards Organisations, “continue 
to encourage the development of international standards and promote their use”. International 
standards shall be transposed into European standards and European law, “wherever possible”. 
And vice versa, the EU is willing to diffuse European standards internationally, particularly 
to neighbouring countries.110 The lead in developing globally accepted standards is seen as a 
lead to markets.
2.1.2.2 Food Standards: Codex
Codex Alimentarius is an international organisation governing foodstuffs and operating under 
United Nations organisations FAO111 and WHO112. Codex documents are global food law113. 
Codex Alimentarius pursues to protect the health of consumers and to promote fair international 
food trade.114 Codex Alimentarius Commission is the highest decision-making body, where the 
104  Commission Communication on Standards 2004, 7.
105  “The International Electrotechnical Commission is the international standards and conformity assessment 
body for all fi elds of electrotechnology.” http://www.iec.ch/.
106  Annex 1 of the Agreement.
107  ISO web page. http://www.iso.org/iso/publications_and_e-products/checklists.htm.
108  ISO 22000 is the standard on food safety management systems, including requirements for any operator 
in the food chain. Other important standards related to the food industry are: ISO/TS 22003:2007, which 
includes requirements for bodies that provide audits and certifi cation of food safety management systems, 
ISO 22005:2007, which is about traceability in the feed and food chain, and ISO 24276:2006, which 
standardises methods of analysis for detecting GMOs. ISO web page. http://www.iso.org/iso/catalogue_
detail?csnumber=35466.
109  ISO web page. http://www.iso.org/iso/about.htm.
110  Commission Communication on Standards 2004, 3-4.
111  Food and Agriculture Organization.
112  World Health Organization.
113  Codex Alimentarius means food law.
114  www.codexalimentarius.net.
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representatives of the approximately 180115 member states meet. The Commission assembles 
every year. The Codex Alimentarius Commission is the most important global actor drafting 
food standards. The European Community, represented by the Commission116, EU Member 
States separately, and China are members of Codex.
Codex documents are in the forms of standards, codes of practice, guidelines, principles, 
recommendations, etc. Standards often relate to product features and can be very precise 
setting for example MRLs (maximum residue levels) for pesticides or medicinal substances 
in foods. For example there is a standard for canned baby food and a standard for frozen 
spinach. Codes of practice guide procedure concerning production, preparation, transport and 
storage, including HACCP systems. Guidelines exist on nutrition and health claims117whereas 
principles are more general and relate to import and export certifi cates. The division between 
different document types is not important as none of the Codex documents are directly binding 
on food industry operators. All of the above-mentioned document types are listed under 
‘standards’ on the Codex web page118.
What makes Codex rules more important is the fact that they are specifi cally referred to in 
two WTO119 agreements: the Technical Barriers to Trade Agreement (TBT Agreement120) and 
the Agreement on Sanitary and Phytosanitary Measures (SPS Agreement121). This means Codex 
standards are used as a reference in trade disputes at the WTO.122 It is important for the EC and 
China to defend their interests in Codex, as they are also members of the WTO123. The role of the 
Codex Commission is to provide a political forum to debate issues. The role of the WTO Dispute 
Settlement Body is to ultimately resolve the issues that cannot be agreed upon.
2.1.2.3 Medicine Standards
The above-mentioned WTO agreement on Technical Barriers to Trade (the TBT agreement) 
applies also to medicines. For example, in the November 2007 meeting of the Technical 
Barriers to Trade Committee, Columbia raised a concern on Argentina’s regulations for 
115  Counted on Codex web page http://www.codexalimentarius.net/web/members_area.jsp?lang=EN, April 
2007.
116  More precisely its Directorate General on Health and Consumer Protection.
117  CAC/GL 23. 1997. Revised 2004, amended 2008.
118  http://www.codexalimentarius.net/web/standard_list.do?lang=en.
119  World Trade Organization.
120  The TBT Agreement covers all mandatory and voluntary technical regulations and standards, including 
testing and certifi cation procedures. The aim of the agreement is that these technical measures do not create 
unnecessary obstacles to trade. Wanhua 2002, 316. 
121  The SPS Agreement defi nes the rights and obligations of members with respect to application of sanitary 
and phytosanitary measures. This means laws and standards on food safety, animal health and plant health. 
122  World Health Organisation web page. Biotech: 20 questions. http://www.who.int/foodsafety/publications/
biotech/20questions/en/. 
123  The EC Member States including Finland have been WTO members since its inception in January 1995, 
and China since December 2001. WTO has 150 members as at June 2009.
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pharmaceuticals. These regulations involve, for example, application of tariffs or fees for 
undertaking verifi cation visits to plants located in the countries of origin124.
The WHO is involved in developing international medicinal products law. They develop 
international norms, standards and guidelines, and provide guidance, technical assistance 
and training to support countries in adopting these standards on medicinal products.125 The 
WHO also organises international conferences of drug regulatory authorities, where medicinal 
products law is discussed. The outcome of these meetings is “Recommendations”, in which 
various areas of medicinal products laws are discussed. They take the form “Member States 
should…”. In 2006, it was agreed that member states should support clinical studies of herbal 
medicines126, and seek effi cient sanctions for false drug advertising, particularly internet 
advertising127. According to European law, the European Medicines Agency (EMEA) shall 
“participate actively in international scientifi c dialogue and to contribute to international 
scientifi c harmonisation and technical cooperation with the WHO”128. China is also involved 
in the WHO discussions and drafting recommendations on medicinal products law.
The ICH (International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use) is a project for global harmonisation of the 
medicine authorisation procedures. Its Steering Committee selects the topics for international 
harmonisation. However, the ICH is not global: it brings together the regulatory authorities 
of Europe, Japan and the United States, in addition to experts from these three regions129. In 
the EU, draft ICH guidelines are subject to EU-wide public consultation. Once adopted by the 
CHMP130 of the EMEA, the ICH guidelines have the same status as other European scientifi c 
guidelines and replace existing guidelines on the subjects covered. ICH guidelines may also 
be developed on subjects that do not come within the scope of scientifi c guidelines.131
The EU and China also work bilaterally on issues of medicine law. The agreement on 
“Consultation and Cooperation Mechanism” was signed in 2008. In 2009, the Chinese SFDA 
met with DG Enterprise of the EC in the fi rst annual high-level working conference under the 
“mechanism”. According to the SFDA, the conference announced the achievements of the 
medicine and medical device workgroups, and discussed establishment of a workgroup on 
cosmetics. In addition, the EMEA was present.132
124  World Trade Organization. Committee on Technical Barriers to Trade. Specifi c Trade Concerns Relating 
to Access of Pharmaceuticals to the Argentine Market. Communication from Colombia. G/TBT/W/280. 30 
October 2007. 
125  WHO web page. http://www.who.int/medicines/areas/quality_safety/regulation_legislation/en/index.html.
126  Icdra. 12th International Conference of Drug Regulatory Authorities. Recommendations. Page 5.
127  Icdra. 12th International Conference of Drug Regulatory Authorities. Recommendations. Page 8.
128  Regulation 726/2004/EC, preamble 27.
129  ICH web page : http://www.ich.org.
130  The Committee for Human Medicinal Products.
131  Procedure for European Union guidelines and related documents within the pharmaceutical legislative 
framework. London, 20 June 2005. EMEA/P/24143/2004. Page 8.
132  SFDA web page at: http://former.sfda.gov.cn/cmsweb/webportal/W43879541/A64029996.html.
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2.2 EU Law on Foodstuffs and Medicines
2.2.1 Hard law133
European law on foodstuffs and medicines is a puzzle consisting of EU laws and Member State 
Laws. Both consist of hard law (binding) and soft law (non-binding) instruments. European 
Union law is prepared by the European Commission. Food safety is under the competence 
of Directorate General on Health and Consumer Protection (DG SANCO)134. DG SANCO 
is responsible for public health, general consumer protection, and food safety in particular. 
Medicine law is drafted by the Commission’s Directorate General for Enterprise & Industry 
(DG Enterprise)135. The main goal of DG Enterprise is to ensure competitiveness of European 
enterprises and facilitate job creation and economic growth136.
The EU Member States also have their own food and medicine laws. The EU has 27 Member 
States as of 2007. The division of work between EU level and member state level legislators is the 
basic question in EU law. According to Nedergaard, European cooperation clearly has federalist 
as well as intergovernmental traits. The mixed traits refl ect the basic contrast in the EU between 
the desire for some degree of supranational governance and the Member States’ perceived need for 
control.137 The EU cannot operate without competences, which are outlined in the articles in the 
EC Treaty. If a question does not belong to EU competence, then Member States have the authority 
to decide upon it.
The competence of the Commission to act in the area of food law can be based on Treaty 
Articles 37, 95, 152 and 153. Sometimes food law is based on more than one Article, such 
as Article 95 on creating the internal market, and Article 152 on safeguarding public health. 
Article 37 concerns agriculture and Article 153 consumer protection. The central legislation 
on medicines from consumer perspective138 is based on Articles 95 and 152. Apparently, food 
and medicine laws are not seen primarily as consumer issues but rather as issues of free trade 
and public health.
Certain questions fall under the exclusive competence of the Community. On food 
and medicine issues, both the EU and the Member States have the competence to enact 
legislation. In this case, the principle of subsidiarity applies, meaning the EU shall take action 
only when it is more effective than action taken at national, regional or local levels139. In 
case of contradiction, the principle of primacy applies: EU law is to be enforced instead of 
contradictory national law.140 Another important principle is the principle of proportionality: 
the EU involvement must be limited to what is necessary to achieve the objectives of the 
133  Hard law here means regulations that are enforceable by courts.
134  The Commissioner in charge of DG SANCO at the moment (2009) is Androulla Vassiliou.
135  The Commissioner at the moment (2009) is Günter Verheugen.
136  European Commission web page. http://ec.europa.eu/enterprise/dgs/index_en.htm.
137  Nedergaard 2007, 7.
138  Directive 2001/83/EC and Regulation 726/2004/EC.
139  European Union web page. http://europa.eu/scadplus/glossary/subsidiarity_en.htm.
140  Tolonen 2003, 111-112.
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Treaties141.142 The proportionality principle also applies to actions of Member States, and has 
been used particularly with regard to limiting the four freedoms143.
Food safety is considered very important particularly from free trade and public health 
perspectives. This leads to the conclusion that EU legislation is usually considered necessary 
and to a situation where the amount of EU legislation is vast. At the moment, EU food law covers 
all the important aspects and functions in the food chain: biological safety (hygiene), chemical 
safety (contaminants, residues, additives etc.) and practically all aspects of food marketing. 
For example in the 2008 novel food proposal, it is stated that Member State action could lead 
to differing levels of food safety, confuse consumers, and endanger the free movement of food 
in the EU144. In the 2008 labelling proposal, it is stated that Community action is needed “for 
the internal market to function smoothly”145. The EU has regulated medicines since 1965, and 
the role of national regulators has been rather small for a long time.
EU law can be divided in primary legislation, secondary legislation, international 
agreements, legal principles, and case law. Primary legislation means the Treaties, which are 
comparable to constitutional law. The two fundamental treaties are the Treaty establishing 
the European Community (EC Treaty) and the Treaty establishing the European Union (EU 
treaty). In this study, we are mainly interested in secondary legislation. Secondary legislation 
means Regulations, Directives, and soft law materials such as Recommendations or Opinions. 
Regulations are directly applicable and binding on everyone, whereas Directives are binding 
on the Member States.146
When choosing a legal instrument, Regulations are today often favoured compared 
to Directives. In the 2008 labelling proposal, it states “a Directive would have lead to an 
inconsistent approach in the Community leading to uncertainty for both consumers and the 
industry”. A Regulation provides “a consistent approach for industry to follow and reduces 
the administrative burden as they do not need to familiarise themselves with the individual 
Regulations in the Member States”.147 With novel foods, the Directive option was not even 
considered in 2008, because there is already a novel food Regulation and the evaluation has, 
since 1997, been based on EU-wide approvals. Instead, the Commission stated why soft law 
is not considered adequate for addressing the issue in question: “Non-legislative action based, 
for example, on a code of good practice or guidelines could not give suffi cient protection and 
would lack legal certainty.”148
Minimum harmonisation means that the EU sets ground which national legislation must 
meet. Legally, this is often done by a Directive, which includes a safeguard clause. In this case, 
EU Member States may enact more restrictive laws if unexpected events such as public health 
141  European Union web page. http://europa.eu/scadplus/glossary/proportionality_en.htm.
142  Both the principle of subsidiarity and the principal of proportionality are established by Article 5 of 
the Treaty establishing the European Community. Protocol (No 30) on the application of the principles of 
subsidiarity and proportionality was Annexed to the EC Treaty in 1997.
143  Raitio 2006, 246. The four freedoms of the EU are: the free movement of persons, goods, services, and 
capital.
144  The proposal for a Regulation on novel foods. Explanatory memorandum. Page 5.
145  Food labelling proposal 2008. Explanatory memorandum. Page 9.
146  European Union web page, EurLex, Process and players. http://eur-lex.europa.eu/en/droit_communautaire/
droit_communautaire.htm#1.6.
147  Food labelling proposal 2008. Explanatory memorandum. Page 11.
148  The proposal for a Regulation on novel foods. Explanatory memorandum. Page 6.
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reasons render the EU mandates too limiting. Of the general consumer protection laws, the 
product safety directive includes a safeguard clause. A problem with minimum harmonisation 
is that national rules can be used for protectionist purposes. According to the Commission’s 
current Consumer Protection Strategy, minimum harmonisation is not a suitable alternative in 
consumer protection issues anymore as it leads to restrictions on free trade149.
Maximum harmonisation means “full” harmonisation. The unfair commercial practices 
directive uses maximum harmonisation, and does not include a safeguard clause. Legislators 
in Member States cannot create rules that are more restrictive on trade than the Directive. 
However, national courts may create varying standards for acceptable commercial conduct 
on a case-by-case basis. Ultimately, the European Court of Justice may have to ensure 
harmonisation through case law, as it resolves disputes that challenge a Member State’s trade 
practices laws.150 This means that not even maximum-harmonisation directives as such can 
amount to full harmonisation. Rules would have to be very detailed in order to fully harmonise 
a subject area, and general clauses would have to be avoided. Full harmonisation is thus 
hypothetical as it would mean no room or need for courts, however, in practice, harmonisation 
will have to come through courts dealing with cases, and ultimately through the ECJ.
The Commission is of the view that consumer protection is better achieved by maximum 
harmonisation, but the foremost concern seems to be the removal of barriers to trade151. MacMaoláin 
has criticised EU food laws for allowing the principle of free movement of goods to underlie 
all harmonising provisions152. This means the profi tability of the European food business is the 
Commission’s foremost concern, at the expense of health and consumer protection. According to 
him, EU law has often become an artifi cially low regulatory “ceiling”. He also argues that much 
of EU food law has developed in reaction to food safety crises and thus neglected quality aspects 
of food, such as nutritional value and ethical issues. MacMaoláin believes national-level regulators 
could be more responsive to citizen’s public health and other concerns.
Above, we have discussed law that is harmonised in the EU either through maximum 
harmonisation or through minimum harmonisation. The actions of Member States would still 
be limited if law were not harmonised since free movement of goods in the EU is guaranteed 
by rules in the EC treaty. Customs duties are prohibited153, and Member States are not allowed 
to quantitatively restrict import154 or export155 of goods. The ultimate quantitative restriction 
is a ban to import for example a food or a medicine. A member state can, however, restrict 
imports if it is necessary for the protection of health and life of humans.156 The European Court 
149  EU Consumer Policy strategy 2007-2013. COM(2007) 99 fi nal. Page 7.
150  Nehf 2006. 
151  EU Consumer Policy strategy 2007-2013. COM(2007) 99 fi nal.
152  MacMaoláin 2007, 2. 
153  Article 25 of the Treaty.
154  Article 28 of the Treaty.
155  Article 29 of the Treaty.
156  Article 30 of the Treaty is called the safeguard clause: “The provisions of Articles 28 and 29 shall not 
preclude prohibitions or restrictions on imports, exports or goods in transit justifi ed on grounds of public 
morality, public policy or public security; the protection of health and life of humans, animals or plants; 
the protection of national treasures possessing artistic, historic or archaeological value; or the protection of 
industrial and commercial property. Such prohibitions or restrictions shall not, however, constitute a means of 
arbitrary discrimination or a disguised restriction on trade between the Member States.”
–25–
of Justice has handled cases related to food and medicine law where it has decided whether 
certain Member State actions have or have not been necessary157.
Different rules apply to maintaining vs. introducing derogations to harmonised rules. When 
legislation is harmonised according to Article 95 in order to achieve free movement of goods, a 
member state can still uphold certain existing national rules deemed necessary for Article 30 or 
other reasons158. Setting up new national rules requires scientifi c evidence on particular problems 
occurring after or caused by European legislation159.160 The Commission must be notifi ed of 
derogations, and if the Commission does not react, derogations are considered legal.
The principle of mutual recognition further clarifi es the roles of the EU vs. its Member 
States when standards are not harmonised by EU level legislation. This principle was 
established by the Cassis de Dijon case already in 1979. It prevents a Member State from 
blocking a product at its borders if the product is approved according to another Member 
State’s reasonable standards. Because food and medicine law is widely harmonised in the EU, 
the Cassis doctrine is not particularly relevant here.
2.2.2 Administrative Soft Law
So far, we have discussed the creation of European hard law norms. Now we turn to soft law, 
which is in the fi eld of foodstuffs and medicines at the EU level created by the Commission 
and the regulatory agencies. Senden sees the European Commission as quite an aggressive 
maker of soft law, and warns that it may use recommendations, codes, etc. as a means to 
impose obligations, which are not in fact entailed in Community law161. To promote democratic 
legitimacy, she supports active participation of the European Parliament in the making of soft 
law162. The Council already consults the Parliament when making recommendations163.
When turning to the agencies EFSA and EMEA, the democratic element is even thinner 
than with the Commission. Supranational regulatory agencies are an important institutional 
innovation in European law. These agencies have emerged since the 1990s, and are set up 
in sensitive policy areas. The agencies replace the traditional committee system as the main 
regulatory institution of the EU. The European Medicines Agency (EMEA) was established in 
157  These cases from the 1970’s and 1980’s have involved for example certifi cates for medicines, food 
fortifi cation, additives, and sausages. Joutsamo et al. 2000, 436-437.
158  Article 95(4): “If, after the adoption by the Council or by the Commission of a harmonisation measure, 
a Member State deems it necessary to maintain national provisions on grounds of major needs referred to in 
Article 30, or relating to the protection of the environment or the working environment, it shall notify the 
Commission of these provisions as well as the grounds for maintaining them.”
159  Article 95(5): “Moreover, ... if, after the adoption ... of a harmonisation measure, a Member State deems 
it necessary to introduce national provisions based on new scientifi c evidence relating to the protection of the 
environment or the working environment on grounds of a problem specifi c to that Member State arising after 
the adoption of the harmonisation measure, it shall notify the Commission of the envisaged provisions as well 
as the grounds for introducing them.”
160  Hollo 2008, 38.
161  Senden 2004, 492.
162  Senden 2004, 482.
163  Senden 2004, 502.
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1993. The European Food Safety Authority (EFSA) was set up in 2002, following the example 
of medicines regulation.164
According to Regulation 726/2004/EC, European medicine law should be based on 
science165. The European Medicines Agency (EMEA) is responsible for preparing scientifi c 
opinions on medicinal product legislation, providing the industry with regulatory and scientifi c 
guidelines, and handling applications in the centralised procedure. The opinions are prepared 
by the EMEA Committees, which are: the Committee for Medicinal Products for Human 
Use (CHMP), the Committee on Orphan Medicinal Products (COMP), the Committee on 
Herbal Medicinal Products (HMPC), and the Committee on Paediatric Medicinal Products 
(PDCO).166 According to Krapohl, the establishment of the EMEA led to a successful 
regulation of pharmaceuticals in the EU. A real single market is emerging and the regulatory 
policymaking seems to function. The EU Member States and the industry evaluate the EMEA 
very positively.167
One goal of setting up the EMEA was that scientifi c advice for future applicants seeking 
marketing authorisation would be generally provided and in greater depth168. The EMEA 
publishes its own guidelines on quality, safety and effi cacy testing requirements; which is 
described as giving scientifi c advice and protocol assistance. The “advice” by the EMEA, 
while understood as law, is not legally binding, so it is in reality soft law, and is in practice 
very important as it gives the regulation target the actual rules on how to act.
According to the General Food Regulation, food law should be based on scientifi c risk 
assessment, which is further defi ned by the precautionary principle. Scientifi c risk assessment 
is the task of the European Food Safety Authority (EFSA), established in 2002. The EFSA 
gives scientifi c advice to the Commission when drafting new laws or making pre-market 
approvals. The EFSA also gives advice to national legislators and food agencies. Similar to 
the EMEA, the EFSA also addresses regulation targets by their opinions and guidelines. They 
advise the applicants on how to draft applications and what information is needed, forming the 
hard law requirements into practical demands.
The reason for setting up the EFSA was to regain the public’s trust after scares related 
to BSE and dioxin. Before EFSA, a committee that was directly a part of the Commission 
handled scientifi c risk assessment in food issues. It had become obvious that the Member 
States and the Commission could not agree among themselves on food law issues based on 
science, and an impartial expert authority was seen as the answer. EFSA’s structure and their 
use of outside experts are meant to ensure that science and politics are distinguished.169
164  Krapohl 2004, 518.
165  Preambles of the Regulation refer to “high level of scientifi c evaluation”, “objective scientifi c criteria 
of quality, safety and effi cacy”, “scientifi c expertise”, and “scientifi c role and independence of the 
committees”.
166  Regulation 726/2004/EC of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for human and veterinary 
use and establishing a European Medicines Agency. The Committee on Pediatric Medicinal Products was 
established in 2007. There is also the fi fth Committee for veterinary medicinal products, which are not 
discussed in this thesis.
167  Krapohl 2004, 519.
168  Regulation 726/2004/EC, preamble 25.
169  ElAmin 2006. 
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The EU faces the task of balancing the interests and goals of 27 economically and culturally 
different Member States in regulating foods or medicines. The crucial issue for successful risk 
regulation is how Member State interests and scientifi c expertise can be integrated. The issue 
of science vs. politics applies both to medicines and foodstuffs. The Member States have long-
term interests in appropriate risk regulation based on science, but they also have short-term 
interests to protect their domestic economy in single cases. Agencies like the EMEA and the 
EFSA were established so that the common long-term interests could prevail.170
Expertise and independence are valuable assets in the current EU where all the Member 
States are perceived to pursue their own interests. Compared to democracy, in other words 
politics, the targets of regulation prefer a scientifi c community to resolve the issues. Separate 
regulatory agencies are preferred compared to the Commission and its committees, because 
the Commission is no model example of transparency.171 For example, with novel foods, most 
stakeholders want EFSA to resolve the issues of whether a food can be regarded as novel 
and whether a food can be authorised. National governments are also distrusted and seen as 
creating nothing but hurdles to trade, often on political grounds.
As a result of the control problem, the Member States have not given the Agencies total 
independency, though. The decision-making procedures still involve the Commission and 
Member-State bodies. In this situation, one has to be aware that the short-term interests of the 
Member States are blocked from being involved. As regards the European regulatory agencies 
of foodstuffs and medicines, the EFSA has been criticised for not being as independent as 
the EMEA.172 Member States of the EU have a larger role in the EFSA decision-making 
procedures than within EMEA procedures. This way politics and national interests infl uence 
European food law more than European medicines law.
According to Herman Koeter, the EFSA’s deputy executive director, it is a challenging task 
for the EFSA to maintain their independence. The EFSA receives pressure from the European 
Parliament, the Commission, national legislators, regulatory agencies, and the food industry. There 
is a push to dilute or strengthen results, and sometimes push for a fi rm opinion in cases where 
science is unable to yield a clear answer. Risk communication is also a sensitive issue. The EFSA 
has decided to inform the public directly on key issues and scientifi c fi ndings, in spite of the public 
sometimes misinterpreting science and turning away from a particular type of food.173 Scandal-type 
media attention is naturally bound to damage a member state or an economic sector. Thus there is 
sometimes political pressure against basing food law on science.174
While the EFSA has trouble in being independent enough, some critics have argued 
that both the EFSA and the EMEA are too independent, as they have no accountability to 
democratically elected agencies. Leino has questioned the legal grounds for EU agencies such 
as the EFSA and the EMEA, and according to her, the role of agencies should be clearly 
-and strictly- defi ned in law. She demands that all legislative acts and also decision-making 
affecting private rights and obligations should be made by politically accountable actors. Such 
powers should not be delegated to agencies,175 and this is far from reality at the moment. With 
170  Krapohl 2004, 520.
171  Leino 2003, 48.
172  Krapohl 2004, 521.
173  Koeter according to ElAmin 2006. 
174  The decision on EFSA location in Parma was itself clearly a political one. 
175  Leino 2003, 49-50.
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foodstuffs and medicines, EU level and national regulatory agencies have very important 
roles in both drafting the law and implementing the law. Aside from giving advice for drafters 
of hard law, the agencies have created a vast amount of documents defi ned as soft law, which 
gives hard law its actual contents. The agencies also have signifi cant discretionary powers in 
law implementation.
According to Krapohl, the solutions are rather simple: the law and the courts. Member 
States must bind the Agencies and also the Commission with substantive legal decision-
making criteria, which can be enforced by the European Courts.176 This means the laws 
need to be clear enough and not replete with concepts open to interpretation, such as “the 
proportionality principle” and “other legitimate concerns besides science”. Laws need to be 
enacted in a manner that allows Member States to truly trust the implementation with an 
impartial authority, and ultimately with the courts.
After discussing the roles of European level regulatory agencies, we have to mention the 
important regulatory role of national regulatory agencies. By interpreting and explaining the 
European and national laws in various ‘guidelines’, the national food and medicine agencies 
also create European law. For example, the Finnish Food Agency has been active in explaining 
to entrepreneurs how they interpret food laws. The food agency has published, among others, 
the following ‘guides’:
 labelling guide, –
 food supplement guide, –
 additive guide, –
 health claim guide, –
 guide on microbiological hazards of food and drinking water, –
 legal guide on sports nutrition, –
 requirements related to food contact materials, –
 guide on sale of farm or household food, –
 guide on food sales outside. –
These guides can be fairly extensive compared to actual laws. For example, the guide on food 
supplements, updated in July 2006, has 58 pages.177 In comparison, the European directive 
on food supplements 2002/46/EC has 7 pages, and the Finnish regulation implementing the 
directive has only a couple of pages. This means the rules are, from the business viewpoint, 
largely based on ‘the guide’. The guide on food supplements is very detailed and important 
issues such as the division between foodstuff and medicine are addressed. This kind of detailed 
advice is, by regulation targets, understood as law. The above-discussed question of combining 
scientifi c independence with democratic accountability applies also to national agencies.
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) uses the 
following phrase to warn people about their unreliable soft law: “This MHRA guidance 
should not be taken as a complete or defi nitive statement of the law. It is not intended as a 
substitute for legal or other professional advice. The MHRA accepts no responsibility for 
any loss or damage caused, arising directly or indirectly, in connection with reliance on 
the contents of this guidance.” This disclaimer is used for example in “A guide to what is a 
176  Krapohl 2004, 520.
177  The guide is available (in Finnish) at http://www.palvelu.fi /evi/fi les/55_519_331.pdf.
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medicinal product”178 and “The Medicines Borderline Section and the Internet”. In the latter, 
the Agency describes its interpretation on what kind of Internet information will make the 
product a medicine instead of food.
Principles of democracy can, and must be, included in agency procedures. There is danger 
that an industry takes over a regulatory agency, which is called regulatory capture. This 
can happen when EU agencies or national agencies work close together with targets of the 
regulation, in this case food and medicine industries. As these industries are important both 
economically and from a human perspective, the companies and their representatives are very 
powerful. They are also eager to defend their own interests and demand legislation that helps 
make business profi table. The agencies must weigh these concerns with consumer and public 
health needs. Citizens need to trust that public health is kept as the guiding principle for 
authorities’ actions.
The basic issue of science vs. politics remains. The issue of whether food law should be 
based purely on science, or on “other legitimate concerns” has been debated in international 
arenas. Besides scientifi c risk assessment on threats to consumer’s health, other concerns 
eligible for consideration in setting food standards are economic sustainability, technological 
feasibility, environmental risks, consumer concerns, animal health and welfare, and ethical/
religious/cultural factors. The EC generally thinks these other concerns are essential in ensuring 
acceptance of food law. The US generally thinks the presumption of taking into account these 
other concerns means opening a Pandora’s box.179
2.2.3 Structure of European Food and Medicine Law
Above, we have discussed the roles of European legislators and regulatory agencies. In this 
chapter, we map out the outcome of their work: the framework of European law on foodstuffs and 
medicines. This does not include standards or self-regulation, which will be discussed below.
2.2.3.1 Foodstuffs
The basic European regulation on foods is the General Food Regulation 178/2002/EC. It 
includes all the general principles of European food law such as the responsibility of food 
industry operators, scientifi c risk assessment, and the precautionary principle. The General 
Food Regulation is referred to in other food laws. A 31-page guidance document from 2004 
specifi cally explains certain Articles of the Regulation that have been unclear to EU food 
chain operators and third country trading partners180.
With regard to biological safety of foods, the most important legal tool is the Regulation on 
the hygiene of foodstuffs181. The hygiene rules take particular account of the HACCP (Hazard 
178  MHRA Guidance Note No. 8 (previously MAL 8) April 2003.
179  Poli 2004, 623-624.
180  Guidance on the Implementation of Articles 11, 12, 16, 17, 18, 19 and 20 of Regulation (EC) N° 178/2002 
on General Food Law. Conclusions of the Standing Committee on the Food Chain and Animal Health. 20 
December 2004.
181  852/2004/EC.
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Analysis and Critical Control Points) principles. Chemical safety is the goal of regulations on 
contaminants182, residues183, and food contact materials184. Proposed regulations on additives185, 
fl avourings186, and food enzymes187 will guarantee the safe use of these substances. Also on 
novel foods, a new Regulation is emerging188. A common procedure for evaluating additives, 
fl avourings, enzymes, and novel foods will be created189. GMO foods are regulated by the 
GMO food regulation190 and the traceability and labelling regulation191.
Food supplements are regulated by their own directive192. It covers food supplements 
consisting of vitamins and minerals. Other supplements are under national law. Food 
fortifi cation with vitamins and minerals is likewise regulated at EU level193 and fortifi cation 
with other substances by national laws. Dietary foods (foodstuffs for particular nutritional 
uses) have to comply with their own rules194.
Laws on food marketing are about to change as the Commission has proposed a new 
Regulation on providing food information to consumers. This regulation will replace the former 
food labelling and nutrition labelling directives. The long-awaited regulation on nutrition and 
health claims in food marketing195 came into force in 2007.
The above-mentioned hard law norms on foodstuffs are supplemented by various soft 
law documents. For example on novel foods, there is the “Commission Recommendation 
concerning the scientifi c information and the safety assessment report required”,196 and on 
health claims, the “Scientifi c and Technical Guidance for the Preparation and Presentation of 
the Application for Authorisation of a Health Claim” by the EFSA197.
2.2.3.2 Medicines
The European rules on medicinal products consist of hard law and soft law. It is almost 
impossible to differentiate between the two. Everything is included in “The Rules Governing 
Medicinal Products in the European Union”, published by the European Commission.198 These 
rules include the following ten volumes:
182  The basic principles of EU legislation on contaminants in food are in Council Regulation 315/93/EEC. 
Maximum residues levels for certain contaminants in food are set in Regulation 1881/2006/EC.
183  Maximum residue limits are set for veterinary medicinal products according to Regulation 2377/90/EC.
184  The Framework Regulation 935/2004/EC sets up general requirements for all food contact materials.
185  COM(2006) 428 fi nal.
186  COM(2006) 427 fi nal.
187  COM(2006) 425 fi nal.
188  COM(2007) 872 fi nal.
189  COM(2006) 423 fi nal.
190  1829/2003/EC.
191  1830/2003/EC.
192  46/2002/EC.
193  1925/2006/EC.
194  Directive 89/398/EEC and specifi c Directives on specifi c dietary foods.
195  1924/2006/EC.
196  97/618/EC.
197  SP/NDA/CLAIMS/WD/1, Rev 4-Final.
198  This collection of rules is available at: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/index.htm.
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Volume 1 – Pharmaceutical Legislation. Medicinal Products for Human use.
Volume 2 – Notice to Applicants. Medicinal Products for Human use.
Volume 3 – Guidelines. Medicinal Products for Human use.
Volume 4 – Good Manufacturing Practices. Medicinal Products for Human and 
Veterinary use.
Volume 5 – Pharmaceutical Legislation. Veterinary Medicinal Products.
Volume 6 – Notice to Applicants. Veterinary Medicinal Products.
Volume 7 – Guidelines. Veterinary Medicinal Products.
Volume 8 – Maximum residue limits.
Volume 9 – Pharmacovigilance – Medicinal Products for Human and Veterinary use.
Volume 10 – Clinical trials. Medicinal Products for human use in clinical trials 
(investigational medicinal products).
Volume 1 includes directives and regulations on human medicines, which are clearly hard law, and 
enforceable by courts. The most important piece of law regarding human medicinal products is 
Directive 83/2001/EC199. The 65-page directive has 127 Articles and a 40-page Annex.
The directive has fourteen Titles:
Title I: Defi nitions
Title II: Scope
Title III: Placing on the Market
 Chapter 1: Marketing authorisation
 Chapter 2: Specifi c provisions applicable to homeopathic medicinal products
Chapter 2a: Specifi c provisions applicable to traditional herbal medicinal products
Chapter 3: Procedures relevant to the marketing authorisation
Chapter 4: Mutual recognition procedure and decentralised procedure
Title IV: Manufacture and importation
Title V: Labelling and package leafl et
Title VI: Classifi cation of medicinal products200
Title VII: Wholesale distribution of medicinal products
Title VIII: Advertising
Title VIIIa: Information and advertising
Title IX: Pharmacovigilance
Title X: Special provisions on medicinal products derived from human blood and 
plasma
Title XI: Supervision and sanctions
Title XII: Standing committee
Title XIII: General provisions
Title XIV: Final provisions.
199  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community 
code relating to medicinal products for human use (Offi cial Journal L 311, 28/11/2001 p. 67 - 128).
200  This means classifi cation into prescription medicines and non-prescription medicines.
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The Annex of the Directive gives the analytical, pharmaco-toxicological and clinical standards 
and protocols in respect of the testing of medicinal products. The Annex refers to Commission 
and EMEA guidelines for further instructions.
Besides Directive 83/2001/EC, another important piece of law is Regulation 726/2004/
EC201, which includes rules of the centralised market authorisation procedure and the working 
rules of the EMEA.
As stated above, the directive on medicinal products does not cover all the detailed 
requirements for medicinal products. Guidelines are needed to complement the hard law. The 
need for a new guideline may be triggered by frequently encountered problems with established 
products, by the development of new technologies, new practices or new therapeutic areas, 
or by international activities202. Guidelines are prepared by experts, and undergo input from 
academia and the industry during consultation. They are intended to be suffi ciently fl exible so 
as not to impede scientifi c progress.203
With Volume 2 (Notice to Applicants), the binding nature of the rules is not as clear. The 
Commission describes the Notice as follows204: “This Notice to Applicants has been prepared 
by the European Commission, in consultation with the competent authorities of the Member 
States and the European Medicines Agency. This Notice has no legal force and does not 
necessarily represent the fi nal views of the Commission. In case of doubt, therefore, reference 
should be made to the appropriate Community Directives and Regulations.”
The Notice to Applicants was fi rst published in 1986 and is regularly updated. It is presented 
in three parts:
 Volume 2A dealing with procedures for marketing authorisation;–
 Volume 2B dealing with the presentation and content of the application dossier; and–
 Volume 2C dealing with Regulatory Guidelines.– 205
Regulatory guidelines in Volume 2C are related to procedural and regulatory requirements 
such as renewal procedures, dossier requirements, summary of product characteristics (SPC), 
package information, readability of the label and package leafl et requirements.206
Volume 2B has particular status compared to other parts of the Notice to Applicants. Volume 
2 B is referred to in the Annex of directive 2001/83/EC: “The particulars and documents 
accompanying an application for marketing authorisation … shall be presented in accordance 
with the requirements set out in this Annex and shall follow the guidance published by the 
Commission in The rules governing medicinal products in the European Community, Volume 
2 B, Notice to applicants, Medicinal products for human use, Presentation and content of the 
201  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying 
down Community procedures for the authorisation and supervision of medicinal products for human and 
veterinary use and establishing a European Medicines Agency (Offi cial Journal L 136, 30/4/2004 p. 1 - 33).
202  Procedure for European Union guidelines and related documents within the pharmaceutical legislative 
framework. London, 20 June 2005. EMEA/P/24143/2004. Page 8.
203  Shah – Griffi n 2003, 44.
204  European Commission web page: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/homev2.htm.
205  European Commission web page: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/homev2.htm.
206  Procedure for European Union guidelines and related documents within the pharmaceutical legislative 
framework. London, 20 June 2005. EMEA/P/24143/2004. Page 4.
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dossier, Common Technical Document (CTD).”207 The particulars and documents “shall be 
presented in strict accordance with the format”.208
The Annex of Directive 2001/83/EC refers also to other parts of Volumes 2 and 3. In 
assembling the dossier for application for marketing authorisation, applicants shall also take 
into account:
 the scientifi c guidelines relating to the quality, safety and effi cacy of medicinal products  –
for human use as adopted by the Committee for Proprietary Medicinal Products (CPMP) 
and published by the European Medicine Evaluation Agency (EMEA) and
 the other pharmaceutical Community guidelines published by the Commission in  –
the different volumes of “The rules governing medicinal products in the European 
Community”.
Volume 3 gives guidelines for human medicines. As opposed to Commission regulatory 
guidelines, these are scientifi c guidelines by EMEA. Guidelines are produced by the 
EMEA Committee on Human Medicinal Products (CHMP) through its Working Parties or 
its membership of the International Conference on Harmonisation (ICH).209 The guidelines 
include:
 Introduction, –
 Quality Guidelines, –
 Biotechnology Guidelines, –
 Non-Clinical Guidelines –
 Clinical Effi cacy and Safety Guidelines, and –
 Multidisciplinary Guidelines. – 210
EMEA prepares scientifi c guidelines in consultation with the competent authorities of the Member 
States. Guidelines exist to “help applicants prepare marketing-authorisation applications for 
medicinal products for human use”. Guidelines are intended to “provide a basis for practical 
harmonisation of the manner in which the EU Member States and the EMEA interpret and apply 
the detailed requirements for the demonstration of quality, safety and effi cacy contained in the 
Community directives”. They also “help to ensure that applications for marketing authorisation are 
prepared in a manner that will be recognised as valid by the EMEA”.211
The role of regulatory and scientifi c guidelines has been clarifi ed by “Procedure for 
European Union Guidelines and Related Documents within the Pharmaceutical Legislative 
Framework”, drafted by the EMEA in 2005. Previously, guidelines have also been given under 
the name “note for guidance”. The term “position paper” has been used on documents that 
refl ect on issues of scientifi c uncertainty. In future, only the term “guideline” will be used. 
207 Annex of Directive 2001/83/EC, Introduction and general principles, point (1).
208 Annex of Directive 2001/83/EC, Introduction and general principles, point (2).
209 Shah – Griffi n 2003, 44.
210 European Commission web page: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/homev3.htm.
211 EMEA introductory note on scientifi c guidelines. http://www.emea.europa.eu/htms/human/
humanguidelines/background.htm.
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Distinction with respect to limited experience and/or the need for ongoing revision will be 
outlined within the scope of the guideline.212
Guidelines are defi ned as follows: “In the pharmaceutical legislative framework, a guideline 
is a Community document that is drafted either:
 to  – fulfi l a legal obligation laid down in Community legislation, or
 to –  provide advice to interested parties on the best or most appropriate way to fulfi l an 
obligation laid down by law.”
Scientifi c guidelines “refl ect a harmonised EU approach and are based on the most up-to-date 
scientifi c knowledge as possible”.213
Guidelines are drafted via an agreed procedure including a concept paper, a draft 
guideline, consultation etc.214 Comments to guidelines are expected for example from other 
regulatory authorities (e.g. FDA and other ICH partners), European industry associations 
and European scientifi c and academic societies, patient or consumer groups and health care 
professionals215.
Guidelines may have different purposes and legal status although the general rule is that 
guidelines do not have legal force216. The defi nitive legal requirements are those outlined in 
the EU Directives, Regulations, and Decisions, as well as national rules. However, guidelines 
are to be considered as a harmonised Community position. If they are followed by relevant 
parties such as the applicants, marketing authorisation holders, sponsors, manufacturers and 
regulators, it will facilitate assessment, approval and control of medicinal products in the 
EU. Nevertheless, alternative approaches may be taken, provided that these are appropriately 
justifi ed.217
Scientifi c guidelines are referred to in the annex to Directive 2001/83/EC and listed in 
the annexes to the Notice to Applicants. In assembling the dossier for an application for a 
marketing authorisation, applicants shall take into account the scientifi c guidelines relating 
to the quality, safety and effi cacy of medicinal products. These guidelines are adopted by the 
scientifi c committees, such as the Committee for Medicinal Products for Human Use (CHMP) 
and the Committee on Herbal Medicinal Products (HMPC), and published by the European 
Medicines Agency (EMEA). These scientifi c guidelines aim to provide a basis for practical 
harmonisation of the manner in which Member States and EMEA interpret and apply the 
212  Procedure for European Union guidelines and related documents within the pharmaceutical legislative 
framework. London, 20 June 2005. EMEA/P/24143/2004. Page 4.
213  Procedure for European Union guidelines and related documents within the pharmaceutical legislative 
framework. London, 20 June 2005. EMEA/P/24143/2004. Page 3.
214  Procedure for European Union guidelines and related documents within the pharmaceutical legislative 
framework. London, 20 June 2005. EMEA/P/24143/2004.
215  Procedure for European Union guidelines and related documents within the pharmaceutical legislative 
framework. London, 20 June 2005. EMEA/P/24143/2004. Page 11.
216  An exception to this rule is the “Note for guidance on minimising the risk of transmitting animal spongiform 
encephalopathy agents via human and veterinary medicinal products”. In accordance with Directives 2001/82/
EC and 2001/83/EC, this Note for Guidance has to be explicitly complied with. Procedure for European 
Union guidelines and related documents within the pharmaceutical legislative framework. London, 20 June 
2005. EMEA/P/24143/2004. Page 4.
217  Procedure for European Union guidelines and related documents within the pharmaceutical legislative 
framework. London, 20 June 2005. EMEA/P/24143/2004. Page 3.
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detailed requirements for the demonstration of quality, safety and effi cacy. They are intended 
to give guidance to applicants and/or sponsors in planning the overall pharmaceutical product 
development, as well as the non-clinical and clinical tests and studies of a compound intended 
to be used as human or veterinary medicinal products and to facilitate the preparation of 
applications for marketing authorisations by the pharmaceutical industry.
In addition to scientifi c guidelines the EMEA also prepares other public documents, which 
do not follow the procedure for guideline preparation. These are public statements, refl ection 
papers, or “Questions and answers” documents.218
2.2.4 Implementing the Law
2.2.4.1 About Pre-Market Control, Post-Market Control, and Penalties
Laws are void without implementation: turning them into practice and making sure they are 
followed. We are interested in how the rules on safety and effi cacy of foodstuffs and medicines 
are controlled. Two basic alternatives are outlined here:
to examine products before they enter the market (pre-market), ora) 
to examine products already on the market (post-market).b) 
Problems with pre-market authorisations systems are that they are often time consuming, 
expensive, and might thus create anti-competitive barriers to or disincentives for entering 
a particular market. According to Philipson - Sun, a critical question in evaluating policies 
for regulating safety and effi cacy of medicines is the optimal point in the speed-safety trade-
off219. The same question will probably be relevant also in regulating functional foods. A 
lengthier review process including larger clinical trials will reduce the probability that 
unsafe and ineffective products enter the market. Simultaneously, patients or consumers are 
denied access to useful products. The pre-market control agencies must search for the right 
balance. Pre-market control is used particularly where products pose a potentially signifi cant 
risk when unsafe. Cartwright sees medicines as the most “obvious” target for pre-market 
authorisation.220
We also have to remember that market-based mechanisms exist to regulate safety and 
effi cacy: products with poor evidence of safety and effi cacy are less likely to be bought. This 
mechanism is, however, complicated by information asymmetries. In addition to questions 
related to demand and profi tability, product liability (fear of litigation) gives fi rms incentives 
to provide safer products. According to studies by Philipson – Sun, product liability might 
be wasteful with medicines. This is because safety levels mandated by the regulatory bodies 
are higher than the fi rms would choose to provide under product liability alone. Still, product 
218  Procedure for European Union guidelines and related documents within the pharmaceutical legislative 
framework. London, 20 June 2005. EMEA/P/24143/2004. Page 13.
219  Philipson – Sun 2008. 
220  Cartwright 2001, 133. 
–36–
liability imposes costs on companies, which are then included in product prices.221 Product 
liability might thus benefi t the patient or consumer in question, but not consumers in general.
Post-market control of consumer products is always necessary in spite of pre-market 
control. Something will always be missed in pre-market analysis, new information on raw 
materials and products will be discovered over time, and unethical fi rms will always market 
products with false claims. Continuous monitoring is needed to discover products that need to 
be taken off the market. Post-market monitoring is also important for the marketers themselves 
as it gives them information on how to improve their products222. With marketing issues 
particularly, competitors also monitor each other’s actions and report false or misleading 
marketing to the offi cials.
Penalties are here discussed as part of implementation of the rules on product safety and 
effi cacy. Penalties are used for many different reasons and are based on different philosophies such 
as prevention of crimes, retribution of crimes, and incapacitation of the offenders.
2.2.4.2 Pre-Market Controls Used in Europe
2.2.4.2.1 Foods
In the EU, particular pre-market authorisation procedures related to foods are in place for:
 food additives and fl avourings, –
 novel foods, –
 GMO foods, and –
 nutrition and health claims. –
All of the above procedures are Community procedures, meaning that the authorisation received 
applies in the whole EU area. According to a Commission proposal, procedures for additives, 
fl avourings, enzymes, and novel foods will be combined in one Common procedure. Details 
of the procedures will be discussed below in connection to safety and effi cacy requirements 
for each type of food products.
In addition to authorisation systems, pre-market notifi cation systems exist in various 
Member States for food supplements, food fortifi cation, and some of dietetic foods. Other 
foods can be produced and marketed without pre-market approval or notifi cation.
For foods where no pre-market control by the authorities exists, pre-market control is still 
performed by the operators themselves. According to the General Food Regulation223, a food 
business operator is best placed to devise a safe system for supplying food and ensuring that 
the food it supplies is safe. Thus, food business operators have primary legal responsibility 
for ensuring food safety224. Food business operators at all stages of production, processing and 
221  Philipson – Sun 2008. These studies are on the American markets.
222  This viewpoint is emphasized by Badea et al. 1996, page 169, as regards medical devices. 
223  General Food Regulation 178/2002/EC, preamble 30.
224  General Food Regulation 178/2002/EC, preamble 30.
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distribution shall ensure that foods satisfy the requirements of food law which are relevant to 
their activities and shall verify that such requirements are met225.
In Finland, food control performed by the operators themselves is called in-house control. 
A food business operator must recognise food safety risks related to his activities and take 
responsibility for controlling these risks. For this purpose, a company must draft a written plan 
of in-house control, which should list critical control points where hygiene or other hazards 
might appear, including methods to control these hazards. These critical points include the 
handling of food in too warm temperatures or possible contamination. Methods of in-house 
control must be effective, timely, and simple.226
An international trend in food business is the weight of control shifting from authoritative 
control towards in-house control. This is perceived to be effective, as the food industry actor 
knows his own processes best. Industry operators are certifying their systems for quality control, 
which facilitates smoother international trade. Certifi ed products access foreign markets easier 
and faster, which promotes exports and lowers costs. Operator control is thus benefi cial also 
for the operators themselves as it enhances product safety and customer satisfaction.
With fl exible laws leaving room for interpretation, regulatory agencies must be aware of 
not using their discretionary power in a discriminatory manner. This is the case with in-house 
control where the regulatory agencies have rather large discretionary powers and can, case 
by case, resolve whether a producer has fulfi lled his in-house control obligations. In Finland, 
fl exibility is seen as an important tool for judging whether self-control systems are adequate. 
The risk assessment rules allow the authorities to focus on most risky businesses. Intensity of 
offi cial control will depend on risk classes, into which business operators are divided. The risk 
class is economically signifi cant as the cost to the operators of offi cial controls depends on 
how frequently the offi cials must visit the operator. It is, however, not clear whether and how 
an operator can complain about falling into a certain risk class.
2.2.4.2.2 Medicines
Medicines may be authorised in several European countries simultaneously by using one of 
three procedures:
the 1) centralised procedure,
the 2) mutual recognition procedure,
the 3) decentralised procedure.
Medicines may also be authorised in a single Member State by using the national authorisation 
procedure of that country. Here we discuss only the Community procedures, in which the 
EMEA and the circa 40 national medicine agencies that control which medicines access the 
market.
We need to separately discuss new, innovative medicines vs. generic medicines. Developers 
of pharmaceuticals typically apply for patents that grant them exclusivity for a certain time 
225  General Food Regulation 178/2002/EC, Article 17(1).
226 Finnish Food Safety Authority web page. http://www.evira.fi /portal/fi /elintarvikkeet/valvonta_ja_
yritt__j__t/omavalvonta/.
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period. After the expiration of patent protection, there is a new market for so called generic 
medicines, which are inexpensive copies of the originator medicine and have a simpler 
authorisation procedure.
The European Medicines Agency (EMEA) was discussed above regarding its role in 
drafting the legislation on medicines. While the EMEA is involved in drafting ‘hard law’, it 
also creates its own ‘soft law’. In addition to this, the EMEA implements the law, meaning 
that it decides how the law is to be interpreted in single cases. Decisions applicable to private 
persons are subject to review by the European courts.
The EMEA coordinates the evaluation and supervision of medicines in the EU227. The P 
most important task of the EMEA is probably pre-market control of medicines. The EMEA 
“contributes to the protection of public and animal health by ensuring that medicines for human 
and veterinary use are safe, effective and of high quality”228. EMEA is a scientifi c community 
like EFSA. The EMEA and its committees have a network of 3500 European experts229, who 
are involved in scientifi c assessment of the products. Inside the EMEA, there are different 
committees for different types of products: the Committee for Medicinal Products for Human 
Use (CHMP), the Committee on Orphan Medicinal Products (COMP), the Committee on 
Herbal Medicinal Products (HMPC), and the Committee on Paediatric Medicinal Products 
(PDCO).230
The CHPM handles applications for ordinary human medicines. The COMP was established 
in 2001. It reviews designation applications from persons or companies who intend to develop 
medicines for rare diseases, so-called ‘orphan drugs’231. From the end of 2004 onwards a 
new Committee on Herbal Medicinal Products (HMPC) will provide scientifi c opinions 
on traditional herbal medicines.232 This latter Committee is the most interesting from our 
perspective, as we are developing berry-based functional food products. In 2007, a Paediatric 
Committee was established within the EMEA233.
The EMEA began its work in 1995, when the European system for authorising medicinal 
products was introduced. This system provides for a centralised and a mutual recognition 
procedure. The EMEA also has a role in the mutual recognition procedure, but is primarily 
involved in the centralised procedure.
In the centralized (Community) procedure234, a single evaluation of the dossier is carried 
out through the respective EMEA Committee. If the Committee concludes that quality, safety 
227  According to European Union web page, the EMEA also cooperates with international partners bringing EU 
contribution to global harmonisation. http://europa.eu/agencies/community_agencies/emea/index_en.htm.
228  European Union web page: http://europa.eu/agencies/community_agencies/emea/index_en.htm.
229  European Union web page: http://europa.eu/agencies/community_agencies/emea/index_en.htm.
230  The EMEA also controls veterinary medicines. The Committee for Medicinal Products for Veterinary Use 
(CVMP) is not discussed here.
231  Because orphan diseases are rare, there are no commercial incentives to research these diseases and 
develop effective therapy. The question of incentives to develop orphan drugs is related to the important issue 
of access to medicines. Incentives used include fee waiver, market exclusivity, and protocol assistance. Shah 
– Griffi n 2003, 42. 
232  European Union web page: http://europa.eu/agencies/community_agencies/emea/index_en.htm.
233  Regulation 1901/2006/EC of the European Parliament and of the Council of 12 December 2006 on 
medicinal products for paediatric use and amending Regulation 1768/92/EEC, Directive 2001/20/EC, 
Directive 2001/83/EC and Regulation 726/2004/EC. Article 3.1.
234  The centralised procedure was created by Regulation 2309/93/EEC, and its scope widened by Regulation 
726/2004/EC.?
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and effi cacy of the medicinal product are suffi ciently proven, it adopts a positive opinion, 
which is sent to the Commission to be transformed in a single market authorisation valid for 
the whole of the European Union.235 Regulation 726/2004/EC236 sets the standards as regards 
the centralised procedure.
For certain human medicinal products237, the centralised procedure is mandatory. These 
products are:
medicinal products derived from  – biotechnology and other high-technology processes,
medicines intended for the treatment of HIV/AIDS, cancer, diabetes or neurodegenerative  –
diseases238, and
designated orphan medicines intended for the treatment of rare diseases. – 239
For medicinal products that do not fall under any of the above-mentioned categories companies 
can submit an application for a centralised marketing authorisation to the EMEA, provided 
the medicinal product constitutes a signifi cant therapeutic, scientifi c or technical innovation 
or the product is in any other respect in the interest of patient health.240 This fl exibility was 
included by Regulation 726/2004/EC to promote EU-wide medicine research and circulation 
of new innovative products. Guidelines clarify which products fall under the optional scope 
of the Centralised Procedure241.
The term of validity of a Community marketing authorisation is fi ve years. Upon the 
expiry of this term, authorisation must be renewed. Thereafter the marketing authorisation is 
normally of unlimited validity. The EMEA can assess the risk-benefi t balance of all medicinal 
products:
when they are placed on the market, –
at the time of the renewal of the authorisation, and –
at any other time the competent authority deems appropriate – 242.
Generic versions of medicinal products authorised through the Centralised Procedure will 
have the option of applying through either the Centralised or the Decentralised or Mutual 
Recognition Procedures. In practice, the Centralised procedure has been open for generic 
235  European Union web page: http://europa.eu/agencies/community_agencies/emea/index_en.htm.
236  Regulation 726/2004/EC of the European Parliament and of the Council of 31 March 2004
laying down Community procedures for the authorisation and supervision of medicinal products
for human and veterinary use and establishing a European Medicines Agency
237  EMEA controls also veterinary medicinal products in their own centralised authorisation procedure. This 
issue is not addressed here.
238  And with effect from 20 May 2008, new medicines for treatment of auto-immune diseases and other 
immune dysfunctions, and viral diseases. Annex of Regulation 726/2004/EC.
239  EMEA web page: http://www.emea.eu.int/htms/aboutus/emeaoverview.htm. The list of medicinal products 
to be authorized by the Community is in the Annex of Regulation 726/2004/EC.
240  Regulation 726/2004/EC, Article 3(2).
241  Human Medicines - EMEA Pre-Submission Procedural Advice. http://www.emea.europa.eu/htms/human/
presub/q01.htm.
242  Regulation 726/2004/EC, preamble 14.
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applications since 2005 when the 10-year data exclusivity periods granted to originator 
products, authorised through the centralised procedure, began to expire.243
The EMEA also takes the fi nal decision in the mutual recognition procedure. In the 
mutual recognition procedure, a competent authority of one Member State (“the Reference 
Member State”) grants authorisation. The competent authorities of other Member States (“the 
Concerned Member States”) should recognise this authorisation, unless there are serious 
grounds for supposing that the product may present a risk to public health. A scientifi c 
evaluation of a matter is undertaken by the respective EMEA Committee, according to a 
Community (EMEA) standard, if Member States disagree about the quality, safety or the 
effi cacy of a medicinal product. This evaluation by EMEA leads to a decision binding on the 
Member States concerned.244
The mutual recognition procedure has to be used by the applicant whenever an application 
for marketing authorisation for a medicinal product concerns two or more Member States. 
The mutual recognition procedure offers an important fl exibility for those medicinal products 
intended only for a restricted part of the European market.245 One can exclude those countries 
from the procedure where markets are not interesting or where problems and opposition are 
suspected.
Authorisation for generic medicines is normally applied for through the mutual recognition 
procedure. Generic medicinal products are not required to re-perform pre-clinical and clinical 
trials. Even so, the documentation and data required is extensive and specifi c. Generics 
applications typically include chemical-pharmaceutical data and the results of bioequivalence 
studies, which demonstrate the quality and the “essential similarity” of the product. For 
information concerning the safety and effi cacy of the molecule, the regulatory agencies are 
referred to the data that was established in the originator product’s application for authorisation. 
This is only possible once the data exclusivity period has expired on that dossier246.247
The decentralised procedure came into operation in late 2005. It is applicable in cases 
where an authorisation does not yet exist in any of the Member States. Identical dossiers 
will be submitted in all Member States where a marketing authorisation is sought. The 
applicant chooses a Reference Member State, which prepares draft assessment documents, 
which are sent to the Concerned Member States. They will either approve the assessment 
or the application will continue into arbitration procedures. The Decentralised Procedure 
involves concerned Member States at an earlier stage of the evaluation than under the mutual 
recognition procedure. This is to minimise disagreements and to facilitate the application for 
marketing authorisation in as many markets as possible.248
Article 8 of the Directive 83/2001/EC lists the particulars and documents that must 
accompany an application for marketing authorisation. The same requirements apply to both to 
243  European Generic Medicines Association web page http://www.egagenerics.com/gen-authorisation.htm.
244  Directive 83/2001/EC, preamble 12.
245  Reform of EU Pharmaceutical Legislation. Commission DG Enterprise MEMO/01/267. Brussels, 
18 July 2001. 
246  Directive 2001/83/EC, as amended by Directive 2004/27/EC, Article 10.
247  European Generic Medicines Association web page: http://www.egagenerics.com/gen-authorisation.
htm.
248  European Generic Medicines Association web page: http://www.egagenerics.com/gen-authorisation.
htm.
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the centralized procedure, the mutual recognition procedure, and the decentralised procedure249. 
Annex I of the Directive 83/2001/EC contains more precise analytical, pharmacotoxicological 
and clinical standards and protocols in respect of the testing of medicinal products. The ethical 
requirements of clinical trials are covered by Directive 2001/20/EC250.
The following research results must be included in an application:
results of physico-chemical, biological or microbiological tests,–
results of toxicological and pharmacological tests,–
results of clinical trials.– 251
Article 10 of the Directive 83/2001/EC grants procedural relief as regards generic medicinal 
products: By way of derogation from Article 8(3) (i), the applicant shall not be required to 
provide the results of pre-clinical tests and of clinical trials if he can demonstrate that the 
medicinal product is a generic of a reference medicinal product authorised in the primary 
procedure at least eight years ago in a Member State or in the Community.” A generic medicinal 
product authorised according to Article 10 shall not be placed on the market until ten years 
have elapsed from the initial authorisation of the reference product.
The defi nition of ‘generic medicinal product’ is important here. The defi nition of ‘generic’ 
was added because the previous rules requiring ‘essential similarity’ were unclear. It is given 
in Article 10(2) (b):
“‘Generic medicinal product’ shall mean a medicinal product which has the same qualitative 
and quantitative composition in active substances and the same pharmaceutical form as the 
reference medicinal product, and whose bioequivalence with the reference medicinal product 
has been demonstrated by appropriate bioavailability studies. The different salts, esters, 
ethers, isomers, mixtures of isomers, complexes or derivatives of an active substance shall be 
considered to be the same active substance, unless they differ signifi cantly in properties with 
regard to safety and/or effi cacy. In such cases, additional information providing proof of the 
safety and/or effi cacy of the various salts, esters or derivatives of an authorised active substance 
must be supplied by the applicant. The various immediate-release oral pharmaceutical forms 
shall be considered to be one and the same pharmaceutical form. Bioavailability studies need 
not be required of the applicant if he can demonstrate that the generic medicinal product meets 
the relevant criteria as defi ned in the appropriate detailed guidelines.”
The current law leads to a situation where a generic is normally available to consumers 
after 10 years from the initial authorisation. The new EU Member States argued unsuccessfully 
for the period of exclusivity to last only six years. They tried this partly to protect their own 
generic industries, but also to preserve affordable access to medicines.252
The holder of the initial authorisation can have the ten-year exclusivity period extended 
to a maximum of eleven years. This is if, during the fi rst eight years of the ten years, the 
249  Regulation 726/2004/EC, Article 6(1) it is referred to Directive 83/2001/EC: Each application for the 
authorisation of a medicinal product for human use shall specifi cally and completely include the particulars 
and documents as referred to in ... Directive 2001/83/EC. 
250  Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation 
of the laws, regulations and administrative provisions of the Member States relating to the implementation of 
good clinical practice in the conduct of clinical trials on medicinal products for human use.
251  Directive 83/2001/EC, Article 8(3)(i).
252  Walley 2005. 
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marketing authorisation holder obtains an authorisation for one or more new therapeutic 
indications, which, during the scientifi c evaluation prior to their authorisation, are held to 
bring a signifi cant clinical benefi t in comparison with existing therapies.253
The rules on generic medicinal products are a compromise between important issues:
If the product is proven to be safe and effective, it is not economically sound to allocate 1) 
more resources for research. There are also ethical reasons for not conducting repetitive 
tests on humans or animals without over-riding cause254.
Innovative fi rms should not be placed at a disadvantage2) 255. There must be an adequate 
benefi t for completing all the required tests and trials.
The summary of product characteristics must contain all the important information on the 
medicine, for example composition in terms of active substances, therapeutic indications, and 
undesirable effects.256 The generic industry complains that summary of product characteristics 
constitutes one of the major hurdles facing a generic medicine’s application for authorisation. 
The generics applicant must introduce the same application fi le with the same summary of 
product characteristics in all Concerned Member States. However, originator products often 
have different summaries in different countries. It is thus a problem when some Member 
States would like the summaries of the originator and the generic to be the same.
Article 10(a) grants another relief, which is often used by herbal medicines:
“By way of derogation from Article 8(3) (i), ..., the applicant shall not be required to provide the 
results of pre-clinical tests or clinical trials if he can demonstrate that the active substances of the 
medicinal product have been in well-established medicinal use within the Community for at least 
ten years, with recognised effi cacy and an acceptable level of safety ... . In that event, the test and 
trial results shall be replaced by appropriate scientifi c literature.”
The requirements on safety and effi cacy of herbal medicines will be discussed below in detail.
2.2.4.3 Post Market Controls in Europe
Like pre-market control, responsibility for post-market control of foodstuffs and medicines 
lies A) with food business operators themselves and B) with the authorities.
2.2.4.3.1 Foods
As stated above, pre-market control applies to certain foodstuffs, not all. Functional foods 
and other innovations have widened the area of pre-market control of foods. Novel foods and 
health claims are scrutinised in the pre-market arena. However, in spite of all the pre-market 
control activities, illegal foodstuffs commonly appear on the market. Post-market control by 
entrepreneurs, authorities, and by competitors and consumers is still needed.
253  Directive 83/2001/EC, Article 10(1).
254  Directive 83/2001/EC, preamble 10.
255  Directive 83/2001/EC, preamble 9.
256  Directive 83/2001/EC, Article 11.
–43–
According to the General Food Regulation, if a food business operator fi nds out it has 
produced or marketed a product not complying with food safety requirements, it shall withdraw 
the product from the market and inform the authorities thereof257. Even if the food conforms 
to applicable specifi c provisions, it can be found unsafe258. This might be the case if there 
is new scientifi c information on an authorised substance, or if the food contains a foreign 
material such as glass or metal, which is not foreseen in legislation259. If the product may have 
reached the consumers, the operator shall effectively and accurately inform the consumers 
of the reason for its withdrawal and, if necessary, recall from consumers products already 
supplied to them260. The authorities need not be informed if the operator withdraws a food that 
has not yet left the immediate control of the operator261.
The General Food Regulation gives the Member States the general task of post market 
control. EU Member States must enforce food law, and monitor and verify that requirements 
of food law are fulfi lled by food business operators at all stages of production, processing 
and distribution. Consequently, they shall maintain a system of offi cial controls and 
surveillance.262
Regulation 882/2004/EC263 (the Control Regulation) gives more specifi c rules on how the 
Member States must arrange their food control systems. For example, authorities should have 
enough qualifi ed and experienced staff, offi cial controls should be regular and proportionate 
to the risk, procedures should be documented, and laboratories involved should comply with 
international standards264. Adequate fi nancial resources need to be available for organising the 
controls, and for this purpose, Member States may levy fees265.
In Finland, food law implementation is the task of the Food Safety Agency. Municipal 
and regional authorities under the Food Safety Agency handle the inspections of facilities and 
products, whereas advertising is mainly supervised at a national level. Imported products are 
under the responsibility of the Customs. The authorities may, for example, prohibit release 
of goods, order labelling to be changed, or order corrective marketing. All decisions can be 
made more effective with conditional fi nes.266 The decisions of food control authorities can be 
appealed in the appropriate (regional) Administrative Court.
257  General Food Regulation 178/2002/EC, Article 19(1).
258  Guidance on the Implementation of Articles 11, 12, 16, 17, 18, 19 and 20 of Regulation (EC) N° 178/2002 
on General Food Law. Conclusions of the Standing Committee on the Food Chain and Animal Health. 20 
December 2004. Page 18.
259  Guidance on the Implementation of Articles 11, 12, 16, 17, 18, 19 and 20 of Regulation (EC) N° 178/2002 
on General Food Law. Conclusions of the Standing Committee on the Food Chain and Animal Health. 20 
December 2004. Page 20.
260  General Food Regulation 178/2002/EC, Article 19(1).
261  Guidance on the Implementation of Articles 11, 12, 16, 17, 18, 19 and 20 of Regulation (EC) N° 178/2002 
on General Food Law. Conclusions of the Standing Committee on the Food Chain and Animal Health. 20 
December 2004. Page 18. 
262  General Food Regulation 178/2002/EC, Article 17(2).
263  Regulation (EC) No 882/2004 of the European Parliament and of the Council of 29 April 2004 on offi cial 
controls performed to ensure the verifi cation of compliance with feed and food law, animal health and animal 
welfare rules.
264  Preambles 11, 13, 14, and 15 of the Regulation, respectively.
265  Preamble 32 of the Regulation.
266  The Finnish Foodstuffs Act 23/2006, section 7. 
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The EU further controls the enforcement and control activities of Member States. As the 
guardian of the European Community Treaties, the Commission is responsible for ensuring 
that Community legislation on foodstuffs is properly implemented and enforced.267 The 
Commission has a special task unit, the Food and Veterinary Offi ce (FVO), 268 which evaluates 
compliance with EU standards and works to make control systems more effective.
The main task of the FVO is to carry out inspections in Member States and in third countries 
that export foodstuffs to the EU. Each year they develop and publish an inspection program, 
identifying priority areas and countries for inspection.269 The results of each inspection are 
published in an inspection report, together with conclusions and recommendations.270 The FVO 
makes recommendations to the country’s food control authority to deal with shortcomings 
revealed during the inspections.
For example on 10 May 2007, the FVO published their reports on Latvian potatoes, Indian fi shery 
and aquaculture products, Nicaraguan fi shery products, pesticides in Moroccan plant products, 
and UK import controls and border inspection posts. The Member State authority is requested to 
present an action plan to the FVO on how it intends to address the discovered problems. The FVO 
evaluates this plan and monitors its implementation through follow-up.271
In addition to reports on each inspection, the FVO produces summary reports on series of 
inspections to several Member States on the same subject, and their annual report. The FVO also 
has a role in developing EU food law, and where appropriate, the FVO may in their inspection 
reports point out areas where legislation is unclear, not functioning properly, or missing. The 
Commission may take these fi ndings into account when drafting new legislation.272
If the Member States fail to control foodstuffs, the EU Commission can revert to Article 
226 procedures273 of the EC Treaty, and ultimately take the matter to the European Court of 
Justice. According to Inglis, the Internal Market safeguard clauses of the Accession Treaties 
give the Commission a more effective instrument regarding the new Member States that joined 
the EU in 2004. The Commission has wide discretionary powers to take action against new 
Member States and force them to comply with the EU laws.274
2.2.4.3.2 Medicines
It was stated above that pre-market control is the dominant regulatory mechanism for 
medicines. In spite of very detailed pre-market control procedure with specifi ed requirements, 
267  European Commission web page: http://ec.europa.eu/food/fvo/index_en.htm.
268  The FVO is part of the DG SANCO (Directorate-General for Health and Consumer Protection) and it is 
based in Ireland. The number of its staff is 163 in May 2007, half of which are on-the-spot inspectors. http://
ec.europa.eu/food/fvo/how_en.htm.
269  European Commission web page: http://ec.europa.eu/food/fvo/how_en.htm.
270  The food control authority of the country visited may comment on the inspection reports at their draft 
stage. http://ec.europa.eu/food/fvo/how_en.htm.
271  European Commission web page: http://ec.europa.eu/food/fvo/how_en.htm.
272  European Commission web page: http://ec.europa.eu/food/fvo/how_en.htm.
273  “If the Commission considers that a Member State has failed to fulfi l an obligation under this Treaty, it 
shall deliver a reasoned opinion on the matter after giving the State concerned the opportunity to submit its 
observations. If the State concerned does not comply with the opinion within the period laid down by the 
Commission, the latter may bring the matter before the Court of Justice.” Article 226 of the EC Treaty.
274  Inglis 2004, 608.
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post-market control is also needed. Post market control is needed to take illegal medicines 
off the market, and to tackle illegal medicinal product advertising. In addition, post market 
control is needed to take products off the market that have originally been authorised but later 
been uncovered as unsafe or ineffective.
Post-market control is performed by entrepreneurs and by authorities. Member States may 
also impose specifi c requirements on doctors and other health care professionals in respect of 
the reporting of suspected serious or unexpected adverse reactions, in particular where such 
reporting is a condition of the marketing authorisation.275 Consumers are also encouraged to 
report side effects of medicines.
Member States must supervise the observance of good manufacturing, laboratory and 
clinical practices. Member States must inform the relevant EMEA Committee and the 
Commission of all instances where a manufacturer or importer fails to fulfi l its obligations.276 
For medicines authorised in the mutual recognition procedure, decentralised procedure, or 
national procedure, the national authorities may revoke product licenses or order a marketer to 
stop marketing illegal medicinal products . In Finland, the authority responsible for post-market 
control is the National Agency of Medicines. For medicines authorised through the Centralised 
Procedure, the EMEA may introduce amendments to the marketing authorisation, and reassess 
the risk-benefi t balance of the product at any time277. These actions lead to withdrawal from 
the market of any medicinal product presenting a negative risk-benefi t balance under normal 
conditions of use278.
Pharmacovigilance means monitoring and reporting of undesirable effects of medicinal 
products. It falls under the responsibility of operators and authorities. Member States must 
have a pharmacovigilance system in place, and the EMEA is responsible for coordinating 
Member States’ pharmacovigilance activities. The pharmacovigilance system shall be used to 
collect information useful in the surveillance of medicinal products, with particular reference to 
adverse reactions in human beings, and to evaluate such information scientifi cally. Information 
on misuse and abuse of medicinal products shall also be taken into account.279
The marketing authorisation holder shall have permanently and continuously at his disposal 
an appropriately qualifi ed person responsible for pharmacovigilance. This person shall make 
sure that all information about adverse reactions received by the company is gathered and 
accessible at least at one point within the Community. This person shall also prepare reports 
to the authorities and provide the authorities all the necessary information for the evaluation 
of the medicinal product.280
2.2.4.4 Penalties Used in Europe
According to the General Food Regulation, Member States of the EU shall lay down the 
rules on measures and penalties applicable to infringements of food law. The measures and 
275  Medicinal Products Directive 83/2001/EC, Article 101.
276  Regulation 729/2004/EC, preamble 31.
277  Regulation 729/2004/EC, preamble 30.
278  Regulation 729/2004/EC, preamble 29.
279  Medicinal Products Directive 83/2001/EC, Article 102.
280  Medicinal Products Directive 83/2001/EC, Article 103.
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penalties provided for shall be effective, proportionate and dissuasive.281 It is similarly stated in 
medicine law that Member States must determine penalties that are effective, proportionate and 
dissuasive.282 EU Member States consider fi nes and/or imprisonment as penalties for breaking 
the rules on safety and effi cacy/marketing or foodstuffs or medicines. In some Member States, 
the penalties are more stringent than in others. Contrary to the Chinese practice, no precise 
euro amounts of fi nes are stipulated by legislation. Instead, penalties are defi ned case by case 
by courts on various levels. Criminal responsibility will be invoked only in exceptional cases, 
as the authorities will endeavour to settle any breach of the regulations by negotiation or other 
out-of-court procedures. They may for example issue prohibitions or information orders as 
discussed above.
In Finland, foodstuff misdemeanour is defi ned in the Food Act, section 79. Foodstuff 
misdemeanours are minor acts contrary to the Food Act, which do not directly cause danger 
to people’s health. This means for example omission of a notifi cation duty, or failure to draft 
a written plan for in-house control. Selling foodstuffs that do not comply with food law 
requirements, and are possibly hazardous to health, constitutes health offence according to 
the Finnish Criminal Code, chapter 44, section 1. a medicine offence is defi ned in chapter 
44, section 5 of the Finnish Criminal Code. Possible Finnish punishments for breaking the 
European or Finnish medicine laws or decisions based on these laws are a fi ne and a maximum 
of one-year imprisonment.
Poisoning foodstuffs or selling poisonous foodstuffs and thus causing a public health 
hazard constitutes endangerment of health, chapter 34, section 4, or gross endangerment of 
health, chapter 34, section 5. The punishment for a health offense is a fi ne or a maximum of 
six months’ imprisonment, for endangering health, four months to four years’ imprisonment, 
and for gross endangerment of health, from two to ten years’ imprisonment. Giving false 
or misleading marketing information constitutes a marketing offense according to chapter 
30, section 1. The punishment for a marketing offense is a fi ne or a maximum of one-year 
imprisonment. The applicable criminal penalties when violating marketing regulations are 
usually of limited size, a few thousand euros.
An example of a functional food -related case is Market Court, MT 1993:023, 9.11.1993, 
Ombudsman vs. Valio Oy where the Finnish company Valio was prohibited from using the 
claim that milk cures/relieves/prevents osteoporosis. There have also been a few cases where 
health claims have been used in an inappropriate way in the marketing of dietary supplements, 
for example MT:1993:008: PSK-Javidos Ab. vs. Vitabalans, which related “high potency 
garlic”. There was also a fl agrant case in 1998 where the Food Agency prohibited the selling 
and importing of Noni Juice. The seller claimed that the product cures cancer, HIV, diabetes, 
rheumatism etc.
In addition to criminal cases, civil cases for damages may be taken to courts on various 
levels. Damage might be caused to a consumer by unhealthy food or misleading food 
advertising. There are some differences in EU Member States concerning burden of proof. 
According to general legal principles applicable in most Member States, the burden of proof 
lies with the plaintiff. In practice, this creates fi nancial problems to consumer associations and 
also to authorities wishing to claim against a manufacturer. It requires enormous resources to 
281  General Food Regulation 178/2002/EC, Article 17(2).
282  Regulation 726/2004/EC, Article 84(1). Directive 83/2001/EC, Article 99. 
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prove scientifi c facts about a product.283. However, where a pre-market authorisation procedure 
exists, the burden of proof is always on the producer. This applies to safety of novel foods and 
substantiation of marketing claims.
The use of unsafe or ineffective medicines may often lead to personal and fi nancial 
damage. Medicines are always somewhat unsafe, in a sense that they have side effects. This 
is one of the most important differences compared to foodstuffs. In most European countries 
including Finland, pharmaceutical injuries insurance covers certain severe284 unexpected 
adverse effects sustained by users of pharmaceuticals. The insurance covers pharmaceuticals 
manufactured, imported or marketed by companies who are members of The Finnish 
Cooperative for the Indemnifi cation of Medicine-Related Injuries. The insurance is voluntary 
for the pharmaceutical companies. The insurer is the Finnish Pharmaceutical Insurance Pool, 
which is made up of three insurance companies. The Finnish Pharmaceutical Insurance Pool 
handles the claims and pays accepted claims.
The insurance only covers personal damage, not fi nancial losses.285 In addition, the insurance 
leaves important areas outside its scope. It does not cover: an injury resulting from medically 
necessary risk taking, injuries where the adverse effect of the pharmaceutical is reasonably 
tolerable, insignifi cant injuries, or failure of the drug to have the intended effect (ineffi cacy).286 
Injuries resulting from use of illegally acquired medicines or misuse of medicines are not 
covered by the insurance, neither are injuries caused by herbal and homeopathic medicines. 
These restrictions might lead to the situation where only serious injuries caused by medicines 
taken for minor diseases are covered by the insurance. For damages other than those covered 
by the insurance scheme, a lawsuit against the pharmaceutical company is needed.
If there is nothing wrong with the medicine itself, but it has been incorrectly prescribed 
or administered by a doctor or pharmacist, the injury is not covered by the pharmaceutical 
injuries insurance. In that case, the injury may be compensable under the Patient Injuries Act. 
The patient injury insurance is mandatory for hospitals etc.
2.2.5 European Standards
Formal standardisation in Europe has a three-level structure, which includes the national 
standards bodies (NSB’s), the three European Standards Organisations (ESO’s), and the 
international organisations discussed above. The ESO’s have been formally recognised by the 
EU by Directive 98/34/EC. These are: CEN287 for the majority of sectors, CENELEC288 for the 
electro-technical area, and ETSI289 in telecommunications. In addition, there are a multitude of 
283  Hill & Knowlton 2000, 18.
284  To qualify for compensation under pharmaceutical injuries insurance, use of pharmaceutical must result 
in a loss of functional ability lasting at least 14 days without interruption or in a permanent physical injury or 
illness or death. Finnish pharmaceutical insurance pool website www.lvp.fi .
285  Finnish pharmaceutical insurance pool website www.lvp.fi .
286  Finnish pharmaceutical insurance pool website www.lvp.fi .
287  Comité Européen de Normalisation. European Committee for Standardisation.
288  Comité Européen de Normalisation Electrotechnique. European Committee for Electrotechnical 
Standardisation.
289  European Telecommunications Standards Institute.
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informal standards bodies290 and of CEN standards for foods, mainly for methods of sampling 
and analysis291.
According to the Commission, standards are an integral part of EU policies. Standards 
are expected to increase competitiveness of enterprises, and to remove barriers to trade 
at international level. They are also seen as part of “better regulation”. According to the 
Commission, European standardisation has proven to be a successful tool for the completion of 
the Single Market for goods.292 Standards are seen as playing a supportive role in legislative acts 
and projects related to goods, services, environment, and consumer protection293. According to 
Schepel, the Commission is holding on to the fi ction that compliance with European standards 
is strictly voluntary. Instead of redefi ning law, hard law is trying to defend its monopoly as the 
only source of mandatory commands.294
The Commission has presented the “New Approach” as a specifi c model of legislation 
where public interest and the interest of private business could be merged. It allows for 
“more fl exible and less stringent forms of legislation” in areas where there is a great need 
for detail. As legislation needs to be simplifi ed, the extension of use of standards beyond the 
goals of the Single Market is seen as “highly desirable”.295 The Commission acknowledges 
that standardisation is “independent and market driven”, but strongly encourages standards 
organisations to further develop standardisation procedures.296 In 2006, the EU created a 
legal basis for the fi nancing of European standardisation297. The Commission saw this as “a 
contribution from the EU side to add value to standardisation in the context of EU policies”298. 
The EU is enthusiastically supporting standards development, and willing to replace law with 
standards, as long as standards are not called ‘law’.
In a society, people share attitudes towards risk and technology, refl ecting a widely 
respected professional ‘common sense’. These shared attitudes make standards, which link 
socially accepted behaviour with legally institutionalised requirements. According to Schepel, 
European standardisation needs to focus on mechanisms for social construction of common 
sense, because Europeanisation uproots standards from their (national) social beddings.299 
This general question of central vs. local legislation is ultimately about whether a member can 
trust the coalition, union, central government, or global actor, etc. to promote the interests of 
all its members.
290  Commission Communication on Standards 2008, 3.
291  CEN webpage at: http://www.cen.eu/cenorm/sectors/sectors/food/index.asp.
292  Commission Communication on Standards 2004, 2.
293  Commission Communication on Standards 2004, 3.
294  Schepel 2005, 406.
295  Commission Communication on Standards 2004, 4.
296  Commission Communication on Standards 2004, 3.
297  Decision No 1673/2006/EC of the European Parliament and of the Council of 24 October 2006 on the 
fi nancing of European standardisation.
298  Commission Communication on Standards 2004, 3.
299  Schepel 2005, 144.
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2.2.6 Self-Regulation
Since the fi rst half of the 1990’s, the EU Commission has been active in establishing a 
completely new framework of food law. It can be argued that food legislation is not only 
getting increasingly complicated, but it is also becoming stricter as more areas are covered. 
The European food industry has attempted to hold back the tide of legislation300, and instead 
favours self-regulation.
The most important actor speaking for self-regulation is the CIAA, Confederation of the 
Food and Drink Industries in the EU.301 CIAA calls for simpler, clearer legislation and shorter, 
less burdensome legal procedures. According to the CIAA, the food and drink industry is one 
of the most regulated sectors in Europe. They claim “better regulation, including industry 
self-regulation, can deliver benefi ts to European consumers faster and help to promote higher 
growth and employment”. They are working for “a better functioning single market, fewer 
administrative burdens, and a more supportive business environment”. According to the 
CIAA, this is needed particularly to help small and medium-sized companies.302
The CIAA considers that “many of the problems faced by the food and drink industry with 
existing legislation should be solved through a better, simpler, more proportionate and a more 
competitive EU regulatory framework”. They recommend the following principles on food law:
Legislation must be  – clear to prevent diverging interpretation,
Legal requirements must be practically  – achievable and enforceable,
Legislation must be based on  – science,
Procedures must be  – clear and predictable, including precise timetables,
Suffi cient  – lead-in times, where possible, are needed to minimize implementation costs.303
To support their argument that self-regulation is a viable alternative, the CIAA has indeed 
drafted numerous documents that can be classifi ed as soft law. The CIAA has for example 
created a voluntary nutrition labelling scheme. They claim that revision of the nutrition 
labelling Directive should be started by considering what self-regulatory initiatives have 
already delivered304. This means some legal requirements could be deleted as unnecessary, 
and the remaining legal requirements should be simplifi ed.305
The food industry’s concerns and suggestions need to be taken seriously by the Commission. 
In particular, the regulatory procedures should be transparent and not waste the efforts of all 
the parties involved. However, the food industry might not actually want to understand all the 
substantial laws as some of the complicated and inconveniently strict laws are burdensome. 
By demanding ‘simple’, we suspect that they simultaneously wish for ‘less restrictive’.
300  ElAmin 2006b. 
301  CIAA membership is made up of 25 National Federations, including 3 observers, 30 EU sector associations 
representing different food industry sectors, and 20 major food and drink companies.
302  http://www.ciaa.be/pages_en/homepage.asp.
303  Review of CIAA Priorities and Objectives for Better Regulation in light of the Commission proposals to 
simplify EU legislation. CPT/003/07E-Final Brussels, 28 February 2007. Page 5.
304  Review of CIAA Priorities and Objectives for Better Regulation in light of the Commission proposals to 
simplify EU legislation. CPT/003/07E-Final Brussels, 28 February 2007. Pages 2-3.
305  Ibid, page 3.
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Also national self-regulation on foods exists. For example in Finland, the food industry and 
the retail trade drafted (in 2003) their recommendations on good practices and recommended 
temperatures and sales times for fresh meat and fi sh. The recommendations included that 
operators agreed to use lower storage temperatures than required by the law. This was considered 
by the Ministry of Trade and Industry to be “a very good project”.306 Self-regulation can work 
well if operators are committed into achieving a common goal like unhealthy competition.
ElAmin claims that the industry should take self-regulation much more seriously if they 
want the legislators to step aside. The industry organizations are giving vague promises 
that they will follow a common line over issues such as advertising, obesity, health claims 
and nutritional content. If they really believe their own codes could be used instead of EU 
legislation, they should take up the challenge and actually draft these codes.307 Irresponsible 
companies cannot be given the responsibility of Europeans’ health.
General problems with self-regulation relate to unclear responsibilities, freeriders, 
implementation and control, and restricting competition308. Interests of dominant companies 
might overweigh public and societal interests309. Future business regulation might increasingly 
be in the form of co-regulation, combining the benefi ts of law and self-regulation310. According 
to Parker and Braithwaite, it is necessary to understand how law connects with other sources 
of normative ordering311. Regulation is pluralised and decentralised, and the new role of states 
is to steer public-private partnerships312.
2.3 Chinese Law on Foodstuffs and Medicines
2.3.1 Rule of Law in China
When discussing Chinese law, concepts such as state, law, or court must not be presumed to 
mean the same as in due to the fact that history and contemporary understanding of law in the 
Chinese society is different from ours. An outright hostility towards law in a Western sense is 
inherent in Chinese history and culture. According to Confucius, what is needed is a situation 
where there are no legal cases313. China started to create a legal system and law in a Western 
sense at the end of the 1970’s, in conjunction with its new open-door policy. In China, law 
was traditionally seen as an instrument of governance for the rulers, and ‘rule of man’ was 
applied instead of ‘rule of law’314. There was law, but it was occupied with implementing the 
Emperor’s orders, and did not relate to agreements or disagreements between citizens, or 
rights of citizens. There was in fact no such thing as a citizen: people were subordinates.
China has created large volumes of legislation in the past 30 years. However, laws are void 
without implementation. After writing the necessary positive laws, China has to create legal 
306  Ministry of Trade and Industry. http://www.ktm.fi /index.phtml?s=1031.
307  ElAmin, Ahmed 2006c. 
308  Tala 2009, 330-331.
309  Tala 2009, 330.
310  See Tala 2009, 331-332 on benefi ts and problems of co-regulation.
311  Parker – Braithwaite 2005, 137.
312  Parker – Braithwaite 2005, 129.
313  Jones 2003, 7. Here Jones cites Bodde – Morris 1967.
314  Kobayashi 2008, 3.
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institutions to make law work in practice. The legal reform is closely connected to the economic 
transition. Government agencies are no longer primarily responsible for managing economic 
entities or planning their economic transactions. In the new economic order, it is enterprises and 
individuals and their relationships that are important. Private actors must believe that they will 
be held to their legal obligations, and that their legal rights will be protected. As the government 
can no longer command market actors to make economic decisions, it needs the ability to use 
administrative sanctions, and the ability to resort to courts.315 Instead of command, the market now 
needs to be guided through law.
This leads us to the concept “rule of law” and the discussion on modern Chinese law that 
revolves around this concept. Several scholars are discussing the development, current level, and 
future direction of rule of law in China316. Building the rule of law has been on the Party agenda 
since the mid-1990s, and the Constitution was amended in 1999 to include the concept317. It states 
in the Constitution that all agencies, administrators and enterprises must abide by law, all acts in 
violation of the law must be investigated, and that no one is above the law318. These are rather 
familiar concepts to Europeans, but novel to the Chinese.
There are narrow and wide concepts of rule of law. The narrow concept is rather formal 
and requires the very basic parts of the legal system to exist, meaning signifi cant restraints 
on the use of powers, supremacy of law, and equality of citizens before the law. In a society 
governed by rule of law, laws need to be general, public, prospective, clear, consistent, and 
capable of being followed, stable, and enforced. Some insist the rule of law must include 
liberal democracy and human rights, and wider theories add political, social, and economic 
concepts. Some writers are of the view that China fulfi ls the narrow criteria. Some argue 
that China is a country of rule by law at best: law is used by the non-democratic state as an 
instrument for social control.319 Peerenboom sees China as following the ‘East Asian model’, 
where economic growth, legal reforms, democratization, and constitutionalism follow each 
other, in this order320.
According to critics, China is far from achieving the rule of law. The Congress needs to 
be strengthened as legislator, the Constitution should be enforced, and the judiciary should be 
independent. Corruption is common among public offi cials: personal favours, bribery, and the 
taking of public monies happen at all levels of government. The legal profession has also been 
inadequate and China is now putting effort into training competent judges and attorneys.321 The 
315  Lichtenstein 2003, 287.
316  See the Rule of Law in China program at the Foundation for Law, Justice and Society, a think-tank 
affi liated with Oxford University’s Centre for Socio-Legal Studies. The scholars in this program have written 
several articles in English on rule of law in China, both generally and as regards certain legal areas such as 
employment or intellectual property. See Foundation for Law, Justice and Society at http://www.fl js.org. See 
rule of law in China publications at http://www.fl js.org/section.aspx?id=607.
317  Wikipedia: http://en.wikipedia.org/wiki/Chinese_law.
318  Article 5 of the Constitution.
319  Qingjian 2002, 301, uses the words “rule through law”. See also Wikipedia: http://en.wikipedia.org/
wiki/Chinese_law. Wikipedia article sites Randall Peerenboom: China’s Long March Toward Rule of Law, 
Cambridge University Press 2002, and Albert Huhg-yee Chen: An Introduction to the Legal System of the 
People’s Republic of China, 1992.
320  Peerenboom 2008, 6.
321  Wikipedia: http://en.wikipedia.org/wiki/Chinese_law. Article sites Randall Peerenboom: China’s Long 
March Toward Rule of Law, Cambridge University Press 2002, and Albert Huhg-yee Chen: An Introduction 
to the Legal System of the People’s Republic of China, 1992.
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legal reform revolves around taking some of the powers away from administrators, who up until 
now have been the legislators, the executors, and the judges.
According to Peerenboom, China’s performance on rule of law might be best judged in 
relation to other countries in its income class322, and China seems to be doing reasonably well 
by that measure323. In addition, there is also critique on the whole discussion on the rule of 
law in China. According to Jerome Cohen, the problem with Westerners is that we never go 
beyond that primitive stage we call the rule of law, and China has always known that law is 
not enough to govern a society,.324 According to Qingjiang, guanxi (social connections) and 
mianzi (face) do still affect implementation of laws in China325.
We are of the view that the mere existence of laws, even laws of technically high quality, is 
not a goal in itself and guarantees nothing more than clarity on paper. The content, substance 
of law, is what matters along with the need to address the requirements of companies and 
individuals. It is therefore essential that stakeholder voices are heard before making laws, and 
essential that laws be implemented in practice. Disputes need to be fairly resolved, whether by 
courts or by other means such as mediation326.
2.3.2 Hard law and Administrative Soft Law
In China, there is a similar situation compared to the EU: the issue of legislative competence of 
central government versus the competence of provinces and cities. In Europe, it is a question 
of EU laws vs. Member State laws, and in China it is a question of national laws vs. local laws. 
Also the question of hard law vs. soft law is relevant in China. Various administrative bodies 
issue regulations and guidelines on food and medicine issues.
In China, the Constitution is not an important part of law. and according to Clarke, it does 
not represent anything, and is perhaps the least important document in the entire legal system327. 
In reality, the Chinese government does not work in the way described in the Constitution.
In theory, the Chinese central government is strong with powerful instruments at its 
disposal. All the powers of localities stem from the centre328. The central government decides 
who controls the provinces: It appoints the government top offi cials and the party top offi cials 
in the provinces. The central government also controls key economic resources like scarce 
raw materials, government investments, foreign loans and budgetary subsidies. Unity of the 
nation and thus strong central government is also culturally favoured: the Han majority of 
people want to see China as one.329 In practice, Chinese localities have been given powers and 
resources to administer the state economy in those localities. Driven by local interests, local 
322  Wealth is highly correlated with good governance indicators, human rights, and other indicators of human 
well-being.
323  Peerenboom 2008 a, 5.
324  Cohen according to Jones 2003.
325  Guanxi can work both ways: it can either assist in enhancing law enforcement, or be used to avoid 
compliance of law. Similarly, law enforcement may also be related to the psychological assessment of saving 
face or losing face of the persons against whom law is enforced. Qingjiang 2002, 301.
326  Lichtenstein 2003, 288.
327  Clarke 2003, 103.
328  Qingjiang 2002, 305.
329  Ren 2000, 102-103.
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leaders have gradually become less obedient to the centre, and centrally promulgated laws are 
unevenly implemented at local level.330
Offi cially, the highest governing body in China is the parliament, the National People’s Congress. 
The amount of representatives has fl uctuated between 2000 and 3500 members. Representatives 
are chosen by indirect election. Local congresses elect the members of provincial congresses, and 
provincial congresses elect the members of the national congress. The authorities of the Parliament 
are extensive. The Parliament enacts the national laws and appoints the prime minister, other 
ministers, and the president. The NPC also decides on the state economic plans and budgets.331 The 
role of the parliament has increased in the recent years.
The NPC chooses among itself a Standing Committee that convenes the parliament, issues 
regulations, interprets laws, and oversees government activities. The chairman of the Standing 
Committee acts as the chairman of the parliament.332 The National Congress, which is led by 
the prime minister, appoints the members of the State Council, which is the highest executive 
organ in China, as well as the highest organ of State administration333.The position of the Party 
has normally been decisive in choosing the members of the State Council334.
According to the Constitution, the state and the communist party work together to rule 
the country. Since the birth of the People’s Republic in 1949, the Chinese communist party 
(Zhongguo gongchandang) has been in a central role in state affairs.335 Offi cially and formally, 
there are also other parties and citizen organisations in China, but their infl uence is not 
signifi cant.336 The real locus of central political power in China lies in the leadership of the 
Communist Party, which exercises power largely through the State Council. The party has 
inherent authority to make rules about anything. For a number of reasons, it now chooses to 
make certain rules through the National People’s Congress.337
The Party has a leading role in central and local government, the army, and economy. 
Party agencies make decisions and issue them to state agencies for implementation. Party 
control maintains a broad reach: the division of power between the Party and the State is 
not defi nitive. In principal, the Party is to effi ciently maintain large issues, but in practice, it 
also involves itself in smaller issues. The same people work for the state and the party: party 
representatives have leading positions also in state government.338
Below the central level, there are both sectorally defi ned ministries and geographically 
defi ned provincial authorities.339 Geographically, China is divided into provinces340, 
330  Qingjiang 2002, 305.
331  Huotari – Seppälä 1993, 128-129.
332  Huotari – Seppälä 1993, 129.
333  Offi cial web page of the Central People’s Government of the People’s Republic of China. http://english.
gov.cn/2008-03/16/content_921792.htm.
334  Huotari – Seppälä 1993, 130.
335  Preamble of the Constitution, see also Amendment 2 of 1993 and Amendment 3 of 1999. Huotari – 
Seppälä, 124.
336  Huotari – Seppälä 1993, 123.
337  Clarke 2003, 111.
338  Huotari – Seppälä 1993, 124.
339  Weixin 1992, 48-49.
340  Hebei, Shanxi, Liaoning, Jilin, Heilongjiang, Jiangsu, Zhejiang, Anhui, Fujian, Jiangxi, Shandong, Henan, 
Hubei, Hunan, Guangdong, Hainan, Sichuan, Guizhou, Yunnan, Shaanxi, Gansu, Qinghai, and Taiwan.
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autonomous regions341, special administrative regions342, and municipalities directly under the 
central government343. Provinces and autonomous regions are further divided into autonomous 
prefectures, counties, autonomous counties and cities, and counties are divided into towns 
and townships.344 Local and provincial legislation is given by local and provincial congresses. 
According to the Constitution and the 2000 Act of Legislation, the NPC Standing Committee 
oversees local regulations, and can annul any local regulations contravening the Constitution 
or national laws345. In practice, however, this responsibility is far from being realised, and 
a large number of local regulations contravene national laws346. According to Weixin, the 
Chinese economy is not actually integrated, even though China is a centrally planned economy 
with one central government and one currency in circulation. There are barriers to the mobility 
of goods and there is a lack of economic cooperation and specialisation within China. The 
administrative frontiers are also economic frontiers.347
The sectoral planning hierarchy also fragments the market. All sectors within the economy 
are organised vertically and headed by ministries under the State Council. Ministries include the 
Ministry of Health, the Ministry of Agriculture, and the Ministry of Science and Technology348. 
The Ministry of Health is the most relevant in regulating foodstuffs and medicines. Also the 
State Food and Drug Administration (SFDA)349, founded in 2003, has its role in drafting 
various guidelines related to safety and effi cacy of foodstuffs and medicines350. According to 
Bian, the SFDA is lacking in authority because it has to co-ordinate among several ministries 
that have a higher administrative rank351. The SFDA is at the moment directly under the State 
Council352, but will be transferred under the Ministry of Health in the upcoming government 
restructure, see below.
Regulations that can be enacted by ministries are called guizhang. These regulations tend 
not to be results of comprehensive planning or strategy. They are rather reactions to problems 
arisen. Within the areas of food and medicines, several different government agencies have 
competence to regulate and supervise the entrepreneurs. When giving guizhang regulations, 
341  Inner Mongolia Autonomous Region, Guangxi Zhuang Autonomous Region, Tibet Autonomous Region, 
Ningxia Hui Autonomous Region, and Xinjiang Uygur Autonomous Region .
342  Hong Kong Special Administrative Region and Macao Special Administrative Region.
343  Beijing, Tianjin, Shanghai, and Chongqing.
344  Weixin 1992, 47.
345  Jian 2003, 506-507.
346  Jian 2003, 508.
347  Weixin 1992, 47.
348  There are altogether 28 Ministries and Commissions under the State Council. In addition, there are at 
least 36 other organisations and institutions directly under the State Council. These include the Customs, the 
Bureau of Statistics, and the Intellectual Property Offi ce. Government’s offi cial web portal: http://english.
gov.cn/links.htm#1. See plans on restructuring the State Council at GOV.cn: Tuesday, 11 March, 2008. http://
english.gov.cn/2008-03/11/content_916738.htm.
349  The State Food and Drug Administration was founded according to the restructuring plan of the State 
Council, approved by the First Plenary Session of the 10th National People’s Congress, and “the State 
Council Notice on Government Structuring”, No.8.2003. The new authority replaced the former State Drug 
Administration. http://www.sfda.gov.cn/cmsweb/webportal/W43879538/index.html.
350  The SFDA has control over foods, medicines, and cosmetics. Its domain is thus similar to that of the FDA 
in the United States. In Europe, food and medicine administration is divided under two separate agencies at 
the EU level and also in most EU Member States.
351  Bian 2004.
352  SFDA web page at: http://www.sfda.gov.cn/cmsweb/webportal/W43879538/index.html.
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administrative organs do not necessarily check whether their guizhang is in agreement with 
laws or former regulations by the same administrative organ or other administrative organs. 
Thus, confl ict among guizhang provisions is not rare.353 This is naturally confusing both to 
regulation targets and those that are supposed to supervise them.
Legal and economic integration of China cannot be realised at once due to the participants 
being separated both geographically and by sectors. The Chinese have created Economic Zones 
as a type of regional economic experiment.354 The establishment of these zones is to encourage 
economic cooperation by promoting the division of labour and competition like in the EU.355 
These are the fi rst steps towards integration of the Chinese economy. According to Weixin, 
the successful realisation of regional integration in China requires institutional arrangements 
similar to those of the EU. Interests of the whole economy and the individual economies need 
to be coordinated. The decision-making procedures are important in this respect.356
According to Article 90 of the Chinese Constitution, “the ministries and commissions issue 
orders, directives and regulations within the jurisdiction of their respective departments and in 
accordance with the statutes and the administrative rules and regulations, decisions and orders 
issued by the State Council”. The Ministry of Health has the competence to legislate on the 
area of foodstuffs and medicines.
The SFDA, on the other hand, does not have hard-law legislative power. However, the SFDA’s 
Department of Policy and Regulations, Division of Regulations, has the following tasks:
“studying and drafting legislation program and annual plan for food and drug  –
administration;
participating in, and/or organising the drafting of Medicine Administration Laws and  –
regulations;
organising relevant authorities to draft laws and regulations for safety management of  –
food, health food and cosmetics
organising and carrying out review, coordination and issue of administrative  –
provisions;
interpretation of the related laws and regulations in accordance with law”. – 357
This means the SFDA is at the moment involved in both important stages of food and medicine 
law: preparing and implementing the laws. The SFDA plans and drafts legislation promulgated 
by the Ministries under the State Council. The Authority also provides its own administrative 
regulations, and interprets laws and regulations.
The division of work between the Ministry of Health and the SFDA will be restructured in the 
future. According to information on the central government’s website in March 2008, China is 
upgrading the Ministry of Health to better monitor the safety of foodstuffs and medicines. The 
SFDA will be transferred under the Ministry of Health. The “new MOH” will be authorised to 
coordinate food safety management, organise investigations into serious food safety incidents, 
and give “due punishment”. The MOH is responsible for the constitution of the national food 
353  Bian 2004. 
354  Weixin 1992, 88.
355  Weixin 1992, 91.
356  Weixin 1992, 86.
357  SFDA web page. http://www.sfda.gov.cn/cmsweb/webportal/W44993659/index.html.
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and medicine laws. The SFDA, after the reform, is responsible for food sanitation permits, 
monitoring food businesses, and monitoring the safety of medicines including their research, 
production, circulation, and use. 358 This means that in the future, the MOH will be giving all 
the laws on foodstuffs and medicines, not the SFDA. The task of the SFDA will be to more 
effi ciently monitor the businesses.
Above, we have discussed the law-making and administrative rule-making procedures. 
Finally, we have to note that courts in China often act like legislative bodies in that they make 
law by issuing interpretations of laws that are binding on the courts. Every year the Supreme 
People’s Court (SPC) issues interpretations, regulations, notices, replies, opinions, and policy 
statements. Most are binding on the courts; others are highly persuasive and likely to be 
followed. The ‘interpretations’ range from general statements to specifi c replies to inquiries 
from lower courts359, and fi ll in the void left by non-existent or vague laws. The main problem 
with this distribution of work between the NPC and the SPC is the SPC not adhering to recent 
process reforms to increase transparency and public participation. The SPC has started to 
respond to this criticism yet the questions of legislative hierarchy still remain.360
2.3.3 Structure of Chinese Food and Medicine Law
2.3.3.1 Foodstuffs
In China, food law is given by the NPC, the State Council, or authorities under the State 
Council. The Food Hygiene Law of 1995 was the fundamental food law in China. Since 
June 2009, the essential piece of food law has been the Food Safety Law. The Standing 
Committee of the National People’s Congress passed the new Food Safety Law on February 
28th 2009, and it came into effect at the beginning of June 2009. Based on the new law and 
Implementing Measures361, Chinese food law and particularly its implementation and control 
will be developed. The new law uses Western terminology in promoting safety “from farm to 
table”. Our focus in this study is primarily on the old law, as the existing law is presently more 
plan than practice.
The Food Hygiene Law of 1995 was basically a modern food law similar to the Codex 
Alimentarius model. According to the Food Hygiene Law, the administrative department of 
public health under the State Council shall formulate or approve and promulgate the national 
hygiene standards, hygiene control regulations and inspection procedures for food, food 
additives, the containers, packaging, utensils and equipment used for food, the detergents 
and disinfectants used for washing food or utensils and equipment used for food, and the 
tolerances for contaminants and radioactive substances in food.362
Other national food laws were based on the Food Hygiene Law. Examples of Chinese food 
regulations based on the former Food Hygiene Law and current Food Safety Law are:
358  GOV.cn Tuesday, March 11, 2008 . http://english.gov.cn/2008-03/11/content_916856.htm.
359  The latter means the Supreme People’s Court acts similarly to the European Court of Justice, which can 
decide how law is to be interpreted in a case that is held by a Member State court.
360  Peerenboom 2008 c, 1.
361  First Implementing Measures were published in April 2009.
362  Food Hygiene Law, Article 14.
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the Novel Food Regulation –
the GMO Food Regulation –
the Health Food Regulation –
the Food Additive Regulation – 363.
For health foods364, there is a national Health Food Regulation by the Ministry of Health, which 
is the basic law on health foods. In addition, there are over 20 other rules or notifi cations by 
the Ministry of Health or the State Food and Drug Administration. These include the “Interim 
Regulations for the Registration of Health Foods”, “Provisions for Health Food Labelling”, 
“General Hygiene Requirements for Health Foods” and the “Notifi cation on Preparing for 
Censoring Health Food Advertisements”. 365 For clarity reasons, combining these in one piece 
of law might be considered in the future.
If the State has not formulated standards for a certain food, the people’s governments of 
the provinces, autonomous regions, or municipalities directly under the Central Government 
may establish local standards for that food and report them to the administrative department 
of public health under the State Council and the competent standardization administration 
department under the State Council for the record.366 The 2009 Food Safety Law upholds 
existing principles of legislative competence. 367. Local standards are plentiful. In Hong Kong, 
for example, there is an abundance of local food law. A general food and medicine code is 
complemented by legislation on specifi c matters368.
According to Kan and Zhang, factors considered in formulating food standards are:
feasibility of standards –  on the basis of research,
current and future  – risk evaluation,
international  – food law codes and standards of other countries, and
industrial –  standards.369
When drafting new food regulations, central and regional government, businesses, associations, 
NGOs, and Internet are consulted370. With reference to better food legislation, Kan and Zhang 
urge that law shall be based on science, and regulators must look at the food chain from 
farm to table. Food law must emphasise the responsibility of food producers and sellers to 
guarantee food safety: food business operators must have effective in-house control, using 
HACCP371 based systems. The businesses are responsible for taking dangerous products off the 
363  Kan and Zhang (2002) use the term “management measures” of these pieces of law. 
364  Health foods are foods which have a specifi c health function, are suitable for a certain group of people, 
and which are not for therapeutic purposes. Health foods will be discussed below as regards requirements on 
their safety and effi cacy.
365  List of Chinese food, drug and cosmetic laws at http://www.chinafdc-law.com/laws/list_1-27_5-118_1.html.
366 Food Hygiene Law, Article 15.
367  According to Article 24 of the new law, local food laws can be developed in the absence of national laws.
368  Hong Kong government web page. http://www.fehd.gov.hk/safefood/foodlaw_list.html#part5.
369  Kan – Zhang 2002.
370  Kan – Zhang 2002.
371  Hazard Analysis and Critical Control Points.
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market. The government should assist by reducing over-detailed regulation and emphasizing 
coordination.372
The Chinese views on how to develop food law sound similar to the European approach, 
where food law is legally based on scientifi c risk analysis, global harmonization is considered 
important from free trade perspectives, and industry is always consulted when drafting new 
legislation. In China, there is not a particular authority like EFSA responsible for scientifi c risk 
assessment as regards food law. Instead, the Ministry of Health and the SFDA, which will in 
the near future be transferred under the Ministry, perform risk assessment.
The new Food Safety Law covers food safety evaluation, monitoring, recall and information 
release. In addition to passing a new Food Safety Law, the government promised to stipulate 
or update more than 7,700 national standards for the safety of foodstuffs, medicines, and 
other consumer goods in 2008. It is not possible to analyse the effect of this vast legislative 
work here. Thousands of standards mean thousands of standardised details. The government 
states that after the current reforms, all the requirements and testing methods should “comply 
with international standards”. Also a more general “National Food Safety Standard” is on the 
way. The national authorities shall prepare it together, and review it through a Committee373. 
Legislators have promised to include the general public in the process of law formulation, and 
to publicly post all the drafts.374
2.3.3.2 Medicines
The basic Chinese law on medicines is the Medicine Administration law along with its 
Implementing Regulations. The National People’s Congress enacted the law itself in 
2001, and the State Council gave the implementing regulations in 2002. More detailed 
information on what is required is to be found in the “Registration Measures” 
given by the SFDA in 2007375.
Similarly to the regulation of foodstuffs, the basic laws on medicines are complemented by 
several pieces of administrative regulations given by the SFDA. This material could be defi ned 
as soft law as the SFDA or its predecessor, the SDA, provides it. The SFDA has an important 
role as a formulator of laws and administrative regulations on medicines. The regulations 
include rules on manufacturing licences, certifi cation for Good Manufacturing Practice, Good 
Clinical Practice, Good Supply Practice, distribution, labelling and packaging, advertising, 
pricing, import-export, etc. Medicine marketing was in 2007 regulated in a stricter and more 
detailed manner because of the problems and scandals related to false advertising.
Regulations on traditional Chinese medicines have existed since 2003. Instead of safety or 
effi cacy evaluation of traditional medicines, these Regulations are focused on general principles 
such as the importance of traditional medicine and its development. Also a regulation on Good 
Agricultural Practice of traditional Chinese medicines has existed since 2002. This regulation 
372  Kan – Zhang 2002.
373  See Articles 13 – 15 of the Food Safety Law Implementation Measures.
374  GOV.cn Saturday, March 8, 2008. http://english.gov.cn/2008-03/08/content_914117.htm.
375  The SFDA promulgated the latest “Measures for the Administration of Drug Registration” on July 10 
2007, and they entered into force in October 1, 2007.
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is interim and given by the SDA, the predecessor of the SFDA. A separate law on scientifi c 
evaluation of traditional medicines is pending, but has caused controversy.
Local government authorities have enacted their own medicine regulations, which may 
supplement and modify some of the national regulations. Local rules exist particularly on 
labelling.
2.3.4 Implementing the Law
2.3.4.1 Pre-market Controls Used in China
2.3.4.1.1 Foods
First of all, enterprises and persons involved in food production and marketing must have a 
licence. Enterprises engaged in food production or marketing as well as food vendors must 
obtain a hygiene license issued by the administrative department of public health before they 
shall be permitted to apply for registration with the administrative departments of industry and 
commerce. No person without a hygiene licence may engage in food production or marketing.376 
The tasks of issuance and control of hygiene licences are delegated to local offi cials377. Food 
safety risk assessment is “a scientifi c assessment performed in order to identify the possible 
adverse impact upon human health by biological, chemical and physical hazards of food”378.
The following food categories are subjected to pre-market control:
food additives –
health foods –
novel foods –
GM foods. –
Here we focus on pre-market procedures for health foods and novel foods, as these are probably 
the most relevant legal categories for our purposes.
Producing health foods requires an additional licence. A health food producer will have to 
apply to the provincial health authorities for a production permit. The permit will be attached 
to the manufacturer’s Hygiene Licence. As do other companies since 2002, health food 
manufacturers must have Good Manufacturing Practices and Hazard Analysis and Critical 
Control Points in place.379
376  Chinese Food Hygiene Law, Article 27. Similarly in new Food Safety Law Implementation Measures, 
Article 18.
377  Article 27.3 of the Food Hygiene Law: The measures for the issuance and control of hygiene licences 
shall be worked out by the administrative departments of public health of the people’s governments of the 
provinces, autonomous regions, or municipalities directly under the Central Government.
378  Food Safety Law Implementation Measures, Article 55.
379  Huang – Lapsley 2005, 286.
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Pre-market registration of medicines and health foods is under the competence of State Food 
and Drug Administration (SFDA), more particularly its Department of Drug Registration.380 
Novel foods, GMO foods, and additives are authorised by the Ministry of Health, and in the 
future, health foods will also be authorised by the Ministry.
All foods with health claims must undergo the approval process set forth by the SFDA. 
A Chinese company submits the application to provincial health administration authorities 
who perform preliminary examination. Upon passing this, the application is submitted to 
the Health Food Evaluation Centre of the State Food and Drug Administration (SFDA). For 
imported foods, the application is sent straight to the SFDA.381
The State Food and Drug Administration, Department of Drug Registration, and the Division of 
Health Foods administer health foods. The tasks of the Division of Health Foods are:
drafting criteria of marketing authorisation and research guidelines for health foods –
evaluation and approval of health foods – 382.
The SFDA issues a Certifi cate of Approval on Health Food for the qualifi ed health food, 
and formulates the label for the product. The Certifi cate can be used in connection with the 
label.383
Prior to submission of the application, the following reports must be obtained from an 
authorised laboratory:
report of toxicology safety assessment, –
report of functionality (effi cacy) evaluation, –
analytical report of active ingredient, –
report of product stability study, –
report of sanitary inspection. – 384
There are more than 30 authorised laboratories in China, although not every laboratory can 
conduct all tests. Each laboratory is allowed to evaluate certain claims according to its capacity. 
The Institute of Nutrition and Food Safety, and the Chinese Centre for Disease Control in 
Beijing test all imported health foods.385
Further regulations for the application procedure are given by a separate piece of law, 
the Regulation on Application and Acceptation of Health Food of Ministry of Public Health 
380  According to the SFDA’s web page, the tasks of SFDA’s Department of Drug Registration are, among 
others,
  – to draft and revise national drug standards,
  – to control approval and registering of new drugs, drugs with national standards, and imported drugs,
  – to implement protection system for traditional Chinese medicines,
  – to draft criteria of marketing authorisation for health food, and
  – to control approval of health foods. http://www.sfda.gov.cn/cmsweb/webportal/W44993641/index.html.
381  The Measures for the Administration of Health Food Registration, which took effect July 2005. Huang – 
Lapsley 2005, 264-265. 
382  SFDA web page. http://www.sfda.gov.cn/cmsweb/webportal/W44993701/index.html.
383  Article 5.
384  Huang – Lapsley 2005, 276-282.
385  Huang – Lapsley 2005, 282.
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(1999). Article 6 of the Regulation lists the necessary documents and samples for domestically 
produced and imported health foods respectively. In addition to the above-mentioned research 
reports, and three product samples, the following information must be included in the 
application for Imported Health Food:
Hygiene Permit Application Form for Imported Health Foods1. 
Product formulation and its relevant scientifi c evidence2. 
Name and content of active ingredient(s) and the analytical procedure for the 3. 
ingredients
Processing techniques and fl owchart4. 
Product quality specifi cation (industry standard)5. 
Inspection reports (as stated previously) by the authorised laboratory6. 
Product packaging design (including product label)7. 
Product manual or description8. 
An entrust contract, is an applicant is an entrustee9. 386
Evidence documents such as product sale permit issued by relevant authority from the 10. 
manufacturer’s country
Other relevant data in support of the approval process.11. 387
The SFDA will evaluate the application with respect to the following aspects:
Health food name: whether it is accurate and scientifi cally sound. –
The application: whether it is complete, translated into Chinese, and legible. –
Formulation: which are the raw materials used. –
Manufacturing technique: whether good manufacturing practice is followed. –
Quality: what is the process for controlling active ingredients. –
Safety: evaluating the toxicological test reports. –
Effi cacy: evaluating the functionality assessment reports. –
Active ingredient: evaluating the analytical report of the active ingredient. –
Product stability: whether the product will last two years of shelf life. –
Hygiene: evaluating the hygiene reports. –
Label and manual: whether they are accurate and true. – 388
If the SFDA approves the health food, it issues an “Approval Certifi cate of Health Food” or 
“Approval Certifi cate for Imported Health Food”. Together with the certifi cate, the product 
receives a serial number such as Foodstuff/Health 2007 No1234. while simultaneously 
receiving the right to use the health food symbol. Both the serial number and the symbol must 
be marked on health food packaging.389 For imported foods, the Certifi cate is inspected by the 
food hygiene and inspection agency at a Chinese entry port390.
386  An entrusted agent of a foreign functional food manufacturer.
387  Health Food Regulation, Article 6. Huang – Lapsley 2005, 282.
388  Huang – Lapsley 2005, 284-285.
389  Huang – Lapsley 2005, 265.
390  Huang – Lapsley 2005, 286.
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The pre-market control is not solely a responsibility of the control authorities. Also the 
food industry operators themselves are responsible for fi nding and controlling risks in their 
activities. According to the Chinese Food Hygiene Law391, “Enterprises engaged in food 
production or marketing shall improve their own system for food hygiene control, appoint 
full-time or part-time workers to control food hygiene and strengthen inspection of the foods 
they produce or market”. It is further stated392 that food and food additives393 may be dispatched 
from factory or sold only after their producers have carried out inspection and found them to 
meet the principles according to the hygiene standards and the hygiene control regulations.
In China, the plan is to further enhance self-discipline of food industry enterprises by creating 
and enforcing a culture of credibility. The New Food Safety Law and its Implementation Measures 
further strengthen the principle of self-control. Enterprises are the fi rst responsible parties for 
food safety. Blacklists of operators are created, and supervision efforts are focused on the most 
susceptible enterprises according to risk management principles.394 This focus on self-discipline 
and supervision based on different risk categories is similar to the European approach. If companies 
themselves were responsible, the authorities would save in supervision costs.
The fi rst Novel Food Regulation in China was issued in 1990. In 2007, a new Regulation395 
was issued and came into force at the beginning of December 2007. To drive the novel 
food industry, the new regulation aims to remove complex approval procedures, 
while tightening food safety measures.396 The government wants to encourage 
scientifi c research and development of novel foods397 and to add greater variety to 
the market.
The aim of the Novel Food Regulation is to strengthen supervision and administration of 
novel foods, and to safeguard the health of consumers.398 The Novel Food Regulation was 
based on the Food Hygiene Law399 of the People’s Republic of China. Novel foods are subject 
to pre-market approval by the Ministry of Health. It is prohibited to manufacture or use as 
food or food raw materials, materials corresponding to the defi nition of novel foods in Article 
2 of the Novel Food Regulation, if they have not yet been approved and published as novel 
foods by the Ministry of Health400.
According to Article 23 of the Novel Food Regulation, “Enterprises manufacturing, 
operating and/or using novel foods shall not claim or imply the therapeutic effects and health 
391  Article 18.
392  Article 24
393  And also food contact materials.
394  Five-Year Plan for Food and Drug Safety. April 2007. Page 9.
395 Ministry of Health: Administrative Measures on Novel Foods.
396  The Ministry of Health according to Chinadaily.com.
397  Novel Food Regulation, Article 4.
398  Novel Food Regulation, Article 1. 
399  In the Food Hygiene Law, it is stated: “Before beginning production of new types of foods or food 
additives using new resources, the enterprises engaged in their production or 
marketing must submit the data necessary for the evaluation of the hygiene and 
nutrition of such products;…. Before beginning production of the above new products, it shall 
also be necessary to provide samples of the products for examination and 
approval, in accordance with the specifi ed procedures for examining and 
approving food hygiene standards.” Article 20.
400  Novel Food Regulation, Article 18.
–63–
functions of the novel food.” If a product is a novel food and health claims are wanted, the health 
food procedure applies, in which case safety and effi cacy are both evaluated by the SFDA. 
Novel food assessment is safety assessment, and does not include effi cacy assessment.
An application for a novel food at the Ministry of Health shall include the following 
materials:
 Application for hygiene administration permit for novel food;(1) 
 Research and production report;(2) 
 Brief summary and fl ow chart of processing techniques;(3) 
 Product quality standards;(4) 
Status on research and production at home and abroad, as well as safety related (5) 
documents;
Product label and instructions; and(6) 
Other materials helpful to assessment and review.(7) 
In addition to these documents, a sealed product sample or 30-grams of raw material is 
required. In the case of imported novel food, it is also required to submit certifi cates by food 
control authorities indicating that the food is considered legal in the exporting country.401
After accepting applications for novel foods, the Ministry of Health organises the 
Assessment Committee to conduct a preliminary technical examination. In case additional or 
corrective materials are needed, the applicant shall cooperate. After the preliminary technical 
examination, the Assessment Committee shall determine the safety test items, test sample 
batches, test methods and testing institutions of the novel food, and decide on whether to 
conduct on-site examination and collect and seal samples, and inform the applicant. Generally, 
testing institutions accredited by the Ministry of Health shall carry out the safety tests. In 
case on-site examination and collection of sealed samples is required, the applicants of 
domestically-produced novel foods shall fi le an application to the local health administration 
department at the provincial level which shall organise implementation of such on-site 
examination, collection and sealing of samples. Applicants of imported novel foods shall fi le 
the applications to the Ministry of Health, who organise the implementation (of the on-site 
examination, collection and sealing-up of samples).402
2.3.4.1.2 Medicines
As with the European system, China also has pre-market control over the dominant regulatory 
mechanisms for medicines. Registration of medicines is under the responsibility of the 
SFDA. Part of its powers has been delegated to local level government authorities (provinces, 
autonomous regions or municipalities directly under the central government). These local 
level authorities can issue manufacturing licenses and approve medicine advertisements403.
Good Manufacturing Practice (GMP) is where medicine safety begins. GMP is a system 
to ensure products are consistently produced and controlled according to quality standards. 
401  Novel Food Regulation Article 11.
402  Novel Food Regulation, Article 12.
403  Tsoi 2007. 
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It is designed to minimise the risks involved in any pharmaceutical production that cannot 
be eliminated through testing the fi nal product. A directive circular issued by the Ministry 
of Health in July 1995 marked the offi cial launch of GMP certifi cation in China. The China 
Certifi cation Committee for Drugs (CCCD) was established in the same year.404
The Chinese pre-market control of medicinal products is based on one authorisation 
procedure, the result of which applies to the whole country. It is stated in the law that local 
people’s governments and offi cials shall not restrict or exclude the entrance of authorised 
pharmaceuticals under the justifi cation of conducting inspections405. The goal is to harmonise 
medicine law in China and to remove local barriers to trade.
The SFDA is responsible for pre-market approval of medicines. There are fi ve divisions 
and one offi ce under its Department of Drug Registration, including:
Division of  – Traditional Chinese Medicine
Division of  – Pharmaceuticals
Division of  – Biological Products
Division of Health Food –
Division of General Management –
Offi ce for Acceptance of Drug Application. – 406
The Department of Drug Registration, Division of Traditional Chinese Medicine has the 
following tasks:
to draft national standards and research guidelines for traditional Chinese medicines,  –
Chinese crude drugs and prepared slices thereof, and natural medicines;
to evaluate and approve new drugs – , drugs with national standards and import products 
of traditional Chinese medicine preparations, prepared slices of Chinese crude drugs, 
Chinese crude drugs and natural medicines;
to evaluate and approve clinical trials of traditional Chinese medicines; –
to approve protected traditional Chinese medicinal products. –
The Department of Drug Registration, Division of Pharmaceuticals has the following tasks, 
among others,
to draft national standards and research guidelines of pharmaceuticals; –
to evaluate and approve new drugs – , drugs with national standards and import drugs;
to evaluate and approve clinical trials of new drugs. –
All new medicines must be registered according to the Registration measures. The registration 
process has three steps: pre-clinical studies, clinical studies, and approval. First, the applicant 
himself conducts the pre-clinical studies. In order to conduct clinical studies, one must apply to 
the provincial authorities with the results of the pre-clinical studies. The provincial authorities 
examine the medicine with assistance from state-sponsored laboratories, and submit their 
404  Wikipedia. http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_China.
405  Medicine Administration Law, Article 69.
406  SFDA web page. http://www.sfda.gov.cn/cmsweb/webportal/W44993641/index.html.
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fi ndings to the SFDA. The SFDA conducts further technical tests and decides whether clinical 
tests will be allowed. If approved, the applicant conducts the clinical studies. The results from 
these studies, accompanied by product samples, will then be sent to provincial authorities 
for manufacture approval. The decision of the provincial authorities407 is subjected to fi nal 
clearance by the SFDA. If approved by the SFDA, the applicant will receive a Certifi cate of 
New Medicine and a Production Approval Number.408
Generic medicines do not require clinical studies unless they are solid oral medicines. In 
order to register for manufacture approval, the applicant must submit pre-clinical studies and 
product samples to provincial authorities. The decision of the provincial authorities is subject 
to fi nal clearance by the SFDA.409
Imported medicines, referring to medicines that are not manufactured in China, must already 
have obtained market approval in the country where they are manufactured. In addition, they 
must undergo clinical testing and be registered in China similarly to new medicines. If the 
medicine does not have a Product License in the originating country, it may still be imported 
if there is a clinical need in China for the medicine in question, and safety and effi cacy are 
confi rmed by independent trials. Imported medicines receive a Pharmaceutical Import 
Registration Certifi cate.410
According to Article 8 of the Medicine Administration Law, to establish a pharmaceutical 
producing enterprise, the following requirements must be met:
 It shall be staffed with legally certifi ed pharmaceutical technical personnel, engineering (1) 
technical personnel, as well as corresponding skilled workers.
 It shall have factory premises, facilities and a sanitary environment suitable for the (2) 
medicines produced.
 It shall have a unit or competent personnel capable of inspecting the quality of the (3) 
medicines produced, as well as necessary instruments and equipment.
 It shall have rules and regulations to ensure the quality of medicines.(4) 
Besides manufacturing, distribution of medicines is under strict control. The Chinese are striving 
to erode the serious problems related to counterfeit or fake medicines. A Pharmaceutical Trade 
License is required for wholesale or retail411 trade of pharmaceuticals. Pharmacies or hospitals 
may also prepare medicinal preparations, provided that they have a Dispensing Permit for 
Medical Organisations412. Medicinal preparations made by medical organisations may not be 
sold on the market413.
407  The production license is issued by the pharmaceutical supervisory and administrative department of the 
province, autonomous region, or municipality directly under the Central government in which the enterprise 
is located. Medicine Administration Law, Article 7. 
408  Medicine Administration Law, Article 31. Tsoi 2007.
409  Tsoi 2007.
410  Medicine Administration Law, Article 39. Tsoi 2007.
411  Medicine Administration Law, Article 14.
412  The permit is issued by the pharmaceutical supervisory and administrative departments of the provinces, 
autonomous regions or municipalities directly under the central government. Medicine Administration Law, 
Article 23.
413  Medicine Administration Law, Article 25.
–66–
According to the Medicine Administration Law, Article 15, to establish a pharmaceutical 
trading enterprise, the following requirements must be met:
 It shall be staffed with legally certifi ed pharmaceutical technical personnel.(1) 
 It shall have business premises, equipment, storage facilities and a sanitary environment (2) 
suitable for the pharmaceuticals in which it trades.
 It shall have a quality control agent or personnel suitable for the pharmaceuticals in (3) 
which it trades.
 It shall have rules and regulations to ensure the quality of the pharmaceuticals in which (4) 
it trades.
Distribution, retail and trading of medicines are subject to more specifi c criteria given in the 
Opinion on Strengthening Supervision of Pharmaceuticals and Promoting the Development 
of a Modern Logistics for Pharmaceuticals. The Opinions provide rules on medicine supply, 
purchase, inspection, storage, etc.414
Hospitals and clinics practicing traditional Chinese medicine must undergo examination 
and be licensed as a medical institution. Practitioners of traditional medicine are required to 
pass a qualifying examination and obtain a license through registration.415
Medicinal product advertising is also under pre-market control. All advertisements have to 
be pre-approved by provincial medicine control authorities. This applies to all pharmaceutical 
advertisements, published through radio, cinematography fi lm, television, newspaper, 
magazine, periodical and other media. An advertiser shall, when applying for advertisement 
examination, submit relevant documentation to the offi cials of the place where the enterprise 
is located416. The offi cials must examine and inspect, prior to publication, the contents of 
advertisements in accordance with the law. Only advertisements which are examined, approved 
and given a pharmaceutical advertising registration number may be published.417
According to Access China Management Consulting Ltd., the Chinese process of 
application and approval for imported medicine registration is “very complex”. They claim that 
Chinese pharmaceutical authorities administer and control the process by various and variable 
administrative measures and regulations with lack of transparency. However, they believe 
that the ongoing consolidation of the regulations will eventually contribute to a healthier 
market environment.418 Proprietary data is often submitted as part of a medicine registration 
application, and some companies have been reluctant to send such sensitive information to 
China out of concern that their intellectual property might be compromised. According to the 
US-China Business Council, there has been progress in protecting proprietary data from unfair 
commercial use.419
414  Tsoi 2007.
415  Chinese Regulations on Traditional Chinese Medicines. Chapter II.
416  The pharmaceutical supervisory and administrative departments of the provinces, autonomous regions, or 
municipalities directly under the central government. Medicine Administration Law, Article 60.
417  Advertising law, Article 34. Medicine Administration Law, Article 60.
418  Access China 2007. 
419  US-China Business Council 2008.
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2.3.4.2 Post Market Controls in China
2.3.4.2.1 Foods
The Food Hygiene Law aimed to ensure the supervision system of national food hygiene: the 
central and regional health executive departments bear the responsibility of supervision420. 
According to Article 17, the departments in charge of control of food production or marketing 
of the people’s governments at various levels shall strengthen control of food hygiene and 
oversee the implementation of the Food Hygiene Law. Supervision of food production and 
marketing is under the responsibility of administrative departments of industry and commerce 
and the administrative departments of public health421.
The new Food Safety Law Implementation Measures contain similar phrases: Local 
people’s governments shall “reinforce food safety supervision”422. Local health authorities 
shall coordinate the work of various food-related authorities and develop local food safety risk 
monitoring programs423. The safety monitoring work itself, such as collecting and analysing 
samples, shall be done by “technical institutions”424.
Article 33 of the Chinese Food Hygiene Law listed the functions of food hygiene supervision 
reasonably precisely:
to provide monitoring of, inspection of and technical guidance for food hygiene;“(1) 
 to contribute to the training of personnel for food production and marketing and to (2) 
supervise the medical examinations of such personnel;
to spread knowledge of food hygiene and nutrition, provide appraisals of food hygiene (3) 
and publicise the existing condition of food hygiene;
to conduct hygiene inspections of sites and designs for the construction, extension or (4) 
renovation of enterprises engaged in food production or marketing and participate in 
the inspection and acceptance of fi nished projects;
to investigate accidents involving food poisoning or food contamination and take (5) 
appropriate measures of control;
to make rounds of inspection and supervision concerning acts in violation of this Law;(6) 
to determine the responsibility of persons who violate this Law and (7) impose administrative 
penalties on them according to law; and
to take charge of other matters that concern food hygiene supervision.”(8) 
According to the Food Hygiene Law, the health authorities of the people’s governments at 
county level or above shall appoint food hygiene supervisors. The supervisors shall be qualifi ed 
specialists certifi ed by the health authorities at the corresponding level. Food h ygiene supervisors 
shall carry out the tasks assigned to them by the administrative departments for health. It was also 
interestingly stated in the Food Hygiene Law that “food hygiene supervisors must enforce laws 
impartially, be devoted to their duties and shall not take advantage of their positions for their own
420  Kan – Zhang 2002. 
421  Food Hygiene Law, Article 29.
422  Food Safety Law Implementation Measures, Article 2.
423  Food Safety Law Implementation Measures, Article 5.
424  Food Safety Law Implementation Measures, Article 9.
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benefi t”.425The law enforcement department has the right to adopt executive controlling measures. 
While carrying out their tasks, food hygiene supervisors may obtain information from the 
producers or marketers of food, request any necessary data, enter the production or marketing 
premises for the purposes of inspection, and obtain free samples in accordance with regulations. 
The producers or marketers of food may not turn down such requests nor hold back any 
information. The food hygiene supervisors shall be obliged to keep confi dential any 
technical data provided by the producers or marketers.426 The local health authorities may take 
provisional measures of control towards a producer or marketer of food who is responsible 
for a food poisoning accident which has already occurred or for which there is evidence of the 
possibility of it occurring. They can seal up the food and its raw materials. Food proven to be 
contaminated should be destroyed.427
The Novel Food Regulation refers to the supervision articles of the Food Hygiene Law. 
It states that local authorities shall conduct supervision and inspections on novel foods 
according to the Food Hygiene Law428. The Ministry of Health shall regularly gather food 
safety information about novel foods, make timely announcements to the public, and, if 
necessary, issue early warnings or reassess the novel food that has food safety problems429. 
The Health Food Regulation similarly refers to the Food Hygiene Law and its post-market 
control mechanisms. As the Food Safety Law has replaced the Food Hygiene Law, the 
control mechanisms of the Food Safety Law currently apply. The Ministry of Health and 
the current authority responsible for health food approvals, the SFDA, have approved 
thousands of health foods, and their supervision is becoming more complicated430.
2.3.4.2.2 Medicines
Post-market control of medicines is under the competence of the SFDA and the local (provincial, 
municipal etc.) authorities. In order to discover any illegal activities, government offi cials shall 
organise investigations on medicines, which have been approved for production or import. They 
are authorised to conduct supervision and inspections over the research, development, production 
and trade of approved medicines, as well as the medical organisations’ use of medicines. The units 
and individuals concerned shall not refuse to comply. Supervisory and administrative offi cials shall 
present certifi cate documents while conducting supervision and inspection, and shall not divulge 
technological and business secrets.431 Also sampling examinations on the quality of medicines may 
be conducted432. The authorities may take administrative coercive measures including sequestration 
and banning against pharmaceuticals and other relevant materials, which have been proven to be of 
possible harm to people’s health.
Production or import licences shall be revoked if it is discovered that:
425  Articles 24 and 35 of the Chinese Food Hygiene Law.
426  Article 35.
427  Article 37.
428  Novel Food Regulation, Article 24.
429  Novel Food Regulation, Article 25
430  Huang – Lapsley 2005, 263.
431  Medicine Administration Law, Article 64.
432  Medicine Administration Law, Article 65.
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curative effects of the medicine are uncertain or poor, –
the medicine produces serious adverse reactions, or –
for other reasons the medicine is harmful to people’s health. –
The medicines whose licenses have been revoked shall not be allowed to be produced, 
imported, sold or used. Those, which have already been produced or imported, shall be 
destroyed or disposed of under the supervision of the authorities.433
Pharmacovigilance activities are under the shared responsibility of operators and the 
State. A reporting system over any adverse reactions of pharmaceuticals shall be practiced 
by the State. Medicine manufacturers, traders, and medical institutions shall conduct regular 
surveys on the quality, curative effects and adverse reactions of the pharmaceuticals they 
have produced, traded or used. When serious adverse reactions possibly related to the use of 
the medicines are discovered, they must be promptly reported to the local medicine control 
authorities and the local health authorities, which will formulate detailed measures to be taken. 
These measures include cessation of production, sale, and use of the medicine.434
2.3.4.3 P enalties Used in China
2.3.4.3.1 Foods
In China, the court system has traditionally not been separated from administration. Cases 
have been handled as police or administrative issues.435 This remains the case with foodstuff 
and medicine administration. The administrators are entitled to carry out various executive 
punishments stipulated in the Foo  Safety Law.
In the former Food Hygiene Law, there were separate penalty regulations for:
whoever causes a food poisoning accident, –
whoever causes a serious food poisoning accident, –
whoever produces or markets foods without a hygiene licence –  ,
whoever fails to comply with hygiene requirements, –
whoever produces or markets food of which the production or marketing has been  –
prohibited,
whoever produces or markets infant or children’s food not conforming to nutrition and  –
hygiene standards,
whoever produces, markets or uses food additives, food contact materials, or disinfectants  –
not conforming to hygiene standards,
whoever produces or markets  – a health food without authorisation, or presents fraudulent 
health claims,
whoever fails to comply with the labelling requirements, –
whoever works without a personal health certifi cate or uses sick personnel. –
433  Medicine Administration Law, Article 42.
434  Medicine Administration Law, Article 71.
435  Huotari – Seppälä 2005, 131.
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For every breach, withdrawal of contaminated products, confi scation of illegal gains, fi nes, 
and revocation of licence are possible. The yuan amounts for fi nes set in the Food Hygiene La, 
rangeg from 1,000 to 50,000 yuan an, ware thus fairly low for large companies, but signifi cant 
for smaller companies. In the new Food Safety Law, the yuan amounts changed. Currently, 
fi nes range from 2,000 yuan to ten times the value of the commodity in question. This 
means there are no maximum fi ne amounts for crimes affecting large volumes of foods. The 
health authorities of the local people’s governments determine the administrative penaltie.. 
The administrative penalty decision may be appealed to the higher health authority436, or to 
a people’s cour437. If someone does not appeal but neither complies with the decision, the 
decision can be enforced by a cour438.
Punishments are not regulated separately in the Novel Food Regulation or the Health Food 
Regulation. Instead, they refer to punishments stipulated by the Food Hygiene Law, which has 
been replaced by the Food Safety Law. For example, manufacturing or operating novel food 
that is not approved by the Ministry of Health, or using novel food that is not approved by the 
Ministry of Health as a raw material for food processing, the enterprise was to be penalised 
by the health administrative department of the people’s government at county level or above 
in accordance with Article 42 of the Food Hygiene Law439. If food was produced under the 
name of health food when it has not been accepted according to the Health Food Regulation, 
penalties listed in Article 45 of the Food Hygiene Law appliey440.
In addition to administrative penalties, violatingwfood laws may lead to civil 
responsibility. This means that if someone causes food poisoning or transmission of disease, 
he must compensate for personal and fi nancial damage.441 Disputes are resolved in mediation, 
arbitration, and courts. The courts do not have adequate powers to enforce judgments, and 
coercive means are not preferred in civil cases. Enforcement of judgments is thus uncertain 
and depends on the local fi nancial interest and relationships of the enforcement authorities to 
banks that are capable of seizing wages.442
For causing a serious food poisoning accident or putting poisonous raw materials in foods, 
criminal responsibility is also possible443. If health authorities abuse their authority and neglect 
their duties, disciplinary sanctions follow. Accepting bribes or causing a serious accident may 
also lead to criminal responsibility of the health authority offi cer444. Violating or threatening 
436  This is called applying for consideration. Ultimately, administrative penalties may be appealed to 
the SFDA. According to the SFDA web page, its Department of Policy and Regulation, Division of Law 
Enforcement Supervision has the following tasks:
  – “administrative activities supervision, hearing, administrative reconsideration, response to lawsuit 
and compensation;
  – guidance on legal construction and law popularisation and publicising within the food and drug 
administration system”.
437  Article 50.1.
438  Article 50.3.
439  Novel Food Regulation, Article 26.
440  Health Food Regulation, Article 29.
441  Food Hygiene Law, Article 48.
442  Seppänen 2005, 594.
443  Food Hygiene Law, Article 39.2.
444  Food Hygiene Law, Articles 51 and 52.
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health authorities leads to criminal responsibility. Otherwise obstructing offi cials will lead to 
an administrative penalty for disrupting public security445.
Civil and criminal cases are handled by people’s courts on various levels. Administrative 
enforcement agencies are not willing to hand over their cases for criminal prosecution, because 
administrative penalties enhance their own operating budgets446. The autonomy of courts and 
the enforcement of judgments are by many scholars considered as problematic in China447. 
The judicial system as a whole is weak and under the control of the Communist Party448. 
Independence of the judiciary relates to the more general concept of rule of law discussed 
above.
2.3.4.3.2 Medicines
Chapter IX of the Medicine Administration Law addresses Legal Responsibility, i.e. 
penalties. The Regulations on traditional Chinese medicine also include details on offences 
and sanctions.449 There are different types of penalty for different types of breaches of the 
Medicine Administration Law. There are separate penalty regulations for those who:
produce or trade in medicines without obtaining a Pharmaceutical Production Licence,  –
Pharmaceutical Trade License, or Dispensing Permit of Medical Organisations450,
445  Food Hygiene Law, Article 53.
446  Mertha 2008, 2.
447  See Seppänen 2005 on how empirical evidence is missing on these issues.
448  Mertha 2008, 2.
449  Chapter V.
450  “Those who produce or trade in medicines without obtaining a Pharmaceutical Production Licence, 
Pharmaceutical Trade Licence, or Dispensing Permit of Medical Organisations, shall be placed under ban, 
have the unlawfully produced and sold medicines and any unlawful income confi scated, and may concurrently 
be fi ned a sum of money more than two but less than fi ve times the value of the medicines unlawfully made 
or sold.” Article 73. 
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produce and sell fake medicines – 451 or medicines of inferior quality452,453
do not comply with the quality control standards for production, trade and research – 454,
purchase medicines from enterprises without the Pharmaceutical Production Licence or –
Pharmaceutical Trade Licence455,
import pharmaceuticals and fail to register at the port – 456,
forge, alter, trade, lease or lend licences or pharmaceutical approval certifi cates – 457,
provide false certifi cates or samples or receive a licence by cheating – 458,
trade in pharmaceuticals and fail to keep purchase records – 459,
sell medicines with incomplete label information – 460,
give or receive commissions in secret or property interests to/from other enterprises or  –
physicians during purchase or sale of pharmaceuticals461,
451  “Those who produce and sell fake medicines shall have his unlawfully produced or sold medicines and 
any unlawful income confi scated, and concurrently be fi ned a sum of money more than two but less than fi ve 
times the value of the medicines unlawfully produced and sold. Those who have an approval certifi cate of 
pharmaceuticals shall have the certifi cate revoked, and be ordered to suspend production or business operations 
pending rectifi cation; if the circumstances are serious, the party shall have Pharmaceutical Production Licence, 
or Pharmaceutical Trade Licence or Dispensing Permit of Medical Organisations revoked.” Article 74.
452  “Those who produce and sell medicines of inferior quality shall have his unlawfully made and sold 
medicines and any unlawful income confi scated, and be concurrently fi ned the sum of money more than two 
but less than three times the value of the medicines unlawfully made or sold; if the circumstances are serious, 
the party shall be ordered to suspend production or business pending rectifi cation, or have the pharmaceutical 
approval certifi cate revoked and his Pharmaceutical Production Licence, or Pharmaceutical Trade Licence or 
Dispensing Permit of Medical Organisations revoked.” Article 75.
453  “The person-in-charge or personnel directly liable in the enterprise or other unit which produces and sells 
fake medicines or produces and sells pharmaceuticals of inferior quality shall not be permitted to engage in 
the production and trade of pharmaceuticals for ten years, if the circumstances are serious. The producers’ 
supplementary materials, packaging materials and production equipment which are used exclusively for 
producing fake medicines and medicines of inferior quality shall be confi scated.” Article 76. “Those who 
provide facilities including transportation, preservation and storage that have been or should have been aware 
of the fakery or inferior quality of the pharmaceuticals, shall have the entirety of his income from such 
transportation, preservation and storage confi scated, and concurrently be fi ned a sum of money more than 
50% but less than three times the value of the unlawful income. Those whose acts constitute a crime shall be 
investigated for criminal liabilities.” Article 77.
454  “Pharmaceutical producing enterprises, trading enterprises, pharmaceutical non-clinical safety appraisal 
research institution, and pharmaceutical clinical testing institutions, shall be served a warning and be ordered 
to amend themselves within a prescribed time limit if they do not carry out the stipulations of the “Quality 
Control Standard of Pharmaceutical Production,” the “Quality Control Standard of Pharmaceutical Trade,” 
the quality control standard of pharmaceutical non-clinical research, and the quality control standard of 
pharmaceutical clinical testing. Those who do not rectify their mistakes within the prescribed time limit 
shall be ordered to suspend production and business operations pending rectifi cation, and be concurrently 
fi ned more than 5000 but less than 20,000 RMB. If the circumstances are serious, they shall have their 
Pharmaceutical Production Licence, Pharmaceutical Trading Licence or Dispensing Permit of Medical 
Organisations revoked.” Article 79.
455  Article 80.
456  Article 81.
457  Article 82.
458  Article 83.
459  Article 85.
460  Article 86.
461  Article 90 and 91.
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act against regulations on pharmaceutical advertising – 462,
are supervisors and issue certifi cates or licences without grounds – 463, or neglect their 
supervisory duties464, or collect illegal fees465,
are inspections agencies and produce false inspection reports – 466,
are supervisors or inspectors and participate in production or trade of  –
pharmaceuticals467.
The administrative penalties include revocation of licences, personal ban to engage in 
pharmaceutical business, confi scation of illegal gains, and fi nes. The amount of the fi ne depends 
on the volumes of the illegal business. The decision to impose administrative sanctions is made 
by the pharmaceutical supervisory and administrative departments at or above the county 
level. The original approval departments shall decide on revocation of licences.468 There is a 
possibility of appeal to the SFDA.
To ensure the marketers take the rules on medicine advertising seriously, the Chinese 
government has made post-market control methods and punishments more severe. 
Advertisements with illegal content will be revoked of all advertising approval numbers, 
and application for advertising approval for the medicine in question will be banned for a 
year. .In the case of illegal advertisements gravely deceiving and/or misleading consumers 
by exaggerating the scope of applicability and effects of the medicine, the medicine will be 
suspended from sale and the marketer ordered to dispel the negative impact of the illegal 
advertising.469
Civil responsibility towards patient consumers is referred to in Article 93 of the Medicine 
Administration Law: “If pharmaceutical-producing enterprises, trading enterprises or medical 
organisations act against this law which results in damages to the users of pharmaceuticals, 
they shall bear liabilities of compensation in conformity with relevant regulations.” Chinese 
law does not require negligence of fault of a manufacturer to give rise to product liability. This 
means manufacturers are liable if any casual links between a defective pharmaceutical and a loss 
of a victim are found. Lawyers recommend product liability insurance for manufacturers.470
Criminal responsibility is also relevant for several types of breach of the Medicine 
Administration Law. For example production or sale of unauthorised, false or inferior quality 
pharmaceuticals471, production of false inspection reports472, and misuse of authority473 may 
constitute crimes.
462  Article 92.
463  Article 94.
464  Article 97.
465  Article 96.
466  Article 87.
467  Article 95.
468  Article 88.
469  Hong Kong Trade Development Council web page. http://www.tdctrade.com/alert/cba-e0705g.htm.
470  Tsoi 2007.
471  Articles 73, 74 and 75.
472  Article 87.
473  Article 99.
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2.3.5 NGO Regulation and Self-Regulation
The Chinese government is calling for the participation of consumers, NGOs474, and food 
companies in establishing food safety standards. In a document submitted to the World Health 
Organization in 2002, China called for increased participation on the part of “consumers, food 
industry and other stakeholders”. China has focused on increasing consumer awareness by 
hosting an annual “Food Hygiene Law Education Week” and implementing other educational 
programs on the importance of sanitary food handling.475 This way some of the responsibility 
can be shifted onto consumers themselves, and the large numbers of food poisoning incidents 
they cause can be lowered.
The civilian consumer protection group system also plays an important role in Chinese 
food regulation. Consumer groups, such as the Chinese Consumer Association, obtain licenses 
from local government authorities to independently regulate and inspect food production 
facilities and plants. They also hear complaints and comments from consumers and report 
back to local government offi cials.476 These groups are important in protecting people’s rights. 
In addition, self-regulation by the industry exists: various chambers of commerce recommend 
their own voluntary standards to food producers. These standards cover many areas of food 
production. Increasingly food producers are adopting voluntary standards in order to achieve 
better market success.477
The new Food Safety Law urges both the industry organisations and social groups to be 
more involved. According to Article 7, food industry organisations shall tighten industry self-
discipline, and guide producers and traders in complying with the law. In Article 8, the state 
encourages social and community groups to conduct educational activities concerning food 
safety laws. Article 8 also urges the media to publicise laws for free, and to monitor acts that 
violate the law. It is interesting that media is also given responsibility on food safety. There 
seems to be a trend of shared responsibility that can additionally be noted in the European and 
American discussions on who is responsible for obesity.
Voluntary approaches have been criticised for not being enough, and greater government 
involvement has been demanded. China must build the capacity to oversee food production 
within its borders. Several severe food safety scandals have been the result of unsafe or 
inferior ingredients in processed foods, or chemical and pesticide residues.478 These problems 
cannot be resolved through self-regulation or consumer awareness only. Food safety must also 
be a priority of the government, not simply of consumers, their organisations, and the food 
industry.
474  The term “NGO”, non-governmental organisation, means organisations outside of state systems, including 
advocacy organisations, non-profi t service-providing institutions, religious groups, and social welfare 
organisations. Ma, 2002. 
475  Li 2005, 30.
476  Li 2005, 30-31.
477  Bian 2004
478  Li 2005, 30.
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2.4 Legal Foundations: Comments
In this chapter, we have discussed the mechanisms in which food and medicine laws are made and 
implemented in the EU and China, without yet examining substantial rules on safety, effi cacy, and 
marketing of medicines. Here we comment on some of these general legal issues.
2.4.1 Pluralism in Sources of Law
A pluralist view of law does not focus on the nation state as the only source of all law. It is 
acknowledged that the sources of law are varied, and may also be found in:
the interaction of states (international law such as WTO and Codex; EU law),–
localities within the nation state (local or provincial regulation; state law in federal –
systems),
shared or collective projects (the internal regulation of corporations; professional self-–
regulation; contracts), and
religious communities or organisations (for example Torah; canon law; Islamic law), or  –
minority ethnic groups (traditional law and custom). 479
A food company or a medicine company can be seen as part of local, national, and global 
networks of communities created through laws and contracts. Above, we have discussed hard 
law, administrative soft law, and self-regulation on various levels. Also, religious rules and 
traditional customs affect the use of foods and medicines. For example, kosher rules could be 
seen as soft law, as kosher certifi cates resemble environmental or fair-trade certifi cates. We 
will not go further into religious rules, even though they are sometimes relevant for developers 
of functional foods.480
Cotterrell links law with community. In a law-and-community perspective, responsibility is 
the individual’s obligation to maintain mutual trust in the community in question. Individuals 
are usually involved simultaneously in many different communities, where responsibility 
is formed and judged. Communities are heterogeneous and potentially confl icting. Liability 
depends on what a reasonable member of a community is expected to know. In practice, the 
most powerful regulation wins. 481 Even though nation states do not produce all the law, they 
are in our opinion still the most important decision-makers. Nation states decide whether or 
not to be part of international agreements, whether or not to delegate legislative power at local 
level, whether or not to tender factual legislative competence to administrative organs, and 
whether or not to leave room for self-regulation and give binding effect to it. The decision of 
how to regulate (on what level, through which instrument, etc.) needs to be a conscious one.
479  Cotterrell 2006, 161-162.
480  For example: Kosher means pure food by Jewish law. Animals need to be slaughtered in that fashion. 
Islamic people will not eat blood, alcohol, or pork meat. Blood is also avoided by certain Christian movements. 
The Orthodox Christian will not eat meat during Lent, the Catholic not on Friday, Hindus will avoid beef in 
particular, and Buddhists should not eat meat at all. Talouselämä 2008.
481  Cotterrell 2006, 164.
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European and Chinese laws have been amended to comply with WTO requirements and, 
as regards food, the Codex standards482. The EC and China are recipients of international food 
standards. The GATT Agreement of the WTO is complemented by the TBT agreement and 
the SPS Agreement. The latter two agreements have similar requirements: non-discrimination 
(most-favoured nation treatment and national treatment), avoiding unnecessary obstacles 
to trade, adopting international standards as far as possible, and the transparency of these 
measures.
Both the EC and China are selective recipients of international standards. For example with 
Codex, standards are taken into account by European legislators and courts483 in so far as they 
are compatible with EC food safety objectives484. Similarly, China will not adopt all Codex 
standards, for example, if differing standards are required to protect the health of Chinese 
citizens, or if there are specifi c issues related to Chinese food industry or supervision485. This 
means that where Chinese food producers are capable of producing very safe food, or where 
China is a net import market, the government is inclined to set standards even higher than those 
of Codex. In areas where China is a net exporting state, China will, to support its exporters, set 
lower standards.486 Exporters must naturally take into account the standards of the recipient 
country, which might be either loose or strict.
The WTO has many critics. Some observers claim the WTO agreements are too invasive 
and deny Members sovereignty; others want the agreements to press further. Some trust 
national governments on issues related to public health and welfare, whereas others view 
domestic regulation merely as protectionism.487 The two factions claim to have a common 
goal, which is human well-being. They differ, though, on how best to achieve this goal, 
either through fl exibility, or consensus. As Rawls states, an ideal market process and an 
ideal legislative process are different entities. Markets are designed for effi cacy, and law, 
if possible, for justice.488Wilkinson sees civil society and development as two areas of the 
important challenges facing the WTO. NGO’s critique the WTO for promoting competition 
between companies and nations leading to suffering of employees and the environment489. 
Simultaneously, developing countries resist putting environmental and employee rights on 
the WTO agendas. This opposition stems from the fear that legislation will be used as veiled 
protectionism, undermining the competitiveness of the South490. The WTO needs to be able to 
satisfy all its Members in order to develop so that it benefi ts all its Members. Trust is crucial 
in this vicious circle.
482  Kan - Zhang 2002. 
483  Codex standards have been referred to by the European Court of Justice. Poli 2004, 616.
484  Poli 2004, 616.
485  Kan –Zhang 2002.
486  Bian 2004.
487  Harvard University web page 2004.
488  Rawls 1971, 207. 
489  Wilkinson 2000, 140.
490  Wilkinson 2000, 143.
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2.4.2 Central vs. Local Laws
When discussing the actors of food and medicine law, the fi rst question to be addressed 
relates to the roles of international actors such as the WTO vs. central governments vs. local 
governments.
Globally, the aim of the Word Trade Organization is to facilitate trade. Barriers to trade 
are considered a hindrance to global economic growth, and therefore agreements such as the 
GATT agreement, the TBT agreement and the SPS agreement aim to remove these barriers. 
These global agreements have signifi cant impacts on companies and consumers, as they affect 
whether or not a product can access a certain market. Although free trade has its opponents, 
lawyers are not openly critical as they 491are more interested in defi ning the conditions for 
exceptions to free trade.
In what situations should the EU be able to block Chinese functional foods from entering 
the EU market? And vice versa? When are they unsafe and/or ineffective? As members of the 
WTO, EU and China would have to show that based on scientifi c risk assessment, the products 
in question are dangerous to human health. Disagreement on the scientifi c issue would have 
to be settled by the WTO dispute resolution body. This sets great demands on WTO dispute 
resolution: it needs to be impartial and transparent, and it needs to be considered just to uphold 
its legitimacy.
According to the law-and-community perspective, international regulation has emerged 
to express social relations. The desire for a coherent legal order has risen out of collective 
experience of international communities.492 For example, a signifi cant part of environmental 
advocacy has been directed at multinational economic institutions rather than through state 
structures. Thus, the environmental movement has contributed to change within the processes 
of global governance.493 However, as transnational legal authority depends on power politics, 
structures in international legal orders are fragile.494 This is the case with the WTO rules: 
their content depends on the negotiation powers of the WTO members. National rules are 
purportedly more stable as they are based on structures of democracy, and - at least to some 
extent - shared values.
In Europe, the legislative competences of the EU and its Member States are stipulated 
by the Treaty establishing the European Community. The principles of proportionality and 
subsidiarity are particularly discussed and weighed in explanatory memorandums of newer 
laws. The result is today often the same: European legislation is considered necessary. 
The simple rationale is that free trade would otherwise suffer. European legislation is also 
considered to better safeguard public health and consumer rights. In the fi elds of food and 
medicine law, EU legislation covers progressively more space, and space for Member State law 
is thus decreasing. Europe-wide industry’s self-regulation makes the question of Community 
competence vs. Member State sovereignty irrelevant. Schepel sees standards as “bottom-up-
integration”.495 It is important to observe that this kind of integration might have happened 
even without government interference. The EU has certainly accelerated integration, though.
491  For example Joutsamo et al. 2000, Mäkinen et al. 2006, and Raitio 2006 simply state free trade as a goal.
492  Cotterrell 2006, 167.
493  O’Brien et al.2000, 158.
494  Cotterrell 2006, 167.
495  Schepel 2005, 73.
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Pasa and Benacchio see European consumer law quite positively: “the interventionist policy 
... in the area of consumer protection has assumed an important autonomous role, as a social 
goal of the European Union, and is no longer seen as merely instrumental in the protection 
of competition”496. Critics argue that EU harmonisation is sometimes used unnecessarily and 
that Member States could better protect the rights of their citizens. Instead of the subsidiarity 
principle, the most serious hindrance to the transfer of tasks to the European level might be 
fear that the EU loses societal legitimacy if it initiates cooperation in areas that the majority of 
Europeans fi nd are illegitimate497.
According to the Chinese constitution, local government has the right to formulate local 
standards if they do not confl ict with national standards, or when there are no national standards. 
Local standards have created problems and barriers to trade. The legal development is also towards 
national harmonisation in China. Central-local tensions have complicated implementation of laws 
in China. Local offi cials are promoted based on their ability to ensure economic growth and social 
stability, regardless of whether national laws are violated498. This means incentives for local offi cials 
should be reshaped if enforcing national laws is seen as a priority.
When discussing harmonisation, it is important to notice the difference between minimum 
and maximum harmonisation. Minimum harmonisation means that local legislators can 
impose stricter laws if considered necessary to protect their citizens. Maximum harmonisation 
means full harmonisation in a sense that local legislators cannot deviate from central law in 
any direction. Maximum harmonisation is often used because it lowers transaction costs for 
traders. There are obvious problems with maximum harmonisation: it does not serve local 
variations in society and culture.
In creating internal markets, an alternative to harmonisation is mutual recognition. In the 
EU, this means that Member States are allowed to have their own standards, but if a product is 
authorised in one country, it cannot be blocked in another. The resulting overall standard might 
be lower or higher than with harmonisation. Often, harmonisation is considered necessary as 
regards essential features such as product safety. With regards to other features, harmonisation 
is not necessary for the creation of an internal market, because mutual recognition applies499.
2.4.3 Science vs. Politics
The science vs. politics issue relates to the central vs. local issue discussed above. Local actors will 
not assign competence to global powers unless they trust them Global actors need to be impartial 
concerning local needs. This introduces politics: politics can be seen as promoting the aims of a 
certain demographic. Global actors need to make decisions based on common good. They have to 
avoid favouring the most powerful, the most visible, or the most diffi cult members. With regard to 
functional foods, this means that law must be based on scientifi c risk assessment. The science vs. 
politics issue also relates to the hard law vs. soft law issue discussed above. Legislators will not 
leave competence in private hands unless they trust them to be impartial, and ‘science’ is seen as 
objective. In reality, science is always intertwined with politics.
496  Pasa – Benacchio 2005, 8.
497  Nedergaard 2007, 184.
498  Peerenboom 2008 a, 6.
499  Joutsamo et al. 2000, 446.
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The WTO presumes there is some kind of international objective assessment of the scientifi c 
evidence to be found. Schepel claims that the SPS Agreement of the WTO “transparently and 
pathetically” elevates Codex standards to the status of scientifi c truth500. In this regard the 
WTO does not have to make ‘political’ decisions, which would spark the legitimacy debate. 
Based on ‘scientifi c truth’, the WTO resolves the issue of whether a certain precaution is 
necessary or not.
The tasks and goals of European and Chinese food and medicine agencies have been 
discussed above. In the EU, the science vs. politics issue is recognised as common good/
public health competing against the interests of national lobby groups. In China, it has been 
questioned whether legislative efforts are driven by safety concerns (health) or by trade 
interests (money). Additionally the role of the SFDA has been scrutinised because of the 
corruption charges against its offi cials501.
When discussing the basic tasks of food and medicine law, the following key questions 
have emerged, both in drafting the law and interpreting it:
the role of the precautionary principle; –
the role of other legitimate factors besides science. –
Firstly, science does not have a solution to everything. It is easy to declare that laws and agency 
decisions must make consumer health their primary objective. However, it is not always clear 
whether a certain chemical is dangerous to a person’s health, or whether an herbal substance 
is effective in preventing a disease. Here we must deal with uncertainty and probabilities. 
Opinions on necessary precaution vary among scientists and among nations, and need to be 
continuously discussed.
Secondly, food and medicine law cannot even in theory and particularly not in practice be 
based merely on science502. Other factors such as small business promotion, promotion of local 
production, employment, human rights and other ethical reasons, etc. might be equally or more 
relevant. Food and medicine law considers more than just health and consumer protection. 
However, further discussion is needed on which are acceptable and which are unacceptable 
“other legitimate factors” besides science. It is accepted that, for example, farmers, businesses, 
consumers, employees, workers, conservatives, liberals, etc. do not always take the same view. 
‘Politics’ is not necessarily a source of all evil: instead it means that in democratic societies, 
people and organisations are permitted to have different opinions. These opinions, however, 
need to be weighed in a manner that legitimate rights of some groups are not suppressed. 
Once agreed upon, regulations need to be applied in an unbiased manner, both nationally and 
globally. Clearly, corruption cannot be tolerated.
According to Bian, it might be typical in developing countries that trade interests are the 
governments’ foremost concern. As China produces more agricultural products than it needs, 
its support of exports is very important.503 In the future, the Chinese focus might shift onto 
500  Schepel 2005, 222.
501  Tsoi 2007.
502  In the new European Nutrition and Health Claim Regulation 1924/2004/EC, it is stated (preamble 30), 
that “In some cases, scientifi c risk assessment alone cannot provide all the information on which a risk 
management decision should be based. Other legitimate factors relevant to the matter under consideration 
should therefore be taken into account.”
503  Bian 2004.
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creating more effective national markets. The EU has also been criticised for attaching too 
much importance to trade. Facilitating exports and imports is important to Europeans, but 
not as important as guaranteeing the function of the European internal market. After all, the 
European internal market consists of 27 countries of interest as market areas.
Schepel views modern governance as linking the political, the scientifi c, and the economic 
spheres of life. Standards bodies are an example of such a link: they connect the global 
marketplace to national politics, scientifi c knowledge to industrial practice, and social custom 
to law.504 Emotional aspects are part of social customs. Regulations intended to protect human 
health are often contentious, as people’s fears and scientifi c evidence do not always correlate. 
Here, emotions are seen as obscuring objective science.505 Emotions such as fear, love, hate, 
or guilt will perpetually encircle science and law.
2.4.4 Hard law vs. Soft law
Both in the EU and in China, and both in regulation of foodstuffs and medicines, the role 
of regulatory agencies is very important. In Europe, this refers to the EFSA and the EMEA, 
along with all the Member State agencies. The agencies are involved both in drafting the laws 
and implementing the laws. In China, administrative organs, such as the ministries and the 
SFDA, provide regulations that are called guizhang. Some of the most important hard laws, 
for example the General Food Regulation in the EU and the Food Safety Law in China, are 
quite basic and general, lacking detail. The details are given by administrative instruments, 
which can be called soft law. This means that a large part of foodstuff and medicine regulation 
is given by the administrators, not the legislators and that this is also the part that is particularly 
relevant from the entrepreneur’s perspective.
The binding nature of ‘guidelines’, ‘notifi cations’, ‘procedures’, etc. varies. In China, 
many actors typically have competence over the same issues, but still do not have to take 
regulations of other actors into account. This leaves regulation targets in an unclear situation 
regarding which regulations to follow. In Europe, soft law guidelines are typically attached 
with statements of the type “this is not binding; only the laws are binding”. This also leaves 
entrepreneurs legally insecure: the agencies presume that soft law guidelines are followed, but 
guidelines can suddenly be abolished or changed, or not be adhered to in individual cases.
In China, with both foodstuffs and medicines, one basic law given by the Congress is 
supplemented by several pieces of legislation given by the Ministry of Health, other ministries, 
or by the SFDA. Soft law includes all the scientifi c, technical and procedural details. This 
division of work between the Congress and the various other authorities has meant that a 
new law is not included in the basic law or any other piece of regulation. Instead, a separate 
piece of regulation is given on each issue. In the future, soft law on both foodstuffs and 
medicines might be codifi ed or collated together in China. In Europe, the EMEA has collated 
the regulatory materials on medicines into volumes combining hard law and soft law materials. 
This enables entrepreneurs to fully understand the regulations affecting their business. Similar 
collections could be published by the EU on food law.
504  Schepel 2005, 35.
505  Harvard University web page 2004.
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Standards have been discussed above as being something in between the public and the 
private. Standards are seen as facilitating growth and trade, and also as the answer to calls for 
better regulation. The European Commission sees standards as a new approach to legislation. 
As standards gain importance, effective participation in standard-making of all interested 
parties needs to be guaranteed506. International standards were recently discussed at a WTO 
Technical Barrier to Trade workshop. It was stressed that during economic crisis, standards 
should not be used for protectionist purposes, and also that developing countries need to be 
involved in setting up international standards.507
According to Koulu, the area of soft law will likely broaden in the future. Soft law is 
favoured by actors who produce it because it is fast and inexpensive as there is no need to fi nd 
a political compromise. The experts can merely draft soft law and publish it. Koulu points 
out that scientifi c expertise of law-makers will not automatically lead to high quality laws. 
Calls for better soft regulation have not emerged, although better regulation as regards hard 
law has received much attention. Soft law is beyond quality control, as the producer of soft 
law can revert to the fact that soft law is non-binding. Problems of legislative competence, 
legal coherence, legal interpretation, or legal protections for regulation targets can similarly 
be avoided.508 Simultaneously, normative terms are used perhaps to make regulation targets 
overlook the non-binding nature of soft law509.
Food and medicine law are typical areas where the above-mentioned reasons for soft law 
and its related problems apply. Detailed food and medicine law is typically given by experts, 
not legislators. Soft law is followed in practice, however, there is still not enough scientifi c 
discussion on competence or soft law quality. Critical evaluation of soft law and its makers is 
necessary in the fi eld of foodstuffs and medicines. Soft law cannot be ignored merely because 
it is by defi nition classifi ed as non-binding. Discourse theories defi ne the frameworks for 
making decisions, for example on law510. In democratic discourse theories, laws are seen as 
collective decisions for common good, as battle results, or as something in between511.Tuori 
sees discourse in the civil society necessary both when laws are made and when they are 
implemented512. Concerning food and medicine law, the civil society consists of companies, 
consumers, healthcare organisations, etc., whose involvement in law-making is necessary to 
uphold legitimacy.
Sideri sees the current development of law as a move away from “government” to 
“governance”, from the formal legal order to informal ones. There is a shift of attention from 
representative democratic structures to engagement of citizens in new governance structures, 
from command and control rules to procedural rules communicating local knowledge, from 
the sovereign state to the responsible citizen, and from hierarchies to networks.513 Sideri 
sees “compromise” as a cognitive lens, through which law is to be examined. Laws refl ect 
506  The Commission lists NGOs, environment, consumers, SMEs, authorities, and business representatives. 
Commission Communication on Standards 2004, 9.
507  WTO news items 16 and 17 March 2009. Available on WTO home page at: http://www.wto.org/english/
news_e/news09_e/tbt_16mar09_e.htm.
508  Koulu 2009, 119-120.
509  Koulu 2009, 121.
510  See Habermas 1992.
511  Sassi 2000.
512  Tuori 2000, 300.
513  Sideri 2007, 2-3.
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temporary balances, bound to change again, especially in decentralised governance structures 
where interested parties are engaged in the decision-making process.514 Laws can thus be 
seen as products of communication between agents and structures515. In the fi eld of foods and 
medicines, we could see companies as citizens communicating their interests to authorities 
and the public, and legislators as governors who provide the necessary structures and facilitate 
this correspondence.
According to Schepel, law is in crisis. It cannot answer to the needs of modern, international 
societies. Like Sideri, Schepel discusses the shift from “government” to “governance”. 
Distinctions between public and private roles and values are becoming fl uid, and the locus 
of regulating is shifting from the state to other, multiple, locations516. If law and state were 
one, we could subjugate all private transnational rulemaking under national legal hierarchies 
stemming from national constitutions. Globalisation and private governance regimes break this 
mould and we need to redefi ne law itself. Schepel sees law as a coupling between fragmented 
social discourses517. Law as a product of nation-state politics might be in crisis, particularly if 
we look at international business. However, there is more to law than harmonising products. 
National legislation still covers many elements of societies and markets where functional 
foods are used: healthcare, school lunches, taxes on different products, media.
The concept of legal certainty518 might have to be reformulated in the new modes of 
governance. If law was seen as a temporary compromise between stakeholders, protecting 
legitimate expectations would mean protecting reliance on the communicative and interest-
balancing process of law-making itself, not so much on predictability of legal rules or their 
implementation. The imperative for legal policy would be co-ordinating public and private 
rulemaking519: promoting procedural integrity of the regulators, diversifying their membership, 
and enhancing their knowledge base520.
2.4.5 Pre-market vs. Post-market Control
As their key task, food and medicine control agencies are responsible for pre-market control 
of foodstuffs and medicines. Pre-market control means deciding, based on scientifi c criteria, 
whether the products are safe and effective. Pre-market control has always been the dominant 
regulatory mechanism for medicines, and today it is also often needed for foods. Besides 
scientifi c assessment of safety and effi cacy, the agencies also decide on the application and 
authorisation procedure itself, for example on how to draft the applications. Impartiality and 
514  Sider 2007, 58.
515  Sideri 2007, 126.
516  Schepel 2005, 31. Schepel refers to Black, Julia: Decentring Regulation: Understanding the Role of 
Regulation and Self-Regulation in “Post-Regulatory” World. Current Legal Problems. 2001.
517  Schepel 2005, 34.
518  Legal certainty forms an important aspect of most legal systems. It operates with sub concepts such 
as non-retroactivity and legitimate expectations. Protecting legitimate expectations means that good faith 
is respected: if parties in question fi rmly believe a particular course of action will be followed and it is 
reasonable for them to do so, they may rely on that expectation. The government can, however, violate their 
faith if it is necessary in order to protect the public interest. Jason-Lloyd 1997, 6.
519  Schepel 2005, 32.
520  Schepel 2005, 413.
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equal treatment of applicants is crucial. This notion was demonstrated in China because a 
key offi cial of the SFDA was executed for taking bribes. In China, the pre-market control 
procedures have been accused of being too complex and burdensome. Also the protection of 
intellectual property has been questionable and made some companies reluctant to apply for 
product registration in China.
Post-market control is also vital. Enhancement of supervision of foodstuffs and medicines is 
currently foremost on the agenda of the Chinese government. The Chinese aim to enhance product 
safety, and to promote social harmony and stability. This means, “establishing a coordinated 
supervision mechanism and upgrading the technical level of inspections and scientifi c testing”.521 
Also in Europe, enhancing control has been one area of focus.
It is an important legal starting point that operators themselves carry the primary 
responsibility for safety control, both pre-market and post-market. As companies have expertise 
on their own products, they should also carry the risks associated with their marketing. With 
foodstuffs, in-house control is often the most important - and sometimes the only - type of 
control. With medicines, the role of administrators is stronger as all medicines are subjected 
to pre-market registration. However, the ultimate responsibility always lies with the operators 
themselves.
Penalties are needed for breaking the rules on product safety and marketing. In Europe, 
penalties have not been used often, and there have been demands that punishments should be 
harder. The lack of criminal trials is considered a positive phenomenon: the system seems to 
work if penalties are rarely needed. The authorities have wide powers, but there is still a sense 
of cooperation in implementing the rules. More than orders, implementation seems to consist 
of negotiations and persuasion. Sometimes the negotiation approach might in practice be due 
to the fact that it is cheaper than going to courts.
In China, administrative penalties are stipulated rather accurately beforehand in yuan 
amounts. These administrative penalties are automatic with no room for consideration. 
Chinese legislators see that this is the best way to guarantee equality. Imposing penalties 
is thus often administrative work, and the court system is not as relevant as in Europe. This 
is due to the deep-seated norm against legal proceedings. Litigation in Chinese courts is 
increasing, but courts are still weak and depend on local governments for fi nancial support and 
enforcement522. China’s initiatives to enhance judicial independence may change this situation. 
China is taking steps to facilitate enforcement of judgments so that local protectionism will 
not be a hindrance523.
In China, several different government agencies create the laws524. The same authorities are 
also responsible for the implementation. It is important to notice that in China, legislation has 
been created very quickly in the past 30 years and implementation lags behind. Laws are typically 
521  Five-Year Plan for Food and Drug Safety. April 2007.
522  Wikipedia. http://en.wikipedia.org/wiki/Chinese_law.
523  Peerenboom 2008 b, 3.
524  Food safety for the Chinese domestic market is regulated by several government entities: the Ministry 
of Agriculture, the Ministry of Health, the Ministry of Commerce, the State Administration of Quality 
Supervision, Inspection, and Quarantine, and the State Food and Drug Administration. These entities have 
different and sometimes overlapping responsibilities. The State Administration of Quality Supervision, 
Inspection, and Quarantine is responsible for imported as well as exported goods. The SFDA oversees all 
medicines, both Western and traditional Chinese medicines, including their advertising.
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stricter than reality. This situation allows the government to fl exibly and suddenly tighten control, 
based on law525. Legislation thus features goals or options rather than reality.
The Chinese Food Hygiene Law and Chinese administrators have been criticised for 
focusing too much on punitive measures and too little on preventive measures such as 
inspection sites or mandatory safety criteria.526 It is easier to impose penalties instead of facing 
the enormous task of building the regulation of entire product chains on trust and negotiations. 
Food and medicine control is particularly challenging due to the huge size and diversity of the 
country.
The Chinese government seems to be dealing with this directly: the administration is 
restructured and competences are reassigned. This should allow the authorities at least to 
be aware of their competences and tasks, which is a good foundation. Authorities and their 
expertise are needed to help regulation targets implement the laws in practice. The new Food 
Safety Law of 2009 creates a new state-level Food Safety Commission to oversee food safety 
monitoring. This Commission will consist of members from the Ministry of Health, the 
Ministry of Agriculture, the General Administration for Quality Supervision and Inspection 
and Quarantine, State Food and Drug Administration, and the State Administration for Industry 
and Commerce.
525  Welin – Kaulo 2005.
526  Li 2005, 29.
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3 FUNCTIONAL FOODS: FOODSTUFFS OR 
MEDICINES? 
In this chapter, we aim to defi ne the boundaries of two legal foodstuffs and medicines. These are 
the two most important legal concepts for the purposes of this study. This includes reviewing 
the legal status of functional foods. 
This chapter forms the background for subsequent chapters, which review the law on 
safety of foodstuffs and medicines (chapter 4), and the law on marketing of foodstuffs and 
medicines (chapter 5). 
3.1 Legal Concepts and their Functions  
According to Tuori, legal concepts are important in systematising surface-level legal 
material.527 New legislation does not function in isolation but is inserted into the legal order’s 
totality. Location of new legislation in this totality is determined by legal concepts. Through 
the legal concepts, material legislation fi nds its place in the legal order.528 Legal concepts of 
‘food’ and ‘medicine’ have the important task of systematising the legal material that governs 
functional foods as we have determined them in chapter 1. The two concepts divide products 
into two categories, for which separate parts of the legal order apply. 
Legal concepts are not legal terms. Terms are linguistic phenomena, whereas concepts are 
semantic phenomena. Concepts are meaning-contents or thought-contents, which can be expressed 
through one or more terms. 529 This means that the terms ‘food’, ‘foodstuff’ and ‘elintarvike’ (the 
Finnish word for food) all express the same concept, i.e. they are synonyms. ‘Medicine’ and ‘drug’ 
also express the same concept, whereas ‘pharmaceutical’ sometimes refers to chemical medicines 
only. Naturally, ‘food’ and ‘medicine’ are also, for example, sociological and medical concepts. 
Each fi eld of science needs to create their own concepts. Legal concepts are formed by lawyers, 
whereas, for example, medical concepts are formed by doctors. 
Lawyers must defi ne legal concepts in order to be able to create and work with legal 
material. Law-making is not a single process leading to a single legal decision. Instead, law is 
made in several processes leading to the production of a legal concept.530 The legal concepts 
527  Legal concepts are products of the legal culture that lies beneath the surface. Legislation and court cases 
are the surface. Tuori 2002, 169.
528  Tuori 2000, 192-193.
529  Frändberg 1983, 84.
530  Zamboni 2008, 523.
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of ‘food’ and ‘medicine’ have been formed through legislation and court cases, as will be 
described below. These concepts can also be developed through jurisprudence. Legal concepts 
are not static: they are continuously clarifi ed, reformulated, and redefi ned. It is worth noting 
that legal concepts might be abolished or replaced by other concepts. 
Rationalism is the ideological base that ties law formation and concept formation together531. 
Legal concepts can be defi ned as rules aiming to build rationality of the law. Rationality 
is built in an interaction where different concepts are coordinated and combined to build a 
rational system. Rationality of the law is not an objective question. It depends on the legal 
system under consideration, and theoretical assumptions of the observer. Rationality can have 
both formal criteria such as consistency and coherence, and substantial criteria such as justice 
or economic effi ciency.532 These criteria of rationality can be applied also to the legal concepts 
of ‘food’ and ‘medicine’. 
Legal concepts are lenses through which lawyers see the world533. However, when defi ning 
legal concepts such as ‘food’ and ‘medicine,’ legislators and courts need help from scientists of 
other fi elds. The separation between foodstuffs and medicines is a question of nutrition, health 
policy, business opportunities, and consumer behaviour. Besides lawyers themselves, experts 
of all these other fi elds must acknowledge the legal concepts. Legal concepts affect consumer 
choice and thus presumably public health. Because of the wide-reaching implications, legal 
concept formulation deserves consideration, and re-consideration when necessary. Business 
law is an interaction where legislators and courts respond to the market situation, and markets 
in turn respond to law. This is also the case in regulating functional foods. By calling business 
law interaction, we do not see law as merely about removing social friction534. Law is also a 
question of values: law should guide ethical behaviour.  
3.2 Europe: Foodstuffs vs. Medicines?  
In Europe, the national authorities determine whether a product is a medicine or a food. 
This categorisation decision is based on European defi nitions of foodstuffs and medicines. 
However, these defi nitions leave room for interpretation. The European Court of Justice will 
ultimately decide how the EU defi nitions are to be interpreted. The national authorities will 
have to follow the ECJ practice. 
3.2.1 Defi nitions in Legislation  
Codex Alimentarius535 defi nes food as: 
“Any substance, whether processed, semi-processed or raw, which is intended for human 
consumption, including drink, chewing gum and any substance which has been used in the 
531  Frändberg 1983, 115. Rationalists believe that rational structures can be created by rational thinking.
532  Zamboni 2008, 523.
533  Tuori 2002, 51.
534  See Pöyhönen 1997, 248. 
535  The UN ‘food code’, jointly made by FAO and WHO. Codex was discussed above in chapter 2.
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manufacture, preparation or treatment of ‘food’”. Food does not include cosmetics or tobacco 
or substances used only as drugs.536 
In the EU, a product can be regarded as a medicinal product either by its marketing 
claims or by its functions. The defi nition of ‘medicinal product’ in the EU medicinal products 
directive537 is the following: 
“Medicinal product:
Any substance or combination of substances presented(a)  as having properties for treating 
or preventing disease in human beings; or
Any substance or combination of substances which may be used in or administered to (b) 
human beings either with a view to restoring, correcting or modifying physiological 
functions by exerting a pharmacological, immunological or metabolic action, or in 
making a medical diagnosis.” 
Of the different functions that medicinal products have, restoring, correcting or modifying 
physiological functions by exerting a pharmacological, immunological or metabolic action 
have implications for functional foods. Making a medical diagnosis is something a functional 
food would not do. 
The defi nition in the Medicinal Products Directive was made to encompass all products 
designed or claiming to deliver a preventive, therapeutic or curative effect, including not only 
products having a genuine effect but also those which are not suffi ciently effective or do 
not have the effect which consumers might expect from their presentation. By submitting 
all products with medicinal functions and claims to a common licensing procedure, it was 
considered that effective and consistent consumer protection could be ensured, not only from 
harmful toxic products as such, but also from a variety of products being used instead of 
proper, effective remedies.538 
The defi nition was changed by the Directive 2004/27/EC539. It was then added that there had 
to be a pharmacological, immunological or metabolic action, if the product is to be regarded 
as a medicinal product by function. The new defi nition thus specifi es the type of action that the 
medicinal product may exert on physiological functions540. The previous defi nition only stated, 
“modifying physiological functions” without specifying different types of ‘actions’ through 
which these ‘functions’ are modifi ed. ‘Physiological functions’ clearly mean the functions of 
the living organism, the physical body. The terms ‘pharmacological’, ‘immunological’ and 
‘metabolic’ are more diffi cult to understand and although they are decisive here, they are not 
defi ned in the directive. The terms still leave room for interpretation on what is considered a 
medicinal function. 
536  Codex General Standard for the Labelling of Pre-packaged Foods (1985), 8.
537  Article 1(2).
538  Coppens et al. 2001, 141.
539  Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending 
Directive 2001/83/EC on the Community code relating to medicinal products for human use. The former 
defi nition was the following: “Medicinal product: Any substance or combination of substances presented 
for treating or preventing disease in human beings. Any substance or combination of substances which may 
be administered to human beings with a view to making a medical diagnosis or to restoring, correcting or 
modifying physiological functions in human beings is likewise considered a medicinal product”.
540  Preamble 7, directive 2004/27/EC.
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According to the Cambridge Advanced Learner’s Dictionary, ‘pharmacology’ means the 
study of medicines and drugs, including their action, their use and their effects on the body.541 
According to Elhurst University542, medicines can be divided into main groups according to 
the following different types of pharmacological actions:
Chemotherapeutic agents used to cure infectious diseases and cancera) 543,
Pharmacodynamic agents used in non-infectious diseasesb) 544, and
Miscellaneous agents such as narcotic analgesics and local anaesthetics. c) 
Immunity means the ability of the body to resist pathogens545, i.e. agents that cause diseases. 
‘Immunology’ means the study of immunity and its causes and effects.546 Immunological 
disorders are conditions where the immune system fails to function properly, such as AIDS. 
‘Immunological action’ in the defi nition of medicinal product thus means something that 
modifi es, corrects or restores physiological functions by affecting the immune system. 
According to the Cambridge Advanced Learner’s Dictionary, metabolism means “all the 
chemical processes in your body, especially those that cause food to be used for energy and 
growth”.547 Metabolic processes are organic processes that are necessary for life. ‘Metabolic 
action’ in the defi nition of medicinal thus means something that modifi es, corrects or restores 
physiological functions by affecting the metabolic system. This could be interpreted to mean 
almost anything that happens in the body to keep the body alive. 
It seems that foods could have ‘pharmacological’, ‘immunological’ or at least ‘metabolic’ 
actions. It seems complicated to defi ne medicines in a manner that would clearly exclude 
foods. A category of “borderline” products has emerged. The European Commission tried 
to resolve the issue of these borderline products by Directive 2004/27/EC. According to 
preamble 7 of the Directive, the defi nition of medicinal products and simultaneously the scope 
of the Medicinal Products Directive needed clarifi cation particularly as a result of scientifi c 
and technical progress. It was stated that there is a growing number of “borderline” products 
between the medicinal product sector and other sectors. The aim was to modify the defi nition 
of medicinal product so as “to avoid any doubt as to the applicable legislation when a product, 
whilst fully falling within the defi nition of a medicinal product, may also fall within the 
defi nition of other regulated products”.548 
Preamble 7 continues: “it is necessary, in case of doubt and in order to ensure legal certainty, 
to state explicitly which of the two colliding provisions have to be complied with”. Where a 
product comes clearly under the defi nition of other product categories, for example food and 
food supplements, the medicinal product directive does not apply.549 New Article 2(2) gives the 
answer in situations where the case is not clear: “In cases of doubt, where, taking into account 
all its characteristics, a product may fall within the defi nition of a ‘medicinal product’ and 
541  Cambridge Advanced Learner’s Dictionary.
542  Elmhurst University web page: Virtual Chemistry book.
543  Sulfa drugs, antibiotics.
544  Cholinergic, Adrenergic, Hallucinogenic, Sedatives.
545  The Free Dictionary. http://www.thefreedictionary.com/immunity.
546  Cambridge Advanced Learner’s Dictionary.
547  Cambridge Advanced Learner’s Dictionary.
548  Preamble 7, directive 2004/27/EC.
549  Preamble 7, directive 2004/27/EC.
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within the defi nition of a product covered by other Community legislation the provisions of 
this Directive shall apply”. This means a product is in unclear cases classifi ed as a medicine. 
The defi nition of food in the EU General Food Regulation does not offer any guidance on 
the categorisation issue: 
“For the purposes of this Regulation, “food” (or “foodstuff”) means any substance or 
product, whether processed, partially processed or unprocessed, intended to be, or reasonably 
expected to be ingested by humans.
“Food” includes drink, chewing gum and any substance, including water, intentionally 
incorporated into the food during its manufacture, preparation or treatment. It includes water 
after the point of compliance as defi ned in Article 6 of Directive 98/83/EC550 and without 
prejudice to the requirements of Directives 80/778/EEC551 and 98/83/EC. 
“Food” shall not include:
feed;a) 
live animals unless they are prepared for placing on the market for human b) 
consumption;
plants prior to harvesting;c) 
medicinal productsd)  within the meaning of Council Directives 65/65/EEC(21) and 
92/73/EEC(22) 552;
cosmetics within the meaning of Council Directive 76/768/EEC(23)e)  553;
tobacco and tobacco products within the meaning of Council Directive 89/622/EEC(24)f) 554;
narcotic or psychotropic substances within the meaning of the United Nations g) 
Single Convention on Narcotic Drugs, 1961, and the United Nations Convention on 
Psychotropic Substances, 1971;
residues and contaminants.”h) 555 
This means that when it comes to products ingested for health reasons, such as functional 
foods, the defi nition of ‘food’ covers everything that is left outside the defi nition of 
‘medicinal product’. A product always has to be either a food or a medicine, not both. The 
Medicinal Products Directive refers to medicinal products as “…substances or combination 
of substances…”. Substance is defi ned as “any matter irrespective of origin which may be 
human, animal, vegetable or chemical. Foods are substances or combinations of substances 
within this broad defi nition. Therefore, the raw materials themselves do not determine the 
classifi cation of a product as food or medicine.556 
550  Council Directive 98/83/EC of 3 November 1998 on the quality of water intended for human 
consumption.
551  Council Directive 80/777/EEC of 15 July 1980 on the approximation of the laws of the Member States 
relating to the exploitation and marketing of natural mineral waters.
552  These Directives were codifi ed and replaced by the Directive on the Community Code Relating to 
Medicinal Products for Human Use 2001/83.
553  Council Directive 76/768/EEC of 27 July 1976 on the approximation of the laws of the Member States 
relating to cosmetic products.
554  Council Directive 89/622/EEC of 13 November 1989 on the approximation of the laws, regulations and 
administrative provisions of the Member States concerning the labelling of tobacco products.
555  Article 2.
556  Coppens et al. 2001, 142.
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3.2.2 European Court of Justice: Case Law 
As stated above, Article 1 of Directive 2001/83/EEC defi nes a “medicinal product” as: 
Any substance or combination of substances presented(a)  as having properties for treating 
or preventing disease in human beings; or
Any substance or combination of substances which may be used in or administered to (b) 
human beings either with a view to restoring, correcting or modifying physiological 
functions by exerting a pharmacological, immunological or metabolic action, or to 
making a medical diagnosis.” 
Medicinal products may well fall under both limbs of the defi nition but the European
Court of Justice (ECJ) has confi rmed that falling under either limb is suffi cient to classify 
it as a medicinal product. [Upjohn 1989]: “Directive 65/65 provides two defi nitions of the 
term “medicinal product”: one relating to presentation, the other to function. A product is 
medicinal if it falls within either of those defi nitions.” 
If we look at the ‘claim’ part of the defi nition, the ECJ has placed considerable emphasis on 
the impression that consumers are likely to form as a result of the product’s presentation. [Van 
Bennekom 1982]: “It is necessary to take the view that a product is presented for treating or 
preventing disease…. whenever any averagely well-informed consumer gains the impression, 
which provided it is defi nite, may even result from implications, that the product in question 
should, regard being had to its presentation, have an effect such as is described by the fi rst part 
of the EC defi nition.” 
The ECJ attaches importance to protecting vulnerable consumers from products that could 
not deliver the claimed medicinal results. [ibid]: “The Directive thereby seeks to protect 
consumers not only from harmful or toxic medicinal products as such but also from a variety 
of products used instead of the proper remedies.” 
The ECJ has ruled557 that a product does not necessarily need to be presented explicitly 
for the prevention or treatment of human diseases to trigger medicinal status. A medicinal 
status may arise from the impression that an average, well-informed consumer would be likely 
to gain. This may derive from aspects such as the product’s composition, pharmacological 
properties, claims and associated commercial and non-commercial communication, its 
presentation (including any similarity to medicinal products) and point of sale, any risk arising 
from prolonged consumption, the way it is used, and its familiarity to the consumer. 
The question whether or not a product is perceived as “medicinal” will be resolved, 
primarily, by reference to the balance of medical and non-medical uses on the label or 
advertising and not to the likelihood of sales for one use rather than another. The nature of 
the product’s constituents is not usually the decisive factor, although if a product contains 
therapeutic levels of pharmacologically active substances, this could well result in it being 
considered a medicine, even if the base-line product is clearly a food. In reality it is likely that 
well established food products would be considered as foods and well-established medicines 
as medicines.558 
557  Case C227-82.
558  Coppens et al. 2001, 143.
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On a literal interpretation of the existing legal texts, any food carrying a medicinal claim 
would become subject to medicinal legal procedures and would require a Product Licence. 
No medicinal product may be placed on the market of a Member State unless a marketing 
authorisation has been issued by the competent authorities of that Member State559 according 
to the Directive 83/2001/EC.560 
In Ter Voort case561, the European Court of Justice ruled that a product that is recommended 
or described as having preventative or curative properties is a medicinal product even if it is 
generally considered as a foodstuff and even if it has no known therapeutic effects in the 
present state of scientifi c knowledge. Conversely, the advertising of a medicinal product to the 
general public shall not contain any material, which suggests that the medicinal product is a 
foodstuff562. This means that if a food-based product makes a medicinal claim, it is a medicinal 
product, probably an illegal one. 
As previously stated, ,a product can be considered as a medicinal product based on its 
functions as well as its claims. It has long been recognised that certain foods are able to restore 
and correct disturbed physiological functions caused by nutrient defi ciencies, e.g. vitamin C 
rich foods will cure scurvy, iodized salt will restore thyroid function, and vitamin A rich food 
will restore night vision. Recent scientifi c literature amply and increasingly indicates that 
many other foods are able to restore, correct or modify physiological functions by virtue of 
the non-nutrient substances they contain.563 This means we could classify almost all foods as 
medicines. 
In law, all foods can be considered medicinal products if ingested with the view to restoring, 
correcting or modifying physiological function. The Advocate General’s Opinion in the 
Delattre case564 states that the function-based defi nition of medicinal products is formulated in 
such broad terms that, if read literally, it can apply both to medicinal products and foods. 
It is important to note that the Delattre case occurred in the period before the new defi nition 
where medicinal action is specifi ed as “modifying physiological functions by exerting 
pharmacological, immunological, or metabolic action”. As discussed above, the terms 
‘pharmacological’, ‘immunological’, and ‘metabolic’, still do not exclude foods. Our science-
based understanding on the relationship between diet and health seems to make it impossible 
to defi ne medicines in a manner that would clearly exclude foods. That is why the legislators 
decided to establish the unoffi cial borderline category of “unclear cases”, at the same time 
directing these products under medicine law. 
The European Court of Justice (ECJ) has ruled that it is the competence of Member 
States’ National Authorities to judge whether a product is a food or a medicinal product. 
The consequence of this is that there cannot be legal certainty at a European level. National 
559  A marketing authorisation for a medicinal product granted by a competent authority in one Member 
State ought to be recognized by the competent authorities of the other Member States unless there are serious 
grounds for supposing that the authorisation of the medicinal product concerned may present a risk to public 
health (Recital 12.)
560  Some products are subjected to a centralised authorisation procedure according to Council Regulation No 
2309/93 of 22 July. 
561  Case C219-91.
562  Medicinal Products Directive, Article 90(g).
563  Coppens et al. 2001, 142.
564  Case C369-88.
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defi nitions might be broader than the European defi nitions.565 According to the European Food 
Lawyers Association, the borderline between foodstuffs and medicinal products is one of the 
remaining food law problems to be resolved. They see the situation where the categorisation 
decision lies with Member States as a severe obstacle to the achievement of the Single Market. 
The regulations on food supplements, fortifi ed products and nutrition and health claims have 
greatly harmonised the area of health-promoting foods.566 The proposed labelling regulation 
will continue this development, leaving only the issue of food vs. medicine unharmonised. 
As the foodstuff vs. medicine issue is still under the competence of EU Member States, we 
will examine the Finnish and UK strategies to cope with the categorisation task. The British 
system is fairly developed and might serve as a model for future EU system performed by the 
EFSA or the EMEA. 
3.2.3 Finnish Practice  
According to section 6 of the Finnish Medicinal Products Act, when necessary, the National 
Agency of Medicines (Lääkelaitos) determines whether or not a product is a medicine. When 
making the decision of categorisation, both the composition and the purpose of use are taken 
into account. The Food Act or other food legislation does not affect the decision. For medicinal 
products, the national authorities also resolve the retail channel of a medicinal product 
(pharmacy only or other stores as well), and whether a medicine requires a prescription or 
not. 
The National Agency of Medicines has published a Pharmacopoeia (1179/2006), where 
all the ordinary medicines and herbal medicinal products are listed. According to section 1 of 
the Pharmacopoeia, other substances and herbs that are medically equivalent to those listed 
and used in a medicinal way can be held as medicines. Also vitamin or mineral preparations, 
where the daily dose exceeds the limits in the pharmacopoeia can be held as medicines, as well 
as vitamin or mineral preparations for children. 
If it is unclear whether the product to be placed on the market is a medicine or not, the 
National Agency for Medicines will, on request, classify the product. It will normally do 
this only on request and requires a fee567. Information on the product should be submitted to 
the Pharmacovigilance Activities unit of the National Agency for Medicines for the decision 
on classifi cation.568 The National Agency for Medicines can also without request classify a 
product as a medicine, if it complies with the defi nition of medicines. 
The Food Safety Agency is also involved in classifi cation. It “recommends” a marketer 
to apply for a classifi cation decision if a food contains substances or herbs listed in the 
pharmacopoeia, or if the amount of vitamins or minerals exceeds the set limits. If the Food 
Safety Agency itself notices that a food supplement contains medicinal materials, it will 
specifi cally recommend the marketer to apply for a classifi cation decision. The Food Safety 
565  Coppens et al. 2001, 142.
566  European Food Law Association. Letter to the Commission. January 2007. 
567  The fee was 85 euros in 2006.
568  National Agency for Medicines web page. http://www.nam.fi /english/pharma_industry/herbal_remedy/
herbal_medicinal_product/index.html.
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Agency also notifi es the National Agency for Medicines of its recommendation.569 Because 
of the pre-market notifi cation procedure for food supplements, it is easy for the Food Safety 
Agency to follow what is put into food supplements. This is not the case for functional foods, 
for which there is not necessarily any pre-market clearance. 
Dosage is the key word in determining whether a product containing medicinal herbs, 
vitamins, or minerals is regarded a medicine. This means the distinction between medicines 
and foodstuffs is often (merely) gradual. With vitamins and minerals, the medicinal doses 
are set beforehand. With herbs, there is more room for discretion. We will look into Finnish 
examples of medicines and non-medicines in chapter 6 when trying to predict how our fi ctional 
products will be classifi ed. 
The system of voluntary clearance will lead to some products with medicinal effects being 
sold as foods. It is not mandatory to get a product classifi ed even if it contains medicinal herbs. 
One can just sell the product as a food and wait to see if the Food Agency and the Medicine 
Agency react. After products are classifi ed as medicines, the marketer must withdraw products 
from food stores. 
3.2.4 UK Practice
In the UK, ‘borderline product’ is a term for products that are not easy to distinguish from a 
medicine, for example, cosmetics or food supplements570. The decision of whether a product is 
a medicine is based on its functions and its marketing, as stipulated in the medicinal products 
directive. Normally, a product which is for use only as a toilet preparation, disinfectant, food or 
beverage is not regarded as a medicinal product, and, therefore, does not require a marketing 
authorisation. Similarly, dietary supplements, containing such familiar substances as vitamins, 
amino acids or minerals, are generally subject to food safety and marketing rules rather than 
medicines control.571 
However, should any of the above contain a pharmacologically active substance or make 
medicinal claims, it would be regarded as a medicine. Medicinal claims are, according to 
MHRA, claims to treat or prevent disease, or to interfere with the normal operation of a 
physiological function of the human body572. The defi nition of a medicinal claim is of course 
based on the longer defi nition in the directive, but the UK defi nition is worth mentioning, 
as every EU member state will see the concept of ‘medicine’ a bit differently, which will 
infl uence the division of foods and medicines. Presenting medicinal claims in labelling and 
advertising will make any cosmetic or food a medicinal product. 
The MHRA’s Borderline Section, similarly to the Finnish NAM, offers advice on the status 
of a product in cases of doubt. The MHRA’s Borderline Section has an online “Borderline 
Medicine Advice Form” for this purpose. A full reply is promised “in due course”. In making a 
decision, the MHRA considers “each individual product on its merits and any information which 
569  The Food Safety Agency Guideline on Food Supplements. Updated December 2006.
570  MHRA web page. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=tr
ue&ssDocName=CON009271&ssTargetNodeId=91.
571 MHRA web page. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=tr
ue&ssDocName=CON009271&ssTargetNodeId=91.
572 MHRA web page. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=tr
ue&ssDocName=CON009271&ssTargetNodeId=91.
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may have a bearing on the product’s status, for example, the claims made for the product, the 
pharmacological properties of the ingredients, whether there are any similar licensed products 
on the market, and how it is presented to the public through labelling, packaging, promotional 
literature and advertisements”.573 
The MHRA has also issued a guidance note related to borderline products. Guidance Note 
8, ‘A guide to what is a medicinal product’ provides detailed information and is intended for 
the guidance of companies who need to consider whether products they propose to place on 
the market are medicinal or not574. The food vs. medicine -issue is discussed in sections 7 and 
8 of the guidance note. “Food” is defi ned as any food, drink or food supplement that is part 
of the diet. Every ingested product is either a food or a medicine. Also articles and substances 
of no nutritional value are foods. A product, which the average consumer would regard as 
something to be eaten, drunk or chewed as part of his/her diet, for example, because of its 
taste, fl avour, or nutritional value, is unlikely to be classifi ed as a medicinal product. However, 
if the product contains one or more ingredients generally regarded as medicinal and indicative 
of a medicinal purpose, it will likely be classifi ed as a medicine.575 
In the guidance note, relevant guidance issued by the Local Authority Coordinating Body 
on Trading Standards (LACOTS) and the Joint Health Claims Initiative’s published Code of 
Practice are also referred to. It is also emphasised, that foods for particular nutritional purposes 
(dietary foods), including dietary foods for special medical purposes, are under separate EC 
and UK legislation.576 
The MHRA reaches a determination as to whether a product is a medicinal product on a 
case–by-case basis, and in the light of:
the defi nitions of medicine and food; –
relevant ECJ and UK precedents; and –
an assessment of all the available evidence. – 577 
Nothing defi nitive can be said about the weight of different pieces of evidence. It is stated 
that no single factor or combination of factors will necessarily be conclusive, or more or less 
important than others. On the contrary, a single factor or combination of factors may be more 
important than others, and may even be conclusive.578 
Medicine based on claims 
In assessing whether a product is “presented for treating or preventing disease”, the MHRA 
considers, explicit and implicit claims which are made for it, and with reference to its 
presentation as a whole. Claims of relief from symptoms, or to cure, remedy or heal a specifi c 
disease or adverse condition of body or mind will also be regarded as medicinal claims. If 
573 MHRA web page. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=tr
ue&ssDocName=CON009271&ssTargetNodeId=91.
574 MHRA web page. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=tr
ue&ssDocName=CON009271&ssTargetNodeId=91.
575  Guidance note, paragraph 7.
576  Guidance note, paragraph 8.
577  Guidance note, paragraph 14.
578  Guidance note, paragraph 14.
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the product, for example, claims to help cope with stress, anxiety and nervous tension, these 
are considered claims to treat or prevent disease. Claims to “protect” or “avoid” may be 
perceived by consumers as having much the same meaning as “prevent”, and would thus also 
be considered medicinal claims.579 
The MHRA does not consider claims to “maintain” or “help to maintain” or “support” 
health or a healthy lifestyle, as medicinal in themselves. The key is whether the product is a) 
said to maintain health or b) to restore some function or organ to a normal state. The latter 
claim would in the UK be considered medicinal.580 
To further help the applicants, the MHRA has listed factors particularly relevant to deciding 
whether a product is a medicine under the fi rst part of the defi nition (medicine based on 
presentation).These are: 
all claims made for the product, both explicit and implicit, including any made on linked  –
“helplines” or in linked publications. “Implicit” claims may include product names.
the context in which the claims are made, and the overall presentation; –
how a product appears to the public, or to those to whom it is promoted; –
the labelling, and packaging/package inserts including any graphics; –
the promotional literature, including testimonials and any literature issued by a third  –
party on behalf of the supplier;
advertisements, including those appearing in “advertorials”, on television, other media  –
and the Internet;
the product form, (capsule, tablet, etc.) and the way it is to be used; –
any particular target of the marketing information/advertising material, for example,  –
population groups with, or particularly vulnerable to, specifi c diseases or adverse 
conditions.581 
In addition to general criteria for evaluating marketing, The MHRA has also produced an 
indicative list of the kind of claims that the MHRA may decide are present in the product as 
treating or preventing disease. The words and phrases listed in Appendix 1 of the Guidance 
note are ones the MHRA has previously decided to be medicinal, in their context. There are 
around 40 of these phrase examples. In addition to clear cases such as “prevents”, “treats” and 
“cures”, the list includes for example: 
“Alleviates”
“Avoids”
“Clears”
“Combats”
“Controls”
“Counteracts”
“Eliminates”
“Fights”
“Heals”
579  Guidance note, paragraphs 15 and 16.
580  Guidance note, paragraph 17.
581  Guidance note, paragraph 18.
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“Helps”
“Protects against”
“Remedies”
“Removes”
“Repairs”
“Restores” “Stops” and “Traditionally used for”.
Medicine based on Function
A product may contain nutritional ingredients, and also ingredients having established use 
as medicine. In these cases, the product may be classifi ed a medicine because of its function. 
What is important is the dosage of the medicinal ingredient. Where there is doubt or dispute 
whether the recommended dosage level of the active medicinal ingredient is “therapeutic” or 
not, the MHRA will seek the advice of its medical and pharmaceutical assessors.582 
The MHRA states, that many herbs have an established or accepted use as medicines, 
for example as a bronchodilator (Ephedra), a respiratory stimulant (Lobelia), a sedative 
(Valerian), a defence against colds and ‘fl u (Echinacea), an anti-depressant (St. John’s Wort), 
a diuretic (Boldo), or an aphrodisiac (Yohimbe bark). The MHRA will generally consider 
products containing ingredients like these in therapeutic doses to be medicinal products on 
the basis that they “may be administered with a view to … modifying physiological function 
in human beings”.583 
The MHRA has listed factors that are particularly relevant to deciding whether a product is 
a medicine under the second part of the defi nition. These are as follows: 
the pharmacological properties of the ingredient(s) and any signifi cant effect(s) they  –
have on physiological function in humans;
the product promotional literature, including testimonials and any literature issued by a  –
third party on behalf of the product supplier;
the product form, (capsule, tablet, etc.) and the way it is to be used; –
the presence of essentially similar licensed or exempt medicines on the UK market. –
any claims, explicit or implicit, which although they may not be claims “for treating or  –
preventing [a specifi c] disease” could suggest to the average consumer that the product 
can be taken “with a view to … restoring, correcting or modifying physiological 
functions in human beings …”.584 
It is interesting that the MHRA uses claims also as indication of the medicinal function. The 
claims and the function could also be seen as separate issues, based on the two parts of the 
medicinal product defi nition. The MHRA sees the two parts of the defi nition intertwined 
and weighs presentation and functions as one question. Based on this notion, it seems that if 
the product combines somewhat medicinal ingredients with somewhat medicinal marketing 
messages it is more likely categorized a medicinal product than a product with only one of the 
above. A strong medicinal function or a strong medicinal claim would be enough. 
582  Guidance note, paragraph 20.
583  Guidance note, paragraph 21.
584  Guidance note, paragraph 23.
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It is even more interesting that selling the product in capsule or tablet form is on both lists: 
Product form is seen indicative both of medicinal presentation and of medicinal function. 
Product form is seen as a message to consumers, the message being ‘this is medicine’, and 
apparently simultaneously as proof of medicinal functions. However, food supplements are 
a completely legal and supposedly familiar category to consumers. Food supplements are 
legally foods: they are merely nutrients in compact form. Food supplements cannot bear 
medicinal claims. 
Herbals
For herbal ingredients, MHRA has provided additional advice. According to MHRA, an 
increasingly large number of products contain herbal ingredients. Following consultation with 
a number of UK Trade Associations the Medicines Borderline Section has put together a 
guidance sheet on herbal ingredients, which includes a list of herbal ingredients and their 
reported uses. This list is not binding in that it would resolve the issue of whether a certain 
herb is a medicine. The status of a product (food vs. drug) is determined on individual basis 
taking into account all the factors detailed in Guidance Note 8.585  
The Procedure for Borderline Products 
In the UK, also specifi c procedural legislation on borderline products has also been created. 
Factual grounds for decisions can still be found in the guidance notes and are under MHRA 
discretion. On 1 March 2000, The Medicines for Human Use (Marketing Etc.) Amendment 
Regulations 2000 came into force. They improve the way in which the MHRA determines 
whether a product is a medicinal product. The aim is a more systematic and transparent 
categorisation procedure (food vs. drug), along with improved compliance and decision 
enforcement. According to the Amendment Regulations, MHRA will give full written reasons 
for its decisions. There is an Independent (Advisory) Review Panel which, on request, 
will consider written and oral representations against MHRA provisional classifi cation 
determinations. Guidance on requesting a review of a Provisional Determination issued by the 
Borderline Section is available. There is now a criminal offence of non-compliance with fi nal 
MHRA decisions.586 
585  In the UK, there are three different kinds of herbal medicines. In addition to herbal medicinal products 
requiring authorisation and traditional herbal medicinal products requiring registration, there are exempted 
herbal medicinal products that can be sold without pre-market control. These exemptions are in section 12 
of the UK Medicines Act. These are herbal remedies on open sale, sold with no other name than their herbal 
constituents and without any written recommendations for use. An herbal remedy exempt from licensing is 
still subject to other legal requirements for medicines, particularly as to labelling.
586 MHRA web page. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=tr
ue&ssDocName=CON009271&ssTargetNodeId=91.
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According to MHRA, this statutory procedure provides a safe regulatory environment in 
which safe and benefi cial products are widely available, and illegal products are promptly 
removed from the market.587 
The MHRA describes the background of its borderline product legislation on its web 
page: “The UK was threatened with Infraction Proceedings at the European Court of 
Justice following the European Commission’s ‘Reasoned Opinion’; early in 1998 that it 
was not enforcing its decisions consistently and without delay.” The Agency published 
Consultation proposals in November 1998. Industry and consumer stakeholders were 
not happy with these fi rst proposals. Based on criticisms, the independent review panel 
was created, the MHRA was required to give full reasons for its provisional and fi nal 
decisions, and burden of proof in criminal issues was shifted back to the Agency. These 
changes to the proposals were presented in July 1999, and all the parties were quite 
happy with the fi nal legislation package. The process is considered transparent and 
effective, and the UK satisfi es its EC obligations. 
The MHRA also has a special determination procedure for cases of emergency:
“In exceptional circumstances, the MHRA is empowered to determine that a product is a 
relevant medicinal product without following the statutory determination procedure if there are 
reasons why it would not be appropriate to follow the procedure. Examples are where:
there is an identifi able risk to public health and /or patient safety; or –
the product is a copy of, or is identical in all material respects to, another relevant  –
medicinal product that has already been the subject of review panel advice.”588 
UK-type systematic and transparent classifi cation procedures might also be created in other 
EU Member States. However, the classifi cation decision will in the future likely be transferred 
under the competence of Community authorities, probably the EMEA. Some Member States 
might be waiting for this move and therefore not create separate borderline categories and 
procedures.  
3.3 China: Foodstuffs = Medicines? 
In the Chinese Medicine Administration Law, pharmaceuticals are defi ned as follows: 
““Pharmaceuticals” are the articles intended for use in the prevention, treatment or diagnosis 
of human diseases, or intended to effect the purposive regulation of human physiological 
functions, for which indications or major functions, usage and dosage are prescribed. They 
include raw traditional Chinese medicinal materials, traditional medicines prepared in 
587 The MHRA has further issued Guidance on the operation of the statutory process, in particular the Review 
Panel’s procedures. Trade associations were involved also in drafting this guidance. http://www.mhra.gov.
uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON009271&ssTargetNo
deId=91.
588  Guidance note, paragraph 24.
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ready-to-use forms, and other prepared Chinese medicines, medicinal chemicals and their 
preparations, antibiotics, biochemical medicines, radioactive drugs, serums, vaccines, blood 
products, diagnostic aids, etc.”589 
The Chinese defi nition of medicines is much more detailed than the European defi nition 
of ‘medicinal products’. However, in practice the same types of product are covered by 
both defi nitions. In China, traditional Chinese medicines are particularly mentioned in the 
defi nition. In Europe, the defi nition of medicines covers traditional herbal medicines. The 
Chinese want to emphasise the fact that modern and traditional medicines are treated equally. 
European attitude can be described as allowing the existence of traditional medicine while 
paying scant attention to it. 
A difference between European and Chinese attitude towards foodstuffs and medicines 
can be detected in the stated task of food law. In China, food is traditionally seen as related 
to health. Interactions between food and health are obvious to the Chinese. The Chinese 
Food Hygiene Law was enacted “for the purpose of ensuring food hygiene and preventing 
food contamination and harmful substances from causing injury to human health in order to 
safeguard the health of the people and improve their physical fi tness”. The goal of the new 
Food Safety Law is more simply stated as “assuring food safety and safeguarding people’s 
health and life”590. 
In the Chinese Food Hygiene Law, food was defi ned as follows: 
““Food” means any fi nished product or raw materials provided for people to eat or drink, 
as well as any product that has traditionally served as both food and medicament, with the 
exception of products used solely for medical purposes.”591 
This means that medicine is not permitted in foods. Still, products that have traditionally 
served as both medicine and food can be used as raw materials, condiments or nutrition 
fortifi ers592. The new Food Safety Law distinguishes between foodstuffs and medicines in 
Article 50: “Medicines can not be added to food, unless the added substance is traditionally 
considered both food and Chinese medicine.” The catalogue of substances that are traditionally 
considered both as food and as Chinese medicine will be published by the executive department 
of health under the State Council. This type of catalogue will offer valuable guidance to 
Western marketers. 
In China, several substances can be used either in foodstuffs or medicines. The major implication 
of a product being classifi ed as a medicine is that it imposes higher requirements for producers and 
sellers. For example, manufacturers of medicines must hold a GMP certifi cate and wholesale and 
retail enterprises a GSP certifi cate. This means the categorisation decision (medicine/non-medicine) 
is as important in China as it is in Europe. However, the classifi cation rules are not clear and the 
SFDA has not published any guidelines on the subject. Companies are consulting the SFDA on a 
case-by-case basis. 593 
The Chinese Advertisement law, Article 19 stipulates: the contents of advertisements for 
foods, alcoholic drinks or cosmetics must comply with the conditions in the relevant hygiene 
589  Article 102.
590  Article 1.
591  Article 54.
592  Food Hygiene Law, Article 10. “Nutrition fortifi er” refers to any natural or artifi cial food additive 
belonging to the category of natural nutrients that is put into food to 
increase its nutritive value. Food Hygiene Law, Article 54.
593  Tsoi 2007.
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licence and no medical jargon or words may be used so as to confuse them with pharmaceuticals. 
The rule is very similar to the EU one: foods and medicines must be separated and therefore 
medicinal claims on foods are prohibited. The Health Food Regulation of 1996 created the 
health food category between regular foods and medicines. ‘Health food’ is a category suitable 
for a product that: 
possesses the general nature of food, –
is able to regulate bodily functions of certain consumer groups, but –
is not meant for a therapeutic purpose.  –
In China, only health foods can bear health claims, and only medicines can bear medicinal 
claims. Article 11 of the Health Food Regulation separates health foods and medicines from 
each other: “Any medicinal product approved by the government should not apply for the 
Certifi cate of Approval on Health Food”. This way the health food category separates health 
foods from regular foods at one end, and medicines at the other end. The function and the claim 
resolve the foodstuff vs. medicine -issue, not the raw material as such. In law, the Chinese 
seem to have adopted the Western idea of separating between health promotion and disease 
prevention. The understanding of the roles of foodstuffs and medicines in consumers’ minds 
is another issue. Products are used by people, laws by businesses. 
3.4 Legal Status of Functional Foods  
As stated above in chapter 1.2., ‘functional food’ is not a legal term. The food industry has 
started to use the term ‘functional’ for food products that in some way promote health or 
enhance performance. The health-effect is achieved through removal of unhealthy ingredients 
(like saturated fats), adding of healthy ingredients that already exist in food (like folic acid) 
or the adding of completely new ingredients.594 Functional foods come in many forms: dairy 
products, beverages, cereals, oils, fats, confectionery, eggs, tomato-based products etc. 
The role of functional foods can be understood if we look at different ways to understand 
health. Using the medicinal way to defi ne health, we note health is the absence of disease. A 
healthy body is like a machine that works well, as opposed to a machine that malfunctions.595. 
In the humanistic view to health, health is seen as something more than the absence of disease. 
The humanistic or holistic view relates health to the ability to function, and the ability to 
achieve goals that are essential for ones happiness.596 The WHO defi nition of health is 
extremely humanistic: “Health is a state of complete physical, mental and social well-being 
and not merely the absence of disease or infi rmity”597. Functional foods perfectly correspond 
to the humanistic view of health. 
Humanists see health as a continuum or alternatively health and sickness as two different 
dimensions. The two views are presented in fi gures A and B. 
594  Elkington – Hailes 1999, 50.
595  Medin 2001, 105.
596  Medin 2001, 105.
597  WHO Constitution, New York 1946.
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A: Health and Disease as a Continuum:  
Health     Disease 
When health is viewed as a continuum (see fi gure A), health and sickness can exist 
simultaneously, and when a person is healthy, he is less sick. When he is sick, he is less 
healthy.598 Closer to the left of the fi gure, people are in good condition and work freely and 
they do not have any symptoms relating to weariness or disease. Closer to the right, people 
have explicit symptoms relating to disease which require treatment. In between, people feel 
generally weak and can display various symptoms (tiredness, depression, irritability) and 
these symptoms can affect their ability to manage life.599 
Bäcklund sees that the role of functional foods is to prevent a person in a state of ‘health’ 
from shifting into the state of ‘labile health’. The function of medicines would be to prevent a 
person from moving from the state of ‘labile health’ into ‘disease’, or to treat or cure diseases. 
She views health/disease as a continuum. Certainly she considers functional foods to be aimed 
at healthy people.600 
B: Health and Disease as Two Different Dimensions: 
Health 
Disease  
When health and sickness are seen as two different dimensions (see fi gure B), they are not 
seen as opposites. In this example, it is possible to be very sick and very healthy at the same 
time, and also not to have any sickness but still not be healthy at all. Health is basically defi ned 
by a person’s happiness. Some observers think that due to this new thinking there has been a 
598  Medin 2001, 106.
599  Kwak – Jukes, 2000a, 99.
600  Bäcklund 1998, 155.
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paradigm shift as today the focus of research is usually about what causes well-being, not what 
causes disease.601 Health is a concept in a totally different dimension to diseases. 
These humanist ways to understand health appeal to functional food developers. With the 
use of functional foods, people can become healthier, even if they cannot directly prevent, 
treat or cure any disease. Here experience of health is decisive602. 
Making the role of functional foods more complex are the products that are aimed at fi ghting 
a certain disease. We must draw the line between disease risk reduction and disease prevention as 
these two are in the same dimension regardless of how you look at it. The separation between risk 
reduction and prevention is where food and medicine law ultimately meet.603 
In practical linguistics, the difference is not clear. An individual might assume that if she 
eats healthy food, she will not suffer from a heart attack, which to her means prevention. In 
medicine, the difference has something to do with mathematics. The term prevention is used 
when preventive therapy will produce a result with a substantial degree of statistical certainty, 
and risk reduction claims are based on epidemiological evidence gained from population-
based studies.604 
According to Coppens et al. 2001, there are three types of medicinal disease prevention: 
Type 1: prevention of disease occurrence. Key characteristics of this type are that the 
disease is not (yet) present, and the therapy can prevent the occurrence of the disease with 
a substantial statistical certainty. This represents the absolute sense of prevention, and is for 
example the purpose of many vaccines. 
Type 2: prevention of episodes of the disease. Key characteristics are that the disease is present, 
and the therapy decreases the number, duration, or severity of disease episodes with a substantial 
statistical certainty. This is exemplifi ed by medicines given to patients with chronic diseases, like 
asthma or epilepsy and should more correctly be considered as part of the management of an 
existing disease, rather than prevention in the absolute sense. 
Type 3: prevention of progression of the patient’s underlying disease. Key characteristics 
are that the disease is present, and that the therapy has been shown to delay the progression of 
the disease with a substantial statistical certainty. In this case, medicines are given to prevent 
the more serious consequences of a disease and to hinder its progression rather than to prevent 
it absolutely. Examples include patients who are either asymptomatic, e.g. lowering blood 
pressure in hypertensive patients, or symptomatic, e.g. decreasing blood sugar in diabetic 
patients or treating HIV-positive patients to slow the progression of AIDS. 
It is accepted that certain types of foods may contribute towards both type 2 and 3 
treatments. These foods for special medical purposes are suitable for the dietary management 
of the particular disease and are regulated at the EU level through Directive 1999/21605. 
601  Medin 2001, 106.
602  Medin 2001, 106.
603  Besides prevent, foods could also possibly treat or cure diseases. In these cases, these foods would clearly 
be medicines, e.g. herbal medicinal products, and there is in practice no confusion. Prevention and risk 
reduction are more diffi cult to separate, because they both affect something that is not yet there.
604  Coppens et al. 2001, 143. The term prevention is also used in nutrition, when avoiding defi ciencies of 
essential nutrients. But prevention in the meaning of food and drug law does not cover this kind of malnutrition 
prevention. The concept in food and drug law is restricted to concern drug effects with the goal to prevent 
particular diseases.
605  Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes.
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Coppens et al. (2001) proposed a concept of disease risk reduction. The key characteristics 
of disease risk reduction are: 
The disease is not present. –
The cause of the disease is multi-factorial, including dietary, behavioural, environmental,  –
and genetic factors.
Modifi cation of certain dietary components, alone, cannot ensure that the disease will  –
not develop, since it does not affect the other factors but, nevertheless, it may help 
signifi cantly to reduce the likelihood of getting a disease.606 
In the current European legal framework for foods and medicines, there are still no defi nitions 
for prevention and risk reduction. There is, however, a defi nition of “reduction of disease 
risk claim”: “any health claim that states, suggests or implies that the consumption of a food 
category, a food or one of its constituents signifi cantly reduces a risk factor in the development 
of a human disease”607. This means that according to European law, reducing disease risk 
means reducing a risk factor in the development of a disease. The concept of disease risk 
reduction takes into account the complexity and the multi-factor nature of diseases as well as 
the complexity of diet.608 This fi ts to Coppens’ et al. idea that a nutrient can signifi cantly lower 
one risk factor in a multi-factorial disease. 
Based on the previous chapters, a functional food could legally be judged as a medicinal 
product, if it is presented for disease prevention.609 In this thesis, ‘functional food’ is used as 
a practical term to describe the products we are interested in. These are products with health 
effects. Legal requirements for so-called functional foods are analysed regarding A) safety 
and B) effi cacy/marketing. This means we end up with novel food legislation and health claim 
legislation, where the term ‘functional food’ has no relevance. 
In one Finnish study of 1999610, consumers found it curious that there was no legal defi nition 
of functional foods. Because there has been a lot of public attention surrounding functional 
foods, some people might have thought that functional foods were a product category with an 
offi cial defi nition. This was not the case so many consumers suspected that the concept was 
just another marketing trick to hoax consumers.611 A legal defi nition of ‘functional food’ might 
have thus strengthened the whole concept of functional foods. Instead of defi ning the term 
‘functional food’, the Europeans have taken the approach to precisely regulate nutrition and 
health claims. ‘Functional food’ can be understood as just one type of marketing claim. The 
Chinese, on the contrary, have created a separate health food category for products on which 
health claims are allowed. 
The Chinese Health Food Regulation defi nes health foods as food products proven to have 
specifi c health functions, designed for a specifi c population to consume, but which are not 
for the purpose of disease treatment. Neither in the EU nor in China is it conclusive whether 
it is possible to bite, chew, taste or swallow the substance. The form of the object does not 
606  Coppens et al. 2001, 144.
607  Nutritional and Health Claim Regulation Article 2(2) (6).
608  Council of Europe guidelines, 17.
609  Coppens et al. 2001, 143.
610  Niva – Jauho 1999.
611  Niva – Jauho 1999, 46.
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determine whether it is a food or a medicine. This is how the law sees it, and this is also how 
consumers see it. Consumers often do not see the two as legal concepts, even though they are 
widely affected by their legal defi nitions. 
The decision on whether the product is a foodstuff or a medicine is important, because 
there are separate pre-market procedures for foodstuffs and medicines with separate laws 
and scientifi c requirements. The functional difference between a foodstuff and a medicine is 
simultaneously a difference in the marketing claim. The function, the product effi cacy, is the 
marketing message. As stated above, one cannot make medicinal claims on foods. 
It is similarly true that: one cannot make health claims on medicinal products. The Finnish 
report on Article 13 health claims contains various claims on products that are considered 
medicinal according to the Medicines Agency. This is because they contain ingredients listed 
in the Pharmacopoeias and/or prevent, treat or cure diseases according to scientifi c studies.612 
The operators do not see their products as medicines, but sell or plan to sell them as foods 
using health claims. However, this is not possible if the product has medicinal functions. After 
the categorisation decision (foodstuff/medicine), one cannot choose between a health claim 
and a medicinal claim. 
As Tuori points out, legal concepts are not innocent: they confer rights and obligations. 
Concepts frame a legal issue and place it in a certain normative context, at the same time 
limiting the possible solutions to regulatory issues.613 This is the case with functional foods 
and the issue of how to regulate them. The concepts of ‘food’ and ‘medicine’ are part of the 
legal culture, and limit our ability to solve the questions of safety and effi cacy of functional 
foods. Therefore, the concepts themselves need to be critically examined. 
Legal reasoning and justifi cation can adhere to sources of law, legal concepts, legal 
principles, or ideological choices. These can be seen as levels, where sources of law form 
the ground level as they are most attached to positive law, and where different types of 
arguments (for example: linguistic, systemic, teleological, moral) are relevant and typical on 
different levels of justifi cation.614 We are of the view that all argument types are relevant 
when legally defi ning the concepts of foodstuff and medicine. Linguistically, legal defi nitions 
create meanings and legal categories that are not the same as in everyday language. Coherence 
naturally requires the meaning of the concepts to be the same across all legislation in a certain 
legal system. This is the systemic argument. However, the legal concepts of foodstuff and 
medicine as against each other will change through time, based on practical, economical, and 
moral reasons. 
Grounds for the strict separation of foods and medicines appear to have changed, which 
allows us to consider changes in the legal concepts. On legislators’ wish, the two concepts 
could be replaced by three concepts, one concept, or no legal concept at all. In the last case, 
we would focus on safety and effi cacy of for example berries, herbs, and chemical substances 
without the need to categorise fi rst. The two legal concepts originally evolved in different 
circumstances compared to the present. In times of fi rst food laws (for example in Finland in 
the 1940s), health-effects of foods were not widely established, and there was no functional 
food business. The concepts of food and medicine are also currently used in Chinese law, even 
612  Report on health claims used in marketing of foodstuffs in Finland, page 25.
613  Tuori 2000, 310.
614  See Raitio 2006, 30-35, on justifi cation levels and argument types.
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though Chinese tradition clearly speaks against the strict separation. The concepts of food and 
medicine came to China in the 1980s from Western laws. 
Both in the EU and in China, there are products that can be sold either as food or medicine, 
depending on whether they are used by and marketed to healthy vs. sick people as is the 
case with garlic, for example. Still, there are the two legal categories that marketers and the 
administrators must recognise. One product cannot be a food and a medicine at the same time, 
two of the same products can. The rationality of this deserves critique.  
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4 SAFETY OF FOODSTUFFS AND 
MEDICINES 
Safety of foodstuffs and medicines is a highly important issue to consumers. New ingredients 
in particular in functional foods, herbal medicines, etc. might be hazardous to health. It is 
possible to overdose on even healthy products or ingredients.
4.1 General Product Safety
4.1.1 Europe
In the EU, directive 2001/95/EC615 governs general product safety. The directive sets 
responsibilities on both the producers and distributors of products. They must be aware of the 
qualities and use of the products, give adequate information to consumers, and take dangerous 
products off the market.616 This means they must themselves be active in ensuring product 
safety. The general product directive applies to products that are: 
intended for consumers or likely to be used by consumers, and –
supplied in the course of a commercial activity – 617. 
Among other consumer products, the directive applies to foodstuffs, medicines, and everything 
in between, including functional foods. However, the general product safety directive applies 
only where there are no specifi c provisions with the same objective in rules of Community law. 
Where products are subject to specifi c safety requirements imposed by Community legislation, 
the general product safety directive applies only to the aspects and risks not covered by those 
requirements.618 
615  Directive 2001/95/EC of the European Parliament and of the Council of 3 December 2001. Applicable as 
from 15 January 2004.
616  Article 5 of the directive.
617  Article 2 (a). The exact defi nition of “product” is “any product - including in the context of providing a 
service - which is intended for consumers or likely, under reasonably foreseeable conditions, to be used by 
consumers even if not intended for them, and is supplied or made available, whether for consideration or not, 
in the course of a commercial activity, and whether new, used or reconditioned”.
618  Article 1(2).
–108–
Requirements for safe foodstuffs and medicines are usually to be found in EU food and 
medicine law. However, the general product safety directive might also still have its role 
regarding these products. According to preamble 5 of the directive, it is very diffi cult to adopt 
Community legislation for every product which exists or which may be developed. That is why 
“there is a need for a broad-based, legislative framework of a horizontal nature to deal with 
such products, and also to cover lacunae, in particular pending revision of the existing specifi c 
legislation, and to complement provisions in existing or forthcoming specifi c legislation, in 
particular with a view to ensuring a high level of protection of safety and health of consumers, 
as required by Article 95 of the Treaty”619. 
According to Article 3(1) of the general product safety directive, “producers shall be 
obliged to place only safe products on the market”. In the absence of a specifi c EU law 
governing the safety of a product, the product shall be deemed safe if it conforms to national 
law of the Member State in whose territory the product is marketed620. If there is no Member 
State law, safety assessment is based on European and member state standards, Commission 
recommendations, product safety codes of good practice, the state of the art and technology, 
and reasonable consumer expectations621. 
There is a safeguard clause included in the directive: even if the product complies with all 
of the above-mentioned norms and criteria, the competent authorities of the Member States 
can still restrict marketing of the product, or require its withdrawal from the market. This is if 
there is evidence that, despite such conformity to norms, the product is dangerous.622 In general 
marketing law, a safeguard clause like this is not included because it leads to restrictions on 
free movement of goods, see chapter 5 below. 
4.1.2 China  
In China, general product safety is regulated by the Consumer Protection Law (1993) and by 
the Product Quality Law (1993, amended 2000). The Chinese consumer protection law can be 
seen as instructions for three different actors: consumers themselves, marketers of consumer 
products, and control authorities. According to Article 7 of the Consumer Protection Law, the 
consumer has the right to purchase only safe products: 
“In purchasing and utilising commodities or accepting services, the consumers enjoy the 
inviolable right of the personal and property safety. The consumers have the right to demand 
the commodities or services provided by the operators agree with the requirements of ensuring 
the personal and property safety.” 
Article 18 states the same from the viewpoint of the sellers: 
“The operators shall guarantee that the commodities or services they provide agree with 
the requirements of ensuring the personal and property safety. In regard to the commodities or 
619  Preamble 5 of the directive.
620  Article 3(2) of the directive.
621  Article 3(3) of the directive.
622  Article 3(4) of the directive. The Member States must inform the Commission of the restrictive measure 
taken. The Commission communicates the information to other Member States unless the Commission 
decides that the measure does not conform to Community law. Article 11 of the directive.
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services which pose potential hazard to personal and property safety, the operators shall make 
true to fact descriptions and clear warning to the consumers, specify and label the correct 
method in utilising the commodities or accepting services and the method of preventing 
the occurrence of injury and damage. When the operators discover that the commodities or 
services they provide cause serious defects and might cause injury or damage to the personal 
and property safety even under correct utilisation of the commodities and acceptance of the 
services, the operators shall promptly report to relevant administrative departments and inform 
the consumers and take measures to prevent the occurrence of such injury and damage.” 
Article 27 states the same one more time, from the viewpoint of the governments: 
“People’s governments at all levels shall strengthen their supervision, prevent the occurrence 
of the act which hazards the personal and property safety of the consumers, and timely put an 
end to the act which hazards the personal and property safety of the consumers.” 
The Chinese Product Quality Law is more specifi c when it comes to product safety. Chapter II 
on Product Quality Supervision states the following: 
“Industrial products which might endanger the health and personal or property safety must 
comply with the national or sector standards for safeguarding the health and personal or property 
safety; and in case of absence of such national or sector standards, they must comply with the 
requirements for safeguarding the health and personal or property safety. 
It is forbidden to produce or to sell industrial products which fail to comply with the 
standards and requirements for safeguarding the health and personal or property safety. The 
concrete measures therefore are provided by the State Council.”623 
The producer and seller’s liability is stated in chapter III: 
“Producers shall be liable for the quality of products they produce. The quality of a product 
shall satisfy the following requirements:
1. being free from unreasonable dangers to the personal or property safety, and conforming 
to the national or sector standards for safeguarding the health and personal or property safety 
if such standards are available;
…” 
Also the product labelling is important regarding product safety: there must be a warning mark 
or warning explanatory words in Chinese language if a product, due to improper use, might 
cause damage to the product itself or might endanger the personal or property safety.624 
Consumer protection laws in China have been accused of being vague and unintelligible. 
Article 7 of the Consumer Protection Law calls on companies to maintain standards of safety 
defi ned as “contemporary technical and professional standards of...the sold goods launched 
into the market.” This can be interpreted to mean that safety standards fl uctuate with the 
shifts of the market, and that companies are only expected to maintain the standards currently 
established by other companies. Article 8 states that businesses cannot be punished for falling 
behind raised standards established by goods entering the market at a later time. 
623  Article 13.
624  Product Quality Law, Article 27(5).
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4.2 Food Safety
4.2.1 EU
4.2.1.1 General Rules on Food Safety  
According to EU General Food Regulation, food shall not be placed on the market if it is 
unsafe625. Food shall be deemed to be unsafe if it is considered to be: 
injurious to health;(a) 
unfi t for human consumption.(b) 626 
Article 14(3) clarifi es the evaluation of safety: 
”In determining whether any food is unsafe, regard shall be had:
to the (a) normal conditions of use of the food by the consumer and at each stage of 
production, processing and distribution, and
to the (b) information provided to the consumer, including information on the label, or 
other information generally available to the consumer concerning the avoidance of 
specifi c adverse health effects from a particular food or category of foods.” 
Article 14(4) takes into account also long-term and cumulative effects, plus particular 
consumer groups: 
“In determining whether any food is injurious to health, regard shall be had: 
not only to the probable immediate and/or short-term and/or long-term effects of that a) 
food on the health of a person consuming it, but also on subsequent generations;
to the probable b) cumulative toxic effects;
to the particular health sensitivities of a c) specifi c category of consumers where the food 
is intended for that category of consumers.” 
Article 14(5) concerns mainly food going bad under time and external conditions: “In 
determining whether any food is unfi t for human consumption, regard shall be had to whether 
the food is unacceptable for human consumption according to its intended use, for reasons 
of contamination, whether by extraneous matter or otherwise, or through putrefaction, 
deterioration or decay.” 
Article 14(6) takes the precautionary principle seriously: “Where any food which is unsafe is 
part of a batch, lot or consignment of food of the same class or description, it shall be presumed 
that all the food in that batch, lot or consignment is also unsafe, unless following a detailed 
assessment there is no evidence that the rest of the batch, lot or consignment is unsafe.” 
625  Article 14(1).
626 Article 14(2).
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Articles 14(7) to 14(9) clarify the role of more specifi c Community or Member State safety 
standards: 
Food that complies with “7. specifi c Community provisions governing food safety shall be 
deemed to be safe insofar as the aspects covered by the specifi c Community provisions 
are concerned.
Conformity of a food with specifi c provisions applicable to that food shall not bar the 8. 
competent authorities from taking appropriate measures to impose restrictions on it 
being placed on the market or to require its withdrawal from the market where there are 
reasons to suspect that, despite such conformity, the food is unsafe.
Where there are no specifi c Community provisions, food shall be deemed to be safe 9. 
when it conforms to the specifi c provisions of national food law of the Member State 
in whose territory the food is marketed, such provisions being drawn up and applied 
without prejudice to the Treaty, in particular Articles 28 and 30 thereof.” 
4.2.1.2 Biological Safety of Food: Hygiene  
EU legislation on biological safety of foods has been revised as of 2006 by the so called 
“hygiene package”. This legislative package includes: 
Regulation 852/2004/EC on  – the hygiene of foodstuffs
Regulation 853/2004/EC on specifi c hygiene rules for  – food of animal origin, and
Regulation 854/2004/EC laying down specifi c rules for the organisation of  – offi cial 
controls on products of animal origin627. 
The new regulations merge and harmonise hygiene requirements previously contained in 
several separate directives. The goal of new hygiene legislation is to make a single, transparent 
hygiene policy applicable to all food and all food operators in the food chain. This would 
enable the EU to manage food safety and future food crises.628 
The Annexes of Regulation 852/2004/EC contain hygiene rules applicable to primary 
production (Annex I), and to other food business operators (Annex II). The hygiene rules in 
Annex II include requirements for rooms where foodstuffs are prepared, treated or processed, 
requirements for movable and/or temporary premises, transport, equipment, food waste, water 
supply, personal hygiene, hygiene of the foodstuffs themselves, wrapping and packaging of 
foodstuffs, heat treatment, and training. 
Annex III of Regulation 853/2004/EC contains hygiene rules for various foodstuffs or 
animal origin, which were previously scattered in different Directives. There are rules on 
meat, fi shery products, eggs, milk, frog’s legs and snails, bivalve molluscs, and processed 
627  All of these were enacted on 21st April 2004, and came into force in the beginning of 2006. The package 
includes also Directive 2004/41/EC repealing certain Directives concerning food hygiene and health 
conditions for the production and placing on the market of certain products of animal origin intended for 
human consumption and amending Council Directives 89/662/EEC and 92/118/EEC and Council Decision 
95/408/EC, 21 April 2004. 
628  European Commission web page. http://ec.europa.eu/food/food/biosafety/hygienelegislation/index_en.htm.
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products. The rules are quite exact, of the type: “Containers used for the dispatch or storage of 
unpackaged prepared fresh fi shery products stored under ice must ensure that melt water does 
not remain in contact with the products”629. 
To facilitate the application of the new hygiene rules, the Commission has enacted a set 
of implementing measures, the most important being the Commission Regulation 2073/2005/
EC which sets down microbiological criteria for foodstuffs. The Commission has also enacted 
various transitional rules that help operators adjust their businesses to fi t the new regime630.
4.2.1.3 Chemical Safety of Food  
Chemical safety of foodstuffs is in Europe guaranteed by regulating: 
food additives, –
food fl avourings, –
contaminants, –
residues and –
food contact materials.  –
The European Commission has in 2008 adopted a legislative package, which updates rules for 
additives631 and fl avourings632, and harmonises EU legislation on food enzymes633 for the fi rst 
time. A common approval procedure for food additives, fl avourings and food enzymes was 
created634. EFSA has an integral role in assessing new substances.635 Only additives, fl avouring, 
and food enzymes that are on the EU lists can be used, and only under the conditions mentioned 
in those lists. Often, they can be used in limited quantities636. 
629  Regulation 853/2004/EC, Annex III, Section VIII, Chapter III. A(4).
630  European Commission web page. http://ec.europa.eu/food/food/biosafety/hygienelegislation/legisl_
en.htm.
631  Regulation (EC) No 1333/2008 on food additives. The regulation, except transitional provisions, will 
apply by 20 January 2010. Additives that are permitted under the old directives 94/35/EC, 94/36/EC and 95/2/
EC will be put Community list of food additives. Their conditions of use are fi rst to be reviewed, and this 
review should be completed by January 2011.
632  Regulation (EC) No 1334/2008 on fl avouring and certain food ingredients with fl avouring properties 
amending Council Regulation (EEC) no 1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and 
Directive 2000/13/EC. The regulation will apply on 20 January 2010. However, the old Regulation 2232/96/
EC will continue to apply until the date of application of the Community list of fl avourings.
633  Regulation (EC) No 1332/2008 on food enzymes and amending Council Directive 83/417/EEC, Council 
Regulation (EC) No 1493/1999, Directive 2000/13/EC, Council Directive 2001/112/EC and Regulation 
(EC) No 258/97. The regulation applies from 20 January 2009, except labelling provisions from 20 January 
2010. National provisions apply in the Member States until the adoption of the Community list of enzymes 
applies.
634  Regulation (EC) No 1331/2008 establishing a common authorisation procedure for food additives, food 
enzymes and food fl avourings.
635  See Luetzow 2006.
636  European Commission web page. http://ec.europa.eu/food/food/chemicalsafety/additives/comm_legisl_en.htm.
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Additives are substances added to foods for some technological purpose, for example to 
preserve, to sweeten or to colour637. Flavourings638 are substances used to give taste and/or 
odour to food. Enzymes are added to perform a technological function for example in the 
manufacture, transport, or storage of a food639. 
Additive, fl avouring, and enzyme rules do not apply to substances added to foodstuffs as 
nutrients, such as vitamins or minerals. The enzyme Regulation does not extend to enzymes 
for nutritional or digestive purposes640. These are regulated under the rules of food fortifi cation. 
See below.
Contaminants are substances that have not been intentionally added to food. Foodstuffs 
may be contaminated by environmental contamination, or in various stages of the food chain, 
for example production, packaging, or transport. The aim of EU legislation is to minimise 
contaminants in foodstuffs. Basic principles of EU legislation on contaminants in food are 
in Council Regulation 315/93/EEC. Maximum levels for certain contaminants in certain 
foods are set in Commission Regulation 1881/2006/EC641. The following contaminants are 
included: nitrate, mycotoxins (afl atoxins, ochratoxin A, patulin, deoxynivalenol, zearalenone, 
fumonisins, T’-2 and HT-2-toxin), metals (lead, cadmium, mercury, inorganic tin), 3-MCPD, 
dioxins and PCBs, and polycyclic aromatic hydrocarbons (PAH).642
Residues are chemicals that are intentionally used in some part of the food chain but which 
are not intended to be present in foods. Animals are treated with medicines, which leads to 
residues of these medicines in meat, milk and eggs643. Plants are fertilised and treated with 
pesticides. Veterinary medicines and their maximum residue levels are evaluated according 
to regulation 2377/90/EC. The basic directive setting maximum residue levels for pesticides 
(90/642/EEC) has been amended dozens of times.
Food contact materials are materials and articles intended to come into contact with 
foodstuffs644. This includes food packaging but also knives and forks, plates and glasses, 
bowls and jars, blenders and mixers. The framework regulation 1935/2004/EC sets up general 
requirements for all food contact materials. Specifi c directives exist for ceramics, regenerated 
637  The full defi nition of “additive” is the following: “any substance not normally consumed as a food in 
itself and not normally used as a characteristic ingredient of food, whether or not it has nutritive value, the 
intentional addition of which to food for a technological purpose in the manufacture, processing, preparation, 
treatment, packaging, transport or storage of such food results, or may be reasonably expected to result, in 
it or its by-products becoming directly or indirectly a component of such foods”. Regulation 1333/2008/EC, 
Article 3(2)(a).In addition, there is a long list of substances that are not considered additives.
638  “Flavourings” are “products: (i) not intended to be consumed as such, which are added to food in order 
to impart or modify odour and/or taste; (ii) made or consisting of the following categories: fl avouring 
substances, fl avouring preparations, thermal process fl avourings, smoke fl avourings, fl avour precursors or 
other fl avourings or mixtures thereof “. There are several additional defi nitions in the Regulations.
639  The full defi nition of “food enzyme” is the following: “a product obtained from plants, animals or 
micro-organisms or products thereof including a product obtained by a fermentation process using micro-
organisms:
(i) containing one or more enzymes capable of catalyzing a specifi c biochemical reaction; and
(ii) added to food for a technological purpose at any stage of the manufacturing, processing, preparation, 
treatment, packaging, transport or storage of foods”. Regulation 1332/2008/EC, Article 3(2)(a).
640  Regulation 1332/2008/EC, preamble 4.
641  This Regulation entered into force on 1 March 2007.
642  Investigations are ongoing on acryl amide, organotins, furan, and ethyl carbamate.
643  European Commission web page. http://ec.europa.eu/food/food/chemicalsafety/residues/index_en.htm.
644  European Commission web page. http://ec.europa.eu/food/food/chemicalsafety/foodcontact/index_en.htm.
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cellulose fi lm and plastics. Food contact materials must be safe and not transfer their 
components into the foodstuff in unacceptable quantities645. Intelligent and active packaging 
is allowed by the new Regulation. If an active packaging changes the composition or sensory 
properties of the product, the changes are evaluated according to rules on additives646.
4.2.1.4 Safety of Dietetic Foods  
Foodstuffs intended to satisfy particular nutritional requirements of specifi c groups of the 
population are called “foods for particular nutritional uses”, “dietetic foods” or “dietary 
foods”. Sometimes they have also been referred to as “PARNUTS” foods. Council directive 
89/398/EEC647 is the framework directive on dietetic foods. 
Foodstuffs for particular nutritional uses are foodstuffs which, owing to their special 
composition or manufacturing process, are clearly distinguishable from foodstuffs for normal 
consumption, which are suitable for their claimed nutritional purposes and which are marketed 
in such a way as to indicate such suitability. A particular nutritional use must fulfi l the particular 
nutritional requirements:
of certain categories of persons whose digestive processes or metabolism are disturbed; or –
of certain categories of persons who are in a special physiological condition and who  –
are therefore able to obtain special benefi t from controlled consumption of certain 
substances in foodstuffs; or
of infants or young children in good health. – 648 
Consideration is given to whether the foods in question are clearly distinguishable for their claimed 
nutritional purposes from ordinary foods. They should be consumed by specifi c group of population 
for a particular physical or physiological condition and/or specifi c disease or disorder, and they 
should be signifi cantly different from ordinary foods in composition.649 Examples of dietetic foods 
are children’s foods, gluten-free foods (for people with celiac disease), low-lactose and lactose free 
products (for people with lactose intolerance), low-sodium products, clinical nutrition (medical 
foods), weight-loss products, and sports nutrition. The marketer decides whether to sell the product 
as a dietetic food.650 Below in chapter 5 we will discuss this marketing decision and alternatives to 
marketing the product as dietetic food. 
The framework directive sets out a framework of rules for the composition, marketing and 
labelling requirements of dietetic foods, including measures to ensure the appropriate use of such 
foods and to exclude any risk to human health. However, the framework directive does not entail 
exact safety criteria. Actual compositional requirements, hygiene requirements, lists of additives, 
purity criteria, etc. are to be found in separate directives for the following foods: 
645  European Commission web page. http://ec.europa.eu/food/food/chemicalsafety/foodcontact/eu_legisl_en.htm.
646  Regulation 1935/2002/EC, Article 4(1).
647  Council Directive of 3 May 1989 on the approximation of the laws of the Member States relating to 
foodstuffs intended for particular nutritional uses (89/398/EEC).
648  Article 1.2. of the directive.
649  Kwak – Jukes 2000b, 111.
650 Food Safety Agency web page. http://www.evira.fi /portal/fi /elintarvikkeet/valvonta_ja_yritt__j__t/
erityisruokavaliovalmisteet/.
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infant formula and follow-on formula – 651,
processed cereal-based foods and baby foods (weaning foods) – 652,
foods intended for use in energy-restricted diets for weight reduction – 653, and
foods for special medical purposes – 654. 
The nutritional substances that can be added to dietetic foods are controlled either through 
positive lists included in the specifi c directives or by Commission Directive 2001/15/EC655, 
the Annex of which has been amended656 to include additional substances657. The Annex has 
5 pages and includes vitamins, minerals, amino acids, carnitine and taurine, nucleotides, and 
choline and inositol.658 The choice of substances should be based primarily on their safety, 
and the permission to use certain substances does not mean that their addition is necessary or 
desirable659. 
Rules on infant formula and follow-on formula were recently revised by Directive 
2006/141/EC660. These are products designed to satisfy the specifi c nutritional requirements 
of healthy infants and young children. Infant formulas are used as sole nutrition, and follow-
on formula as the primary liquid element in the diet as the infant grows and starts to eat solid 
food. Processed cereal based foods and other baby foods, regulated by Directive 2006/125/
EC661, are intended for use by infants while they are being weaned, and by young children as 
a supplement to their diet and/or for their progressive adaptation to ordinary food662. “Infant” 
means a baby under the age of 1, and “young child” a child between the ages of 1 and 3. 
Weight-loss-foods are regulated by directive 96/8/EC663. The Directive lays down 
compositional criteria for weight-control products that are either A) total daily diet replacements 
651  Commission Directive 2006/141/EC of 22 December 2006 on infant formula and follow-up formula and 
amending Directive 1999/21/EC.
652  Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby 
foods for infants and young children.
653  Commission Directive 96/8/EC of 26 February 1996 on foods intended for use in energy-restricted diets 
for weight reduction.
654  Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes.
655  Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for specifi c 
nutritional purposes in foods for particular nutritional uses.
656  By Commission Directive 2004/5/EC of 20 January 2004 and by Commission Directive 2006/34/EC.
657  Addition of substances into infant formula, follow-up formula, processed cereal-based foods and baby 
foods intended for infants and young children is regulated in separate directives covering these dietetic foods. 
Addition of substances into medical foods is regulated by both the separate directive (vitamins and minerals) 
and the general directive (amino acids). Addition of substances into weight-loss foods is covered by directive 
2001/15/EC.
658  Most of allowed substances can be used in all dietary foods, but some amino acids can be used only in 
medical foods.
659  Directive 2001/15/EC, preamble 4.
660  Commission Directive 2006/141/EC of 22 December 2006 on infant formula and follow-up formula and 
amending Directive 1999/21/EC.
661  Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby 
foods for infants and young children (Codifi ed version).
662  Article 1(2).
663  Commission Directive 96/8/EC of 26 February 1996 on foods intended for use in energy-restricted diets 
for weight reduction
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or B) individual meal replacements664. The compositional criteria include energy, protein 
quantity and quality, fat quantity and type, minimum and maximum levels for dietary fi bre, 
and minimum levels for certain vitamins and minerals. 
Medical foods (dietary foods for special medical purposes) are foods that are specifi cally 
formulated, processed and intended for the dietary management of diseases, disorders or 
medical conditions of individuals who are being treated under medical supervision. These 
foods are covered by Directive 1999/21/EC665. Medical foods are intended for the feeding of 
people whose nutritional requirements cannot be met by normal foods or other dietary foods666. 
This means medical foods are not a suitable legal category for functional foods. Medical 
foods in practice are liquids or powders that contain carbohydrates, fat etc., for example for 
cancer patients. 
Medical foods may be marketed within the Community only if they comply with the rules 
laid down in the Directive. The formulation of medical foods shall be based on sound medical 
and nutritional principles. Their use, in accordance with the manufacturer’s instructions, 
shall be safe, benefi cial, and effective in meeting the particular nutritional requirements of 
the persons for whom they are intended, as demonstrated by generally accepted scientifi c 
data, and the foods must comply with the compositional criteria specifi ed in the Annex of the 
Directive.667 
A separate directive does still not regulate foods for athletes, even though they are included 
in the framework directive list of groups of dietary foods for which specifi c rules shall be set 
out. The directive has been “looming in the background” for a long time, as manufacturers 
were already in the beginning on 2005 worried about its possible restrictive and negative 
effects668. 
In the White Paper on Food Safety, the Commission announced the intention to introduce a 
specifi c Directive on foods intended to meet the needs resulting from intense muscular effort. 
There is a report of the Scientifi c Committee on Food on composition and specifi cation of 
food intended to meet the expenditure of intense muscular effort, especially for sportsmen669, 
and an Opinion on safety aspects of creatine supplementation670. The Directive was circulating 
in draft form in 2004 and 2005. According to “Consumers for Health Choice”, the publication 
of the proposal has been delayed by the successful campaign of the European Specialist Sports 
664  Article 1(2) of the Directive.
665  Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes.
666  More precisely: “patients with a limited, impaired or disturbed capacity to take, digest, absorb, metabolise 
or excrete ordinary foodstuffs or certain nutrients contained therein or metabolites, or with other medically-
determined nutrient requirements, whose dietary management cannot be achieved only by modifi cation of the 
normal diet, by other foods for particular nutritional uses, or by a combination of the two”. Article 1(2)(b) of 
the directive.
667  Art. 2-3.
668  Callard 2005. Sports nutrition is becoming more mainstream as more people are working out. Sports 
nutrition covers product areas such as energy and endurance, recovery and refuelling, and rehydration. 
Products are for example in the form of bars (high-complex carbohydrate and high-protein) or drinks (isotonic/
hypotonic). Also caffeine and creatine are used in products. 
669  Adopted by the SCF on 22 June 2000, corrected on 28 February 2001.
670  Adopted by the Scientifi c Committee on Food on 7 September 2000.
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Nutrition Alliance (ESSNA)671. The European and American supplement industries strongly 
oppose legislation on their products. They are mainly concerned about bans on several 
ingredients and stronger, “higher-potency” products. 
The framework directive also requires the Commission to report on the desirability of 
special legislation on foods intended for people suffering from diabetes. According to the 
Commission, “initial consultations with interested parties have been held on this issue”. The 
Commission intends to report on the desirability of special provisions for foods for diabetics. 
The Commission also intends to put forward legislative proposals but the timing of this is 
unclear672. 
Dietetic foods differ from normal foods in that some of them include a pre-market 
notifi cation system. EU Member States must ensure that dietetic foods comply with the 
requirements set by the directives. They can use pre-market notifi cation to achieve this goal. 
In Finland, pre-market notifi cation is required for the following products:
low lactose of lactose free dairy products, –
low sodium products, including low sodium or no sodium table salts, –
gluten free foods, –
some weight loss products (others than meal or diet replacements), –
some medical foods – 673, and
other foods complying with the defi nition of dietetic food, for example foods for people  –
with high cholesterol.674 
In Finland, pre-market notifi cation is not required for the following dietetic foods: 
infant formula and children’s foods –
some weight loss products (meal or diet replacements – 675)
some medical foods –
sports nutrition –
foods for diabetics. – 676 
671  Consumers for Health Choice describes itself as an exceptionally successful lobby. They are in 
practice lobbying for Health Product Manufacturers. Consumers for Health Choice web page. http://www.
consumersforhealthchoice.com/index.php?option=com_content&task=view&id=35&Itemid=61.
672  European Commission web page. http://ec.europa.eu/food/food/labellingnutrition/diabetic/index_en.htm.
673  Medical foods must be notifi ed if they are manufactured in Finland or outside European Economic Area, 
and imported to Finland for the fi rst time. This means that if medical foods are already on the market in some 
other European country, they need not be notifi ed when imported to Finland.
674 Food Safety Authority web page. http://www.evira.fi /portal/fi /elintarvikkeet/valvonta_ja_yritt__j__t/
erityisruokavaliovalmisteet/ilmoitus_erityisruokavaliovalmisteen_markkinoille_saattamisesta/.
675  As compositional criteria for meal or diet replacements are given by Directive 96/8/EC, they need not 
case-by-case pre-market control.
676 Food Safety Authority web page. http://www.evira.fi /portal/fi /elintarvikkeet/valvonta_ja_yritt__j__t/
erityisruokavaliovalmisteet/ilmoitus_erityisruokavaliovalmisteen_markkinoille_saattamisesta/.
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4.2.1.5 Safety of Food Supplements  
Food supplements, regulated by Directive 2002/46/EC677, are concentrated sources of nutrients 
or other substances with a nutritional or physiological effect, whose purpose is to supplement the 
intake of nutrients in the normal diet. They are foods marketed in dose form, i.e. as pills, tablets, 
capsules, liquids in measured doses etc.678 Products typically contain vitamins, minerals, amino 
acids, fi bre, etc. Food supplements have no relevant energy content. Food supplements and dietetic 
foods are sometimes used for similar purposes, such as for weight loss or as sports nutrition. What 
often separates dietetic foods and food supplements is their energy content.679 Dietetic foods replace 
meals and diets; food supplements do not. Formulas that contain pure carbohydrates or proteins are 
dietetic foods.680 
Food supplements are distinguishable from functional foods because of their form. The 
basic requirement for functional foods, as defi ned above in chapter 1.3., is that they can be 
consumed as a part of total diet and in the form of ordinary foods. From their appearance, 
food supplements are more like medicines. Medicinal claims are not, however, permitted in 
food supplements, either. This is because the defi nition of food supplements does not allow 
medical uses. 
Safety of food supplements is regulated in the EU by a list of permitted substances. Annex 
II of Directive 2002/46/EC is a list of permitted vitamin or mineral preparations that may be 
added for specifi c nutritional purposes in food supplements. Commission Directive 2006/37/
EC to include additional substances has amended it. The trade of products containing vitamins 
and minerals not listed in Annex II has been prohibited since August 2005681. The European 
Food Safety Agency (EFSA) may consider vitamin and mineral substances for inclusion in 
the lists following the evaluation of an appropriate scientifi c dossier concerning the safety and 
bioavailability of the individual substance.682 Pre-market notifi cation applies to production or 
marketing of food supplements, if a Member State requires it. For example, Finland requires 
pre-market notifi cation. 
As far as vitamins and minerals are concerned, the Directive does two things. First, it 
establishes lists of the vitamins and minerals and their forms that can be used in the manufacture 
of food supplements. Second, it foresees the setting of maximum levels for vitamins and 
minerals in food supplements. These levels will be established in the next few years on the 
basis of the advice the Commissions will receive from the scientists. The setting of maximum 
677  Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation 
of the laws of the Member States relating to food supplements.
678  More precisely, “food supplements” means foodstuffs the purpose of which is to supplement the normal 
diet and which are concentrated sources of nutrients or other substances with a nutritional or physiological 
effect, alone or in combination, marketed in dose form, namely forms such as capsules, pastilles, tablets, pills 
and other similar forms, sachets of powder, ampoules of liquids, drop dispensing bottles, and other similar 
forms of liquids and powders designed to be taken in measured small unit quantities. Article 1(a).
679 The Finnish Food Safety Agency considers the energy content irrelevant, if the maximum dosage does 
not exceed 200 kJ per day. Finnish Food Safety Agency guidelines on food supplements, updated December 
2006, page 5.
680  Finnish Food Safety Agency guidelines on food supplements, updated December 2006, page 22.
681  Under certain conditions, Member States may provide derogations until the end 2009, for vitamins and 
minerals and their forms not included in the Directive.
682  European Commission web page. http://ec.europa.eu/food/food/labellingnutrition/supplements/index_en.htm.
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limits is complicated, as the total intake of nutrients from all sources must be taken into 
consideration. 
 In 2006, the Commission issued a Discussion Paper on the setting of maximum and 
minimum amounts for vitamins and minerals in foodstuffs683. The Commission received several 
comments684, and the Commissioner Kyprianou gave a collective answer to these comments685. 
In July 2007, the European Commission issued an “Orientation Paper” to selected parties 
including the Member States. Legislative proposals were awaited - or feared - in 2008. 
The maximum amounts of vitamins and minerals will probably be set both for fortifi ed 
foods as well as for food supplements686. Stakeholders, such as the Finnish government, 
supported this approach presented in the Discussion paper. At the end of 2007, the European 
Commission was “fi nalising approaches that allow the determination of maximum levels of 
vitamins and minerals for both food supplements and fortifi ed foods”687. Some health product 
manufacturers were concerned about the effects of the future legislation688. Others welcomed 
it and referred to it as a legally and scientifi cally “balanced” approach689. It is possible that 
maximum levels will be lower for fortifi ed foods than for food supplements, as the risks with 
fortifi ed foods are more diffi cult for the consumer to assess 690.
Besides the maximum and minimum levels of vitamins and minerals, another important 
question related to food supplements remains to be answered. By July 2007, the European 
Commission was to present a report on the advisability to include additional categories of 
substances, besides vitamins and minerals, into the legal provisions for food supplements691. 
This would mean harmonising the rules on food supplements consisting of botanicals and 
herbals, amino acids, and fatty acids. 
Other substances in food supplements besides vitamins and minerals are at the moment 
regulated on national level692. In Finland, the rules are given in “the guide on food supplements” 
by the Food Safety Authority693. Above we have discussed problems with soft law, of which 
the food supplement guide is a good example. Important issues are resolved by a detailed 
document which is not binding and not available in languages other than Finnish.  
683  European Commission web page. http://ec.europa.eu/food/food/labellingnutrition/supplements/discus_
paper_amount_vitamins.pdf.
684 European Commission web page. http://ec.europa.eu/food/food/labellingnutrition/supplements/resp_
discus_paper_amount_vitamins.htm.
685  January 2007.
686  Fortifi ed foods will be discussed in the next chapter.
687  Alliance for Natural Health. ANH Position Paper: Proposed European Model for MRLs not Fit for 
Purpose. 24 October 2007. Page 2. 
688  Alliance for Natural Health. ANH Position Paper: Proposed European Model for MRLs not Fit for 
Purpose. 24 October 2007. 
689  European Responsible Nutrition Alliance (ERNA) according to EAS news.
690  Opinion of the Finnish Ministry of Trade and Industry. 29 September 2006. Available at European Commission 
web page: http://ec.europa.eu/food/food/labellingnutrition/supplements/documents/fi nland_en.pdf.
691  This is required by Article 4(8) of the Directive: “Not later than 12 July 2007, the Commission shall 
submit to the European Parliament and the Council a report on the advisability of establishing specifi c rules, 
including, where appropriate, positive lists, on categories of nutrients or of substances with a nutritional or 
physiological effect other than those referred to in paragraph 1, accompanied by any proposals for amendment 
to this Directive which the Commission deems necessary.” This means other nutrients than vitamins or 
minerals. The Commission has apparently failed to present the report in time.
692  Silano et al. 2004, 115. 
693  Available at http://www.palvelu.fi /evi/fi les/55_519_331.pdf.
–120–
4.2.1.6 Safety of Fortifi ed Foods  
According to the General Principles of the Codex for the Addition of Essential Nutrients for 
Foods, fortifi cation or enrichment means: 
the addition of one or more essential nutrients to a food, –
whether or not it is normally contained in the food, –
for the purpose of preventing or correcting a demonstrated defi ciency of one or more  –
nutrients,
in the population or specifi c population groups.  –
The fortifi cation or enrichment of various foods is conducted for the purpose of nutritional 
need or for a commercial purpose. Taking into account that functional foods are often made 
by adding some functional substances, the law on enriched or fortifi ed foods has a signifi cant 
implication for functional foods694. There is a wide range of nutrients and other ingredients 
that might be used in food manufacturing, including vitamins, amino acids, essential fatty 
acids, fi bre, various plants and herbal extracts. The substances used in fortifi ed foods are thus 
practically the same as the substances used in food supplements. 
Regulation 1925/2006/EC695 harmonises the provisions on the addition of vitamins and 
minerals substances to foods696. Since January 2007, only certain vitamins and minerals can 
be added, and only in certain forms697. Annex I of the Regulation lists vitamins and minerals 
which may be added to foods. Annex II lists the sources of vitamins and minerals which may be 
added to foods. There are soft law guidelines on how to have substances added to these lists698. 
Annex III lists substances whose use in foods is prohibited, restricted or under Community 
scrutiny. Member states can impose a notifi cation requirement for food fortifi cation. For 
example in Finland, production or marketing of a fortifi ed food must be notifi ed beforehand 
to the Food Safety Agency. 
Minimum amounts of vitamins and minerals in fortifi ed foods are linked to the notion of 
signifi cant amount. The Regulation provides for the setting of maximum amounts of vitamins and 
minerals in fortifi ed foods. The Commission’s discussion paper on the setting of maximum and 
694  Kwak – Jukes 2000b, 112-113.
695  Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on 
the addition of vitamins and minerals and of certain other substances to foods.
696  “Annex I of the Regulation is a list of vitamins and minerals which may be added to foods. Annex II is 
a list of the sources of vitamins and minerals which may be added to foods. Annex III is a list of substances 
whose use in foods is prohibited, restricted or under Community scrutiny. At the end of a transitional period, 
only vitamins and/or minerals listed in Annex I, in the forms listed in Annex II, may be added to foods.” 
http://ec.europa.eu/food/food/labellingnutrition/vitamins/index_en.htm. EFSA evaluates substances before 
changing the lists.
697  There is a transitional period that lasts until January 2014. During this time, Member States may provide 
derogations for vitamins and minerals and their forms not included in the Directive. This applies to products 
that were on the European market in 2007 and on which there is no unfavourable EFSA opinion.
698  European Commission. Health and Consumer Protection Directorate General. Administrative Guidance on 
Submissions for Safety Evaluation of Substances Added for Specifi c Nutritional Purposes in the Manufacture 
of Foods. Available at: http://ec.europa.eu/food/food/labellingnutrition/nutritional/adm_guidance_safety_
substances_en.pdf.
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minimum amounts for vitamins and minerals in foodstuffs is related both to food supplements and 
fortifi ed foods, and was discussed above. This legislation is expected soon. 
Article 8 of the Regulation 1925/2006/EC also gives the possibility to legislate on 
substances other than vitamins and minerals699. This means that fi bre fortifi cation might in 
the future be regulated in the same manner as vitamin and mineral fortifi cation is. Currently, 
addition of these other substances is regulated only at member state level. The situation is thus 
the same as with food supplements. 
Foods can be fortifi ed for the whole population as well as a specifi c population group. Some 
of fortifi ed foods can be sold as dietetic foods. For example fortifi ed breakfast cereals cannot 
be considered as a dietetic food, since dietetic foods are for certain categories of people. If a 
certain food is distinctively fortifi ed with essential nutrients for the special dietary requirement 
of a specifi c group of the population, it could be sold as a dietetic food. A fortifi ed food might 
even be sold as a medical food (a subcategory of dietetic foods, see above) if its benefi ts are 
specifi ed for patients with conditions where medical supervision is necessary.700
4.2.1.7 Safety of Novel Foods 
Finally, we will discuss the safety of novel foods. For a functional food developer, this might 
be the most important European legal category to be aware of.
4.2.1.7.1 Background 
Throughout history, foods prepared and used in traditional ways have been judged to be safe on 
the basis of long-term experience. In today’s risk analysis, a food is considered safe when we 
are reasonably certain that it will cause no harm if it is used as intended, under the anticipated 
conditions of consumption. Some foods are not safe in absolute terms but contain natural 
toxicants like solanin in potatoes.701 In these cases, safety is related to how the food is used. In 
the potato case, we simply do not eat the green part and consider the product safe. 
Foods are usually complex mixtures of macro- and micro-constituents. Foods provide 
energy and nutrients and have traditionally been regarded as natural, benefi cial and necessary 
products whose safety and nutritional value need not be questioned. Regulatory approaches 
have focused on restricting hazards outside the food itself. This means regulating food 
additives, processing aids, and contaminants of natural or industrial origin. Foods as such 
have traditionally not been systematically subjected to nutritional or toxicological evaluation. 
Nutritional evaluation of foods and of diets has not been performed, but such nutritional 
evaluations have not been used as a basis for a safety assessment of individual foods.702 
699  “The procedure provided for in this Article shall be followed where a substance other than vitamins or 
minerals, or an ingredient containing a substance other than vitamins or minerals, is added to foods or used 
in the manufacture of foods under conditions that would result in the ingestion of amounts of this substance 
greatly exceeding those reasonably expected to be ingested under normal conditions of consumption of a 
balanced and varied diet and/or would otherwise represent a potential risk to consumers.”
700  Kwak – Jukes 2000b, 113.
701  European Food Information Council EUFIC Review 04/2000. 
702  European Commission Recommendation on Novel Foods, Annex, Part I, Chapter 3.2.
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During the 1970s, food technology developed rapidly. New products and processes were 
developed, especially in response to a perceived shortage of food, particularly a shortage 
of animal protein. Methods were developed to produce protein foods from new plant and 
microbial sources, and to use textured plant proteins as meat analogues and extenders. Many 
countries had experience in evaluating the safety of food additives and contaminants, but there 
was little experience in evaluating safety of new foods or food ingredients. It was recognised 
that it was inconsistent to require extensive testing for food additives but not for foods or food 
ingredients that might be consumed at much higher levels.703 
In 1972, the Protein Advisory Group of the United Nations (PAG/UNU) issued Guidelines 
for the Preclinical Testing of Novel Sources of Protein and Guidelines for the Human Testing 
of Supplementary Food Mixtures. This was an attempt to ensure systematic safety evaluation 
of novel foods that had appeared on the market, and focused on novel microbial proteins. The 
Guidelines were revised and re-issued by the United Nations University in 1983. The scope of 
the revised Guidelines was expanded to cover Preclinical Testing of Novel Sources of Food 
and Human Testing of Novel Foods. Novel foods were defi ned as foods not previously eaten 
by humans. The guidelines identifi ed the main categories of information needed to evaluate 
the safety of novel foods. They also discussed some of the problems with testing novel food 
safety.704 
Testing novel food safety is diffi cult because they are often complex mixtures of many 
substances, and because they are used in signifi cant levels and to replace other foods. The usual 
way to test the safety of a substance in food is to feed it to laboratory animals. There is ample 
experience of doing this with additives or contaminants. Feeding studies will show the level in the 
diet at which animals show no adverse effects. After this, the maximum level of intake from human 
food is estimated to ensure that there is a large safety margin, often more than 100 times. This is 
possible because the additive or contaminant can be included in animal diets at much higher levels 
than the anticipated level in human food.705 
A novel food, on the other hand, is often used at signifi cant levels and might reach a level 
of 10 percent of a human diet. It is then impossible to feed the food to animals at 100 times 
higher levels. Even if it was possible to feed the food to animals at higher levels than intended 
for humans, and the animals would actually eat the food, the food would upset the nutritional 
balance of the diet. This means the diet of the animal would be worse simply because the test 
food replaces everything else. As foods are often complex mixtures of macro- and micro-
nutrients, it is diffi cult to determine which nutrients cause the effects in animal studies. This is 
why new approaches to safety assessment have been developed for novel foods. For example, 
a novel food is always compared to a conventional counterpart, if applicable.706 
The UK Government introduced a notifi cation scheme for novel foods including testing 
guidelines in 1984 and the Netherlands followed. Starting at the beginning of the 1990s, novel 
food regulation followed scientifi c development and focused on genetically modifi ed food. 
International organisations and governments developed guidelines on assessing GM food. 
703  European Food Information Council EUFIC Review 04/2000. 
704  European Food Information Council EUFIC Review 04/2000. 
705  European Food Information Council EUFIC Review 04/2000. 
706  European Food Information Council EUFIC Review 04/2000. 
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After many years of discussion the European Union Novel Food Regulation came into 
force in 1997.707 The Chinese Novel Food Regulation had already come into force in 1990. In 
Europe, the Regulation has been applied to all foods developed or imported after July 1997. 
GM foods were separated from the novel food regulation in 2002. Several problems still exist 
with the regulation of novel foods, and a new European regulation was proposed in 2008. 
4.2.1.7.2 European Defi nition of Novel Food  
According to the current EU regulation708, novel foods are foods that are new in the context of 
normal foods: “This Regulation shall apply to the placing on the market within the Community 
of foods and food ingredients which have not hitherto been used for human consumption to 
a signifi cant degree within the Community…”709. The food (or food ingredient) must also fall 
under the following categories: 
It has  – a new or intentionally modifi ed primary molecular structure.
It consists of  – micro-organisms, fungi or algae, or is isolated from them.
It is a food or a food ingredient consisting of/isolated from –  plants or a food ingredient 
isolated from animals, excluded foods and food ingredients obtained by traditional 
propagating or breeding practices and having a history of safe food use.
To it has been applied  – a novel production process, where the new process gives rise 
to signifi cant changes in the composition or structure of it, and the changes affect its 
nutritional value, metabolism or level of undesirable substances.710 
This means that novel foods are foods containing components or ingredients that are not 
considered natural in relation to the food concerned. Two basic groups of novel foods are 
foods containing new synthetic ingredients and foods containing new biological ingredients.
Verhagen et al. (2009) have identifi ed a ‘grey area’ of unidentifi ed novel foods. This means 
there are new foods on the European market that for some reason are not considered as novel 
foods. They further divide the grey area of novel foods into two categories: 
food products or ingredients for which the Regulation leaves too much space for (1) 
interpretations, and
food products or ingredients that are not novel according to the Regulation, because it (2) 
contains gaps. 
There are several products on the market that fi t into these categories. Camel milk, pitaya 
fruit, acai berry, argan oil, and mangosteen fruit are examples of products where the criterion 
‘human consumption to a signifi cant degree’ may be an issue. The cryogenisation process for 
707  Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning 
novel foods and novel food ingredients.
708  Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning 
novel foods and novel food ingredients.
709  Art. 1(2).
710  Art. 1(2).
–124–
cocoa butter and the processes for making meat substitutes could be examples of ‘signifi cant 
changes in production processes’.711Examples of gaps in legislation relate for example to new 
target groups, growth stages of crops, and single product intake vs. total ingredient intake.712 
The EU novel food regulation is under reconstruction. The Commission gave its proposal713 
in January 2008, six years after the Discussion Paper on Novel Foods in 2002714. A revision 
of the regulation is deemed necessary in order to “refl ect the fact that genetically modifi ed 
food no longer falls under its scope, to create a more favourable legislative environment for 
innovation in the food industry, and to better facilitate both internal and external trade in 
foodstuffs”715 The European Novel Food Regulation will most likely be totally rewritten with 
effects also on the defi nition of novel food. The Commission has proposed the following 
defi nition of novel food (Article 2(a) of the proposed Regulation): 
food that has not been used for human consumption to a signifi cant degree within the (i) 
Community before 15 May 1997;
The use of a food exclusively as or in a food supplement shall not be suffi cient 
to show whether it has been used for human consumption to a signifi cant degree 
within the Community before 15 May 1997. However, if a food has been used 
exclusively as or in a food supplement prior to that date, it can be placed on the 
Community market after that date for the same use without being considered as 
a novel food. ...
food of plant or animal origin when to the plant and animal is applied a non-traditional (ii) 
breeding technique not used before 15 May 1997; and
food to which is applied a new production process, not used before 15 May 1997, where that (iii) 
production process gives rise to signifi cant changes in the composition or structure of the 
food which affect its nutritional value, metabolism or level of undesirable substances. 
711  Verhangen et al. 2009, 4.
712  Verhagen et al. 2009, 5-6.
713  Proposal for a Regulation of the European Parliament and of the Council on novel foods and amending 
Regulation (EC) No XXX/XXXX [common procedure]. COM(2007) 872 fi nal. Brussels, 14.1.2008. The 
Regulation that will be amended is the Regulation on additives, fl avourings, and enzymes, 1331/2008/EC.
714  Commission gave its discussion paper in 2002: “Discussion paper on implementation of Regulation (EC) 
No. 258/97 SANCO D4 July 2002”. The discussion paper presented some of the issues that have emerged 
in relation to the regulation and it also gave future options regarding the possible revision of the regulation. 
About 40 stakeholders, including e.g. governments, industry, and scholars, gave their comments on the 
discussion paper. There was also a stakeholder meeting in January 2003. After this, a consult fi rm prepared a 
summary of stakeholder views in July 2003 in form of “Summary Report Stakeholder Submissions - Revision 
of the Novel Food Regulation”. They also gave their recommendations on how to develop the regulation. 
The next step was that the Evaluation Section of the Commission prepared the “Evaluation Report on the 
Novel Food Regulation 258/97 Concerning Novel Foods and Novel Food Ingredients”. They also gave their 
recommendations on how to change the regulation. This was in January 2004. The “summary report” and 
the “evaluation report” were then summarized in “Evaluation of Regulation (EC) no 258/97 of the European 
Parliament and of the Council of 27 January 1997 concerning novel foods and novel food ingredients (Novel 
Food Regulation). Executive Summary.” In June 2006, an online consultation on the revision of Novel Food 
Regulation (EC) N° 258/97 was launched by the Commission. Based on this, the Commission carried out an 
impact assessment for a future legislative proposal. Based on the discussion paper, the stakeholder comments, 
the summary report, the evaluation report, the executive summary, the online consultation, and the impact 
assessments, novel food regulation is to be revised. 
715  European Commission web page. http://ec.europa.eu/food/food/biotechnology/novelfood/initiatives_en.htm.
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A novel food is not necessarily a so-called functional food, because ‘functionality’ is related 
to health. Likewise, a functional food is not necessarily novel, because the health effect might 
be based on ingredients that have been on the market for a long time. Therefore the two types 
of product are not related in terms of defi nition and legislative aspects.716 However, novel food 
legislation is the safety regulation that a functional food developer will most likely have to 
deal with. This is if the product in question is a normal food with some health-enhancing novel 
ingredient(s). 
Besides foods in food form, the novel food regulation has been interpreted to apply to 
food supplements as well, i.e. foods in pill form. These foods will have to go through the food 
supplement procedure and the novel food procedure. For example, novel food applications have 
been made using noni fruit powder, noni leaf powder, or tree lignan in food supplements717. 
There has been some confusion on the issue of whether novel food legislation applies also 
to food additives or fl avourings. There is a problem particularly with food ingredients that 
have multiple purposes, e.g. technological, nutritional and physiological uses. This kind of 
substance could be used as an additive, as a supplement or as an ingredient in other foods.718 
If there are only technological uses for the novel substance, then authorisation under additive 
law only would be appropriate. Otherwise, it could be reasonable to authorise all uses in one 
procedure. The Commission has stated that under the current rules an additive might need an 
authorisation according to Novel Food Regulation if the safety level laid down for a type of 
additive does not correspond to the safety level laid down for novel foods.719
The Commission novel food proposal clarifi es the scope of the Regulation. According to 
Article 2(2) of the proposed Regulation, it does not apply to additives, fl avourings, enzymes, 
extraction solvents, vitamins or minerals, or GMO foods. 
Applicability of novel food regulation to novel production procedures has also been unclear. 
It is generally understood that this category does not apply to production processes themselves 
but to foods signifi cantly changed by a new production process. It is generally not very well 
understood, what the “signifi cant changes” are in food composition or structure that bring the 
process under novel food regulation. According to the Regulation, the resulting product of a 
novel process is only considered to be a novel food, if the process results in changes in the 
chemical composition or structure of the food or food ingredient, which affect its nutritional 
value, metabolism or level of undesirable substances. 
According to the Commission Recommendation, this class of novel foods comprises 
foods and food ingredients which have been subjected to a process not currently used in 
food production. Examples of novel processes for food production are new types of heat 
processing, non-thermal preservation methods, new processes to chill or freeze products, to 
dehydrate products, and the application of new processes catalysed by enzymes720. 
In its discussion paper, the Commission suggested three possible options to deal with novel 
food production processes: 
716  Mogensen 1998, 107.
717  Finnish Food Agency guidelines on food supplements, updated 2006, pages 22-23.
718  Executive Summary on Novel Foods 2004, 2.
719  Executive Summary, 2.
720  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 4.
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Remove the category. General food safety regulations are enough to deal with safety of a) 
products produced by new techniques.
Category remains. The concept of ‘signifi cant change’ is clarifi ed. This means drafting b) 
guidelines and giving expert advice to applicants.
Both novel foods and novel processes are assessed according to Novel Food c) 
Regulation. 
Option c) was deemed unnecessary as there would not be clear public health or other benefi ts 
in subjecting all new processes to a heavy pre-market procedure. This requirement would 
probably have discouraged development of new processes.721 Most stakeholders supported 
the b) approach where the category of novel procedures remains in the Regulation. Practically 
everyone stated that the concept of “signifi cant change” should be clarifi ed. The problem with 
the approach is that the uncertainty can only be reduced, not eliminated altogether.722 There 
will always be borderline cases. 
The Commission has proposed to maintain the category for novel production processes. 
In preamble 6) of the proposal, it is stated that “novel food should ... include ... foods 
modifi ed by new production processes, such as nanotechnology and nanoscience, which 
might have an impact on food. The Commission has not defi ned ‘signifi cant change’ more 
accurately. Apparently, the Commission has decided to leave this task to EFSA or Committee 
guidelines. 
An important problem in the current defi nition of novel food is that a food is novel in the 
EU regardless of its use in third countries. This is a problem mainly to producers of plant-
based products. For example, Chinese or Andean vegetables or berries that have not been used 
in Europe are novel foods requiring authorisation, even in cases where they have been used by 
people for millennia and are considered safe. This approach is similar to the strict European 
approach towards traditional herbal medicines, discussed below. 
Third-country representatives considered the novel food regulation a non-tariff barrier for 
trade. According to Hermann723, current practice of the regulation has discouraged investment in 
supply chains, and hindered market development. There might be markets in Europe for example 
for many different kinds of exotic vegetables, fruit and berries. European consumers might be 
willing to pay for these “new” products and more variable diets. Some of these might be so called 
functional foods; others might be interesting just for taste. In the other end of the supply chain, 
production and export of these plant-based products would generate income for poor farmers in 
developing countries. In addition, this would be good for biodiversity conservation. Both the third 
country producers and European consumers would thus benefi t from removal of hinders on South-
North trade.724 
It is notable that the novel food regulation seems to work in the opposite direction as 
our very own European public organisations and projects seek to assist developing countries 
in poverty alleviation. There are, for example, Swiss and Netherlands organisations and 
numerous research projects that are concerned with linking poor farmers with the market for 
exotic foods. Besides getting people out of poverty, these efforts aim at adding investment in 
721  Novel food discussion paper 2002, 15.
722  Novel food discussion paper 2002, 15.
723  Hermann 2004, 1.
724  Hermann 2004, 1.
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biological resources, which have signifi cant underutilised potential in many Southern countries. 
Questions of ethical trade are closely related: the actors are trying to build economically, 
socially and environmentally sustainable development. These organisations or farmers do not 
understand why it is so diffi cult to get the products into the EU market. In this way there is 
also a humanitarian aspect to novel food legislation. 
In 2006, the EU novel food regulation was discussed as a trade concern at the WTO725. 
Concerns were raised by Peru, Ecuador, Colombia, Paraguay, the Philippines, India, Bolivia 
and Brazil.726 These are all countries where different plant-based products compared to Europe 
are used, putting these plants under the defi nition of ‘novel food’ in the EU. 
In the WTO meetings, Southern countries questioned the justifi cation for giving different 
treatment to “products of bio-diversity” traditionally consumed outside the EU, compared 
to foods consumed within the EU.727 This different treatment is of course due to the very 
defi nition of novel food: novel foods are essentially foods that have not been consumed in 
the EU area. There is no tangible scientifi c ground for this kind of defi nition. The defi nition 
could just as well divide countries into two lists: countries where use counts, and countries 
where use does not count and scientifi c evidence on safety is required. Instead of science, the 
defi nition is in fact based on practical reasons. It is easier to gather information on familiar 
substances that are close to the Europeans. It would be too much work to be aware of all the 
foods used in the world. 
The quarrel on the defi nition of novel food is, not surprisingly, about money. At the WTO 
meetings, Peru pointed to the cost involved in providing the scientifi c studies to back up claims 
of safety. The EU defended the regulation by saying that there are genuine safety concerns 
for products within the loose category of “products of biodiversity”.728 This is of course true 
as plants may very well contain poisonous materials. But this reasoning does not justify how 
some plant products can be considered safe just based on use (use in EU), and some other plant 
products cannot be considered safe just based on use (use outside EU). 
The EU also replied that the scope of application is not limited to third countries, but 
affects all producers operating in the EU market. This is true, as the regulation applies to all 
foods marketed in the EU after 1997. Also European producers using Southern plants as raw 
material must go through the novel food procedure if they would like to sell their product in 
Europe. The Southern countries have never claimed the regulation is discriminatory in relation 
to those who use the Southern plants. They merely cited the fact that Southern plants are 
considered novel, European plants not. 
As a sign of perhaps being willing to change the defi nition of novel food, the EU said 
it welcomed examples of products approved in other markets and for which the regulation 
creates obstacles for development. They said this kind of information is useful in the further 
elaboration of the regulation.729 The Commission has received this same message in gathering 
stakeholder opinions. The current situation in practice is that many exotic foods are sold 
without novel food authorisation. The marketers do not consider their foods novel or take the 
725  The March meeting and the June meeting of the SPS Committee (the WTO committee dealing with plant 
and animal health and food safety - sanitary and phytosanitary measures).
726  WTO web page. http://www.wto.org/english/news_e/news06_e/sps_june06_e.htm.
727  WTO web page. http://www.wto.org/english/news_e/news06_e/sps_june06_e.htm.
728  WTO web page. http://www.wto.org/english/news_e/news06_e/sps_june06_e.htm.
729  WTO web page. http://www.wto.org/english/news_e/news06_e/sps_june06_e.htm.
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deliberate risk of getting caught and being removed from the market. The novel food process 
is considered too burdensome and unpredictable. When a law is impossible to live by, it is not 
obeyed. 
According to the Proposal, plants not used in Europe are still considered novel but a 
simplifi ed procedure is created for them. “Traditional food from a third country” is defi ned 
as “novel food with a history of food use in a third country, meaning that the food in question 
has been and continues to be part of the normal diet for at least one generation in a large part 
of the population of the country”730. We will return to the principal and simplifi ed procedures 
in the next chapter. 
Currently, the marketer must himself determine whether his product is novel according to 
the Regulation. This means the burden of proof is on the marketer on whether for example 
his product has been sold before 1997 or whether there is substantial equivalence to another 
product. It the producer is unsure of whether the product is novel, he can consult the authorities. 
The process of determining whether a food or food ingredient falls within the scope of the 
defi nition is in Article 13 of the Novel Foods Regulation731. According to Article 13, the 
Commission Standing Committee for Foodstuffs can be consulted by the applicant or by the 
national authority of the member state. 
Several stakeholders have indicated that they would appreciate an instrument whereby they 
could obtain a decision on whether or not their products are novel foods. This kind of advanced 
decision could be made by EFSA. The ruling would have legal validity throughout the EU. 
This would remove some of the costs related to uncertainty and thus promote innovation in 
foods732. It has also been suggested that a publicly accessible novel food database be created. 
In this database or network, information on novel food status of individual products could be 
exchanged.733 
According to the Proposal734, where necessary, it may be determined in accordance with 
the procedure referred to in Article 14(2), whether a type of food falls within the scope of 
the Novel Food Regulation. The procedure in Article 14(2) means the Committee procedure. 
The Commission’s Standing Committee on Food Chain and Animal Health will resolve the 
issue of whether the food is novel. According to the defi nition of novel food735, the Committee 
will also set further criteria for assessing if a food has been used for human consumption to a 
signifi cant degree within the Community before 15 May 1997. This will probably be done in 
the form of scientifi c opinion or guideline. 
730  Article 3(2)(b) of the proposed Regulation.
731  Art. 1(3).
732  According to CIAA, uncertainty of novel food procedures is detrimental to innovation and new product 
development. The fi rst uncertain issue here is whether a food is novel in the fi rst place. CIAA: Economic 
impact assessment of the way in which the EU novel foods regulatory approval procedures affect the EU food 
sector.
733  Novel food summary report 2003, 4.
734  Article 2(3) of the proposed Regulation.
735  Article 3(2)(a)(i) of the proposed Regulation.
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4.2.1.7.3  Current Procedures of Evaluating Safety
Currently, there are two different novel food procedures in use. Pre-market authorisation is the 
primary procedure. Pre-market notifi cation (the simplifi ed procedure) applies to foods that are 
substantially equivalent to existing foods.
WHO and OECD originally introduced the concept of substantial equivalence with particular 
reference to GMO foods. The concept of substantial equivalence embodies the idea that existing 
organisms used as foods can serve as a basis for comparison when assessing the safety of a modifi ed 
or new food. If a new food is found to be substantially equivalent to an existing food, it can be 
treated in the same manner with respect to safety.736
The application of the principle of substantial equivalence was extended from the 
evaluation of GMO foods to the evaluation of foods from novel sources and processes. In 
terms of safety, substantially equivalent novel foods are comparable to their conventional 
counterpart. Establishment of substantial equivalence is not a safety or nutritional assessment 
in itself. Conversely, if a novel food is not substantially equivalent to an existing food or food 
component, this does not imply that it is unsafe. It merely indicates that such a food must be 
evaluated on the basis of its unique composition and properties.
The establishment of substantial equivalence is thus “an approach to compare a potential 
new food with its conventional counterpart”. The notion implies that the substantially similar 
novel foods are presumed just as safe as traditional foods. From a risk management perspective, 
this leaves a lot of questions unanswered. We don’t know exactly how safe traditional foods 
are. We just don’t know all the diet-health mechanisms. A food might be similar to a traditional 
food that will later prove dangerous. A food might be almost identical to a safe food, but the 
slight difference might make it dangerous.
According to the Commission, the establishment of substantial equivalence contains a 
dynamic element. This means that when a food is continually modifi ed, the basis of comparison 
changes. The most recent novel food is compared with an appropriate former novel food 
and not necessarily with the most traditional counterpart.737 A consumer is reassured by the 
presumption that “another little change will probably be meaningless”.
The comparison of the old food and the novel food may be simple or very lengthy depending 
upon experience with and the nature of the novel food in question. The technical approach to 
establishing substantial equivalence differs between whole animals, plants, microorganisms, 
chemical food ingredients and novel processes.738
The advantages of the comparative approach are:
the comparator defi nes a standard that meets the acceptable level of safety, –
 it is practicable, and –
 animal tests are restricted to situations where they are of real value.  – 739
Again we see that food law is not based on pure science but practical issues. We cannot 
analyse all the foods on the market, so we presume the old foods are safe. We also presume 
736  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.3.
737  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.3.
738  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.3.
739  European Food Information Council EUFIC Review 04/2000. 
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that novel foods are safe if they are equivalent to old foods. Besides being unscientifi c and 
discriminatory, the concept of substantial equivalence is unavoidably blurred. 
The decision on the authorisation of a novel food is made jointly for the whole EU and 
Member States, and Commission takes part in this decision-making. At present, novel food 
applications are lodged with Member States. They make the Initial Assessment of the safety 
of the product. In practice, the process has always continued from initial assessment to a 
Community decision740. For example in Finland, the Food Agency handles applications on 
novel foods. There is an expert body called the Board of Novel Foods that assesses the 
applications from the safety point of view.
An alternative for the current system is that applications are to be lodged with the EFSA. 
This would be simpler, in that applicants would still deal with a single authority. Applicants 
would not have to go through the occasional artifi cial process of selecting which Member 
State is the one where they fi rst market a food. Also consistency of decisions might improve. 
This would promote legal certainty and equality of applicants. During the Commission’s 
consultations, the majority of stakeholders were of the view that the EFSA should handle 
novel food applications, as it is an impartial scientifi c organisation consisting of food science 
experts.
In its Discussion paper, the Commission identifi ed the major problem of the novel food 
process as being too lengthy. It has been a constant complaint that the current two to three 
years is too long of a period for the assessment to last. The novel food process signifi cantly 
postpones the time of the product accessing the market. With medicines, there are absolute 
timeframes in which the authorities must handle the application. The food industry is 
reasonable in demanding similar treatment. Setting exact timeframes would make the legal 
treatment more predictable and facilitate planning by entrepreneurs.
In their comments to the Commission discussion paper, stakeholders were unanimous in 
urging the Commission to streamline the decision-making procedure in order to make it quicker. 
However, the quality of risk assessment and risk management cannot be compromised. One 
important suggestion by the stakeholders was that there should be strict deadlines for each 
stage of the procedure. These deadlines would apply to the EFSA and the Commission.741
Many stakeholders believed that putting the EFSA in charge of the risk assessment would 
speed up things, particularly if applications will in the future be fi led directly with the EFSA. 
Stakeholders also trust the EFSA to make quality assessments, see above. All stakeholders agree 
that legal recourse against a decision to authorise or not authorise a novel food should be guaranteed. 
This would also be according to European on Human Rights, where every person is guaranteed to 
appeal a decision affecting his or her rights or responsibilities. 
The novel food process has been strongly criticised by the European food industry for 
being unpredictable and anti-innovation. According to the CIAA, most in the food industry 
have always known that “food innovation in Europe is not possible without a fundamental 
reform of current procedures”742. According to a report prepared for the CIAA in 2007, R&D 
expenditure on food products by companies tends to be lower in the EU compared to other 
countries. Also, the EU tends not to be the highest priority target market for new food product 
development. As a result, improved products are not available to European consumers. The 
740  Novel Food Discussion paper 2002, 21.
741  Summary Report 2003, 2.
742  CIAA Statement on proposed Novel Food Regulation. 14.1.2008.
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report also suspects that income and employment generation in the EU are lower than they 
would be in a “more innovation-friendly regulatory environment”. 743 
The CIAA report identifi es major impacts of the current EU Novel Foods Regulation that 
contribute to explaining why food companies tend to ignore the EU market for novel product 
development, as compared to the US market. First, there is the uncertainty regarding the novel 
food status and the timing of the procedure. There is a risk of delays of three years to fi ve years 
in obtaining approval. This uncertainty has made some investments of marginal value, and 
signifi cantly diminished the economic incentive to bring products to the EU market. Secondly, the 
current approval mechanism encourages companies to be market followers rather than innovators. 
Followers to market experience lower costs and risks than novel food innovators, and hence can 
easily earn higher rates of return than innovators.744 
The report concludes that if the EU Novel Foods regulation is to better create an environment 
that encourages food innovation, each of these defi ciencies should be addressed. The time taken to 
authorise a novel food should be reduced. Incentives to encourage innovation should be considered. 
For this purpose, the report suggests exclusive access to markets or compensation for data provision. 
Uncertainties should be minimised.745
4.2.1.7.4 Proposed Procedures 
Common Procedure 
According to the Commission proposal, novel foods will in the future be evaluated by the 
EFSA in the Common Procedure for novel foods, additives, fl avourings, and enzymes746. 
According to preamble 17 of the proposed Novel Food Regulation, “in order to simplify 
procedures, applicants should be allowed to present a single application for foods regulated 
under different sectoral food laws”. This means that a substance that has multiple uses can be 
authorised in one procedure, for example as a novel food and as an additive. 
As regards the procedure for updating the Community list, the proposal for Novel Food 
Regulation, more particularly its Article 7, refers to the proposal on the Common Procedure, 
more particularly its Article 14, which in turn refers to the Council Decision 1999/468/
EC laying down the procedures for the exercise of implementing powers conferred on the 
Commission. It would be clearer for the marketers if the novel food evaluation procedures 
were described in the Novel Food Regulation itself. 
The Common Procedure is based on risk assessment carried out by the EFSA and a risk 
management system in which the Commission and the Member States operate within the 
framework of a regulatory committee procedure. This means the Commission shall be assisted 
by the Standing Committee on the Food Chain and Animal Health. On the basis of scientifi c 
assessments by EFSA, the Commission creates, maintains, and updates a general positive 
list for each category of substances concerned. The lists and their updates will be given in 
743  Brookes 2007, 6.
744  Brookes 2007, 6.
745  Brookes 2007, 6.
746  Regulation (EC) No 1331/2008 establishing a common authorisation procedure for food additives, food 
enzymes and food fl avourings.
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the form of regulations. The inclusion of a substance on one of the lists means that its use is 
authorised in general for all operators on the Community market. 747 The Commission will 
make decisions on the lists based on EFSA opinions, Community law, and “other legitimate 
factors”748. 
There are strict timelines involved in the Common Procedure. Applications will be sent to 
the Commission, which will seek an opinion from the EFSA. The EFSA will have 6 months 
to give their opinion749. After this, the Commission will have 9 months to give their draft 
Regulation750. The Standing Committee on Food Chain and Animal Health shall deliver its 
opinion within a time limit, which the chairman may lay down according to the urgency of 
the matter751. After this, the Commission shall adopt the measures envisaged, if they are in 
accordance with the opinion of the Committee752. If the opinion is not in accordance with 
the draft regulation, the matter will be submitted to the Council, which will have 3 months 
to adopt it or oppose it. If the Council does neither, the Commission may adopt the proposed 
regulation.753 
The timelines indicate that the procedure as a whole should generally last not much 
longer than one and a half years. Timelines are what the industry has wanted of novel food 
evaluation, and the proposed procedure is an improvement compared to current novel food 
procedures. Novel food producers should also be satisfi ed with the EFSA being in charge of 
risk assessment. The EFSA is trusted by the industry as an impartial actor. 
According to Article 6 of the proposed Novel Food Regulation, “a novel food may be 
included in the Community list only if it meets the following conditions:
it does not, on the basis of the scientifi c evidence available, pose a safety concern to the a) 
health of the consumer under normal consumption conditions;
it does not mislead the consumer, by the way it is presented or by its intended use;b) 
in the case where it is intended to replace another food, it does not differ from that food c) 
to such an extent that its normal consumption would be nutritionally disadvantageous 
for the consumer”. 
According to Article 10 of the proposed Novel Food Regulation, in assessing the safety of 
novel foods, the EFSA shall: 
compare, where appropriate, if the food is as safe as food from a comparable food (a) 
category already existing on the market in the Community or as the food that the novel 
food is intended to replace;
take into account for traditional food from a third country, the history of safe food use.” (b) 
747  Commission Proposal COM (2006) 423 fi nal, page 2 (Explanatory Memorandum).
748  Article 3(4) and Article 7 of the proposed Regulation on the Common Procedure.
749  In duly justifi ed cases where the EFSA requests additional information from applicants, the period may be 
extended. Article 6(1) of the proposed Regulation on the Common Procedure.
750  Article 7 of the proposed Regulation on the Common Procedure. The 9-month period may be extended if 
the Commission needs additional information from applicants. Article 8(1).
751  Decision 1999/468/EC, Article 5(2).
752  Decision 1999/468/EC, Article 5(3).
753  Article 14(2) of the proposed Regulation, referring to Article 5(6) of Decision 1999/468/EC. The Parliament 
will also be informed on the proposal, and it may force the Commission to re-examine the measures.
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The safety test is a comparison. The novel food is compared to the old EU food, which is 
presumed safe. Also with third country foods, safety is presumed to be based on long-term 
use. Safety in absolute terms would be impossible to achieve. However, research will continue 
to bring negative impacts of old foods to our knowledge. The concept of presuming familiar 
things safe is used in law not only for scientifi c but for practical and political reasons. Even 
though used in regulation, this kind of presumption cannot be the base of natural science. 
Traditional Foods from Third Countries
By the current Regulation, the novelty of plants, animals or microorganisms is defi ned by their 
novelty in the Community. Species not previously used in Europe are considered new, and a 
full description is needed to assess their role in the European food supply. With reference to 
history of the organism, the description should include information on the past and present 
use of the food in other parts of the world. Such information should also include past and 
present methods to obtain raw materials and food, e.g. by raising, harvesting, slaughtering, 
and capture, procedures for fermentation and preparation, description of transport and storage 
conditions, and its traditional role in the diet at locations outside the Community.754
Considering information on previous human exposure to the novel food, it is acknowledged 
that documentation on previous use of the novel food source in the Community or in other 
parts of the world is important to establish a baseline for assessment. However, it is also fi rmly 
stated that history of food use outside the Community is not of itself a guarantee that the 
novel food can be safely consumed in the Community. There might be traditional handling and 
preparation habits that prevent adverse effects of foods that in other conditions might be toxic. 
These cultural issues must be included in describing human exposure to the food.755
In its discussion paper, the Commission presented different alternatives for the new 
simplifi ed procedure:
Simplifi ed procedure for exotic traditional foods (with history of safe use in third a) 
countries).
Three different categories of novel foods with different requirements and proceduresb) :
 innovative products with claimed consumer benefi ts, –
 innovative products without claimed consumer benefi ts, and –
 exotic traditional foods. –
Only one procedurec)  and same safety requirements for all products.
As stated above, the Commission eventually chose option a). Option c) seems fair and 
would have been the clearest one. In practice, it would have been unreasonably burdensome 
to demand all the same scientifi c evidence of all novel foods. Option b) would have been 
analogous to pre-market approval of medicines: Every product would go through pre-market 
approval process, but products are subject to different requirements as to the type and quantity 
of data they must provide.756 By option b), the Commission must have meant that health claim 
754  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 5.
755  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 5.
756  Novel food discussion paper 2002, 20.
–134–
evaluation would, if necessary, be added on top of the novel food procedure. Safety evaluation 
as such would have been the same for innovative products with and without claims.
After the long debate and problems at the WTO, the proposed Regulation creates a new 
procedure for traditional foods from third countries (Article 8). They are still considered a 
subcategory of novel foods, but they are not included in the Community list of authorised 
novel foods. Instead, a separate list of traditional foods will be created and published on the 
Commission website.
According to the Proposal, a food business operator intending to place a traditional food from 
a third country on the market in the Community shall notify it to the Commission. The notifi cation 
must indicate the name of the food, its composition and country of origin. The notifi cation shall be 
accompanied by documented data demonstrating the history of safe food use in the third country.757 
According to proposed Article 3(2)(c), “history of safe food use” means that the safety of the food 
in question is confi rmed with compositional data and from experience of use and continued use in 
the normal diet of a large part of the population of a country. This means the marketer will still be 
required to show safety, and it may be a complex task.
The Commission shall forward the notifi cation including the demonstration of history of 
safe food use without delay to the Member States and the EFSA758. Within four months from 
the date on which the notifi cation is forwarded by the Commission, a Member State and the 
EFSA may inform the Commission that they have reasonable safety objections, based on 
scientifi c evidence, to the placing on the market of the traditional food concerned. In that 
case, the food shall not yet be placed on the market, and the notifi cation will transform into an 
application in the primary procedure for authorisation of novel foods. The Commission will 
inform the food business operator of objections within fi ve months of the notifi cation.759
If no reasoned safety objections, based on scientifi c evidence, have been raised and no 
such information has been communicated to the food business operator itself, the traditional 
food may be placed on the market in the Community after fi ve months from the date of the 
notifi cation. The Commission shall publish a list of traditional foods from third countries that 
may be placed on the market in the Community760.
The proposed procedure seems reasonable from the viewpoint of the marketer: in fi ve 
months, he will either have a permission to put the product on the market, or he will have 
learned about his notifi cation being objected and transferred into an application. It remains to 
be seen whether the Member States will try to reject traditional food notifi cations on artifi cial 
grounds. In that case, the notifi cation procedure would lose its benefi ts, waste time, and only 
create an additional hurdle to reaching the market.
4.2.1.7.5 Required Scientifi c Evidence on Safety 
Even though the procedures change, the Commission Proposal does not intend to alter the scientifi c 
evidence required to show safety, apart from creating the new simplifi ed procedure for traditional 
foods. The detailed requirements for novel food applications are specifi ed in the Commission 
757  Article 8(1) of the proposed Regulation.
758  Article 8(2) of the proposed Regulation.
759  Article 8(3) of the proposed Regulation.
760  Article 8(5) of the proposed Regulation.
“
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Recommendation 97/618/EC761. Scientifi c aspects of the information necessary to support 
applications are specifi ed in the Annex of the Recommendation, Part I. The information should be 
presented according to Part II of the Annex. Member States should draw up their initial assessment 
reports according to Part III of the Annex. 
When new ingredients are used or a food is produced in a new way, the implications for consumer 
safety and nutritional value require consideration. Information is needed on any issue relating to both 
these aspects.762 This information must be included in a novel food application763. 
Safety evaluation includes toxicity tests, showing the product does not cause mutations and 
cancer. The assessment of the nutritional value of foods presents further scientifi c challenges. 
Foods are complex chemical mixtures, which are more diffi cult to evaluate than the impact of 
a single chemical. We don’t know the exact mechanisms on how different patterns of nutrient 
intake affect health. For example, so-called modifi ers of toxic effects might be naturally present 
in certain foods. It is thus diffi cult to exactly defi ne the concept of nutritional balance.764 
Analytical studies of the composition of the novel food are required. Studies are needed for the 
establishment of substantial equivalence, in which case the simplifi ed procedure applies, and as a 
prerequisite for nutritional and toxicological assessments. Study methods have to be standardised 
and validated, and the analyses and data presented have to be based upon sound scientifi c principles. 
Both substances inherently present and substances derived from the process must be analysed. 
Investigations should focus especially on determining contents of:
critical nutrients  – (both macro- and micronutrients), and
critical toxicants –  and anti-nutritional factors.765 
Toxicological requirements for a novel food are considered on a case-by-case basis. 
Toxicological data is needed in three different scenarios: 
Substantial equivalence can be established to an accepted traditional food or food 1) 
ingredient. In this case, no further testing is needed.
Substantial equivalence can be established except for a single or few specifi c traits of 2) 
the novel food. In this case, further assessment of safety should focus specifi cally on 
these traits.
Neither partial nor total substantial equivalence can be established. In this case, the 3) 
wholesomeness of the whole novel food or macronutrient has to be assessed using an 
appropriate combined nutritional-toxicological approach.766 
761  97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientifi c aspects and the 
presentation of information necessary to support applications for the placing on the market of novel foods and 
novel food ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of 
the European Parliament and of the Council.
762  Commission Recommendation, Annex, Part I, Chapter I.
763  Hermann 2004, 7. Wheat has considerable allergenic potential due to the presence of gluten proteins, 
potatoes involve hazards posed by glycoalcaloids (green colour caused by sunshine), and green leafy 
vegetables contain nitrate and oxalate.
764  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.2.
765  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.4.
766  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.7.
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In scenario 3), the wholesomeness assessment has to take into account: 
identity, chemical structure and physico-chemical properties of the novel food, –
potential intake based on the proposed use, –
potential exposure of particularly vulnerable population groups, and –
the likely effects of processing. – 767 
Nutritional implications must be considered both at expected normal intakes and at maximum 
levels of consumption. Evaluation is based on literature, product compositional analysis and, 
if needed, data from animal studies. Attention should be paid to particular nutritional needs 
of groups such as infants, children, pregnant and lactating women, the elderly, and those with 
chronic diseases like diabetes. The greater the role of the product in the diet the more extensive 
the nutritional assessment must be. Human nutritional assessment data are needed both on 
short-term and long-term effects.768 
Nutritional and toxicological aspects are integrated in the assessment of a novel food. Nutritional 
properties of the food (e.g. energy value, protein content, and bioavailability of micronutrients) 
affect the toxicological testing programme: the anticipated role of the product in the diet determines 
how much food is given to test animals.769 The greater the predicted dietary exposure the more 
extensive the required toxicological testing programme will have to be770. 
However, it is impossible to predict exactly how much the product will be used and what 
products it will replace. This is why a surveillance programme should accompany marketing 
of a novel food. The consumption pattern might affect the acceptability of the novel food.771 
This notion is rather unclear because the presumption is that a novel food cannot be authorised 
if it is unsafe or unwholesome. Because the surveillance programme is a recommendation 
only, consequences for not following the surveillance programme are unclear. 
Foods and food ingredients which fall within the scope of the novel food regulation, can 
be divided in categories which differ in complexity and in the issues that need to be addressed. 
These categories are:
simple chemically defi ned substances or mixtures of these, –
complex foods such as plants, animals, micro-organisms or food components such as  –
fats, proteins, or fi bre; and
foods processed in a novel procedure. – 772 
The Commission Recommendation gives structured schemes on the types of information 
that are considered essential to establish the safety of particular classes of novel foods. The 
Recommendation is not legally binding, and the schemes are therefore provided “for guidance 
only”. However, if an applicant wants to omit certain information from a dossier requested in 
any of the schemes, the scientifi c justifi cation for this should be given. The results of any other 
767  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.7.
768  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.8.
769  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.6.
770  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.7.
771  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 3.5.
772  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 4. In the Recommendation, there 
are additional three categories listed for GM products, which no longer fall under the novel food regulation.
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investigations (not required by the schemes) relevant to safety assessments, which have been 
carried out must be reported.773 In practice, the information according to the Recommendation 
is usually the required minimum information.
The information schemes are the following:
Specifi cation of the novel food, –
Effect of the production process applied to the novel food, –
History of the organism –  used as the source of novel food,
Anticipated intake and extent of use of the novel food, –
Information on previous human exposure –  to the novel food or its source,
Nutritional information on the novel food, –
Microbiological information on the novel food, –
Toxicological information on the novel food. – 774
The need for comparative data between the novel food and its counterpart are emphasised in 
these schemes. The presence of new toxins, anti-nutritional factors or allergens (or increased 
levels thereof) will indicate the need to assess their safety implications. The nutritional impact 
of the novel food introduction into human diets must always be assessed, unless the old food 
and the novel food are nutritionally equivalent.775
4.2.1.7.6 Decisions / Regulations? 
The third important question with novel foods, besides what is considered novel and what is 
considered safe, is whether others can market the novel food after one company has received 
authorisation. At the moment, decisions under the Novel Food Regulation are addressed to 
the applicant. If authorisation is granted, only the applicant is able to place the novel food in 
question on the market. Another marketer must submit another application or notifi cation. 
There are in essence two alternatives to manage the issue: 
 Decisions addressed to individuals.a) 
 Regulations with general application. b) 
According to the Commission, decisions have the advantage that they provide the regulator 
with more certain and comprehensive information about the novel foods that are legally on 
the market.776 When they know the fi rms that have applied, it is easy to determine that other 
marketers are conducting illegal business. The decision approach also allows enforceable 
conditions to be attached to the decision. By this, the Commission means that for example 
post-market surveillance requirements can easily be imposed on the fi rm in question.777 This is 
because the Commission knows the names of the fi rms by the fact that they have applied. It is 
773  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 5.
774  Commission Novel Food Recommendation 1997, Annex, Part I, Chapter 5.
775  European Food Information Council EUFIC Review 04/2000. 
776  Novel food discussion paper 2002, 17.
777  Novel food discussion paper 2002, 17.
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more diffi cult to impose precise obligations to parties that are not known by the Commission, 
and perhaps do not even themselves know that their product is a novel food and that they have 
certain legal criteria that bind them. 
A possible downside of the decision approach is, according to the Commission, that creating 
effective monopolies may not be advisable unless there are very good grounds for it.778 After 
all, freedom of competition is one of the cornerstones of the European Union. 
The regulation approach, on the other hand, has the benefi t of being binding to all relevant 
parties, indicating the labelling requirements are binding on all the sellers of the product, 
not just the applicant. The regulation approach would save the authorities from multiple 
applications, and it would also save the competitors from monopolies.779 The regulation could 
also include other uses for the food products than the ones that the applicant applies for. For 
example it could include the use of a berry in juice, jam, etc. 
The Commission has indeed proposed the regulation approach: it is proposed that a Community 
list of authorised novel foods will be created780. The list would be applicable to all, and only novel 
foods on the list could be placed on the market. At the same time, a system of rewarding applicants 
with data exclusivity for 5 years has been suggested. This is a compromise between the decision 
approach and the regulation approach, and corresponds to the Regulation on claims, which also 
created the Community lists and the 5-year protection for proprietary data. With medicines, 
proprietary data included in the application is protected for 10 years. 
Article 12 of the proposed Regulation stipulates the rules on proprietary data: 
“On request by the applicant, supported by appropriate and verifi able information 
included in the application dossier, newly developed scientifi c evidence and proprietary 
scientifi c data provided to support the applications, may not be used for the benefi t of 
another application during a period of fi ve years from the date of the inclusion of the 
novel food in the Community list without the agreement of the applicant.” 
According to preamble 20 of the proposed Regulation, the data exclusivity is granted “under 
specifi c circumstances in order to stimulate research and development within the agri-food 
industry, and thus innovation”. The protection of scientifi c data provided by one applicant does 
not prevent other applicants from seeking the inclusion in the Community list of novel foods 
on the basis of their own scientifi c data781. This means a competitor can choose between: 
producing the same or similar data himself: comparing the toxicological and nutritional  –
properties of an old food and the novel food,
reaching an agreement with the fi rst applicant to use the data, in practice: buying the  –
data from the fi rst applicant,
waiting 5 years and using the fi rst applicant’s data free of charge.  –
The 5-year exclusivity sounds similar to an intellectual property right. However, patent 
protection is more far-reaching as it blocks competitors even if competitors developed the 
778  Novel food discussion paper 2002, 18.
779  Novel food discussion paper 2002, 17.
780  Article 5 of the proposed Regulation.
781  Preamble 20 of the proposed Regulation.
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invention themselves782. Patent protection is also longer: 20 years. According to the European 
patent convention, patent protection is available for a product or a method that is novel, 
involves an inventive step and is susceptible of industrial application783. Some innovative 
foods are thus also eligible for patent protection. The patent application could also be done in 
vain, in case of the novel food application being rejected. 
One could argue that patent protection is enough and that other kinds of exclusivity rules 
are not needed. A company could patent what is patentable, and other innovations would be 
available to competitors in the spirit of freedom of competition. However, data exclusivity of 
a novel food application is different from protecting the product itself. The 5-year rule rewards 
the performing of safety tests on the product, not the product innovation. The patent system is 
not faultless in promoting innovation, hence other forms of intellectual property, proprietary 
rights, and data protection are created.784 
Trademark protection is another issue. It could be argued that trademarks are enough, and that 
no rules on data exclusivity are needed. The marketer of a novel food can register the name of the 
product as a trademark. If no period of exclusivity were granted, the developer of the novel food 
would still be the fi rst to market, have some lead on his rivals, and be in the best position to build 
his brand to make himself the market leader. However, this lead has not been considered suffi cient 
by food industry operators to make innovation profi table, at least according to the 2007 report 
produced for the CIAA. Based on data exclusivity, the trademark and brand holder will have more 
time to recoup his investment and to build his brand among the consumers. 
One might think that small companies, which are often market followers, would have 
preferred the full regulation approach where they can simply copy the large company. 
However, we cannot only focus on the followers. The compromise version might be best 
for all companies as it always rewards the fi rst to market. The compromise approach leaves 
the copying competitor three different options between which he can choose, based on cost-
effi ciency: to duplicate the effort, to agree with (pay for) the fi rst to market, or to wait for 5 
years and follow. 
4.2.1.8 Safety of Genetically Modifi ed Foods 
Genetically modifi ed organisms (GMOs) are organisms in which man has altered the genetic 
material (DNA). The technology that enables this is called “modern biotechnology”, “gene 
technology”, “recombinant DNA technology” or “genetic engineering”. It allows selected 
individual genes to be transferred from one organism into another. Genes are today modifi ed 
primarily to improve crop protection. This is done by transferring bacterium or virus genes 
that give the plant greater resistance against insects or viruses, or increased tolerance towards 
herbicides. Under development are plants with improved disease or drought resistance, crops 
with increased nutrient levels, fi sh species with enhanced growth characteristics and plants 
782  If the competitor used the invention at the time of the patent application, he may be granted a licence. If 
he used it at the time when the application became public, he may be granted a compulsory licence.
783  Articles 54, 55, and 57 of the European Patent Convention.
784  Here we must mention that some European countries have rules on utility model protection. This “little 
patent” could be suitable for many food products, but is not available everywhere. 
–140–
or animals producing pharmaceutically important proteins such as vaccines.785 Globally, new 
GMO foods must go through pre-market safety evaluation.786
EU legislation on GMO approval has been in place since the beginning of the 1990s. Between 
1991 and 1998, the marketing of 18 GMOs was authorised in the EU by a Commission decision. 
Then began the so-called moratorium, during which no authorisations were granted due to 
resistance to the whole idea of GMO food. New EU legislation on GMO foods came into force 
in 2004. This includes the regulation on genetically modifi ed food and feed787, its implementing 
regulation788, and the GMO traceability and labelling regulation789. Until April 2004, GMOs were 
evaluated under novel food legislation. The new regulatory framework on GMOs aimed to address 
the concerns of EU Member States and EU consumers. It was designed to build confi dence in the 
authorisation system so that the moratorium could be ended.790
The GMO food regulations apply to:
 GMOs for food use;(a) 
food containing or consisting of GMOs(b) 
food produced from or containing ingredients produced from GMOs(c) 791.
Food produced “from” a GMO is covered; food produced “with” a GMO is not. The determining 
criterion is whether or not material derived from the genetically modifi ed source material is present 
in the food. Processing aids, which are only used during the production process, are not covered by 
the defi nition, because they are not expected to become an ingredient of the food.792
GMO food must not:
 have adverse effects on human health, animal health or the environment;(a) 
 mislead the consumer;(b) 
785  WHO web page. http://www.who.int/foodsafety/publications/biotech/20questions/en/.
786  According to WHO, the safety assessment of GM foods generally investigates: “(a) direct health effects 
(toxicity); (b) tendencies to provoke allergic reaction (allergenicity); (c) specifi c components thought to have 
nutritional or toxic properties; (d) the stability of the inserted gene; (e) nutritional effects associated with 
genetic modifi cation; and (f) any unintended effects which could result from the gene insertion”. http://www.
who.int/foodsafety/publications/biotech/20questions/en/.
787  Regulation 1829/2003/EC of the European Parliament and of the Council of 22 September 2003 on 
genetically modifi ed food and feed.
788  Commission Regulation 641/2004/EC of 6 April 2004 on detailed rules for the implementation of 
Regulation 1829/2003/EC of the European Parliament and of the Council as regards the application for the 
authorisation of new genetically modifi ed food and feed, the notifi cation of existing products and adventitious 
or technically unavoidable presence of genetically modifi ed material which has benefi ted from a favourable 
risk evaluation.
789  Regulation 1830/2003/EC of the European Parliament and of the Council of 22 September 2003 concerning 
the traceability and labelling of genetically modifi ed organisms and the traceability of food and feed products 
produced from genetically modifi ed organisms and amending Directive 2001/18/EC.
790  WHO web page. http://www.who.int/foodsafety/publications/biotech/20questions/en/.
791  Regulation 1829/2003/EC, Article 3.
792  Cana – Schliessner 2005. Here we only discuss safety rules of fi nal products. Contained use of GMOs 
is covered by Directive 90/219/EEC, and deliberate release into the environment of GMOs by Directive 
2001/18/EC. 
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 differ from the food which it is intended to replace to such an extent that its normal (c) 
consumption would be nutritionally disadvantageous for the consumer793.
There is a single European authorisation procedure that covers both human food and animal 
feed. Applications are submitted fi rst to the competent authority of the Member State where 
the product is fi rst to be marketed. The application is then made available to the EFSA, which 
is responsible for the scientifi c risk assessment. The Commission will draft a proposal for 
granting or refusing authorisation. The Standing Committee on the Food Chain and Animal 
Health will approve the Commission’s proposal. If the Committee does not approve the 
proposal, the draft Decision is submitted to the Council of Ministers, which can either adopt 
or reject it. If the Council does not act within three months or does not obtain a qualifi ed 
majority for the adoption or rejection of the Commission’s proposal, the Commission shall 
adopt the decision.794
Foods containing maximum 0.9 percent GMOs795 are excluded from the scope of the EU 
GMO food regulations, provided that this presence is adventitious or technically unavoidable. 
GMOs approved so far have been maize and soy derivatives, rapeseed oil and cottonseed 
oil796. Post market monitoring of GMOs is performed by national food agencies.
European consumers remain unenthusiastic about GMO food due to several factors. When 
GMO foods fi rst came to the European market, the consumers could not see the benefi t of 
them. The products were not less expensive and did not taste better. The European consumers 
also distrust risk assessments, as there have been several food safety scandals in Europe 
particularly in the 1990s797 Generally, consumers tend to accept gene technology in medicine 
much easier than gene technology in food798. This is related to the basic ideas of foodstuffs and 
medicines: medicines are used based on a calculation of risks and benefi ts to health. Everyone 
acknowledges that medicines have side effects. For foods, unfamiliar risks related to one’s 
health are not accepted.
The Commission assessment reports of the GMO Regulations 1829/2003/EC and 
1830/2003/EC have been published799 but no revision of the Regulations is planned. The 
CIAA wants the European Commission to recognise that GMO contaminations can occur, 
despite the efforts of all partners in the food chain. They say discussion on the enforceability 
of the European GMO regulatory system is necessary.800 According to the WHO, feasibility 
and methods for post-marketing monitoring of GMO food products are under discussion801.
793  Regulation 1829/2003/EC, Article 4.
794  European Commission web page. http://ec.europa.eu/food/food/biotechnology/gmfood/qanda_en.pdf.
795  Of the food ingredients considered individually.
796  European Commission web page. http://ec.europa.eu/food/food/biotechnology/authorisation/index_en.htm.
797  WHO web page. http://www.who.int/foodsafety/publications/biotech/20questions/en/.
798  WHO web page. http://www.who.int/foodsafety/publications/biotech/20questions/en/.
799  Report from the Commission to the Council and the European Parliament on the implementation of 
Regulation 1830/2003/EC concerning the traceability and labelling of genetically modifi ed organisms and the 
traceability of food and feed products produced from genetically modifi ed organisms and amending Directive 
2001/18/EC. COM(2006) 0197 fi nal. 
800  Review of CIAA Priorities and Objectives for Better Regulation In light of the Commission proposals to 
simplify EU legislation. CPT/003/07E-Final Brussels, 28 February 2007 Page 5.
801  WHO web page. http://www.who.int/foodsafety/publications/biotech/20questions/en/.
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4.2.2. China 
4.2.2.1 The Challenge of Food Safety in China  
Food safety is today a major concern in China. It is important both for Chinese food export and 
domestic markets802. Food safety efforts are more advanced in the export sector803, and more 
recently in the domestic sector. According to Calvin et al., “China’s efforts are an important 
case study of a country’s striving to elevate standards in its food and agriculture sector to 
international food safety standards”.804 
For exported food, the Chinese government has succeeded in arranging a strict regulation 
system. It is usual that developing countries have, to promote their exports, stricter standards 
for exported food. The Chinese system was created as a response to bans of Chinese food 
in foreign countries. The Export-Oriented System monitors food products from exporting 
companies at every step, from the pesticides and chemicals used on farms to food processing 
facilities to packaging plants. Exporting food companies must obtain special licences from 
the Export-Oriented System administration.805 The approach taken resembles the European 
farm-to-table approach. 
The reasons for regulating the export industry stricter are: 
The export industry is easier to regulate because it is smaller than the general food industry. –
The export industry is a more motivating target as the exports generate considerable  –
revenue, and China wants to keep up its international reputation.806 
According to Calvin et al, many of China’s food safety problems can be traced back to the 
farm level. It is diffi cult to standardise and monitor production practices of the Chinese food 
production sector, which is composed of 200 million farm households. Important issues 
include both chemical and biological hazards. Chinese farmers must rely on heavy use of 
fertilizers to get production out of intensively cultivated soils. Chinese farmers also use many 
highly toxic pesticides. Some farmers have scant understanding of correct chemical use. They 
may harvest immediately after applying a pesticide, which results in excessive residues in 
the harvested product. Antibiotics are widely used to control disease in livestock, poultry, 
and aquaculture products. Industrialisation and lax environmental controls have also led to 
802  Since the 1990s, China has been an important exporter of food products such as vegetables, apples, 
shrimp, and poultry. However, China has recently had problems with food export because Chinese food has 
failed to meet stringent food safety standards in Japan, Europe, and other countries. Also Chinese consumers 
are more and more interested in food safety because of some domestic food contamination scandals. 
803  Chinese food must meet the international food safety standards, and the increased costs of achieving 
these standards might have an effect on growth of Chinese food exports. Chinese foods have been rejected 
because of excessive antibiotic residues (EU rejected shrimp 2001, EU and Japan rejected poultry 2001, and 
EU rejected honey 2002), excessive pesticide residues (Japan rejected frozen spinach in 2002-2003, EU and 
Japan rejected tea 2002) and parasites (South Korea rejected fermented cabbage in 2005). Calvin et al. 2006, 
18. News reports of product rejects compiled by USDA, Economic Research Service.
804  Calvin et al. 2006, 17. 
805  Li 2005, 30.
806  Li 2005, 30.
–143–
concern about heavy metals in food products. Untreated human and animal waste in fi elds and 
water raises the risk of microbial contamination.807 
The Chinese system of food marketing is another challenge to safety monitoring supervision. 
Millions of Chinese small food businesses often keep no record of what they buy and sell. In 
Europe, traceability of foods in the food chain is one of the key principles. Ensuring traceability 
is more diffi cult when there are millions of growers and buyers dealing with small volumes, 
as in China.808 The Chinese food companies are now promoting approaches to gain greater 
vertical control over the food chain.809 
The Chinese Government aims at building a food safety system for exports that will establish 
China’s international reputation for producing safe food. China has also been raising domestic 
food safety standards and implementing inspection and testing systems for consumer products 
and agricultural commodities. In 2005, offi cials announced plans to update a 1995 law covering 
consumer food products. In 2006, the Chinese legislature adopted a law that establishes a national 
framework for building a system that ensures the safety and monitoring of agricultural products. 
Local governments have also been active in promoting safer food.810 According to Article 70 of 
the 2009 Food Safety Law, the State Council is responsible for formulating emergency plans for 
national food safety incidents. The primary actor responsible for preventing the food incident from 
spreading is naturally the organisation where an incident occurs811. 
This increased weight on food safety is due to several serious food scandals where dozens 
of people have died. This has prompted a wave of new regulations and clean-up campaigns 
from the central government812. The focus on food safety includes harsh punishments for 
those breaking the laws. For example Zheng Xiaoyu, former head of the State Food and Drug 
Administration, was sentenced to the death penalty in May 2007 on charges of taking bribes 
and dereliction of duty813. 
According to Huang, food safety has improved in recent years thanks to measures taken 
by the government to enhance supervision. The general situation of food security concerning 
vegetables, meat, grains, fruits, dairy products, aquatic products and other food is healthier. 
However, supervision over food security is still weak in suburbs and rural areas, and about 8 
percent of domestic food cannot reach the national food safety standards.814 China will need 
equally severe food safety control for its domestic consumers than it already has in place for 
exports. The milk scandal of September 2008 shows that China still has a long way to go.
807  Calvin et al. 2006, 18.
808  Calvin et al. 2006, 18.
809 Firms have used a model in which the company leases land and controls production directly, and a model 
in which they use production contracts with growers that specify chemical use and production methods. Good 
agricultural practices (GAPs) and use of a type of Hazard Analysis and Critical Control Point (HACCP) are 
promoted. Calvin et al. 2006, 19.
810  Calvin et al. 2006, 20.
811  Food Safety Law of 2009, Article 71.
812  Reuters AlertNet. http://www.alertnet.org/thenews/newsdesk/PEK337799.htm.
813  China Today web page. http://www.chinatoday.com/law/a.htm.
814  Huang Hai, assistant minister of commerce. July 19 2005. Press conference reported by China Internet 
Information Centre.
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4.2.2.2 General Safety Requirements of Foods  
In China, the Food Hygiene Law of the People’s Republic of China815 was enacted for the 
purpose of ensuring food hygiene, preventing food contamination and harmful substances 
from injuring human health, safeguarding the health of the people and improving their 
physical fi tness.816 The Food Hygiene Law was in 2009 replaced by the Food Safety Law. The 
implementing regulation of the Food Safety Law was also published in 2009. The safety of 
primary agricultural products is under the Law of the People’s Republic of China on Quality 
of Agricultural Products. 
The Food Hygiene Law had nine chapters: 
Chapter One: General provisions
Chapter Two: Food hygiene
Chapter Three: Hygiene of food additives
Chapter Four: Hygiene of food contact materials
Chapter Five: Formulation of food hygiene standards
Chapter Six: Food hygiene control
Chapter Seven: Food hygiene supervision
Chapter Eight: Legal responsibility
Chapter Nine: Supplementary provisions.817 
The new Food Safety law has ten Chapters: 
Chapter One: General Provisions
Chapter Two: Surveillance and Assessment of Food Safety Risks
Chapter Three: Food Safety Standards
Chapter Four: Food Production and Trade
Chapter Five: Inspection and Testing of Food
Chapter Six: Food Import and Export
Chapter Seven: Response to Food Safety Incidents
Chapter Eight: Supervision and Administration
Chapter Nine: Legal Liabilities
Chapter Ten: Supplementary Provisions 
The new law is more comprehensive in detailing who is responsible for what, focusing on the 
critical points where there have been problems in the past. The main structure and content of 
the two laws are similar, though. We discuss both laws here, as the principles of the former law 
have been transferred into the new one.  
According to Article 6 of the Food Hygiene Law of 1995, food shall be non-toxic and harmless, 
conform to proper nutritive requirements and have appropriate sensory properties such as colour, 
815  Passed in the 16th conference of the 8th national congress in Oct.30, 1995, and announced as No.59 
Chairman Order, and implemented since the date of announcement.
816  Article 1.
817  Kan – Zhang 2002.
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fragrance and taste. According to Article 7, foods intended specially for infants and preschool 
children shall conform to their specifi c nutritive and hygienic standards promulgated by the 
administrative department of public health under the State Council. 
Article 8 of the Food Hygiene Law listed the hygiene requirements for food production 
and marketing. These were very similar to the ones in the EU hygiene legislation. They 
included organising clean and tidy food production facilities, the water used, disinfectants, 
toilets, sewage and garbage, washing hands, clean work clothes. They included also rules on 
clean tableware, safe storage and transportation, and clean packaging materials. The Chinese 
hygiene rules are more precise than the European ones and picture the different situation 
and tradition of food production and marketing. The Chinese hygiene rules are of the type: 
“measures shall be taken to eliminate fl ies, rodents, cockroaches and other harmful insects and 
to remove conditions for their propagation”. 
Article 8 of the Food Hygiene Law contained a reference to local, more specifi c norms: 
“The hygienic requirements for food production or marketing undertaken by food vendors and 
persons engaged in the food business in urban and rural markets shall be formulated specifi cally 
according to this Law by the standing committees of the people’s congresses in the provinces, 
autonomous regions, or municipalities directly under the Central Government.” This Article 
has been considered problematic. The delegation of more specifi c food hygiene legislation to 
local legislators has led to inconsistent standards and confusing licensing requirements818. 
According to Article 9 of the Food Hygiene Law, the production and marketing of foods in 
the following categories shall be prohibited: 
foods that can be injurious to human health because they are putrid or deteriorated, 1) 
spoiled by rancid oil or fat, moulded, infested with insects or worms, contaminated, 
contain foreign matter or manifest other abnormalities in sensory properties;
foods that contain or are contaminated by toxic or deleterious substances and can thus 2) 
be injurious to human health;
foods that contain pathogenic parasites, microorganisms or an amount of microbial 3) 
toxin exceeding the tolerance prescribed by the State;
meat and meat products that have not been inspected by the veterinary health service or 4) 
have failed to pass such inspection;
poultry, livestock, game and aquatic animals that have died from disease, poisoning or 5) 
some unknown cause, as well as products made from them;
foods contaminated by use of fi lthy or seriously damaged containers or packages, or 6) 
fi lthy means of conveyance;
foods that impair nutrition or health7)  because they are adulterated or misbranded;
foods processed with non-food raw materials; foods mixed with non- food chemical 8) 
substances, or non-food stuffs used as food;
foods that have expired the date for guaranteed quality;9) 
foods of which the sale has been specifi cally prohibited, for the prevention of diseases 10) 
or other special reasons, by the administrative department of public health under the 
State Council or by the people’s governments of the provinces, autonomous regions, or 
municipalities directly under the Central Government;
818  Li 2005, 29. 
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foods that contain additives not approved for use by the administrative department of 11) 
public health under the State Council or residues of pesticides exceeding the tolerance 
prescribed by the State; and
other foods that do not conform to the standards and requirements for food hygiene. 12) 
According to Article 10 of the Food Hygiene Law and Article 50 of the Food Safety Law, 
food must not contain medicinal substances, with the exception of those materials that have 
traditionally served as both food and medicines and are used as raw materials, condiments or 
nutrition fortifi ers. This means medicinal plants can be used as food. They will not be classifi ed 
as medicines requiring a product licence just because they contain a medicinal substance. The 
same plant can be used as nutrition for healthy people and as medicine for sick people. 
4.2.2.3 Biological and Chemical Safety Issues 
In China, besides the former Food Hygiene Law or the current Food Safety Law, there are 
a number of lower level decrees on particular biological safety issues on different types of 
products. These are, for example, separate regulations giving specifi c hygiene rules on food 
irradiation, meat and meat products, milk and milk products, eggs and egg products, aquatic 
products, condiments, sugar, alcohol, grain, edible vegetable oil, tea, edible mushrooms, street 
food, student food etc.819.
Chinese food safety efforts at the farm level are primarily concerned with chemical residues 
in spite of the fact that food poisonings and deaths from microbial contamination exceed 
those from farm chemical exposure. China is developing good agricultural practice guidelines, 
ChinaGAPs, which will address minimising the risk of microbial contamination.820
The Ministry of Agriculture is the lead agency promoting food safety at farm level. The 
ministry has created standards intended to guarantee that foods are free of contaminants. The 
“pollution-free programme” and the “green food programme” have standards specifying 
tolerances for harmful materials in soil, water, and air.821 They also regulate the use of fertilisers 
and pesticides, and set maximum residue levels. The programs include certifi ed production 
areas and trademarked symbols for use on consumer products. Packaged products carry 
information on the fi rm, which is a step towards a traceability system. Compliance is enforced 
by regular testing of soil, water, and air, and random testing of fi nal products for residues.822
The above-mentioned programs are voluntary, and not yet commonly followed. In 2005, 
about 6 percent of the volume of agricultural production met the pollution free standard, and 
1 percent the green standard, which is stricter.823 The decision to produce green or pollution-
free food is usually made by local offi cials or agribusiness enterprises, not the individual 
farmers824. The trend is inevitably towards green food, though. This is because exports require 
819  Kan – Zhang 2002.
820  Calvin et al. 2006, 20-21.
821  More specifi cally, the green food program defi nes two categories of green food. AA green food is equal 
to organic food, and A green food is between normal food and organic food. A green food is more realistic in 
China, as Chinese land is already heavily polluted. GMOs can be used in A but not AA green food.
822  Calvin et al. 2006, 20. 
823  Calvin et al. 2006, 20.
824  Calvin et al. 2006, 21.
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adherence to rather strict rules, and also because Chinese consumers are becoming more aware 
and cautious. Bian sees green food as a suitable compromise between organic food and normal 
food, particularly for developing countries. Following the green food standard does not make 
food too expensive, but use of fertilisers and pesticides is still heavily restricted.
Besides regulations on contaminants and residues, chemical safety is the goal of regulations 
on food additives825 and food contact materials826. In Chinese law, “food additive” refers to any 
synthetic compound or natural substance put into food to improve its quality, colour, fragrance 
or taste, or for the sake of preservation or processing. “Nutrition fortifi er” refers to any natural 
or artifi cial food additive belonging to the category of natural nutrients that is put into food to 
increase its nutritive value.827
According to Article 11 of the Food Hygiene Law, the production, marketing and use 
of food additives must conform to the hygiene standards for use of food additives and the 
hygiene control regulations. Food additives that do not conform to the hygiene standards and 
the hygiene control regulations may not be marketed and used. Specifi c standards on additives 
are given by the 2002 “Administrative Provisions for Food Additive Hygiene”828.
In 2005, Chinese government organisations announced that food additives constitute 
the greatest threat to food safety in China. To address this problem, authorities promised to 
increase the number of quality specifi cations of food additives in line with global standards. In 
2005, less than a quarter of all state quality specifi cations for food additives can be compared 
with international standards. The government promised to increase this ratio to at least a half 
by 2007.829
Food contact materials were regulated by Articles 12 and 13 of the Food Hygiene Law: 
“Containers, packaging, utensils and equipment used for food must conform to the hygiene 
standards and the hygiene control regulations. The raw materials for making containers, 
packaging, utensils and equipment used for food must meet hygiene requirements. The 
fi nished products should be easy to clean and disinfect. According to AP-Foodtechnology.
com, the new Food Safety Law has alerady boosted food packaging business in China. The 
law has created demand for “coated materials with barriers designed to keep bacteria out and 
freshness in the package”830.
4.2.2.4 Safety of Health Foods: Raw Materials 
Functional foods, fortifi ed foods, and vitamin and mineral supplements are in China regulated 
as health foods. Health foods are foods which have a specifi c health function, are suitable for 
a certain group of people, and which are not for therapeutic purposes. Requirements on health 
food safety and effi cacy are here discussed separately, even though these two aspects are in 
China evaluated in a single procedure. Health food effi cacy and claims are discussed in chapter 
825  In 2002, 431 varieties of food additives and 1040 varieties of spices had been approved by the Ministry 
of Health. Kan – Zhang 2002.
826  Kan – Zhang 2002.
827  Chinese Food Hygiene Law, Article 54: Defi nitions.
828  MOH regulation; Order No. 26; Promulgation Date: 2002-03-28; Effective Date: 2002-03-28.
829  Functional Ingredients March 2005. China News. 
830  News article at ap-foodtechnology.com, by Rory Harringon 20 October 2009.
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5. Procedural rules on health foods (concerning the pre-market authorisation procedure) were 
discussed above in chapter 2. 
The legal basis for Chinese health food regulations was formerly in Articles 22 and 23 of 
the Chinese Food Hygiene Law. In Article 22 of the Chinese Food Hygiene Law, it refers to 
specifi c rules on health foods: “With regard to food indicated to have specifi c health functions, 
the product and its description must be submitted to the administrative department of public 
health under the State Council for examination and approval. Hygiene standards and control 
measures for the production and marketing of the product are then formulated by the authority.” 
According to Article 23 of the Food Hygiene Law, the food claiming to have specifi c health 
functions may not be harmful for human health. The content of the product manual shall be 
accurate and truthful while the functions and ingredients of the product shall be identical with 
the marketing claims.831 
The new Food Safety Law states the same rules on health foods in its Article 51. It is 
fi rst stated, “the state executes strict regulations on health foods”. Health foods may not pose 
acute, sub-acute or chronic hazard to the human body. Labels and instructions may not refer to 
disease treatment or prevention, all information and claims must be truthful, and the product 
must comply with the information. 
The Health Food Regulation of 1996832 and its subsequent amendments give more precise 
rules on health foods. The Health Food Regulation was enacted to strengthen the administration 
and supervision of health foods, ensuring the quality of health foods according to the Food 
Hygiene Law833. The regulations focus on evaluation and approval of health foods, and are 
as such directed more at authorities than at entrepreneurs. However, there are also sections 
regulating production and marketing of health foods.
The regulations establish minimum safety and effi cacy requirements for health foods as 
follows:
raw materials and fi nal products must comply with food hygiene requirements and shall  –
not cause any acute, sub chronic, or chronic harm to human body,
necessary animal and/or human tests must have confi rmed a clear and stable health effect, –
formulation and dosage must be based on scientifi c evidence (the functional ingredient  –
should be identifi ed but when that is impossible, at least the raw materials that cause 
the effect shall be listed),
therapeutic effects shall not be claimed in labelling or advertising. – 834
In addition to general hygiene rules, safety of health foods is controlled via controlling the 
choice of raw materials. A separate Notifi cation from 2002835 governs the raw materials of 
health foods. First of all, the Notifi cation aims to clear the situation of overlapping pieces of 
legislation. Novel foods are considered a separate issue from health foods. If a health food 
has novel ingredients, the Novel Food Regulation shall be followed. Further, if the health 
831  Article 23 of the Chinese Food Hygiene Law.
832  Ministry of Health: Administrative Regulations on Health Food, Order No. 46 (Promulgation Date: 1996-
03-15; Effective Date: 1996-06-01.)
833  Article 1.
834  Health Food Regulation, Article 4. Huang – Lapsley 2005, 266.
835  Ministry of Health: Notifi cation on Further Standardising the Management of Raw Materials for Health 
Food (Directive, Document No.:WeiFaJian[2002]51, Promulgation Date: 2002-02-28.
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food uses food additives, additive law applies. Additionally, there are particular rules on 
fungal health foods836, probiotic health foods837, and nuclei acid type of health foods838. These 
products should follow these procedures respectively.839
If health foods involve protected wild animals or plants, they should be applied according 
to Notifi cation of Restraining the Produce of Health Food using Wild Animal and Plants as 
Raw Materials of Ministry of Public Health of the Notifi cation of 5th July 2001 restraining the 
use of certain single materials840 that have anti-desert function in the wild.841 
Other health food raw materials are regulated by three lists given by the Annexes of the 
Health Food Raw Material Regulation: 
List I includes materials that can be used either as foods or medicines. –
List II includes materials that can be used as health food materials. –
List III includes materials that are prohibited as health food materials.  –
The more complicated rules are given by point 5 of the Raw Material Notifi cation: 
First of all, if health foods involve products (or materials) of animals or plants, the  –
number of products (or materials) of animals or plants can not exceed 14.
If health foods use products (or materials) that are not listed in the List of Materials  –
which are used as either Foods or Medicines, the number of products or materials of 
animals or plants cannot exceed 4.
836  Regulation on Evaluation and Examination of Fungal Health Foods, valid from March 23rd 2001. Fungal 
health food means food with specifi c health function, which uses edible macro-fungi and carpophores and 
fi laments or fi lament macro-fungi. Fungal health food must be safe and dependable, i.e. safe for eating, non-
toxic and not harmful. The strains used in production must have clear and stable characteristics of biology, 
genetics and functionality. Article 3. Only certain fungus species are permitted as health food ingredients. The 
permitted fungus species are the following: Saccharomyces cerevisae, Candida atilis, Kluyveromyces lactis, 
Saccharomyces carlsbergensis, Paecilomyces hepiali Chen et Dai, sp. Nov, Hirsutella hepiali Chen et Shen, 
Ganoderma lucidum, Ganoderma sinensis, Ganoderma tsugae, Monacus anka, Monacus purpures. Huang – 
Lapsley 2005, 266. If an entrepreneur wants a fungus to be added on the list, an application to the SFDA has 
to be made.
837  Regulation on Evaluation and Examination of Probiotic Health Foods, valid from March 23rd 2001. 
Probiotic health food means preparation which promotes ecological balance of bacterial colony in the 
intestine and is benefi cial to human health. Article 2. The probiotic strains must belong to one of the normal 
bacterial colonies in human body. It is allowed to use live or dead bacteria and bacterial metabolites. The 
probiotic health food must be safe and dependable, i.e. safe for eating with no adverse reactions. The 
strains used in production must have clear and stable characteristics of biology, genetics and functionality. 
Only certain probiotic bacteria are allowed as health food raw materials. The permitted probiotics are the 
following: Bifi dobacterium bifi dum, Bifi dobacterium infantis, Bifi dobacterium longum, Bifi dobacterium 
breve, Bifi dobacterium adolescentis, Lactobacillus bulgarius, Lactobacillus acidophilus, Lactobasillus casei 
subsp. Casei, Streptococcus thermophilus. Huang – Lapsley 2005, 266. If an entrepreneur wants a probiotic 
to be added on the list, an application to the SFDA has to be made.
838  This means health foods using DNA or RNA as raw material. The purity of DNA or RNA must be above 
80 percent, and the recommended dosage for nuclei health foods should be 0,6g-1,2g per day. Huang – 
Lapsley 2005, 266.
839  Points 1, 2, and 3 of the Notifi cation.
840  Wild liquorice, saussurea involucrate, xxx and xxx. There is no English word for the latter two.
841  Point 4 of the Notifi cation.
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If health foods use products (or materials) of animals or plants not listed in the List of  –
Materials, which are used as either Foods or Medicines and neither in List of Materials, 
which can be used in Health Foods, the number of products (or materials) of animals or 
plants can not exceed 1. This product (or material) of animal or plant should go through 
safety and toxicology evaluation according to the Novel Food Regulation. 
If you want to use a material outside both lists, you can only use one which cannot be on the 
third list of forbidden materials. If you wish to use materials on the fi rst and the second list 
or merely on the second list, you can use four materials altogether. If you can settle with the 
materials listed in the fi rst list, then you can have 14 materials. Normal food materials are not 
included in this number, only materials with health effects. 
Category I includes approximately 90 materials, for example Hawthorn fruit (Fructus 
Crataegi), Barbary wolfberry fruit (Fructus Lycii), Lotus leaf (Folium Nelumbilis), Lotus seed 
(Semen Nelumbilis), Hemp seed (Fructus Cannabis), Ginkgo seed (Semen Ginkgo), Oyster 
Shell (Concha Ostreae), Honey (Apis Melifera), Peppermint (Herba Menthae), Peach seed 
(Semen Persicae), and Tangerine peel (Citrus Reticulata).842
Some of the products containing these materials will be classifi ed as traditional medicines. 
Whether a product is a health food or a traditional medicine will depend on functions and 
marketing claims of the product. See the separation of foodstuffs and medicines above in 
section 3.
Category II includes approximately 110 materials, for example Ginseng root, leaf and 
fruit (Radix Ginseng, Folium Ginseng, Fructus Ginseng), Deer embryo (Fetus Cervi), Deer 
bone (Fel Cervi), White peony root (Radix Paeoniae alba), Red peony root (Radix Paeoniae 
rubra), Aloe vera (Herba aloe), Magnolia fl ower (Flos magnoliae), Tortoise shell (Carapax et 
Plastrum testudinis), and Ginkgo leaf (Folium Ginkgo).843
Category III includes approximately 60 materials, for example Poppy capsule (Pericarpium 
Papaveris), Quicksilver (Mercury), Chinese azalea fl ower (Flos Rhododendri mollis), Lily of 
the valley grass (Herba Convallariae majalis), Mung bean blister beetle (Lytta Caraganae 
pallas), and Blowfi sh (Globefi sh, Tetraodontiforms syn. Plectognathi).844
In addition to complying with the lists, the product must pass a toxicological safety 
assessment. There is a Ministry of Health standard845 establishing requirements for toxicological 
testing. Animal test requirements vary from no need for toxicological testing to four tiers of 
tests (tier I: acute toxicity; tier II: genetic toxicity; tier III: sub-chronic toxicity; tier IV: chronic 
toxicity).846
The test requirements depend on the categories of the raw materials. If the product is made 
of common foods and Category I ingredients, and processing and consumption of the food are 
traditional, no tests are required on raw material of fi nished products. However, if the product is 
processed and consumed so that dosage is greater than normal, tests are needed on fi nal products. 
For foods made of category II ingredients, tests on the fi nal product are always needed. For those 
842  See complete list by Huang – Lapsley 2005, 267-269.
843  See complete list by Huang – Lapsley 2005, 269-272.
844  See complete list by Huang – Lapsley 2005, 272-274.
845  Ministry of Health: Technical Standards for Testing and Assessment of Health Food. Promulgation date 
14 February 2003, effective 1 May 2003. 
846  Huang – Lapsley 2005, 274-275.
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other ingredients that are not common foods, or category I or II ingredients, tests are always needed 
both on the raw material and the fi nished product. The strictest requirements apply if the raw 
material has no historical human consumption data at all.847
There is no specifi c legislation on food supplements in China and food supplements thus 
do not form a separate legal category. The pre-market authorisation requirements depend on 
whether the supplement contains vitamins, minerals, or something else, and whether or not 
health claims are presented on the product. As stated above, only health foods are allowed to 
bear health claims in China. This applies to foods in food form and food supplements.
For those supplements that contain authorised vitamins or minerals, there is a special 
procedure under the Health Food Regulation. They need to obtain an “Approval Certifi cate 
for Health Food” prior to production, but clinical tests on safety and effi cacy of the vitamin 
or mineral are not required. The producer still needs to show hygiene, stability etc. Other 
supplements such as those containing dietary fi bres, proteins, or amino acids, are considered 
common foods where no pre-market control applies. For common foods, health claims are not 
allowed. If health claims are required, the supplement must undergo the whole health food 
process.848
4.2.2.5 Safety of Novel Foods 
4.2.2.5.1 Defi nition of Novel Food 
There is a new Regulation on novel foods in China849. The previous Regulation dates back to 
1990. Everything that has appeared on the Chinese market since 1990 has been considered 
novel. The new Chinese defi nition of novel foods is the following850: 
Animals, plants and micro-organisms that are not traditionally consumed in China;(1) 
Raw food materials that are derived from animals, plants and micro-organisms and are (2) 
not traditionally consumed in China;
New varieties of micro-organisms that are used during food processing;(3) 
Raw food materials the original composition or structures of which are changed by the (4) 
adoption of new techniques during production. 
According to the previous defi nition in the 1990 law, novel foods are newly manufactured, 
newly discovered and newly introduced materials, which people are not accustomed to 
eating or are accustomed to eating in very local places, and meet basic requirements as 
food. The concept of novel food includes raw materials and fi nal products.851 The Novel 
Food Regulation does not cover GMO food or additives, which are regulated separately. 
Novel foods must undergo a pre-market assessment by the Ministry of Health. Foods 
listed in Article 2 but not yet approved and published as novel foods by the Ministry of 
847  Huang – Lapsley 2005, 275.
848  Huang – Lapsley 2005, 266.
849  Administrative Measures on Hygiene of Novel Foods. 2007.
850  Novel Food Regulation 2007, Article 2.
851  Novel Food Regulation 1990, Article 2.
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Health shall not be manufactured, operated or used as food or raw food materials852. A 
producer must himself evaluate whether his food product is novel. The Ministry of Health 
will make the decision once it has received and reviewed a novel food application, and 
inform the applicant if the novel food is considered a regular food853. This means novel 
food evaluation starts by evaluating whether the food is in fact novel. The Ministry of 
Health will publish a list of products that have been considered regular foods854, and this 
list will help later applicants in determining whether an application is necessary. 
A consumer will recognise a novel food from labelling: “Novel foods or food products 
containing novel foods shall be labelled in compliance with relevant government regulations and 
names indicated in the labels shall be identical to that announced by the Ministry of Health.”855 
As the new regulation came into force, there were some 340 novel foods on the market. 
These may be reviewed to comply with the new rules. An example of a novel food authorised 
according to the previous regulation is the sugar replacement Isomalt, made by Palatinit. 
It was the fi rst non-Chinese food to pass the Chinese Novel Food approval process set by 
the Ministry of Health in September 2006. The approval allows Isomalt to be labelled as a 
“New Resource Food” instead of just an “additive”. The producer believes this will make the 
ingredient more attractive to food makers and that the novel food status will help to differentiate 
the ingredient from similar products on the market. Palatinit claims that most other polyols 
have been approved under the food additive standard. The novel food standard is perceived as 
more diffi cult but potentially more valuable.856
4.2.2.5.2 Safety Requirements of a Novel Food
According to Article 5 of the Novel Food Regulation, “Novel food shall comply with the Food 
Hygiene Law of the People’s Republic of China, pertinent regulations, rules and standards, and 
shall not cause any acute, sub acute, chronic or other latent health hazards”. Food safety is the very 
goal of novel food legislation, and because the food is novel, safety of long-term use in particular 
is not easily determined. Food safety assessment of novel food shall follow the principles such as 
risk assessment and substantial equivalence857. Risk assessment refers to “scientifi c evaluations 
on known or potential negative effects of food borne hazards which human body exposes to 
upon human health, including four steps: hazard identifi cation, hazard characterisation, exposure 
assessment and risk characterisation”858. The doctrine of substantial equivalence means that to avoid 
unnecessary or duplicative research efforts, essential similarity to traditional or already authorised 
products is used as proof of safety. 
The Ministry of Health has an Expert Assessment Committee on Novel Foods that is 
responsible for safety assessment of novel food. The Assessment Committee is composed 
of experts in fi elds of food hygiene, toxicology, nutrition, micro organisms, processing 
852  Novel Food Regulation 2007, Article 18.
853  Novel Food Regulation 2007, Article 13.
854  Novel Food Regulation 2007, Article 15.
855  Novel Food Regulation 2007, Article 22.
856  AP-foodtechnology.com. News 26/09/2006. 
857  Novel Food Regulation 2007, Article 6.
858  Novel Food Regulation 2007, Article 28.
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techniques, chemistry, pharmacology, etc.859 The Assessment Committee shall exercise its 
safety assessment on the basis of the following materials and data:
source of novel food, –
traditional consumption history, –
processing techniques, –
quality standards, –
main ingredients and contents, –
estimated intake, –
usage and scope of application, –
toxicology, –
biological features, –
genetic stability, –
pathogenicity and toxicity of strains of microbiological products, and –
other scientifi c data. – 860  
The Ministry of Health may reassess an approved novel food in any of the following 
circumstances:
With the development of science and technology, recognition of food safety and (1) 
nutrition about approved novel food has changed;
Challenges raised against food safety and nutritional quality of novel food;(2) 
As required by supervision and monitoring of novel food.(3) 
If the approved novel food fails to pass the reassessment, the Ministry of Health may announce 
prohibition on production, business operation and use of the food.861 
The Chinese criteria for establishing novel food safety are similar to the European 
legislation. The nutritional aspect of safety is relevant in China in a manner similar to the 
European approach. Safety of a novel food is not regarded as such but rather as part of the diet 
where the novel food replaces another food. In addition to the Chinese Novel Food Regulation, 
there will be further, more precise, regulations on novel foods: “Ministry of Health formulates 
and promulgates safety assessment regulations, technical specifi cations and standards of novel 
food”.862 One can expect a similar puzzle of regulations as with Health Foods. It would be 
simpler if regulation targets could read the novel food regulations in one piece of law. 
4.2.2.5.3 Decisions or Regulations? 
According to the Chinese Novel Food Regulation, the Ministry of Health publishes the list of 
approved novel foods, which, based on characteristics of different novel foods, should cover 
contents such as: 
859  Novel Food Regulation 2007, Article 7.
860  Novel Food Regulation 2007, Article 8.
861  Novel Food Regulation 2007, Article 9.
862  Novel Food Regulation 2007, Article 6. 
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 generic name (including Latin name), –
 species, –
 source, –
 biological characteristics, –
 adopted techniques, –
 main ingredients, –
 edible parts, –
 dosage level, –
 scope of application, –
 ethnical group of application, –
 intake amount, –
 and quality standards; –
 for micro organisms, their strain numbers – 863 shall also be indicated.864 
According to Article 20 of the Novel Food Regulation, “Food manufacturers shall verify the 
Ministry of Health’s announcement and make sure their products are substantially equivalent 
with the announced items before they start manufacturing or using the novel food.” This means 
the list of approved novel foods will serve other operators as proof of established safety. The 
operators need not repeat the novel food application. Substantial equivalence is defi ned in 
Article 28 of the Regulation: 
“Substantial equivalence: means that if raw materials or food ingredients of a novel 
food are substantially equivalent to traditional food or food ingredients or approved 
novel food in terms of species, source, biological characteristics, main ingredients, 
edible parts, dosage level, scope of application and group of application, and their 
processing techniques and quality standards adopted are basically identical, the novel 
food is considered equally safe as the traditional counterpart and has substantial 
equivalence.” 
This means that in China, a food is legally equivalent to traditional foods if a previously 
authorised substantially equivalent novel food exists. In Europe, the same situation at the 
moment calls for a notifi cation. For example Noni fruit was fi rst in Europe authorised as a 
novel food in 2002, after which it has been notifi ed dozens of times. As described above, 
discussions on the property nature of the novel food authorisation have been ongoing in 
Europe. It has been proposed that instead of decisions, novel food authorisations should be 
given as regulations applicable to all operators. The efforts of the applicant would in this case 
be rewarded by granting a period of exclusivity to the research data on safety. 
863  According to freedictionary.com, strain means “a group of organisms of the same species, having distinctive 
characteristics but not usually considered a separate breed or variety”. For example with probiotics, safety and 
functionality are strain dependent, and genus, species, and strain number are often given in labelling. Coueret 
et al. 2004.
864  Novel Food Regulation 2007, Article 14.
–155–
4.2.2.6 Safety of Genetically Modifi ed Foods 
Chinese GMO legislation has existed since the early 1990s, and been developed since. However, 
a Regulation on the Hygiene of GMO Foodstuffs was not enacted until 2002865. GMO foods 
were regarded as normal food before 2002. According to Bian, Chinese legislation on GMOs 
foods has been practical and responded simply to the need for food. Increasing amounts of 
GMO food are imported into China, particularly soybeans, especially from the United States. 
Academia or the public have not been consulted in GM issues or their regulation.866
There are fi ve major government agencies that oversee GMOs in China.867 This inevitably leads 
to a situation where the farm to table -approach is not fulfi lled, and overlap and confl ict is bound 
to happen. For agricultural GMOs that are intended for use as raw materials, importers must apply 
for an agricultural GMO safety certifi cate from the Ministry of Agriculture. The Ministry of Health 
is primarily responsible for regulating GMO food.868 Foreigners intending to export fi nished GMO 
food to China will need to apply for a safety certifi cate from the Ministry of Health. The application 
must include an assessment report on GM food safety and its nutritional quality, produced by a 
testing agency accredited by the Ministry of Health. In addition, the exporter must show documents 
to prove that the GMO food has been approved for use in the exporting country.869
Under the GMO Food Regulation, all foods made from animals, plants or micro organisms, 
whose genome composition is modifi ed through biotechnology, need to undergo a safety 
assessment and approval process. The GMO Food Expert Committee established by the Ministry 
of Health carries out the safety assessment, within 6 months of receiving an application870. The 
865  Administrative Measures on Hygiene of GMO Foodstuffs, Regulation No. 28 (2002) of the Ministry of 
Health, was issued on 8 April 2002. Other GMO regulation includes:
  – Regulations on Genetic Engineering Management, Regulation No. 17 (1993) of the State Commission 
of Science and Technology.
  – Regulations on Safety Control of Agricultural Genetically Modifi ed Organisms, Regulation No. 304 
(2001) of the State Council.
  – Implementation Regulations on Safety Assessment of Agricultural Genetically Modifi ed Organisms, 
Regulation no. 8 (2002) of the Ministry of Agriculture, issued on 5 January 2002.
  – Implementation Regulations on Safety of Import of Agricultural Genetically Modifi ed Organisms, 
Regulation no. 9 (2002) of the Ministry of Agriculture, issued on 5 January 2002.
  – Implementation Regulations on Labelling of Agricultural Genetically Modifi ed Organisms, Regulation 
No. 10 (2002) of the Ministry of Agriculture, issued on 5 January 2002.
866  Bian 2004. China imported 11.3 million tons of soy already in 2002, and imports were increasing.
867  They are: the Ministry of Science and Technology, the Ministry of Agriculture, the Ministry of Health, 
the State Environmental Protection Administration, and the General Administration for Quality Supervision 
and Inspection and Quarantine. MOST is responsible for national research and development of science 
and technology. It is the competent authority responsible for genetic engineering. Each process of genetic 
engineering (research and experimentation, fi eld testing, pre-market production testing etc.) is subject to safety 
assessment and safety control measures. The National Genetic Engineering Safety Committee supervises 
and coordinates these activities. Wanhua 2003, 99. The Ministry of Agriculture (MOA) is in charge of 
agricultural GMO Regulation. Wanhua 2003, 100. SEPA is responsible for China’s environmental protection 
and biodiversity conservation. Wanhua 2003, 100. AQSIQ is the Chinese customs offi ce. The Ministry of 
Foreign Trade and Economic Cooperation (MOFTEC) is also involved in formulating GMO regulations. 
Wanhua 2003, 101.
868  Wanhua 2003, 100. 
869  Wanhua 2003, 106.
870  Wanhua 2003, 105.
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safety assessment includes nutrition assessment. Also unanticipated effects must be taken into 
account. 871 The Ministry of Health administers the list of authorised GMO foods. GMO food must 
also be labelled as such, see chapter 5.
Critics claim that China’s control of GMO use in agriculture is poor. For example in 2005, it was 
discovered that illegal genetically modifi ed rice was being grown and sold in a Chinese province872. 
The GMO Food Regulation makes the Ministry of Health responsible for inspections, but does not 
specify how these control activities shall be carried out. Chinese GMO regulations are still under 
development, and China ratifi ed the Cartagena Protocol on Biosafety873 in 2005. China’s adherence 
to international agreements is important, as China is potentially the largest GMO producer and 
consumer874 in the world.875 
4.3 Medicine Safety 
4.3.1 EU: Different Categories of Medicinal Products  
In Europe, safety and effi cacy requirements for human medicines are governed by directive 
83/2004/EC. Besides provisions applicable to all medicinal products, there are specifi c 
provisions for:
herbal medicinal products, –
traditional herbal medicinal products, –
homeopathic medicinal products, –
immunological medicinal products – 876,
radiopharmaceuticals – 877, and
medicinal products based on human blood or human plasma.  –
Particular provisions on immunological medicinal products, radiopharmaceuticals, and 
medicinal products based on human blood or human plasma are not discussed here.
871  Wanhua 2003, 100.
872  China Internet Information Centre. http://service.china.org.cn/link/wcm/Show_Text?info_id=149812&p_
qry=gmo.
873  A global protocol that aims to regulate international trade of GMOs. The Cartagena Protocol on Biosafety 
is part of the Convention on Biological Diversity. http://www.cee-foodindustry.com/news/ng.asp?n=60140-
gmo-issues-step.
874  For example in 2006, China imported 28.27 million tons of soybeans, a historical high. Most of them were 
GM-soybeans. Soyatech web page: http://www.soyatech.com/news_story.php?id=1725.
875  Wanhua 2003, 107-108.
876  ‘Immunological medicinal product’ means any medicinal product consisting of vaccines, toxins, serums 
or allergen products. Directive 83/2001/EC, Article 1.4.
877  ‘Radiopharmaceutical’ means any medicinal product which, when ready for use, contains one or more 
radionuclides (radioactive isotopes) included for a medicinal purpose. Directive 83/2001/EC, Article 1.6.
–157–
4.3.1.1 Modern Medicines878  
Here we discuss the substantial safety criteria for medicines. The pre-market authorisation 
procedures for medicines were discussed above in chapter 2. 
According to Regulation 726/2004/EC879, “in the interest of public health, authorisation 
decisions under the centralised procedure should be taken on the basis of the objective scientifi c 
criteria of quality, safety and effi cacy of the medicinal product concerned, to the exclusion of 
economic and other considerations”. However, Member States can exceptionally prohibit the 
use in their territory of medicinal products for human use, which “infringe objectively defi ned 
concepts of public policy and public morality”.880. 
Authorisation shall be refused for products that are harmful in the normal conditions of 
use881. According to Directive 2001/83/EC882, the concepts of harmfulness and therapeutic 
effi cacy can only be examined in relation to each other. Safety and effi cacy are relative 
concepts depending on the progress of scientifi c knowledge and the use for which the medicinal 
product is intended. With medicines, the potential risks must be outweighed by the therapeutic 
effi cacy of the product.883 Substantial safety criteria as such are not given in the legislation. 
The authorities must weigh the evidence on safety vs. effi cacy on a case-by-case basis. Safety 
of medicines is thus primarily controlled via the standards on tests and trials that must be 
performed884. 
Another means to guarantee safety is to grant authorisations subject to conditions that 
are considered essential for the safe and effective use of the medicinal product885. These 
conditions include pharmacovigilance, which means that the authorisation holder must 
monitor, scientifi cally evaluate, and report the effects of the medicinal product. Also, doctors 
are required to report suspected adverse reactions. The renewal of a product licence relies 
particularly on data on Pharmacovigilance886. 
Medicine safety is also always related to information given in marketing: there are strict 
requirements on the mandatory information that must be given to prescribed users to guarantee 
safe use of medicines. This information includes contraindications, instructions on proper use 
of the product, dosage, interactions with other products, etc. Marketing rules will be discussed 
below in chapter 5. 
878  ‘Modern medicine’ is not a legal term. Modern medicines are here presented as a category of medicinal 
products for which there are no particular provisions in the medicinal products directive, and to which the 
normal safety requirements and the primary procedure for medicinal products evaluation thus apply.
879  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying 
down Community procedures for the authorisation and supervision of medicinal products for human and 
veterinary use and establishing a European Medicines Agency.
880  Regulation 726/2004/EC, preamble 13. 
881  Directive 2001/83/EC, Article 26.
882  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the 
Community code relating to medicinal products for human use.
883  Directive 2001/83/EC, preamble 7.
884  These standards are important for public health reasons, and to enable free movement of goods.
885  Directive 2001/83, Article 32(4).
886  Directive 2001/83/EC, Article 24.
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4.3.1.2 Herbal Medicinal Products  
Herbal medicinal products are plant-based medicines. In the EU they are used for various 
health problems, for example, as cough remedies, to help circulation, to fi ght muscular pain, 
to help digestion, as cold remedies, for calming and sleeping, as laxatives, for bladder and 
kidneys and as remedies for the liver887.
Regulation of herbal medicines is challenging. Herbal medicine used to be the only 
medicine. Modern medicine was then developed and legislation created. Now that herbal 
medicine is gaining popularity in the West, it also has to be considered by regulators. Even 
though traditional medicine is available in several countries, regulation is not highly developed. 
Herbal medicine was probably seen as something too complex to deal with. The underlying 
diffi culty is that a scientifi c understanding of traditional medicine and acceptance by the 
international community is not yet strong. Differences in culture, history and religion explain 
differing attitudes towards herbal medicine from country to country. Even fi nding a common 
language between traditional and western medicine has proven diffi cult.888
There are many legal questions to be answered regarding herbal medicine. First of all, 
there is a need to develop research protocols fi t for the evaluation of the safety and effi cacy of 
traditional medicine. Post-market surveillance systems to monitor the adverse effects must be 
created. There is an enormous amount of both thousands of years-old and new information that 
must be shared to avoid duplication of efforts. Related to information, intellectual property 
issues must be resolved.889
The EU defi nition of herbal medicinal product is in the medicinal product directive, Article 
1(30):
“Herbal medicinal product: any medicinal product, exclusively containing as active 
ingredients one or more herbal substances or one or more herbal preparations, or 
one or more such herbal substances in combination with one or more such herbal 
preparations.”
Herbal substances are “all mainly whole, fragmented or cut plants, plant parts, algae, fungi, 
lichen in an unprocessed, usually dried, form, but sometimes fresh”. Certain exudates that have 
not been subjected to a specifi c treatment are also considered to be herbal substances. Herbal 
substances are precisely defi ned by the plant part used and the botanical name according to the 
binomial system (genus, species, variety and author).”890
Herbal preparations are “preparations obtained by subjecting herbal substances to 
treatments such as extraction, distillation, expression, fractionation, purifi cation, concentration 
887  Germany and France dominate the European herbals market with 39 % of sales value in Germany and 
29% in France. Silano et al. 2004, 108.
888  Ministry of Science and Technology web page. http://www.most.gov.cn/eng/policies/regulations/200608/
t20060823_35603.htm.
889  Ministry of Science and Technology web page. http://www.most.gov.cn/eng/policies/regulations/200608/
t20060823_35603.htm.
890  Medicinal products directive, Article 1(31).
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or fermentation. These include comminuted or powdered herbal substances, tinctures, extracts, 
essential oils, expressed juices and processed exudates.”891 
Herbal medicinal products are used both to prevent and treat diseases. They are usually 
used in addition to conventional treatments. They are often used in chronic conditions such 
as severe pain, rashes, or problems in the digestive system, and when conventional medicine 
cannot help. The diseases that are treated by herbal medicinal products range from minor 
ailments to serious diseases like cancer. There are about 1500 medicinal plants in use in 
Europe. The most popular ones are: ginseng (Panax ginseng), evening primrose (Oenothera 
biennis892), St. John’s Wort (Hypericum perforatum893), ginkgo (Ginkgo biloba894), purple 
Echinacea (Echinacea sp.895), and garlic (Allium Sativum). 
The producer of an herbal medicinal product must have a product licence before marketing 
the product. In connection with the product licence, the authority assesses whether the safety 
and effi cacy in the presented indication can be considered adequate. To guarantee the quality 
and safety of the product, an herbal medicinal product must be produced in an authorised 
facility.896 
To receive a product licence, the Medicinal Products Directive897 requires that applications 
for authorisation to place a medicinal product on the market have to be accompanied by 
a complete dossier of documents. This dossier contains information relating to the results 
of physico-chemical, biological or microbiological tests as well as pharmacological and 
toxicological tests and clinical trials carried out on the product and thus proving its quality, 
safety and effi cacy. This applies in principle to all medicinal products, if no exception is made 
in some other Article of the Directive. 
Article 10(a) of the Directive grants this kind of a relief, which is often used by herbal medicines: 
“By way of derogation from Article 8(3)(i), ..., the applicant shall not be required to provide 
the results of pre-clinical tests or clinical trials if he can demonstrate that the active substances 
of the medicinal product have been in well-established medicinal use within the Community 
for at least ten years, with recognised effi cacy and an acceptable level of safety ... . In that 
event, the test and trial results shall be replaced by appropriate scientifi c literature.” 
Factors which have to be taken into account in order to establish a preset use of medicinal 
products are:
the time over which a substance has been used, –
quantitative aspects of the use of the substance, –
the degree of scientifi c interest in the use of the substance (refl ected in the published  –
scientifi c literature), and
the coherence of scientifi c assessments. – 898 
891  Medicinal product directive, Article 1(32).
892  In Finnish: helokki.
893  In Finnish: mäkikuisma.
894  In Finnish: neidonhiuspuu.
895  In Finnish: punahattu.
896  Enkovaara 2002, 23.
897  Article 6.
898  Directive 2001/83/EC, Annex I, Part III: Toxicological and Pharmacological tests. II Performance of tests. 
I. Well-established medicinal use. Point (a).
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Different periods of time may be necessary for instituting well-established use of different 
substances. In any case, the required period of time for instituting a well-established medicinal 
product is at least 10 years from the fi rst systematic and documented use of that substance as 
a medicinal product in the Community.899 
According to the Annex of the Medicinal Products Directive, the documentation should 
cover all aspects of the safety assessment. It must include a review of the relevant literature, 
taking into account pre- and post marketing studies and published scientifi c literature on 
epidemiological studies. Comparative epidemiological studies are particularly important. 
All documentation, both favourable and unfavourable, should be communicated. Particular 
attention must be paid to any missing information and justifi cation must be given as to why 
demonstration of an acceptable level of safety can be supported although some studies are 
lacking. If some of the data concerning a product is different from the product intended for 
marketing, the applicant must explain the relevance of this data. Applicants are instructed to 
put a special emphasis on post-marketing experience with other products containing the same 
components.900 
Applications for herbal medicinal products are usually based on review of existing literature. 
What is notable is that an herbal medicine not used within the Community does not benefi t 
from the literature derogation. Herbal medicines used only in third countries must thus always 
go through the primary procedure including all the pre-clinical tests and clinical trials.
In Finland, most herbal medicine product licences are based on a national evaluation 
procedure by the National Administration for Medicines901, which comes under the Ministry 
of Social and Health Issues. The National Agency of Medicines grants a selling permit for an 
herbal medicinal product, and simultaneously decides on where it can be sold. The alternatives 
are pharmacy, natural product store or grocery store. This decision depends on the purpose of 
use, possible risk factors, and need for guidance902. Herbal medicines cannot be sold through 
pyramid schemes, mail, or the Internet.  
4.3.1.3 Traditional Herbal Medicinal Products 
As stated above, marketing of an herbal medicinal product requires an authorisation to be 
granted on the basis of results of tests and experimentations concerning quality, safety and 
effi cacy. For medicinal products that are, according to adequate published data, of established 
use903, there is no need to provide safety and effi cacy data. 
Still, a signifi cant number of herbal medicinal products, despite their long tradition, do 
not fulfi l the requirements of a well-established medicinal use with recognised effi cacy and 
an acceptable level of safety. These products are not eligible for a marketing authorisation as 
described above. New tests and experimentations could be carried on such products to make 
899  Directive 2001/83/EC, Annex I, Part III: Toxicological and Pharmacological tests. II Performance of tests. 
I. Well-established medicinal use. Point (a).
900  Directive 2001/83/EC, Annex I, Part III: Toxicological and Pharmacological tests. II Performance of tests. 
I. Well-established medicinal use. Points (b), (c), (d), and (e).
901  In Finnish: Lääkelaitos.
902  Bäcklund 1998, 156.
903  In the meaning of Article 10, para 1, letter (a), point (ii) of the medicinal products directive, and as 
specifi ed in Part 3 of Annex 1 of the same Directive. 
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it possible to authorise them under the above-mentioned procedure. However, this would be 
expensive and it would be diffi cult to justify animal tests and human clinical trials on products 
for which a longstanding tradition of use makes it possible to evaluate safety and effi cacy.904 
These were stated as reasons for a simplifi ed procedure called ‘traditional-use registration’, 
which was created by Directive 2004/24/EC for traditional herbal medicinal products. The 
Member States have had to apply the new legislation since 2005. To maintain these products on 
the market, the Member States had enacted various requirements and procedures. Harmonised 
rules were considered appropriate, as the differing member state rules distorted competition 
and did not always adequately address the safety and effi cacy issues.905 
The simplifi ed procedure is applicable to products which fulfi l all of the following criteria906:
they have indications exclusively appropriate to traditional herbal medicinal products “(a) 
which, by virtue of their composition and purpose, are intended and designed for 
use without the supervision of a medical practitioner for diagnostic purposes or for 
prescription or monitoring of treatment;
they are exclusively for administration in accordance with a specifi ed strength and (b) 
posology;
they are an oral, external and/or inhalation preparation;(c) 
the period of traditional use(d)  as laid down in Article 16c(1)(c) has elapsed;
 the data on the traditional use of the medicinal product are suffi cient; in particular (e) 
the product proves not to be harmful in the specifi ed conditions of use and the 
pharmacological effects or effi cacy of the medicinal product are plausible on the basis 
of long-standing use and experience”. 
The period of traditional use is decisive here. The period is 30 years, of which at least 15 are 
within the community area. The Alliance for Natural Health, along with other organisations, 
campaigned to accept 30 years demonstrated safe use anywhere in the world. They claimed 
that limiting non-EU use would prevent interesting and benefi cial herbs discovered in parts 
of the world with very strong herbal cultures (e.g. China, India, South East Asia, South 
Africa, South America) from being brought to Europe. They argued that the legislation would 
strongly impact future innovation, and have the effect of freeze-framing the industry in the 
early 1990s.907 The Commission and the Parliament did not accept these arguments. 
In the traditional-use registration, the applicant must provide the authorities with 
bibliographical or expert evidence to prove that the medicinal product in question, or a 
corresponding product, has been in medicinal use for at least 30 years preceding the date 
of the application, including at least 15 years within the Community. He must also deliver a 
bibliographic review of safety data together with an expert report. The authorities may also 
request additional data that is considered necessary for assessing the safety of the medicinal 
product.908 According to Article 16 f of the Medicinal Products Directive, a Community list 
904  Silano et al. 2004, 108.
905  Preamble 3 of Directive 2004/24/EC.
906  Medicinal products directive, Article 16a(1).
907  Wogan’s Silent Betrayal web page at http://www.silentbetrayal.com/vitamins.htm.
908  Directive 2001/83/EC, Article 16c(1)(c) and (d).
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of traditional herbal medicines is created. If the medicinal product is on this list, the applicant 
does not need to deliver the above-mentioned bibliographical and expert reports. 
The herbal medicinal product may also contain vitamins or minerals for the safety of which 
there is well-documented evidence. The action of vitamins or minerals must support be ancillary 
to the effect of the herbal active ingredients regarding the specifi ed claimed indication.909 This 
refl ects the fact that most of the traditional combination products between herbal and non-herbal 
ingredients are indeed combinations with vitamins and minerals910. 
If the authorities judge that a traditional herbal medicinal product fulfi ls the criteria for 
authorisation of normal medicinal products (Article 6 of the medicinal products directive) or 
registration as a homeopathic medicinal product (Article 14 of the medicinal products directive), 
the traditional herbal medicine alternative does not apply.911 If there is suffi cient scientifi c literature 
to prove established medicinal use, recognised effi cacy and an acceptable safety level, the applicant 
should apply for marketing authorisation for the product912. 
The amendment concerning traditional herbal medicinal products clarifi es the previous 
situation, where the distinction between medicinal and non-medicinal use of some herbs 
was blurred913. Some food-form products with health effects now go under the defi nition of 
traditional herbal medicinal products. However, the scientifi c grounds for creating the category 
sound weak. The category was created because there is not enough evidence on some herbs, 
but still these products are considered safe and effective enough to be sold to consumers. The 
scientifi c difference between “well-established use” and “traditional use” remains unclear. 
Third country use applies for neither. 
4.3.1.4 Homeopathic Medicinal Products  
Homeopathic medicinal products are defi ned in Article 1.5 of the medicinal products directive 
2001/83/EC:
“Homeopathic medicinal product: Any medicinal product prepared from products, 
substances or compositions called homeopathic stocks in accordance with a homeopathic 
manufacturing procedure described by the European Pharmacopoeia or, in absence 
thereof, by the pharmacopoeias currently used offi cially in the Member States. A 
homeopathic medicinal product may also contain a number of principles914.” 
Homeopathy is an alternative medicine attempting to treat “like with like”. In homeopathy, 
the sick are treated with extremely diluted agents that, in undiluted doses, produce similar 
symptoms in the healthy. It is asserted that the therapeutic potency of a remedy can be increased 
909  Medicinal products directive, Article 16a(2).
910  Silano et al. 2004, 110.
911  Medicinal products directive, Article 16a(3).
912  National Agency for Medicines web page: http://www.nam.fi /english/pharma_industry/herbal_remedy/
traditional_herbal/index.html.
913  Silano et al. 2004, 108.
914  According to freedictionary.com, principle means “a constituent of a substance, especially one giving to it 
some distinctive quality or effect”. This means that a homeopathic product can contain several acting agents.
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by serial dilution of the drug, combined with mixing and shaking techniques. Homeopathy is 
inconsistent with laws of chemistry and physics.915 Better-quality clinical trials on the effects 
of homeopathy are more likely to give negative results.916 
Homeopathic medicines can be authorised in the primary procedure for medicines or 
registered through a simplifi ed procedure. According to preamble 21 of the medicinal products 
directive, particular characteristics of homeopathic medicinal products create a need for a 
simplifi ed procedure for certain homeopathic products. These characteristics are “the very low 
level of active principles … and the diffi culty of applying … conventional statistical methods 
relating to clinical trials”. 
The special provisions concerning the simplifi ed procedure applicable to homeopathic 
medicinal products are in chapter 2 of the medicinal products directive. Article 14 lists the 
conditions for the simplifi ed procedure: 
“Only homeopathic medicinal products which satisfy all of the following conditions may 
be subject to a special, simplifi ed registration procedure:
they are administered orally or externally, –
no specifi c therapeutic indication  – appears on the labelling of the medicinal product or 
in any information relating thereto,
there is  – a suffi cient degree of dilution to guarantee the safety of the medicinal product; 
in particular, the medicinal product may not contain either more than one part per 10000 
of the mother tincture or more than 1/100th of the smallest dose used in allopathy with 
regard to active substances whose presence in an allopathic medicinal product results 
in the obligation to submit a doctor’s prescription.”
From a safety point of view, dilution is the key. Homeopathic products are very weak. The 
safety requirements for homeopathic medicinal products are the same regardless of whether or 
not an indication is suggested. According to Finnish agency of medicines917, either the safety 
must be demonstrated through original studies, or it must be shown on the basis of published 
literature that the dilution concerned is safe in relation to the method of administration in 
question. An expert statement on the safety of the product should also be presented. 
As explained above, believers of homeopathy consider that the effective ingredient is 
effective even when highly diluted. From the effi cacy point of view, a very critical notion is to 
be found in article 14.3: No proof of therapeutic effi cacy is required of the homeopathic products 
registered according to the simplifi ed procedure. Article 15 lists the information needed in the 
simplifi ed procedure: bibliographical data concerning the product’s homeopathic nature, data 
915  Wikipedia. http://en.wikipedia.org/wiki/Homeopathy.
916  Shang et al. 2005. 
917  National Agency for Medicines web page. http://www.nam.fi /english/pharma_industry/herbal_remedy/
homeopathic/index.html.
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on the stability of the product etc.918. According to preamble 23 of the Medicinal Products 
Directive, “it is desirable in the fi rst instance to provide users of these homeopathic medicinal 
products with a very clear indication of their homeopathic character and with suffi cient 
guarantees of their quality and safety”. “Guarantees of effi cacy” was left out on purpose. 
Homeopathic medicinal products, other than those qualifi ed for the simple procedure shall 
be authorised and labelled in accordance with Articles 8, 10 and 11, i.e. like normal medicines. 
These are products with therapeutic indications or in a form which may present risks which 
must be balanced against the desired therapeutic effect919. 
A Member State may refrain from establishing a special, simplifi ed registration procedure 
for the homeopathic medicinal products. This means a compromise: countries that do not 
value homeopathy can keep the products off the market. Countries that trust homeopathy, 
can allow them to exist via the simplifi ed procedure. The practitioners of homeopathy and 
other complementary and alternative medicines (CAM) claim that the situation where 
Member States can make up their own minds creates several problems. Of course they wish 
their treatments would be recognised everywhere. European countries vary greatly regarding 
regulation of CAM products and practitioners. In some countries, practitioners can operate 
freely and products are available to patients. Health insurance providers even reimburse some 
CAM products. Authorities and doctors in the new Member States are apparently reluctant to 
accept CAM products.920 
The consumer can choose to trust or not to trust homeopathy. The homeopathy 
business sees the European harmonisation of the legislation on homeopathic medicine in 
1992921 as a turning point constituting “offi cial recognition of homeopathic medicine in 
all EU countries”. The supporters claim that, “this Community recognition demonstrates 
homeopathic medicine’s integration into the European medical and pharmaceutical 
world”. 922 The scientifi c grounds for creating the simplifi ed procedure for homeopathic 
918  Article 15: “An application for special, simplifi ed registration may cover a series of medicinal products 
derived from the same homeopathic stock or stocks. The following documents shall be included with 
the application in order to demonstrate, in particular, the pharmaceutical quality and the batch-to-batch 
homogeneity of the products concerned:
  – scientifi c name or other name given in a pharmacopoeia of the homeopathic stock or stocks, together 
with a statement of the various routes of administration, pharmaceutical forms and degree of dilution 
to be registered,
  – dossier describing how the homeopathic stock or stocks is/are obtained and controlled, and justifying 
its/their homeopathic nature, on the basis of an adequate bibliography,
  – manufacturing and control fi le for each pharmaceutical form and a description of the method of 
dilution and potentisation,
  – manufacturing authorisation for the medicinal product concerned,
  – copies of any registrations or authorisations obtained for the same medicinal product in other Member 
States,
  – one or more specimens or mock-ups of the outer packaging and the immediate packaging of the 
medicinal products to be registered,
  – data concerning the stability of the medicinal product.”
919  Preamble 25 of the medicinal products directive.
920  The European Council for Classical Homeopathy. 31 January 2007. A response to: Communication from the 
Commission. Consultation regarding Community action on health services, Brussels, 26 September 2006.
921  With the adoption of two directives concerning homeopathic medicine for human and veterinary use.
922  Boiron Group homeopathy site at: http://www.boiron.com/en/htm/homeopathy-today/homeopathy-
regulation.htm.
–165–
medicines are questionable. The “diffi culty of applying conventional statistical methods 
relating to clinical trials” is used as a ground for special legislation, but the legislator 
does not explain this diffi culty.  
4.3.2 China 
In China, there are essentially two different kinds of medicinal products on the market: modern 
medicines and traditional Chinese medicines. With regard to modern medicines, there are 
specifi c standards for narcotics, psychotropic substances, toxic drugs for medicinal use, and 
radioactive medicines923. These will not be discussed here.
4.3.2.1 Modern Medicines  
In the past few years, China has signifi cantly modernised its legislation on medicines, in order 
to guarantee their safety, effi cacy, and quality. China has simultaneously enhanced intellectual 
property protection, which is particularly important to the medicine industry.924 
The central government authority responsible for medicine control is the State Food and 
Drug Administration. A new medicine can be put into production only after the SFDA has 
approved it and issued a registered document of approval925. A new medicine which has 
completed its clinical tests and been approved after appraisal shall be issued a certifi cate of 
new medicine by the SFDA926. 
First, production and sale of fake medicines is prohibited. A fake medicine has any one of 
the following characteristics: 
Its components do not comply with State pharmaceutical standards.(1) 
A non-medical substance is passed off as a medicine, or one medicine is passed off as (2) 
another.927 
A medicine is legally a fake medicine in any of the following cases: 
Where the use of the medicine has been prohibited by the SFDA;(1) 
Where the medicine is produced and imported without a legal approval or sold without (2) 
being inspected according to the law;
Where the medicine has deteriorated;(3) 
Where the medicine has been contaminated;(4) 
Where the medicine has been produced of medicinal materials without obtaining a (5) 
registration document of approval for the materials.
923  Based on Medicine Administration Law, Article 35.
924  Tsoi 2007.
925  Medicine Administration Law, Article 31.
926  Medicine Administration Law, Article 29.
927  Medicine Administration Law, Article 48.
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Where the indications or the functions marked on the label do not fall within the (6) 
prescribed scope.928 
Second, production and sale of medicines of inferior quality is prohibited. This refers to 
medicines whose components do not conform to State pharmaceutical standards929. These 
standards are the “Pharmacopoeia of the People’s Republic of China” and the pharmaceutical 
standards promulgated by the SFDA.930 A medicine shall be handled as medicine of inferior 
quality also in any of the following cases: 
An expiry date is not indicated or is altered; or(1) 
A registration number is not indicated or is altered; or(2) 
The medicine has passed its expiration date; or(3) 
The packages and containers which have direct contact with pharmaceuticals have not (4) 
obtained approval; or
The medicine has been added to presumptuously with colour or preservative additives, (5) 
spice, disguising odour or supplementary materials; or
The medicine fails to meet the prescribed standards in other respects(6) 931. 
Import of medicines whose curative effects are uncertain or poor, or which produce adverse 
reactions or have other harmful effects on people’s health is prohibited932. 
4.3.2.2. Traditional Chinese Medicines  
4.3.2.2.1 What is Traditional Chinese Medicine 
Traditional Chinese Medicine means a medical science governing the theory and practice 
of traditional Chinese medicine. It is an ancient Chinese system of medicine that includes 
meditation, herbal and nutritional therapy, restorative physical exercises and massage, and 
acupuncture933. Here we are mainly interested in herbal medicines. Herbal medicines and 
plant-based functional foods have important features in common, but the differences of the 
legal categories affect strategy on product development and marketing. 
According to a recent survey, the number of traditional Chinese medicines is close to 
13000. Of these, over 11000 are of plant origin; the rest are of animal or mineral origin. This 
means traditional Chinese medicine often refers to herbal medicine.934 
Since the 1920s, traditional Chinese medicines have been investigated in terms of modern 
medical science. Chemical ingredients and fractions have been isolated from herbs, and 
their actions studied. Since the 1950s, the Chinese government has paid a lot of attention 
to the development of traditional Chinese medicine. Colleges focused on the subject have 
928  Medicine Administration Law, Article 48.
929  Medicine Administration Law, Article 49.
930  Medicine Administration Law, Article 32.
931  Medicine Administration Law, Article 49.
932  Medicine Administration Law, Article 38.
933  Spondylitis Association of America. Web page at: http://www.spondylitis.org/patient_resources/glossary.aspx.
934  The Essentials of Traditional Chinese Herbal Medicine 2003, 1.
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been established in every province and autonomous region; hospitals and research institutes 
have been set up at national, provincial, municipal and even county level. New chemical 
ingredients are isolated. New forms of herbal remedies are instant powders, tablets, injections 
and capsules.935 
Medicines of plant origin form the main part of traditional Chinese medicine. Their 
species, habitat, collection season, collection method, and storage are thus important factors 
determining their quality and effi cacy. For example, some plants need to be collected when 
fl owers are in full bloom, others when fl owers are still in bud. Medicines from fruits are 
usually collected when the fruits are ripe, medicines from roots in late autumn or spring, and 
medicines from bark in early summer.936 
Herbal medicines are processed before being taken as medicines. Sometimes the purpose 
of processing is increasing potency, and hence effectiveness. Sometimes it is minimising or 
eliminating side effects or toxicity. Sometimes processing makes drugs easier to prepare or 
store. Methods of processing can be divided into physical processing, liquid processing, fi re 
processing and processing by both water and fi re. Side effects are often reduced by boiling or 
steaming.937 
Diseases are classifi ed into two major categories: cold and hot. Medicines to counteract 
these diseases are cool, cold, warm or hot. In terms of yin and yang, cool and cold belong 
to yin, and warm and hot belong to yang. Hot diseases are ones where body temperature, 
blood pressure, respiratory rate, and saliva secretion are high. Cold diseases are the opposite. 
Hot diseases are treated with cold medicines and the other way around. Hot or warm drugs 
stimulate the central nervous system; promote the metabolic system and so on. Cold and cool 
drugs tranquilise, sedate, and have anti-microbial and anti-infl ammatory actions.938 The taste 
of a drug is related to its therapeutic capability.939 
In terms of safety or toxicity, traditional Chinese medicines can be classifi ed as non-toxic, 
slightly toxic, moderately toxic and extremely toxic. Even some extremely toxic herbs thus have 
their medical uses. According to ancient literature, it is stated that no drug is non-toxic if taken in 
excessive doses or for too long a period of time. When using traditional Chinese medicines, the 
properties, actions and toxicity are weighed against one another. Medicines are chosen according to 
the syndrome, and the doctor must look at the situation as a whole. 940 Dosage and method and time 
of administration are determined simultaneously941. For mild diseases and for children and other 
weak persons, dosage is smaller942. 
This approach is similar to Western medicine where it is acknowledged that all medicines 
have side effects, a risk-benefi t ratio is applied, and appropriate dosage is an integral part of 
treatment. The biggest difference is that in traditional Chinese medicine, a large part of the 
information is based on long history of use, not exact clinical trials. 
When discussing medicine safety, interactions of substances have to be taken into account. 
This includes medicine-medicine interactions and medicine-food interactions. 
935  The Essentials of Traditional Chinese Herbal Medicine 2003, 2.
936  The Essentials of Traditional Chinese Herbal Medicine 2003, 3.
937  The Essentials of Traditional Chinese Herbal Medicine 2003, 4-5.
938  The Essentials of Traditional Chinese Herbal Medicine 2003, 5-6.
939  The Essentials of Traditional Chinese Herbal Medicine 2003, 6.
940  The Essentials of Traditional Chinese Herbal Medicine 2003, 8.
941  The Essentials of Traditional Chinese Herbal Medicine 2003, 10-11.
942  The Essentials of Traditional Chinese Herbal Medicine 2003, 10.
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In clinical practice, traditional Chinese medical doctors usually prescribe around ten or 
more herbs to make the best possible mixture in each individual case of symptoms. The 
medicines in a mixture can be classifi ed into four categories:
the principal medicine(s) provides the principal curative action, –
the adjuvant medicine(s) strengthens this action and treats secondary symptoms, –
the auxiliary or corrective medicine(s) relieves secondary symptoms or tempers the  –
action of the principal medicine,
the conductive medicine(s) directs the action to the right part in the body. – 943 
Medicines in a prescription can either reinforce each other, weaken each other, neutralise side effects 
of each other, counteract each other (resulting in no therapeutic action), or are totally incompatible, 
where two drugs put together will result in enhanced side effects or toxicity.944 
There are lists of counteracting and incompatible medicines available to doctors. There 
are eighteen incompatible medicaments and nineteen medicaments of mutual restraint. For 
example, if Radix Veratri Nigri (lilu) is put together with Radix Ginseng, there will be serious 
side effects. If Radix Ginseng is put together with Faeces Trogopterorum (wulingzhi), Ginseng 
neutralizes the effect of Trogopterum. The mechanisms of these actions are not clear.945 As 
there are 11000 medicinal herbs in use, and relatively few are cited in the above-mentioned 
incompatibility list, it is evident that a lot more research is needed on herbal interactions. 
There is also a list of herbs that should not be used during pregnancy, as they might harm 
the foetus or cause abortion. Drugs that are prohibited or should be used with caution during 
pregnancy are those that have a drastic action or are very toxic. These are for example Flos 
Genkwa and Radix Euphorbiae Pekinensis. Also, drugs that are very warm or purgative should 
be avoided.946 
There are also guidelines on unwanted medicine-food interactions. Uncooked or cold food 
is not suitable for a person suffering a cold syndrome. Hot and greasy food is not suitable 
for persons with a hot syndrome: for example, insomniacs should not ingest chillies. Some 
medicaments do not work well together with for example Chinese green onion, garlic and 
radish. Peppermint counteracts turtle fl esh, honey counteracts scallions, and so on.947  
4.3.2.2.2 The Law on Traditional Chinese Medicine 
According to the Chinese Medicine Administration Law948, “the State shall develop both modern 
and traditional medicines and encourage their role in the prevention and treatment of diseases 
and in health care”. Further, “the State shall protect the resources of wild medicinal resources 
943  The Essentials of Traditional Chinese Herbal Medicine 2003, 8-9.
944  The Essentials of Traditional Chinese Herbal Medicine 2003, 9.
945  The Essentials of Traditional Chinese Herbal Medicine 2003, 9.
946  The Essentials of Traditional Chinese Herbal Medicine 2003, 9.
947  The Essentials of Traditional Chinese Herbal Medicine 2003, 9.
948  The Medicine Administration Law of the People’s Republic of China, revised at the Twentieth Meeting 
of the Standing Committee of the Ninth National People’s Congress on February 28, 2000. The revised law 
entered into force as of December 1, 2001. 
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and encourage the domestic cultivation of Chinese traditional medicinal crops”.949 Traditional 
medicine is clearly given more weight compared to the European law on medicines. 
The national Regulations on Traditional Chinese Medicine have been effective as of 
October 2003950. These Regulations do not specify rules on safety, effi cacy and marketing 
of traditional medicines. Instead, the Regulations are focused more on attitudes towards and 
roles of traditional medicine. The objectives of the Regulations include: 
the development of the science of traditional Chinese medicine, –
the promotion of the development of undertakings engaged in traditional Chinese  –
medicine, and
the protection of public health. – 951 
The Regulations apply to institutions and individuals engaged in healthcare involving 
traditional Chinese medicines, as well as to education, research and international cooperation 
related to the subject. The objectives of the State are to protect, support, and develop traditional 
Chinese medicine. The aim is to place equal stress on traditional Chinese medicine and Western 
medicine and encourage development and integration of both schools.952 
The Regulations on Traditional Chinese Medicine do not include criteria on product safety, 
effi cacy and marketing. Product development, production, marketing, use, supervision, and 
administration with respect to traditional Chinese medicines must comply with the Medicine 
Administration Law of the People’s Republic of China. It is stated in Article 6, that the 
preparation of Chinese medicines shall be in accordance with the “Pharmacopoeia of the 
People’s Republic of China”, or in accordance with the “Preparation Standards” laid down 
by the department administering health in that province, autonomous region or municipality 
under the direct control of the Central Government. 
Many of the safety problems with traditional Chinese medicines are due to poor quality. 
This means the plant itself might be safe, but due to heavy metal contamination or adulteration 
with prescription drugs, the product is dangerous. There may also be quantitative variations in 
constituents, which affect safe use of the product.953 Quality issues are not discussed here, as 
we are more interested in the safety of the therapeutic ingredient itself. 
As stated above, the law does not specify criteria on traditional medicines yet. The safety 
of traditional medicines is guaranteed by the traditional guidelines described in the previous 
chapter. At the beginning of 2007, the Chinese Ministry of Health completed the drafting 
of Law on Traditional Chinese Medicine, which was submitted to the State Council. The 
949  Article 3.
950  Regulations of the People’s Republic of China on traditional Chinese medicine. Adopted at the Third 
Executive Meeting of the State Council on 2 April 2003. Promulgated by Decree No. 374 of the State Council 
of the People’s Republic of China on 7 April 2003. (Gazette of the State Council of the People’s Republic of 
China, 30 May 2003, Issue No. 15, Serial No. 1086.) 
951  Summary of the Chinese Regulations on Traditional Chinese Medicines by the WHO’s “international 
digest of health legislation”. Available on the WHO web page at: http://www.who.int/idhl-rils/frame.
cfm?language=english.
952  Summary of the Chinese Regulations on Traditional Chinese Medicines by the WHO’s “international 
digest of health legislation”. Available on the WHO web page at: http://www.who.int/idhl-rils/frame.
cfm?language=english.
953  Barnes 2003.
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drafting of the law had drawn considerable attention from the National People’s Congress 
(NPC) and government departments.954 The goal of the Chinese government is to strengthen 
supervision on the sources of Chinese medicines, improve the administrative system for Good 
Chinese Medicine Production Practice (GCMP), push forward the implementation of GCMP 
and ensure the production quality of Chinese herbal medicines.955 
Improving the legal framework on traditional medicine is among the important goals set 
by the Chinese government for the forthcoming years. The goal is to establish and improve a 
system of Chinese traditional medicine standards. A comprehensive classifi cation system of 
Chinese medicine is needed. Technical pre-market evaluation criteria shall be set, followed with 
post-market control criteria. To strengthen the knowledge base, research-guiding principles of 
reference materials will be formulated, and a Chinese medicine library for standard materials 
will be established. China will actively advocate the establishment of international standards 
for traditional medicines.956 
In China, Traditional Chinese Medicine is under the administration of State Administration 
of Traditional Chinese Medicine and Pharmacology, which is under the Ministry of Health. 
National strategies, laws and regulations governing Traditional Chinese Medicine are in 
place to guide and promote the research and development in the industry.957 Also the Ministry 
of Science and Technology has initiated a programme that has ambitious goals related to 
Traditional Chinese Medicine. They have a programme called “International Traditional 
Chinese Medicine Programme for Cooperation in Science and Technology”. The aim is to 
facilitate integration of traditional medicine with Western medicine all over the world. 
4.4 Conclusions on Food and Medicine Safety in EU and China  
In law, there are no particular safety requirements for functional foods. This is because in law, 
there are no ‘functional foods’. The legal safety criteria for functional foods are those that are 
stipulated for microbes, additives, contaminants and residues, fortifi cation, novel foods, and 
GMOs, or, they are the safety criteria stipulated for (herbal) medicines. The safety criteria set 
for foodstuffs vs. medicines differ considerably, the main difference being that medicines have 
side effects. 
The general aim of food safety legislation is the same in EU and China: protecting consumers 
from unhealthy products, encompassing biological and chemical hazards. Both in Europe and 
China, there are several regulatory categories with specifi c safety rules on different types of 
food products. These categories relate to different types of technological or chemical risks. In 
China, additives, health foods, novel foods, and GM foods are regulated separately. All have 
their separate pre-market authorisation procedures. In Europe, separate legislation exists on 
additives, food supplements, food fortifi cation, dietetic foods, novel foods, and GMO foods. 
The Chinese health food category covers a wide range of products and includes the 
European categories of food supplements, fortifi ed foods, and dietetic foods. Functional foods 
954  People’s Daily Online. January 17 2007. Available at: http://english.people.com.cn/200701/14/
eng20070114_341062.html
955  Five-Year Plan for Food and Drug Safety. April 2007. Page 12.
956  Five-Year Plan for Food and Drug Safety. April 2007. Pages 12-13.
957  Chinese Symbols web page. http://www.chinese-symbols.com/chinese-medicine/chinese-medicine.html.
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will often fi t to the Chinese category of health foods. The category of novel foods is more 
restricted in China than in Europe, and functional foods will likely not be categorised as novel 
foods in China. 
In Europe, there is no single category for health foods or functional foods. Functional foods 
might legally be classifi ed as ‘normal foods’ or dietetic foods. This is basically a marketing 
question and will be discussed below. European fortifi cation rules and novel food regulations 
are often are relevant to functional foods if products contain something additional or new as 
compared to common, basic, old-fashioned food products. 
The rules on medicine safety are also largely the same in EU and China. Compared to 
food safety, medicine safety is more relative to the effi cacy of the product, whereas food 
safety is more of an absolute requirement. The risk/benefi t ratio is applied to medicines. All 
effective medicines have some side effects and should only be used if needed. 958 Medicine 
safety is guaranteed by strict procedures on tests and trials, scientifi c risk assessment, 
pharmacovigilance, and by comprehensive user information. With herbal medicines, safety 
assessment is affected by nature: the plants vary as to where they grow. 
In Europe, food that is familiar is presumed safe. Both the European novel food regulation 
and the European legislation on herbal medicines are more sympathetic to European products. 
This has been a constant cause for disputes in the international arena. In China, there have 
been serious incidents both with unsafe foods and unsafe medicines. China has the dual task 
of convincing both their own citizens and other countries of the safety of Chinese foodstuffs 
and medicines. 
958  Kwak – Jukes 2000a, 105.
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5 MARKETING OF FOODSTUFFS AND 
MEDICINES
5.1 General Marketing Rules
5.1.1 EU
Regulating advertising is one of the basic elements of consumer protection law. In the EU, the 
Misleading Advertising Directive from 1984959 provided minimum standards to ban misleading 
advertising. The directive was updated in 1997 to allow comparative advertising under certain 
conditions. That Directive stipulated that Member States shall ensure that adequate and 
effective means exist to combat misleading advertising960. As the Directive did not give any 
specifi c rules, national differences remained.
The UCP directive of 2005961 introduced a general duty on all businesses not to trade unfairly 
with consumers. Member States should have implemented the directive by December 2007. 
The directive is applicable to all business-to-consumer commercial practices. The concept 
of ‘commercial practice’ is not limited to advertising. It encompasses “any act, omission, 
course of conduct or representation, commercial communication including advertising and 
marketing”962. The directive applies to unfair business-to-consumer commercial practices 
“during and after a commercial transaction in relation to a product”963.
The general clause contains the general ban on unfair commercial practices. Two defi ning 
criteria are used to identify an unfair commercial practice - a commercial practice is regarded 
as unfair if it meets the following two, cumulative criteria:
959  Council Directive 84/450/EEC of 10 September 1984 relating to the approximation of the laws, regulations 
and administrative provisions of the Member States concerning misleading advertising.
960  For the purposes of the directive, ‘advertising’ means “the making of a representation in any form in 
connection with a trade, business, craft or profession in order to promote the supply of goods or services, 
including immovable property, rights and obligations”. ‘Misleading advertising’ means “any advertising which 
in any way, including its presentation, deceives or is likely to deceive the persons to whom it is addressed or 
whom it reaches and which, by reasons of its deceptive nature, is likely to affect their economic behaviour or 
which, for those reasons, injures or is likely to injure a competitor”. Article 4(1).
961  The UCP Directive, directive on unfair commercial practices 2005/29/EC of 11 May 2005.
962  Article 2(d).
963  Article 3.1.
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The practice is contrary to the requirement of 1. professional diligence. Professional 
diligence is “the special skill and care which a trader may reasonably be expected to 
exercise, commensurate with honest market practices and/or general principle of good 
faith in the trader’s fi eld of activity.”
The practice 2. materially distorts or is likely to materially distort the average consumer’s 
economic behaviour. The criterion “to materially distort the economic behaviour of 
consumers” means using a commercial practice to appreciably impair the consumer’s 
ability to make an informed decision, thereby causing the consumer to take a transactional 
decision that he would not have otherwise taken.
Two main categories of unfair commercial practices - “misleading” and “aggressive” practices 
- are described in more detail. A commercial practice is misleading if it either:
Contains false information and is therefore untruthful, –  or
In any way, including overall presentation, deceives or is likely to deceive the  – average 
consumer, even if the information is correct and
Causes or is likely to cause him to take a transactional decision that he would not have  –
otherwise taken.
Omissions might also be considered misleading. It is misleading to:
Omit material information that the  – average consumer needs, according to the context, 
to take an informed transactional decision;
Hide or provide material information in an unclear, unintelligible, ambiguous or  –
untimely manner;
Fail to identify the commercial intent of the commercial practice if not already apparent  –
from the context.
Regulating aggressive commercial practices is new at the EU level. A practice is considered 
aggressive if the average consumer’s freedom of choice or conduct is signifi cantly impaired. 
The Directive contains a list of criteria to help determine whether a commercial practice uses 
harassment, coercion, including physical force, or undue infl uence. “Undue infl uence” means 
“exploiting a position of power in relation to the consumer so as to apply pressure, even 
without using or threatening to use physical force, in a way which signifi cantly limits the 
consumer’s ability to make an informed decision.”
Finally, the Black List contains the list of those practices, which shall, in all circumstances, 
be regarded as unfair and thus banned – without applying the average consumer test964.
964  The black list includes, without going into details of each marketing method:
Trust marks and codes 
Bait advertising 
Bait and switch 
Limited offers: Special offer, today only! 
Language of after-sales service: Marketing in English, after-sales services in Swedish 
Advertising products which cannot be legally sold  
 Misleading impression of consumers’ rights: “Special for you” 
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The Directive provides for special protection to vulnerable consumers. When a commercial 
practice is targeted at a specifi c group of consumers, the impact of the practice will be assessed 
from the perspective of the average member of the group in question. For example, in the case 
of advertising to children, the average child of the relevant age group will be the benchmark. 
Certain commercial practices are prohibited since they typically affect vulnerable consumers 
in that case. Examples of such practices include: 
claiming that products are able to facilitate winning in games of chance, a) 
falsely claiming that a product is able to cure illnesses, dysfunction or  b) 
malformation, or
including in an advertisement a direct exhortation to children to buy advertised products or c) 
persuade their parents or other adults to buy advertised products to them.
Some of the UCP protections replicate previous legislation of various Member States, but others 
are new.965 The Misleading Advertising Directive did not contain any Black List of practices 
that are banned under all circumstances, and there was no common standard for protecting 
vulnerable consumers. According to the Commission, the new legislation “harmonises EU 
rules on business-to-consumer commercial practices, with the aim of clarifying consumers’ 
rights and boosting cross-border trading”966.
Advertorials: “Mixed messages” 
Security as marketing argument: Unduly playing on fear of security risks 
Decoy: “Reputable brand, or maybe not?” 
Pyramid schemes 
False claims regarding moving premises or cessation of business: “End of lease! All stock 
must go!” 
Facilitation of winning chances: How to win the lottery 
False claims about curative capacity: “Trickium 24 cures disease” 
Market information 
Prizes: “Congratulations! You have won a prize” 
Falsely creating the impression of free offers: “Free sunglasses” 
Products not ordered 
Professional trader disguised as consumer 
After sales services: “Europe-wide guarantees” 
Pressure selling: “Yes, you can leave once the paperwork is done” 
Aggressive doorstep selling: “Yes, I will leave, once the paperwork is done” 
Persistent and unwanted solicitations: “With the third phone call maybe a contract will be 
agreed...” 
Insurance claims: No one picks up the phone 
Direct exhortations to children: “Go buy the book!” 
Inertia Selling 
Emotional pressure 
Prize Winning.
965  The UK Department of Trade and Industry. The Unfair Commercial Practices (UCP) Directive. Executive 
Summary of the Consultation on implementing the EU directive on Unfair Commercial Practices and 
Amending Existing Consumer Legislation. December 2005. 
966  European Commission web page. http://ec.europa.eu/dgs/health_consumer/dyna/enews/enews.cfm?al_id=37.
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The directive uses maximum harmonisation, which means that Member States may not 
impose more restrictive national legislation. Dickie critiques the Commission’s push for 
maximum harmonisation in consumer protection. According to Dickie, the idea of high 
common maximum level of consumer protection, presented as an objective in the Commission’s 
Consumer Protection Strategy 2002-2006967, is novel and without grounds968. The Consumer 
Protection Strategy 2007-2013 clearly states that minimum harmonisation might have been 
suitable in the past but “full harmonisation” is the Commission’s current approach969.
Howells et al. also critique the maximum harmonisation approach in consumer protection. 
They point out that European consumers have different expectations concerning consumer 
law. There is empirical evidence suggesting that 80% of Finns trust regulators to guarantee 
consumer rights, as opposed to 20% of Greek consumers. This difference in expectations 
concerning legal protection means a difference in expectations concerning how cautiously one 
must behave when acting on the consumer market. It is diffi cult to adapt European legislation 
based on maximum harmonisation to such variations, without leading to considerable losses 
to consumers left with ‘false’ expectations. 970
It has to be noted that the UCP Directive protects the economic interest of the consumer, 
and only indirectly other interests such as health or safety. In addition, taste and decency are 
outside the scope of application of the Directive.971 Health and safety are regulated separately 
by general product safety and sector-specifi c product safety requirements, discussed in chapter 
4 above.972 The right to safe and healthy products and the right to adequate information are not 
actually far from each other. As opposed to physical safety, marketing rules could be seen as 
guaranteeing economic safety of consumers.
The UCP directive only applies in business-to-consumer relationships. If interpreted 
literally, this means that competitor companies may not base claims on the directive. UK 
marketers have proposed an interpretation according to which competitor businesses are 
still entitled to retain rights of action under the directive, as companies are harmed if their 
consumers are deceived973. It is stated in the Directive that it “indirectly protects legitimate 
businesses from their competitors who do not play by the rules”974. This means the directive is 
not directly meant to protect competitors. However, the right of action is not exactly limited to 
consumers, either. It is also acknowledged that there are commercial practices which, although 
not harming consumers, may hurt competitors and business customers, and that Commission 
should consider further legislation addressing these issues975. In the future, competitor 
companies may base their demands on business-to-business legislation, without having to 
grasp on indirect protection through their consumers.
967  EU Consumer policy strategy 2002-2006. 
968  Dickie 2003. 
969  EU Consumer policy strategy 2007-2013, 16. 
970  Howells et al. 2006, 258.
971  The Unfair Commercial Practices Directive. An information leafl et on European Commission web page 
at http://ec.europa.eu/consumers/cons_int/safe_shop/fair_bus_pract/ucp_en.pdf.
972  The Unfair Commercial Practices Directive. An information leafl et on European Commission web page 
at http://ec.europa.eu/consumers/cons_int/safe_shop/fair_bus_pract/ucp_en.pdf.
973  British Brands Group 2007. The British Brands Group is particularly worried about copycat packaging 
and inadequate means to tackle it.
974  Preamble 8.
975  Preamble 8.
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Marketers continue to come up with new, innovative practices, which might be considered 
unfair. The UCP directive with its general clause may be used as a tool to contribute to uniform 
application of existing and future EU information, advertising, and labelling requirements. 
Where Lex specialis976 exists, it takes precedence over the UCP directive. However, the UCP 
directive potentially improves enforcement of Lex specialis rules, because it provides national 
consumer protection authorities with an additional legal basis to enforce the information 
requirements. An omission to provide material information which the average consumer needs 
can be misleading under UCP. Therefore, UCP may also be used as a tool to fi ll in gaps in 
labelling and advertising legislation.977 This applies for example to marketing of foodstuffs 
and medicines.
However, interpretation of UCP through case law is slow. The UCP Directive foresees no 
committee where unclear issues could be settled. The Commission might therefore develop 
some kind of informal “guidance” system to alert business and enforcement authorities of 
Commission’s interpretation of unfair commercial practices. Member States could not be 
legally obliged to comply with Commission interpretations. According to the Commission, 
the guidance approach has proved helpful to economic operators in similar cases where new 
law risked creating uncertainty.978
The impossibility to include all the scientifi c and technical details in legislation together 
with the impossibility of leaving all the interpretation to courts here seems to lead to the 
guidance approach. The guidance approach leads to soft law, which is often welcomed by 
regulation targets but the binding nature of which is legally unclear. If we give a general 
directive like the UCP directive, we have to carefully consider who we want to interpret it 
and fi ll in the gaps. Making binding interpretation can be left either to courts or to a specifi c 
Committee. In addition, non-binding instruments can be used.
5.1.2 China
The general rules on marketing are in China given by the Advertisement law979. The law is formulated 
to “regulate advertising activities, to promote the sound development of the advertising sector, to 
protect the lawful rights and interests of consumers, to maintain the social and economic order, and 
to let advertisements play an active role in socialist market economy”980. It concerns Advertisers, 
advertising agents and advertisement publishers acting within the territory of the People’s Republic 
of China. Advertisement is defi ned as “any commercial advertisement, which a supplier of goods 
or services pays for, to introduce their goods or services whether directly or indirectly through the 
media in all its forms to Public at large”981.
976  Here Lex specialis means sector-specifi c rules on marketing.
977  Labelling: competitiveness, consumer information and better
regulation for the EU. A DG SANCO Consultative Document February 2006, 4.
978  Labelling: competitiveness, consumer information and better
regulation for the EU. A DG SANCO Consultative Document February 2006, 4.
979  Advertisement Law of the People’s Republic of China. Adopted at the 11th Meeting of the Standing 
Committee of the Eighth National People’s Congress on October 27, 1994, promulgated by Order No.34 of 
the President of the People’s Republic of China on October 27, 1994, and effective as of February 1, 1995.
980  Article 1.
981  Article 2.
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The Chinese law is more specifi c than the European directive. The most general rules of 
advertising are given in Articles 3 to 5: Advertisements must be factual and lawful, and comply 
with the principles of advancing socialist culture and ideology982. An advertisement must not 
contain any information, which is false and or misleading so as to deceive the consumers983. 
Advertisers, advertising agents and publishers engaged in advertising activities shall act 
according to law and administrative regulations in a spirit of fairness and integrity984.
The specifi c rules on the contents of advertisements are given in Chapter 2 of the Law. 
According to Article 7, the contents of advertisements shall:
lead towards the physical and mental health of the people, –
promote the improvement in quality of goods and services, –
protect the lawful rights and interests of consumers, –
comply with social morality and professional ethics, and –
safeguard the dignity and interests of the state. –
It is noteworthy that promoting health is fi rst mentioned among advertising tasks. Article 
8 mentions health again: “Advertisements may not impair the physical and mental health 
of minors and the disabled”. Foodstuffs and medicines are both widely used and widely 
advertised consumer products having direct effects on health. Therefore, it is safe to say that 
regulating food and medicine advertising is one of the key tasks of consumer protection law, 
and perhaps the most important task of advertising law.
According to Article 9, statements in advertisements of the performance, origin of 
production, use, quality, producer, etc. of the goods advertised shall be clear and explicit. 
References to scientifi c information are covered by Article 10: Data, statistical information, 
investigation and survey information, digest and quotes used in an advertisement shall be 
factually true and accurate, and their sources mentioned. These rules have implications also 
on functional food marketing, where performance and use of goods is often mentioned, and 
where scientifi c information is often referred to. There are also special advertising rules on 
patented products in Article 11985.
According to Article 13, an advertisement shall be distinguishable, and make consumers 
identify it as an advertisement. The mass media may not publish advertisements in the form of 
news reports. An advertisement published through the mass media shall bear the advertisement 
mark to distinguish it from new items so that consumers may not be misled. In the Chinese 
Law, there is no direct rule on comparative advertisement. According to Article 12 of the 
Advertisement law, an advertisement may not belittle the goods or services of other producers 
and manufacturers or operators.
The European and Chinese general rules on advertising have much in common. Advertising 
must be clear, true, and accurate. Advertisements must be identifi able as such, and competitors 
may not be demeaned. Both sets of rules comply with the general marketing codes by the 
982  Article 3.
983  Article 4.
984  Article 5. 
985  An advertisement involving patented goods or patented methods shall clearly indicate the patent number 
and type of patent. Products which have not been patented shall not be passed off as being patented. The 
use in advertisements of unsuccessful patent applications or those which have been terminated, nullifi ed or 
invalidated is prohibited.
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International Chamber of Commerce and there seems to be a global understanding on these 
fair marketing practices.
However, important cultural differences remain as parts of general national advertising 
laws. Article 7 of the Chinese Advertisement law is an example of Chinese cultural features:
“Advertisements may not contain any of the following:
the national ,fl ag, national emblem or national anthem of the People’s Republic of China,1. 
the names of state organs or names of staff of state organs,2. 
such words as the “state-level”, the “highest-level” or the “best”,3. 
matters hindering social stability or endangering the safety of life or property, or 4. 
harming the public interest,
matters hindering the public order or violating good social customs,5. 
pornographic, superstitious, horrid, violent or unpleasant matters,6. 
ethnic groups, racial, religious or sex discrimination matters,7. 
matters hindering environmental and natural resources protection, and8. 
matters that are prohibited by laws and administrative regulations.”9. 
Parts of this list could not exist in a European directive as the Chinese concept of free speech 
is rather narrow, and matters harming social order and the state must be avoided. The Chinese 
interpretation of what is “pornographic” or “unpleasant” is also different from the European 
interpretation of what is considered indecent or immoral.
In addition to general rules applicable to advertising of all products, the Chinese Advertisement 
law includes special rules on medicine marketing. These will be discussed below.
5.2 General Rules on Food Marketing986
5.2.1 EU
5.2.1.1 Prohibition of Misleading Food Advertising
In the EU, the general food regulation987 is the basic law both with regard food safety and as 
regards food marketing. Article 8 regulates the protection of consumers’ interest. It states: 
“Food law shall aim at the protection of the interest of consumers and shall provide a basis 
for consumers to make informed choices in relation to the foods they consume. It shall aim at 
the prevention of:
fraudulent or deceptive practices;(a) 
the adulteration of food; and(b) 
any other practices which may mislead the consumer.”(c) 988
986  This means rules other than those applicable to claims.
987  Regulation 178/2002/EC laying down the general principles and requirements of food law, establishing 
the European Food Safety Authority, and laying down procedures in matters of food safety.
988  This article refl ects the same principle as Article 1 of the Misleading and Comparative 
Advertising Directive codifi ed by 2006/114/EC/.
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Article 16 of the Regulation concerns presentation. It is more precise than Article 8: “Without 
prejudice to more specifi c provisions of food law, the labelling, advertising and presentation of 
food and feed, including their shape, appearance or packaging, the packaging materials used, the 
manner in which they are arranged and the setting in which they are displayed, and the information 
which is made available about them through whatever medium, shall not mislead consumers.” 
This statement is fairly comprehensive. It aims to cover all means of misleading the consumer. 
However, more specifi c provisions of food law are mentioned. These rules apply to special types 
of foods and are discussed below.
5.2.1.2 General Rules on Food Labelling
In addition to being cognisant with the rules on food advertising, a marketer must know what 
information he must give to consumers. In Europe, as in most countries, the ingredient list 
must appear on the package of a food product.989 Hence the fi rst requirement for the marketer 
is to know what is in the food. Nutrient information/nutrition labelling (for example how 
much fat, lactose or vitamin C the product contains) is optional in Europe, if a nutrition claim 
is not presented. Where nutrition claims appear on labelling, in presentation or in advertising, 
with the exclusion of generic advertising, nutrition labelling will become compulsory.990
General food labelling991 is governed by Directive 2000/13/EC992, which is a codifi ed version 
of Directive 79/112/EC. The directive concerns the labelling of foodstuffs to be delivered as 
such to the ultimate consumer and certain aspects relating to the presentation and advertising 
thereof993. It also applies to foodstuffs intended for supply to restaurants, hospitals, canteens 
and other similar mass caterers994. For the purpose of the Directive, ‘labelling’ means any 
words, particulars, trade marks, brand name, pictorial matter or symbol relating to a foodstuff 
and placed on any packaging, document notice, label, ring or collar accompanying or referring 
to such foodstuff995.
Most of the provisions date back to 1978. One major recent amendment to the food- labelling 
directive was introduced in 2003. This amendment makes it obligatory for all ingredients to be 
indicated on the label. The new labelling rules particularly help consumers suffering from food 
allergies or consumers who wish to avoid eating certain ingredients for any other reason. The 
new rules foresee that all ingredients in foodstuffs will have to be included on the label and 
abolish the previous 25% rule which meant that it is was not obligatory to label the components 
of compound ingredients that make up less than 25% of the fi nal food product.996
989  Ingredients must be listed in descending order in terms of total content.
990  Nutrient information is given per 100 g in Europe, or per serving.
991  Specifi c labelling issues such as origin labelling or welfare labelling are not discussed here as they are not 
particularly relevant to functional foods.
992  Directive 2000/13/EC of the European Parliament and of the Council 20 March 2000 on 
the approximation of the laws of the Member States relating to the labelling, presentation and 
advertising of foodstuffs.
993  Article 1(1).
994  Article 1(2).
995  Article 1(3).
996  European Commission web page. http://ec.europa.eu/food/food/labellingnutrition/foodlabelling/comm_
legisl_en.htm.
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According to the European Commission, the evolution of both the foodstuffs market and 
consumers’ expectations as to the information given has led to the need to update this legislation. 
That is why the Commission is currently preparing to modernise the law on food labelling997, 
among other rules on labelling of consumer products. According to DG SANCO998, they are 
focusing on “better regulation” as a means to contribute to achieving growth and jobs999.
The Commission is ready to rethink the entire labelling scheme. Benefi ts of simplifying 
and clarifying the structure and scope1000 of the existing labelling legislation are weighed. The 
directive might for example be turned into a regulation1001. Commission suggested that maybe 
food and non-food labelling might be considered as a whole. Prescription vs. fl exibility of the 
rules is also reconsidered. The Commission is also considering self-regulation or co-regulation 
in labelling issues1002. In developing labelling rules, the Commission must also think of how 
to deal with small and medium-sized enterprises (SMEs), as the costs of introducing labelling 
changes will generally be higher for SMEs.
As a result of a consultation process launched by the Commission in 2006, stakeholder 
views on labelling issues were received. The majority of respondents wanted food labelling 
and non-food labelling to be distinct. As one might imagine, the food industry would like to 
see as few legislative requirements as possible. The industry would prefer self-regulation as 
regards voluntary labelling, keeping rules on mandatory labelling in ‘hard law’. Consumer 
organisations and organisations for health and animal welfare would like to see as many 
legislative requirements as possible. They do not trust self-regulation like codes of practice. 
Also, predictably, views of governments are between these extremes, as they must search 
for the right balance.1003 Most stakeholders welcomed the new legislation to be in a form 
of regulation. The mandatory requirements currently listed under Article 3.1 of Directive 
2000/13/EC were not questioned by stakeholders1004.1005
997  Labelling: competitiveness, consumer information and better regulation for the EU. A DG SANCO 
Consultative Document February 2006.
998  DG SANCO is the Health and Consumer Protection Directorate General of the European Commission.
999  The Consultative Document 2006, 1. Consumer policy is a part of the Lisbon Strategy, where the EU 
is aiming to create growth and employment. See Commission press release: “A new Consumer Strategy: 
Consumers must lead the drive for growth and jobs.” IP/07/256. Date: 27/02/2007.
1000  Information that must be provided might for example be distinguished from information that should be 
available for the purchaser of the foodstuff. Labelling: competitiveness, consumer information and better 
regulation for the EU. A DG SANCO Consultative Document February 2006. Page 6.
1001  Labelling: competitiveness, consumer information and better regulation for the EU. A DG SANCO 
Consultative Document February 2006. Page 5.
1002  Labelling: competitiveness, consumer information and better regulation for the EU. A DG SANCO 
Consultative Document February 2006. Page 3. See chapter 2.2 on European hard law and soft law.
1003  Summary of results for the consultation document on: “Labelling: competitiveness, consumer information 
and better regulation for the EU”. December 2006. Directorate E – Safety of the Food Chain. Unit E4 – Food 
law, nutrition and labelling. Pages 4-5.
1004  Summary of results for the consultation document on: “Labelling: competitiveness, consumer information 
and better regulation for the EU”. December 2006. Directorate E – Safety of the Food Chain. Unit E4 – Food 
law, nutrition and labelling. Page 10.
1005  Summary of results for the consultation document on: “Labelling: competitiveness, consumer information 
and better regulation for the EU”. December 2006. Directorate E – Safety of the Food Chain. Unit E4 – Food 
law, nutrition and labelling. Pages 8-9.
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In January 2008, the Commission proposed to put food labelling and nutrition labelling 
directives together in one legal instrument, a regulation1006. The proposed rules include the 
requirement that the print size of the mandatory particulars on label must be at least 3 mm1007. 
The draft Regulation also extends the current requirements for allergen labelling to cover non 
pre-packed food, including food sold in restaurants and other catering establishments1008. Rules 
on origin labelling will also be specifi ed to avoid situations where the consumer is misled for 
example by the fact that the raw materials come from one place and the manufacturing process 
takes place in another1009. Nutrition declaration will also be mandatory, see the next chapter.
The proposal leaves room for Member States to promote additional national schemes 
provided they do not undermine the EU rules. While manufacturers or retailers could always 
use the EU’s main nutrition labelling system, national schemes would offer food businesses an 
alterative way of discharging the labelling obligation. This kind of fl exibility has already been 
criticised for creating barriers to trade.1010
5.2.1.3 Nutrition Labelling
The Nutritional Labelling Directive 90/496/EEC concerns nutrition labelling of foodstuffs to 
be delivered as such to the ultimate consumer. It also applies to foodstuffs intended for supply 
to restaurants, hospitals, canteens and other similar mass caterers.1011 It does not apply to natural 
mineral waters or other waters intended for human consumption or to food supplements.1012 
The Directive applies without prejudice to the labelling provisions of Council Directive 
89/398/EEC on foodstuffs intended for particular nutritional uses and specifi c Directives as 
referred to in Article 4 of that Directive1013.
For the purposes of the Directive, ‘nutrition labelling’ means any information appearing 
on labelling and relating either to the energy value or to the amount of the following nutrients: 
protein, carbohydrate, fat, fi bre, sodium, and vitamins and minerals listed in the Annex1014 of 
the Directive and present in signifi cant amounts.
The most important principle of the Nutritional Labelling Directive is:
if nutrition claims are not presented, nutritional labelling is optional, and –
if a nutrition claim appears –  on labelling, in presentation or in advertising, with the 
exclusion of generic advertising, nutrition labelling is compulsory.1015
1006  Proposal for a Regulation of the European Parliament and of the Council on the provision of food 
information to consumers. COM(2008) 40 fi nal. Brussels, 30.1.2008.
1007  Article 14(1) of the proposed Regulation.
1008  Article 9 of the proposed Regulation: List of mandatory particulars. Allergens are listed in Annex II of 
the proposal.
1009  Food labelling proposal 2008, page 9. Explanatory memorandum. 3.) Legal elements of the proposal.
1010  Warnock 2008. 
1011  Article 1(1).
1012  Article 1(2).
1013  Marketing of these dietetic foods is discussed in the following chapter.
1014  The list of vitamins and minerals is updated according to a procedure se out in Art 10. 
1015  Article 2.
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The only nutrition claims permitted are those relating to energy and/or to protein, carbohydrate, 
fat, fi bre, sodium, vitamins and minerals and to substances which belong to or which are 
components of a category of those nutrients. Vitamin and mineral claims are limited to those 
defi ned in the Annex of the Directive and if these are present in a signifi cant amount. A 
signifi cant amount is defi ned as 15 % of the recommended daily allowance.1016
As stated above, a nutrition claim triggers nutrition labelling. There are two alternatives 
for nutritional labelling. When the claim relates to energy value, protein, carbohydrates or 
fat, the amounts of all of these shall be given. When the claim is made for sugar, saturates, 
fi bre or sodium, the amounts of all of these shall also be given.1017 Whenever a claim is made, 
the amounts of starch, polyols, mono-unsaturates, polyunsaturates, cholesterol, and vitamins 
or minerals that are listed in the Annex and that are present in signifi cant amounts must also 
be given1018. There is one other additional requirement for nutritional labelling, which has 
to be abided by even if a claim is not made: If the amount of polyunsaturates and/or mono-
unsaturates and/or the cholesterol rate are given, the amount of saturates must also be given. 
In this case, the amount of saturates is not considered to be a nutrition claim1019. In other cases 
where no claim is made, nutritional information can be given, as long as it is accurate.
Nutritional information shall be expressed per 100 g or per 100 ml. In addition, this information 
may be given per serving as quantifi ed on the label or per portion, provided that the number or 
portions contained in the package is stated.1020 The amounts mentioned are to be those of the food 
as sold. Where appropriate, this information may relate to the foodstuff after preparation, provided 
that suffi ciently detailed preparation instructions are given and the information relates to the food 
as prepared for consumption.1021 Information on vitamins and minerals must also be expressed as a 
percentage of the recommended daily allowance.1022
According to the Commission, there is a need to revise the nutrition labelling directive 
to address fundamental issues relating to nutrition labelling1023. Commission gathered 
stakeholder input on this subject in 2006. It has been suggested that nutrition labelling should 
be mandatory. At the moment, many companies are voluntarily providing the information 
(estimates suggest a range of between 30% and 85% for pre-packaged foods)1024. Consumers 
are in favour of mandatory nutrition labelling, the industry isn’t. Both sides and also member 
state governments might be willing to settle for a compromise solution. This would make 
nutrition labelling mandatory but grant derogations, create transitional measures and offer 
necessary fl exibilities1025. When discussing what should be on the nutrient list, the ‘Big 4’ (i.e. 
1016  Article 3.
1017  Article 4(1-2).
1018  Article 4(3).
1019  Article 4(4).
1020  Article 6(2).
1021  Article 6(4).
1022  Article 6 (5)(a).
1023  Labelling: competitiveness, consumer information and better regulation for the EU. A DG SANCO 
Consultative Document February 2006, Page 7.
1024  Labelling: competitiveness, consumer information and better regulation for the EU. A DG SANCO 
Consultative Document February 2006, Page 7.
1025  Summary of results for the consultation document on: “Labelling: competitiveness, consumer information 
and better regulation for the EU”. December 2006. Directorate E – Safety of the Food Chain. Unit E4 – Food 
law, nutrition and labelling. Page 15.
–184–
energy, protein, fat, carbohydrates) and the ‘Big 8’ (i.e. the Big 4 plus saturated fat, sugar, fi bre 
and sodium) were most often mentioned1026.
In January 2008, the Commission fi nally gave a proposal combining the current food 
labelling directive 2000/13/EC and the nutrition labelling directive 90/496/EEC. The proposal 
is for a Regulation of the European Parliament and of the Council on the provision of food 
information to consumers1027. It is not surprising that the regulation form was chosen instead 
of a directive, see chapter 2.
The most controversial point in the proposal is the introduction of mandatory labelling of 
key nutrients. The proposal adopts the Guideline Daily Amount (GDA) approach instead of 
the traffi c lights approach favoured by the UK’s Food Standards Agency and the European 
Consumer Association (BEUC).1028 For example in Finland, the GDA approach was voluntarily 
adopted by the industry in 20071029.
According to Article 29(1) of the proposed Regulation, the nutrition declaration shall 
include the following:
 energy value;(a) 
the amounts of fat, saturates, carbohydrates with specifi c reference to sugars, and salt.(b) 
These would need to be given per 100g or 100ml1030 and also by reference to GDAs1031. 
According to Article 29(2) of the proposed Regulation, the nutrition declaration may also 
include the amounts of trans fats, mono-unsaturates, polyunsaturates, polyols, starch, fi bre, 
protein, or certain vitamins and minerals. Trans fats would appear on nutrition declarations 
for the fi rst time.
5.2.1.4 Marketing of Dietetic Foods
Foodstuffs for particular nutritional uses are also known as dietetic foods, defi ned in 
Directive 89/398/EC. Dietetic foods are foodstuffs which, owing their special composition or 
manufacturing process, are clearly distinguishable from foodstuffs for normal consumption, 
which are suitable for their claimed nutritional purposes and which are marketed in such a 
way as to indicate such suitability.1032 Above (chapter 4), we have already discussed the safety 
aspects of dietetic foods. Here we look at dietetic foods from a marketing perspective.
“A particular nutritional use must fulfi l the particular nutritional requirements:
of certain categories of persons whose digestive processes or metabolism are disturbed; or(i) 
1026  Summary of results for the consultation document on: “Labelling: competitiveness, consumer information 
and better regulation for the EU”. December 2006. Directorate E – Safety of the Food Chain. Unit E4 – Food 
law, nutrition and labelling. Page 16.
1027  COM(2008) 40 fi nal. Brussels, 30.1.2008.
1028  Warnock 2008.
1029  Elintarviketeollisuusliitto ry. Tiedote 7.2.2008. 
1030  Article 31(2) of the proposed Regulation.
1031  Article 31(3) of the proposed Regulation.
1032  Article 1(2)(a), Directive on Foodstuffs Intended for Particular Nutritional Uses, 89/398/EC. Foodstuffs 
for particular nutritional uses have their own fortifi cation rules, set out in Commission Directive 2001/15.
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of certain categories of persons who are in a special physiological condition and who (ii) 
are therefore able to obtain special benefi t from controlled consumption of certain 
substances in foodstuffs; or
of infants or young children in good health.”(iii) 1033
The fi rst rule on dietetic food marketing is the permission to use the word ‘dietetic’. The 
products in sections (i) and (ii) may be characterised as ‘dietetic’ or ‘dietary’1034. For 
normal products, the use of words ‘dietetic’ or ‘dietary’ is forbidden. This means that in the 
labelling, presentation and advertising of foodstuffs for normal consumption, the use of the 
adjectives ‘dietetic’ or ‘dietary’ either alone or in conjunction with other words, to designate 
these foodstuffs is prohibited. Also all other markings or any presentation likely to give the 
impression that a dietetic food is involved are prohibited for normal products.1035. The second 
rule on dietetic food marketing is that for dietetic foods, nutrition labelling is mandatory 
regarding the amount of energy, protein, carbohydrates, and fat therein1036.
Specifi c rules on specifi c dietetic foods are to be laid down by specifi c directives1037. These 
groups1038 are:
instant formula and follow-on formula, –
processed cereal-based foods and baby foods for infants and young children, –
food intended for use in energy-restricted diets for weight reduction, –
dietary foods for special medical purposes (medical food), –
foods intended to meet the expenditure of intense muscular effort, especially for  –
sportsmen, and
foods for persons suffering from carbohydrate-metabolism disorders (diabetes). –
Directives on sports nutrition and diabetes foods are still missing as previously stated in chapter 
4. The special directives include marketing rules. For example in the directive on weight-loss 
foods, it is stated that “the labelling, advertising and presentation of the products concerned 
shall not make any reference to the rate or amount of weight loss which may result from their 
use or to a reduction in the sense of hunger or an increase in the sense of satiety”1039.
Drawing the line between ordinary foods with health claims and foodstuffs for particular 
nutritional uses has come up in different forms. Foods with health effects appear to be following 
two separate marketing lines: as normal foods and as dietetic foods. It is often possible that a 
foodstuff that has scientifi cally proven health-promoting effects will go under the defi nition 
of dietetic foods. Where a special diet is obeyed, it is often to reduce the risk of becoming 
ill. For example, persons with high cholesterol can use products with plant sterols to lower 
1033  Article 1(2)(b).
1034  Article 2(1).
1035  Art. 2(2).
1036  If the product contains less fat that 50 kJ/100g, only energy content has to be given. The long list of 
nutrition labelling is mandatory if you want to give the amount of sugar, fi bre, sodium, or saturated fats as 
something else than a nutritional special feature of the product. See previous chapter on ‘short’ and ‘long’ lists 
in nutrition labelling.
1037  According to Article 4.1 of the Directive on dietetic foods.
1038  As listed in Annex I of the Directive on dietetic foods.
1039  Article 5(3).
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the cholesterol levels in blood serum. This would be a particular nutritional use. For these 
products, product-specifi c risk reduction claims also seem appropriate, as the products lower 
the risk of coronary heart disease1040.
Certain functional foods can be classifi ed as dietary foods if they are specially formulated 
and/or provide a part of the population health benefi ts over and above their normal nutritional 
values. Certain functional foods clearly are not dietary foods, as they provide the whole 
population with health benefi ts over and above their normal nutritional values.1041 This means 
that a product with a health claim such as “antioxidant” could not be classifi ed as a dietetic 
food, and that a product with a health claim such as “lowers blood pressure” could.
Sometimes it is diffi cult to distinguish between “ordinary dietetic food” and medical 
food1042. Specifi cation of benefi ts can be a criterion to determine this. Since functional foods 
are by defi nition a part of a normal diet and they do not need any medical supervision, they 
are clearly distinguished from medical foods. If a certain food can provide distinctive dietary 
requirements to a patient requiring medical supervision, it can be sold as a medical food. If it 
can provide health benefi ts to a specifi ed group of people or to people in general, it should be 
sold as either an ordinary dietetic food or an ordinary food with a health claim.1043
As stated above in chapter 4, the directive on dietetic foods establishes a notifi cation 
system. The primary purpose of the notifi cation system is not to verify the claim but rather 
to ensure that the food in question is distinguishable from foodstuffs for normal consumption 
and is suitable for the claimed nutritional purpose. However, several national administrations 
have indicated that they also verify the claim being made. Under the Directive, companies 
have to submit a model of the label used and may also be asked to produce scientifi c work 
and data1044.
5.2.1.5  Marketing of Food Supplements
With regard to marketing information on food supplements1045, the Directive 2002/46 details 
rules for their labelling. The marketer must provide information on the vitamin and mineral 
content, and on the proper use of the product. The name under which food supplements are 
sold shall be “food supplement”1046.
The labelling shall bear the following particulars:
1040  Swedish report 2001, 34. 
1041  Kwak – Jukes 2000b, 111.
1042  The defi nition of foodstuffs for special medical purposes was given above in chapter 4. 
Medical foods are a category of foods for particular nutritional uses specially processed or formulated and 
intended for the dietary management of patients and to be used under medical supervision. They are intended 
for the exclusive or partial feeding of patients with a limited, impaired or disturbed capacity to take, digest, 
absorb, metabolise or excrete ordinary foodstuffs or certain nutrients contained therein or metabolites. 
Directive 1999/21/EC Article 1(2)(b).
1043  Kwak – Jukes 2000b, 112.
1044  Article 9.
1045  See defi nition of ‘food supplement’ above in chapter 4.
1046  Article 6(1).
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the names of the categories of nutrients or substances that characterise the product or (a) 
an indication of the nature of those nutrients or substances;
the portion of the product recommended for daily consumption;(b) 
a warning not to exceed the stated recommended daily dose;(c) 
a statement to the effect that food supplements should not be used as a substitute for a (d) 
varied diet;
a statement to the effect that the products should be stored out of the reach of young (e) 
children.1047
Otherwise, the general marketing rules and the general food marketing rules apply. Marketing 
must not be misleading, and unfair commercial practices such as pyramid schemes are 
prohibited. Like foods in food form, food supplements also need to include an ingredient list, 
including statements on common allergens.
5.2.1.6 Marketing of Novel Foods
There are special labelling requirements for novel foods. According to Regulation 258/97/EC 
/on novel foods, the fi nal consumer must be informed of:
any characteristic or food property (such as composition, nutritional value or nutritional (a) 
effects, or intended use of the food) which renders a novel food or food ingredient no 
longer equivalent to an existing food or food ingredient1048. In this case, the labelling 
must indicate the properties modifi ed, together with the method by which the property 
was obtained.
the presence of material which is not present in an existing equivalent foodstuff and (b) 
which may have implications for the health of certain sections of the population;
the presence of material which is not present in an existing equivalent foodstuff and (c) 
which gives rise to ethical concerns.1049
This means labelling has to give information on substances that traditional, equivalent 
products do not have, for example on allergenic proteins, or on materials that may cause 
ethical insecurity in some consumer groups. Information on changed composition, nutritional 
quality or purpose of use compared to normal product must also be given. In the absence of 
an existing equivalent food or food ingredient, appropriate provisions shall be adopted where 
necessary in order to ensure that consumers are adequately informed of the nature of the food 
or food ingredient1050. When authorising a product, the labelling question is resolved at the 
same time. The product labels are customized and accepted for each product separately.
1047  Article 6(3).
1048  “A novel food or food ingredient shall be deemed to be no longer equivalent ... if scientifi c assessment, 
based upon an appropriate analysis of existing data, can demonstrate that the characteristics assessed are 
different in comparison with a conventional food or food ingredient, having regard to the accepted limits of 
natural variations for such characteristics.”
1049  Article 8(1).
1050  Article 8(2).
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With novel food labelling, one should notice that mandatory statements required by 
Community law shall not be considered as claims. They are thus not in the scope of the 
Nutrition and Health Claim Regulation, which covers only claims made on a voluntary basis. 
This applies for example to statements on cholesterol for products containing phytosterols, 
phytostanols, or their esters.1051 The Commission Regulation 608/2004/EC1052 requires that the 
labelling of these products includes a statement that the product is intended exclusively for 
people who want to lower their blood cholesterol level1053.
According to the proposed Regulation on novel foods, a Community list of authorised 
novel foods will be created. The decision to include a food on the Community list shall include, 
where appropriate, specifi c additional labelling for novel foods sold to the consumer1054.
5.2.1.7 Marketing of GMO Food
Regulation 1830/2003/EC concerns the traceability and labelling of genetically modifi ed 
organisms and the traceability of food and feed products produced from genetically modifi ed 
organisms. In Europe, GMO food must be labelled as such.
“For products consisting of or containing GMOs, operators shall ensure that:
for pre-packaged products consisting of, or containing GMOs, the words ‘This product (a) 
contains genetically modifi ed organisms’ or ‘This product contains genetically modifi ed 
[name of organism(s)]’ appear on a label;
for non-pre-packaged products offered to the fi nal consumer the words ‘This product (b) 
contains genetically modifi ed organisms’ or ‘This product contains genetically 
modifi ed [name of organism(s)]’ shall appear on, or in connection with, the display of 
the product.”1055
This means the labelling requirement applies to products such as fl our, oils, and glucose syrups 
if they are from a GMO source, such as GM soy or maize. Products produced with GMO 
technology, cheese produced with GMO enzymes, for example, does not have to be labelled. 
Neither do products such as meat, milk and eggs from animals fed on GMO animal feed.1056 
Consumers have expressed complaints and demanded to know about GMO use in the whole 
production chain.
Conventional products, i.e. products created without recourse to genetic modifi cation, may 
be accidentally contaminated by GMOs during harvesting, storage, transport or processing1057. 
1051  Scientifi c Committee on Food Safety and Animal Health. Guidelines on the Implementation of the 
Regulation 1924/2006/EC. December 2007. Page 5.
1052  Commission Regulation (EC) No 608/2004 of 31 March 2004 concerning the labelling of foods and food 
ingredients with added phytosterols, phytosterol esters, phytostanols and/or phytostanol esters.
1053  Article 2(3). Article 2 also stipulates other important mandatory statements that have to be used on the 
labels to inform the consumers on the safe and proper use of these products.
1054  Novel food proposal 2007, page 7.
1055  Article 4(B)(6).
1056  UK Food Standards Agency. GM Labelling. 2 August 2007. 
1057  European Commission web page. Questions and answers on the regulations of GMOs in the European 
Union. Page 16. http://ec.europa.eu/food/food/biotechnology/gmfood/qanda_en.pdf.
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Where GMOs are present in a proportion no higher than 0.9%, these products are exempted 
from the labelling requirement, provided that traces of (authorised) GMOs are adventitious 
or technically unavoidable1058. This is the case when operators demonstrate to the competent 
authorities that they have taken adequate measures to avoid the presence of this material1059.
5.2.1.8 Marketing of “Junk Food”
In Europe, discussions on advertising of so-called junk food have been going on. In the UK, 
advertising of foods and drinks with high fat, salt and sugar content has been restricted since 
June 2007 and these foods cannot be marketed during television programming aimed at under 
sixteen-year-old viewers. The UK Offi ce of Communications1060 also considered forbidding 
all food advertising aimed at children.1061
The UK food and drink industry had previously self-regulated advertising: some had 
withdrawn from advertising to younger children. However, the food industry was “shocked” 
when the Ofcom restrictions came to its attention. They would have preferred the restriction to 
only apply to programs for children up to the age of nine as had been discussed. They would 
have preferred longer transition periods. It was revealingly noted, that the restrictions “quite 
possibly affect sales of many popular products”.1062 Because the very goal of these restrictions 
is to limit children’s consumption of junk food, they target sales reduction. We could ask what 
the real goal of self-regulation was; to postpone regulation?, to build a better company image? 
Also the demand for longer transition periods seems ungrounded. It does not take years to stop 
advertising during children’s programs. The restrictions create a real incentive to reformulate 
existing products and to develop new products.
The US consumer lobby groups say that Americans could use the UK way as an example. 
They say voluntary ad restrictions in the US are a proven failure and that the UK approach is 
far more effective. They also say that the US voluntary measures are promulgated merely to 
forestall government action and to make life easier for advertisers.1063 This is unfortunately 
often the case with self-regulation: the industry will not be the fi rst to impose stringent 
limitations on itself.
More and more people are of the view that unhealthy food should be treated the same way 
as tobacco and alcohol. It is clear to practically every consumer that poor diet causes health 
problems equivalent to those caused by tobacco and alcohol. The food industry might claim 
that it is their constitutional right to market their legal products. But parents might claim that 
it is their children’s constitutional right not to receive marketing material on harmful products. 
Junk food can still be sold to children. It would be radical indeed if McDonalds, Burger King, 
and KFC would stop selling to children altogether.
1058  Article 4(C) (8).
1059  European Commission web page. Questions and answers on the regulations of GMOs in the European 
Union. Page 16. http://ec.europa.eu/food/food/biotechnology/gmfood/qanda_en.pdf.
1060  Ofcom is the independent regulator and competition authority for the UK communications industries. 
www.ofcom.org.uk.
1061  Fletcher 2006. 
1062  Warnock 2006 according to Fletcher 2006. 
1063  This is claimed to be part of the Bush Administration strategy oriented to protecting business, not 
consumers. Jacobson 2006. 
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Marketing restrictions on junk food do not directly affect functional foods, but are 
interesting as they are a step towards the regulatory direction that is anti-junk-food. This kind 
of “nutritionist’s approach” to regulation is favourable to developers of functional foods. This 
approach already manifests itself in the nutrition and health claim regulation, which allows 
claims to be made only if the nutritional profi le of the product is under the agreed limit. It 
has also been suggested that unhealthy foods should be taxed more heavily than others, or 
that people with diet related diseases should pay for these diseases themselves. Junk food 
advertising could also be prohibited altogether, also for adults. In the future, drastic measures 
like this might be considered. The producers and restaurants would be forced to reformulate 
their product palettes and menus so that every burger and candy bar had a less-fat less-sugar 
alternative or replacement. This could create more market potential for functional foods.
5.2.2 China
5.2.2.1 General Rules on Labelling and Advertising
Like in Europe, there is certain mandatory information that must be given to consumers on 
foods. Article 21 of the Food Hygiene Law concerned food labelling:
“Any standardized packaged food or food additive must, according to the requirements for 
different products, have
the name of the product, –
the place of manufacture, –
the name of the factory, –
the date of manufacture, –
the batch number (or code number), –
the specifi cations, –
the formula or principal ingredients, –
the date of expiration for guaranteed quality, –
the method of consumption or use, and –
other such information. –
The product description for any food or food additive shall not contain exaggerated or false 
advertising. The label of the food package must be clearly printed and easy to read. Foods sold 
on domestic markets must have labels in the Chinese language.”
5.2.2.2 Nutrition Labelling
Until recently, nutrition labelling was not nationally regulated in China. According to a new 
regulation, Administrative Measures on Food Nutrition Labelling, China requires basic 
nutritional labelling on all food packaging from May 1, 2008. Labels are required to show how 
much protein, fat, carbohydrate and sodium is in a food, and may also show the cholesterol, 
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sugar and vitamin content. The rules stress that nutritional labelling must be accurate and 
objective.1064 The same regulation covers nutrition claims.
China has worked together with ASEAN1065 countries1066 to remove barriers to food 
and beverage trade.1067 Promoted by ILSI1068 South East Asia Region, these countries have 
standardised nutrition labelling and scientifi c substantiation of claims1069. Codex guidelines on 
nutrition labelling (amended 2006) have been used as reference.1070
It seems that all over the world, harmonisation of the laws is seen as an important tool to 
facilitate food trade. However, countries are mainly focused on neighbouring countries when 
harmonising the rules. In Europe, the main goal is to promote free trade in the European 
Community. Still, nutrition labelling is based on similar principles in Europe, China, and 
for example the United States. This is because of makers of international standards, here 
particularly Codex and ILSI. For instance, the Codex guidelines are fairly identical to national 
regulations regarding nutrition labelling and nutrition claims.
5.2.2.3 Marketing of GMO Foods
China started implementing new rules on GMOs in 2002. GMO foods have their special 
labelling requirements1071. As discussed above in chapter 4, the Ministry of Health administers 
the list of authorised GMOs. The Agricultural GMO Labelling Regulations prohibit sales and 
imports of listed GMOs (such as soybeans, corn, rapeseed, cotton seed, and tomatoes) unless 
they are clearly labelled as genetically modifi ed products.1072 This is to ensure traceability of 
GMOs and to protect consumers’ right to information.
5.3 Claims in Food Marketing: Nutrition Claims, Health Claims
5.3.1 Claims as Statements of Effi cacy
The meaning of the word ‘claim’ is generally well understood. A widely accepted defi nition 
of a ‘claim’ is that of Codex Alimentarius (1991). This defi nition applies to claims in food 
marketing. Claim is defi ned as “any representation, which states, suggest or implies that a 
1064  Reuters Beijing January 11 2008.
1065  Association of Southeast Asian Nations.
1066  Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, 
Thailand, Vietnam.
1067  See: “Memorandum of Understanding between the Association of Southeast Asian Nations and the 
Government of the People’s Republic of China on Strengthening Sanitary and Phytosanitary Cooperation. 
Singapore, 20 November 2007.”
1068  International Life Sciences Institute. 
1069  According to ILSI South East Asia Region, they “promote the development of a harmonized approach for 
food safety standards”. ILSI South East Asia Region web page at: http://southeastasia.ilsi.org/about/.
1070  Chinese Nutrition Society. Web page at: http://www.cnsoc.org/asp-bin/
GB/?page=8&class=104&id=455.
1071  Provisions for Labelling Administration of Genetically Modifi ed Farm Products (MOA regulation; Order 
No. 10; Promulgation Date: 2002-01-05; Effective Date: 2002-03-20.
1072  Food Navigator news. http://www.foodnavigator.com/news/ng.asp?id=43552-gmo-labels-launched.
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food has certain characteristics relating to its origin, nutritional properties, nature, production, 
processing, composition, or any other quality”.1073 According to the new EU defi nition, 
“claim” in connection to food marketing means “any message or representation, which is not 
mandatory under Community or national legislation, including pictorial, graphic or symbolic 
representation, in any form, which states, suggests or implies that a food has particular 
characteristics”1074.
Food claims, and particularly those related to nutrition and health, have become a legally 
interesting question mainly because of functional foods.1075 With medicines, the rules on 
effi cacy and claims have been in place for a long time. Medicines have to be effective, and 
are therefore tested regarding their fi nal health effects in human subjects. The clinical tests 
are randomised and controlled. It is clear that medicines are marketed by telling what disease 
they treat.1076 Functional foods have changed the picture. Now also foods can be effective 
in fi ghting disease or keeping one healthy. This means effi cacy and claims of foods must be 
regulated. A product is generally considered effective, if it is scientifi cally proven to have a 
positive impact on health.
In functional food marketing, claims are often related to nutritional science. A key issue on 
science-related marketing claims is the level of scientifi c proof required including the system to 
substantiate the claims. The substantiation system shall not become a disincentive for product 
developers, and it needs to build product acceptance by consumers. The process for the establishment, 
verifi cation, and use of claims should be scientifi cally sound and credible. At the same time, the 
process should be fl exible and pragmatic.1077
There are different types of health effects, and different types of marketing claims. Claims 
on foodstuffs and medicines can be divided in three main categories, two of which belong to 
foods and one to medicines:
Nutrition claims simply state nutritional facts without directly referring to health problems. 
Nutrition claims are scientifi cally and politically rather simple compared to health claims.
Health claims state that a product enhances health or reduces the risk of a disease. 
Health claims are legally the most diffi cult claim category. It is diffi cult to determine 
which health effect should enable the making of which claim, and at the same time to 
draw the line to medicinal claims.
Medicinal claims state that a product might cure, treat or prevent a disease. In law, 
medicinal claims are reserved for medicinal products and are thus prohibited on foods.
Nutrition claims, health claims, and medicinal claims are factual claims, which the marketer 
has to be able to substantiate. This is in comparison to claims that are regarded as common 
appraisals, like claiming your product is “great” or equivalent.
1073  Codex General Guidelines on Claims, 31.
1074  Nutritional and Health Claim Regulation, Article 2(2)(1).
1075  Other types of claims in modern food marketing relate, for example, to ethical and environmental 
questions.
1076  We will return to medicine marketing below.
1077 Richardson 1998, 205.
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5.3.2 Codex Guidelines on Nutrition and Health Claims
At international level, the Codex Alimentarius adopted Guidelines on Nutrition Labelling 
in1985, General Guidelines on Claims in 1991, and Guidelines for the Use of Nutrition Claims 
in 1997. In 2004, the latter was amended to include health claims.
According to Guidelines on Nutrition Labelling1078, and Guidelines for Use of Nutrition 
and Health Claims1079,
“nutrition claim means any representation which states, suggests or implies that a food 
has particular nutritional properties including but not limited to the energy value and 
to the content of protein, fat and carbohydrates, as well as the content of vitamins and 
minerals. The following do not constitute nutrition claims:
the mention of substances in the list of ingredients;(a) 
the mention of nutrients as a mandatory part of nutrition labelling;(b) 
quantitative or qualitative declaration of certain nutrients or ingredients on the label if (c) 
required by national legislation.”
According to Guidelines for Use of Nutrition and Health Claims, nutrition claims are divided into 
nutrient content claims and nutrition comparative claims. Nutrient content claims describe the level 
of a nutrient contained in a food, for example, “source of calcium”, “rich in fi bre”, “low in fat”. 
Nutrient comparative claims compare the nutrient levels and/or energy value of two or more foods, 
for example “reduced”, “more than”, “increases”.1080
According to Guidelines for Use of Nutrition and Health Claims, “Health claim means any 
representation that states, suggests, or implies that a relationship exists between a food or a 
constituent of that food and health.”1081 Health claims include the following:
nutrient function claims, –
other function claims, and –
reduction of disease risk claims. –
Nutrient function claim is a nutrition claim that describes the physiological role of the nutrient 
in growth, development and normal functions of the body.1082 This means that nutrient function 
claims are regarded both as nutrition claims and as health claims. The reason for this rather 
confusing regulatory solution is that nutrient function claims were previously defi ned as the 
third type of nutrition claims. When health claims were included in the Guidelines, nutrient 
function claims were transferred under health claims without changing their defi nition. 
1078 Codex Alimentarius Guidelines on Nutrition Labelling. CAC/GL 2/1985. Amended 2003 & 2006. 
Section 2.4.
1079 Codex Alimentarius Guidelines for Use of Nutrition and Health Claims. CAC/GL 23/1997, Rev. 1/2004. 
Section 2.1.
1080  Sections 2.1.1. and 2.1.2.
1081  Section 2.2.
1082  Section 2.2.1.
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According to current Guidelines, claiming what a nutrient does is evaluated according to the 
same principles as other health claims.
Other function claims concern “specifi c benefi cial effects of the consumption of foods or 
their constituents, in the context of the total diet on normal functions or biological activities of 
the body”. Such claims relate to “a positive contribution to health or to the improvement of a 
function or to modifying or preserving health”.1083
Reduction of disease risk claims “relate the consumption of a food or food constituent, 
in the context of the total diet, to the reduced risk of developing a disease or health-related 
condition”. Risk reduction is, “signifi cantly altering a major risk factor(s) for a disease or 
health-related condition”. The Guidelines clarify the difference between risk reduction and 
prevention: “Diseases have multiple risk factors and altering one of these risk factors may or 
may not have a benefi cial effect. The presentation of risk reduction claims must ensure, for 
example, by use of appropriate language and reference to other risk factors, that consumers do 
not interpret them as prevention claims.”1084
On health claims, Codex Guidelines require scientifi c substantiation of the claim, adequate 
labelling to instruct the consumer, and that the health benefi t arises from the consumption of a 
reasonable quantity of the food in question. They also require that national authorities should 
ban health claims on foods that contain nutrients or constituents in amounts that increase the 
risk of disease or an adverse health-related condition.1085 This means that the food should be 
healthy as a whole.
When drafting European claim legislation, “due consideration” was given to the defi nitions 
and conditions set in the above-mentioned Codex Guidelines1086. European defi nitions 
of ‘nutrition claim’ and ‘health claim’ are similar to the Codex defi nitions. The European 
‘nutrition profi le’ requirement corresponds to the Codex principles, and European regulation 
also separates between function claims and disease risk reduction claims. However, the 
separation between nutrient function claims and other function claims was not adopted from 
Codex.1087 The Chinese have also followed Codex guidelines in their 2008 regulation on 
nutrition labelling and claims1088.
5.3.3 EU Rules on Nutrition and Health Claims
5.3.3.1 Regulation Background: Prohibition of Medicinal Claims
In the European Union, the question of health claims was obscure for a long time. According 
to the Food Labelling Directive 2000/13/EC, medicinal claims are prohibited. Member States 
interpreted this prohibition on making medicinal claims on the basis of national tradition, which 
1083  Section 2.2.2.
1084  Section 2.2.3.
1085  Section 7.
1086  Regulation 1924/2006/EC, preamble 7.
1087  We will return to the European claim legislation in the next chapter.
1088  Nutraingredients.com news 13 May 2008 at http://www.nutraingredients.com/Regulation/China-takes-
big-step-forward-in-nutrition-labelling.
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lead to legal uncertainty. Literal interpretations of legal texts prevailed in some Member States, 
and an approach based on the perceived spirit of the legislation was applied in others.1089
According to Article 2(1) of the Food Labelling Directive,
“The labelling and methods used must not:
be such as could mislead the purchaser to a material degree, particularly:(a) 
as to the characteristics of the foodstuff and, in particular, as to its nature, identity, (i) 
properties, composition, quantity, durability, origin or provenance, method of 
manufacture or production;
by attributing to the foodstuff effects or properties which it does not possess;(ii) 
by suggesting that the foodstuff possesses special characteristics when in fact all (iii) 
similar foodstuffs possess such characteristics;
subject to Community provisions applicable to natural mineral waters and foodstuffs (b) 
for particular nutritional uses, attribute to any foodstuff the property of preventing, 
treating or curing a human disease, or refer to such properties.”
Similarly, according to the Directive on dietetic foods1090, the labelling and the labelling 
methods used, the presentation and the advertising of the products must not attribute properties 
for the prevention, treatment, or cure of human disease to the products covered by the directive 
or imply such properties. The prohibition of medicinal claims is also repeated in the food 
supplement directive 2002/46/EC1091: “The labelling, presentation and advertising must not 
attribute to food supplements the property of preventing, treating or curing a human disease, 
or refer to such properties”. This means the same rules apply to all foods: medicinal claims 
are prohibited.
The prohibition of medicinal claims is absolute, regardless of whether the substance of the 
claim is true. The absolute prohibition is founded on the state of scientifi c knowledge at the 
time of the formulation of the original Directive 79/112/EEC, over 20 years ago. Since then 
scientifi c knowledge of the relationship between diet and health has advanced considerably. 
No direction is given in the Directive on health claims, which lie in-between nutrition claims 
and medicinal claims. This is because in 1979, food was clearly seen as nutrition. The Food 
Labelling Directive contains a provision1092 according to which the Commission shall come 
up with a non-exhaustive list of types of claims that should be prohibited or restricted, but all 
attempts at developing more detailed legislation on claims over the past years failed. Coppens 
and al. were of the view that unambiguous defi nitions for foodstuffs and medicinal products 
should be set, disease risk reduction claims should be allowed on foods, and medicinal claims 
should be left to medicines.1093
The legislative stalemate at European level acted as a stimulus to national authorities to 
produce quasi-legal ‘guidelines’ and ‘voluntary agreements’. These initiatives were generally 
regarded as stopgap measures, until legislation was to be adopted at the EU level.1094 For 
1089  Coppens et al. 2001, 141.
1090  Article 6(1).
1091  Article 6(2).
1092  Article 2(2).
1093  Coppens et al. 2001, 140.
1094  EU Food Law August 2001, 11.
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example Sweden, the UK, and the Netherlands developed their systems for evaluating health 
claims, and also the Finnish Food Agency provided information on their interpretation of the 
Food Labelling Directive. This was in the form of Health Claim Guidelines1095 of 2002, a piece 
of soft law by the Food Agency.
The situation from the 1990’s to 2006 was that European health claim regulation varied 
from non-existent legislation implying totally prohibited claims, to non-existent legislation 
representing widely allowed claims, to allowed but strictly regulated claims. It was considerably 
more diffi cult to get a functional food product on the market in for example Germany, Italy or 
Switzerland than it is in the UK or Sweden1096. Hill & Knowlton found in their study concluded 
in 2000 that the most liberal approach regarding health claims in the EU was in Finland, 
France and the UK. The most restrictive were Austria, Belgium, Germany, Italy, Luxembourg 
and Portugal. The rest, i.e. Sweden, Denmark, Holland, Spain, Ireland, and Greece share the 
middle ground.1097 A marketer needed to get acquainted with the practice in each country. The 
law on food claims was simultaneously too strong and too weak: prohibiting some important 
legitimate claims, while tolerating others, which were misleading and unsubstantiated1098.
In Finland, the distinction between disease risk reduction and prevention was acknowledged, 
and all types of health claims were allowed. Disease risk reduction claims were, however, not 
regulated by the Foodstuffs Act itself but its preparatory materials, supplemented by soft law 
guidelines. A government’s proposition to law of the year 20011099 set the rules on disease risk 
reduction claims: The health effect must be scientifi cally proven, and the marketer must give 
information on the importance of total diet, and claim-related information on the composition 
of the product1100. According to Health Claim Guidelines, the scientifi c evidence to back up 
the health claim must be on the product as sold. The Economy Committee pointed out that 
prevention and disease risk reduction are not far apart1101.
The explanation concerning disease risk reduction claims was left out of the law itself, as 
the Finnish government expected a change in the Food Labelling Directive and postponed 
reforms until the anticipated amendment of the Directive. The Finnish regulators also referred 
to Codex guidelines and to CIAA proposals.1102 In other words, Finns were confi dent that 
disease risk reduction claims would be allowed in the EU, but they did not dare change the 
Foodstuffs Act just yet.
In the meantime, the scientifi c consensus underlying health claims for foods was 
investigated by International Life Science Institute (ILSI) Europe. The conclusion of the EU-
funded concerted action of Functional Food Science in Europe, FUFOSE, was the Consensus 
Document on Scientifi c Concepts in Functional food in Europe. The consensus document 
focused mainly on scientifi c and technological aspects of functional foods, but also mentioned 
claims. The ILSI document supported the development of enhanced function claims and 
disease risk reduction claims.1103
1095  In Finnish: Terveysväitteiden valvontaopas. The Guide is only available in Finnish.
1096  Food Engineering & Ingredients, October 2001, 18.
1097  Hill & Knowlton 2000, 33.
1098  Winkler 1998, 192.
1099  HE 73/2001: Hallituksen esitys Eduskunnalle laiksi elintarvikelain 6 ja 24 §:n muuttamisesta.
1100  HE 73/2001.
1101  Talousvaliokunnan mietintö 9/2001.
1102  In the proposition to law, HE 73/2001.
1103  Diplock et al. 1999, S24.
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The ILSI/EU concerted action proposed a scientifi c basis to claims: markers should be 
classifi ed according to their relationship to the target function or disease endpoint. If evidence 
is based on functional markers, meaning markers of target function or biological response, a 
function claim might be justifi ed. If evidence were based on an intermediate endpoint marker 
of disease, a disease risk reduction claim would be justifi ed. In the latter case, the intermediate 
endpoint marker would have to be shown to be signifi cantly and consistently modulated by 
the food product.1104
Heasman and Mellentin criticised the ILSI project. They said the scientists should have 
utilised research evidence from the social science and policy literatures when trying to 
develop a communication and health claim policy. Heasman and Mellentin claimed that the 
ILSI project produced outstanding review of the science in relation to functional foods, but 
in the fi nal consensus document where the authors mapped out a policy and communications 
strategy for health claims and functional foods, they made a serious omission. They should 
have used academic research in the areas of communications, social marketing and public 
health practice, but they acted as though empirical and theoretical work in these areas was 
non-existent.1105
After the FUFOSE program, ILSI Europe and the EU Commission started in 2001 a 
European network program PASSCLAIM. The aim of this program was to assess the research 
on functional foods, their health effects and the claims made on them. Scientifi c experts, 
regulators and industry took part in the program, and the results were presented in 2003. 
The PASSCLAIM program produced models of utilising clinical nutrition research and 
communicating the results to consumers.1106
Council of Europe1107 also took part in the debate and published in July 2001 a technical 
document giving Guidelines Concerning Scientifi c Substantiation of Health-Related Claims 
for Functional Foods. The document was given for debate in the European Parliament. The 
Council of Europe guidelines divide health-related claims in two: enhance-function claims 
and reduction of risk of disease claims. According to the paper, both enhanced function claims 
and disease risk reduction claims can be either generic or product-specifi c. Generic claims 
are based on a consensus in the scientifi c community regarding a diet-disease relationship. 
The claim can be used for any product provided that it fulfi ls certain compositional criteria. 
Product-specifi c claims, on the other hand, imply that the food product per se has certain 
physiological effects, which are observed when the food product is consumed in realistic 
amounts.1108
1104  Diplock et al., S25.
1105  Heasman – Mellentin 2001.
1106  Salminen – Mykkänen 2002, 34.
1107  The Council of Europe is a political organisation, which was founded on 5 May 1949 by ten 
European countries in order to promote greater unity between its members. It had 47 member 
states in 2008. The main aims of the organisation are to reinforce democracy, human rights and the 
rule of law and to develop common responses to political, social, cultural and legal challenges in 
its member states. The Council of Europe adopts European Conventions and agreements, which 
create the basis for a common legal space in Europe. Council of Europe web page at: http://www.
coe.int/T/e/Com/about_coe/.  
1108  Guidelines, 10.
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According to Council of Europe guidelines, the scientifi c substantiation should be based 
on all data available (including experimental studies), but it should primarily be based on the 
results of well-designed human studies with the food or the nutrient, the component or the 
ingredient in the proposed food. These studies include observational, epidemiological, and, 
most importantly, nutrition intervention studies. The studies should be conducted according to 
the generally recognised principles of good practices.1109 This means that Council of Europe 
suggested a similar system to drug approval.
Communication of the health benefi ts to the consumer should inform on the quality of 
a particular food, but it should also play an education role. This education should concern 
especially the importance of adequate nutrition and the relationships between diet and well-
being and between diet and disease risk.1110 The suggested precise rules on communication of 
health-related claims were the following:
trigger nutrition labelling, –
be truthful, unambiguous and understandable, –
make clear that the health-related claim applies only to the functional food consumed  –
in the context of a total dietary pattern,
not encourage over-consumption of a given food product to the detriment of others, –
include information of the quantity of the functional component or ingredient, –
include information on the target group or potentially vulnerable segment of the  –
population if appropriate,
include information on how to consume or use the functional food to obtain the claimed  –
effect if appropriate.1111
Communication of health-related claims should also include the documentation of the scientifi c 
evidence behind the claims. Such documentation should:
refer to the process of scientifi c substantiation and its principles, –
be based on, but not misinterpreting or overemphasising, the scientifi c substantiation, –
give a clear and truthful summary of the appropriate scientifi c data, –
describe how the scientifi c data supporting the health-related claim has been collected  –
and evaluated,
explain the plausibility in terms of scientifi c knowledge, and –
indicate where and how the dossier should be available to health professionals and  –
research scientists.1112
1109  Guidelines, 9.
1110  Guidelines, 15.
1111  Guidelines, 15-16.
1112  Guidelines, 16.
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The European Food and Drink Industry, CIAA1113, created its own code of practice on the use 
of health claims. The code was developed to help manufacturers prepare the documentation 
necessary for the substantiation of health claims and to establish guidelines for the 
communication of health claims to consumers. CIAA said that legal framework governing 
claims was incomplete and infl exible. Regulations were applied differently from one Member 
State to another, and Codes of Practice existed in some Member States. In order to achieve a 
level playing fi eld throughout the EU, CIAA believed that the use of a single set of guidelines 
adhered to by the whole European Food and Drink Industry would contribute to reducing 
barriers to trade pending clarifi cation or change in the legislation.
The CIAA code applied to the use of health claims in labelling, advertisement and 
promotion of foods without prejudice to specifi c regulations, which exist for certain categories 
of food. “The code addresses neither nutrition claims, already defi ned by Codex Alimentarius 
nor dietetic claims as defi ned by EU legislation and Codex Alimentarius nor medical claims.” 
Nutrition and medicinal claims never really were a problem: the problem was health claims, 
because they are for products that are genuinely something between foods and medicines. 
Health claim is defi ned as ‘any claim establishing a relation between a food or a constituent of 
that food and health whether it is good health or a condition related to health or disease’.
The CIAA code recognised two types of health claims: enhanced-function claims and 
disease risk reduction claims. These are the same types that were also recognised by the ILSI 
project and the Council of Europe guidelines.
General Principles of the Code are summarised in the following:
Communication of health claims should be in line with the  – scientifi c substantiation. 
It should be truthful and must not mislead, exaggerate or deceive either directly or 
indirectly.
The claim should indicate an appropriate amount of intake required in order to obtain  –
the desired effect.
Health claims should be justifi ed in the context of the whole diet and must be applicable  –
to the amount of food normally consumed.
The more specifi c rules on communication are the following:
The likely consumer perception of the health claim should be taken into account. –
Health claims should be complete, truthful and not misleading. –
1113  According to the CIAA (Confédération des Industries Agro-Alimentaires de l’UE, Confederation 
of the Food and Drink Industries of the EU) they are “the offi cial mouthpiece of the food and drink 
industry in the European Union on issues common to the whole food and drink industry”. They 
describe their actions as follows: “CIAA is the favoured partner of the EC institutions. CIAA is 
composed of affi liated national federations, European sector associations and European food and 
drink companies grouped as an association. CIAA provides expertise within its expert groups and 
policy committees, which comprise manufacturers from all the countries of the European Union. 
CIAA establishes policy guidelines, which are aimed at a Community or international audience. 
CIAA has infl uence over the legislative process of the Community institutions and international 
organisation and it executes policy guidelines via its secretariat in Brussels.” For example the 
Finnish Food Industry Association (Elintarviketeollisuusliitto) is a member of CIAA.
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Health claims should only be made for a food as part of a total dietary pattern and  –
should not encourage over-consumption of a given food to the detriment of others.
Health claims should be consistent with the nature and scope of the evidence. –
Health claims should not denigrate other foods or imply that other foods cannot  –
contribute to a healthy diet.
There must be no implications that the food for which a claim is made is the only way  –
to reduce the risk of a disease or illness.
Channels other than the label can usefully complement the information on the product. –
The more specifi c rules on substantiation are summarised in the following:
The collected evidence must show that the consumption of the food can result in the health 
effect that is claimed:
In those cases for which scientifi c consensus exist,  – bibliographic evidence will normally 
be suffi cient.
For other claims the extent of the scientifi c evidence required should be determined on  –
a case by case basis and should include human studies where appropriate.
Reliability of evidence denotes it has to be
consistent in itself,  –
able to meet accepted scientifi c standards of statistical and biological signifi cance,  –
plausible in terms of the relationship between intervention and results and  –
provided by several sources including human studies. The totality of the evidence should  –
be systematically reviewed. Evidence can be derived from peer reviewed scientifi c 
literature, in vitro studies, animal models, clinical studies, epidemiological studies, or 
any other relevant studies.
The CIAA code refers to the results of the FUFOSE program: The EU Concerted Action on 
Functional Food Science in Europe requires that claims be based on the establishment and 
acceptance of either validated markers of improved physiological function or of intermediate 
endpoint markers of reduced risk of disease.
Human studies must be carried out in a representative sample of the population or population 
group concerned in accordance with good clinical practice. The use of internationally accepted 
and validated methods and of biological markers is recommended when they exist. They 
should demonstrate effi cacy with respect to the specifi c physiological effect(s). An effective 
level and frequency of consumption should be suggested for a food claiming to have a positive 
effect on health. The effect must be studied over suffi cient time to allow adaptation to occur 
and should consider confounding factors such as health status at the time of the study, use of 
medication and/or smoking.
The effect must be quantitatively, statistically and biologically signifi cant. The measured 
effect must be shown to be suffi ciently important to justify the claim. If the composition 
or manufacturing processes change substantially, or if new scientifi c developments occur, 
additional checks must be carried out to ensure the continued validity of the claim. It must 
be shown that the specifi c functional substance(s) is (are) present in the quantity and form 
needed to justify the claim throughout shelf life when stored under the conditions indicated 
–201–
on the label. A normal or recommended serving size, conditions of use and consumption 
pattern should be incorporated into an assessment of the relevance of the concerned food 
with a nutritional intake of the population. Companies are encouraged to have their scientifi c 
evidence peer-reviewed.
The main European Consumer Association, Bureau European Union de Consommateurs 
(BEUC), was basically against health claims. In its view a single food product is neither 
healthy nor unhealthy. In contrast, only the diet can be healthy or unhealthy. They said all 
claims must be presented in the context of a balanced healthy diet. Claims should not be 
permitted on products that contradict well-established dietary advice, e.g. which contain high 
quantities of fat, sugar or salt.1114 The requirements for scientifi c documentation and labelling 
requirements were more or less the same as in Council of Europe and CIAA guidelines.
For years, plans to introduce provisions into Community law to govern health claims 
existed. The Commission’s directorate general for health and consumer protection ordered 
a study from consultancy fi rm Hill & Knowlton in the 90’s. Their task was to study the legal 
situation in Member States relating to nutritional claims, health claims and ethical claims. Also, 
opinions of different interest groups were studied and based on their fi nding the consultants 
gave recommendations. The study was performed in the fi rst half of 1999, and the results were 
given to the Commission in April 2000.
According to the Hill & Knowlton study, consumer groups acknowledged the need for 
health claims, and called for strict legislation to cover:
pre-clearance of all claims, –
precise substantiation criteria to allow claims to be used (not positive or negative lists), –
reinforced post verifi cation systems, –
better consumer information about the relationship between diet and health, and –
a shift in the burden of proof onto the maker of the claim. – 1115
The food industry opinions were the following:
EC rules are needed regarding health claims. –
New types of health claims should be allowed, and the Food Labelling Directive should  –
be changed to allow this.
Clear criteria for presenting health claims are needed –
There should be no system for pre-market approval, but well-defi ned post clearance  –
verifi cations are in order.1116
Food producers considered it a problem that different countries interpret the Food Labelling 
Directive and its prohibition of medicinal claims differently. This is the usual reason for 
harmonising an area of law: varying legislation creates restrictions to trade.
Majority of offi cial parties and legislators were of the following view:
1114  BEUC guidelines 2000, 4-7.
1115  Hill & Knowlton 2000, 11.
1116  Hill & Knowlton 2000, 12.
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EC rules regarding health claims are needed, and the Food Labelling Directive should  –
be changed to allow new types of health claims.
The work in Codex could form the basis of allowing new types of claims. –
The defi nition of food should be clearer so that drawing the line to medicinal products  –
would be less complicated.
For generic claims, a positive list could be made up. Pre-market approval for product- –
specifi c claims might be reasonable.1117
Voluntary codes can work as a temporary solution while waiting for the EC rules on  –
health claims.1118
Based on opinions of these three important interest groups (consumers, industry and 
governments) Hill and Knowlton proposed the following:
To protect consumers, health claims should be regulated clearly at EC level. –
The Food Labelling Directive should be changed so that it would literally allow  –
enhanced function claims and disease risk reduction claims.
A list on general permissible claims should be created, and a notifi cation procedure for  –
so called new claims.
The Nutrition Labelling Directive (Directive 90/464/EC) should be changed to comply  –
with Codex guidelines on nutrition claims.
The Misleading Advertising Directive (Directive 84/450/EC) should be changed to  –
cover the control mechanisms for claims.
The defi nition of food should be clarifi ed. – 1119
A campaign to educate consumers on the connection between nutrition and health  –
should be arranged.
After the Hill & Knowlton report, the Commission1120 continued to prepare new legislation 
on claims and published a discussion paper on nutritional and functional claims in 2001. 
The discussion paper was based on the idea that harmonisation is needed because of all the 
different rules restricting trade. The discussion paper presented different alternatives for 
defi ning ‘claim’, requirements for presenting a claim and for systems of assessment and 
acceptance of claims.
On nutrition claims, the paper suggested banning claims relating to dietary cholesterol1121, 
considered the possibility to require some kind of nutritional profi le of “low fat” foods, and 
presented suggestions on defi nitions of “low fat”, “sugar free” etc. For the so-called functional 
1117  Here generic seems to mean established, where product-specifi c means innovative.
1118  Hill & Knowlton 2000, 12.
1119  Since the study, food has been defi ned in the General Food Regulation, but all that defi nition says is that 
foods that are medicines are not foods. 
1120  The Directorate General on Health and Consumer Protection, DG SANCO.
1121  This is because dietary cholesterol is not a major factor in coronary heart disease and there is a danger of 
confusion with blood cholesterol levels. Consumers do not seem to understand the difference between dietary 
and blood cholesterol. High blood cholesterol is usually related to a diet rich in saturated fats.
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claims, the paper suggested giving fi rst the presence of the nutrient and then its role in human 
physiology, for example: “High on protein. Protein helps build and repair body tissues.”1122
The paper stated that claims must be substantiated with scientifi c evidence and that evidence 
must be relevant to consumers in terms of the fi nal product they eat. The paper suggested a 
pre-market authorisation for nutritional and functional claims, and a list of acceptable and 
agreed claims for each nutrient or substance, including specifi c wording.1123
There were over 880 responses to the DG SANCO paper and it was hard to see how the 
different positions could be resolved and a consensus for a proposal reached.1124 For example, 
Italy was of the view that food claims “cater solely for commercial interests.” They thought the 
novel foods trend is dangerous and spoils all the food traditions. They warned that subsequent 
studies often revise the virtues of specifi c foods, no attention is paid to over consumption, 
and that a combined consumption of enriched products can cause problems. The UK, on the 
contrary, saw claims as enabling consumers to make healthy diet choices.
Besides nutritional and functional claims, the UK wanted health claims, and disease reduction 
claims, to be debated. Also, many other Member States, the food industry (particularly CIAA), 
and consumer groups commented on the absence of health claims from the fi rst paper. They 
were in all probability left out, as they were considered even more diffi cult, as viewpoints on 
health claims vary from not wanting health claims at all, to those which would accept some 
claims under certain rules, to those that have a much more liberal policy. 1125
There was a large amount of pressure on the Commission: several stakeholders demanded 
legislation governing health claims. No one wanted to live in a non-harmonised state. This 
implies that legislation was considered necessary. The UK continued to allow a reduction 
of risk claims, and this resulted in confl ict with the Commission, as Commission offi cials 
said these were illegal.1126 The Commission promised to prepare a Proposal for a Regulation 
on nutrition, functional and health claims. They planned that the Commission might adopt 
the proposal in early 2003. The Commission thus decided to put food claims together and 
abandoned the idea of separate discussion paper and proposal for health claims.1127
While waiting for the Commission proposal, a system where a list of claims was authorised, 
based on established scientifi c evidence, seemed attractive to both consumers and industry. 
This kind of blanket approval provides certainty and does not involve a lengthy approval 
procedure.1128 There seemed to be a fair amount of consensus on scientifi c substantiation of 
claims, and the importance of the total diet. Hill & Knowlton also proposed a notifi cation 
procedure for novel claims, which was something the industry opposed but the consumers 
applauded.
In July 2003, the Commission adopted a proposal for a Regulation on the use of nutrition 
and health claims made on foods1129. According to the Commission, “the main objectives of 
the Commission’s proposal are to achieve a high level of consumer protection and increase 
1122  Other examples established by Codex: ”Calcium aids in the development of strong bones and teeth”; 
”Iron is a factor in red blood cell formation” and “Vitamin E protects the fat in body tissues from oxidation”.
1123  Discussion paper on nutrition and functional claims, 10.
1124  EU Food Law November 2001, 7.
1125  EU Food Law November 2001, 7.
1126  EU Food Law June 2001, 10.
1127  European Commission’s Food Safety web page July 10, 2002.
1128  EU Food Law August 2001, 13.
1129  COM(2003) 424 fi nal. Brussels, 16.7.2003.
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legal security for economic operators. It also aims to ensure fair competition and promote and 
protect innovation in the area of food. By adopting rules on the information given about foods 
and the nutritional values appearing on labels, the Commission was aiming to ensure that 
consumers would be able to make informed and meaningful choices when it came to food and 
drinks. The health and nutrition claims rules will also contribute to a higher level of human 
health protection, as it ties in with the Commission’s campaign for healthier lifestyle choices 
by allowing citizens to know exactly what they are consuming.”1130 The Commission tried to 
respond to all the demands presented: particularly consumers wanting more reliable information 
and the industry wanting clear and harmonised rules not discouraging innovation.
The European Parliament held its fi rst reading vote on the Commission’s proposal in May 
2005.1131 The parliament tried to delete both the article on the authorisation procedure and 
the article on nutrition profi les. The Internal Market Committee of the European Parliament 
voted to delete the articles in April 2005. On the authorisation procedure, the vote was 20 for 
deletion and 14 against. The result of the vote on nutrition profi les was 19 for deletion and 14 
against. With both Articles, the EPP (Christian-Democrats) and ALDE (Liberals) voted for 
deletion, and the PES (Socialists) and Greens voted against deletion.1132 The Commission did 
not accept the deletions and gave another proposal including the contested articles.
In June 2005, EU health ministers unanimously endorsed the Commission’s proposal, 
including the provision for nutrient profi les and the authorisation procedure, during a fi rst 
reading vote at the Health Council. The European Parliament second reading vote took 
place in May 2006.1133 Formal adoption of the Regulation by the Parliament and the Council 
occurred in December 2006. Regulation1924/2006/EC1134entered into force in January 2007, 
and became applicable in the beginning of July 2007. This means that after all the years of 
discussion and preparation, the EU fi nally has a regulation on nutrition and health claims. The 
Regulation is analysed in detail below.
5.3.3.2 General Requirements on Claims
Regulation 1924/2006/EC applies to nutrition and health claims made in commercial 
communications, whether in the labelling, presentation or advertising of foods to be delivered 
as such to the fi nal consumer. It also applies in respect of foods intended for supply to 
restaurants, hospitals, schools, canteens and similar mass caterers.1135 Nutrition and health 
claims may be used on foods placed on the market in the European Community only if they 
comply with the provisions of the Regulation.
Article 3 lists “the general principles for all claims”. The use of nutrition and health claims 
shall not:
1130  European Commission’s Food Safety web page September 21st 2006.
1131  European Commission web page at: http://ec.europa.eu/food/food/labellingnutrition/claims/index_en.htm.
1132  Foodnavigator news 20 April 2005. http://www.foodnavigator.com/news/ng.asp?n=59508-imco-votes-to.
1133  European Commission web page at: http://ec.europa.eu/food/food/labellingnutrition/claims/index_en.htm.
1134  Regulation 1924/2006/EC of the European Parliament and of the Council, of 20 December 2006, on 
nutrition and health claims made on foods.
1135  Article 1(2).
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be false, ambiguous or misleading;(a) 
give rise to doubt about the safety and/or the nutritional adequacy of other foods;(b) 
encourage or condone excess consumption of a food;(c) 
state, suggest or imply that a balanced and varied diet cannot provide appropriate (d) 
quantities of nutrients in general1136;
refer to changes in bodily functions that could give rise to or exploit fear in the consumer, (e) 
either textually or through pictorial, graphic or symbolic representations.
Article 5 lists “the general conditions” for claim use. The use of nutrition and health claims 
shall only be permitted if the following conditions are fulfi lled:
the presence, absence or reduced content in a food or category of food of a nutrient (a) 
or other substance in respect of which the claim is made has been shown to have a 
benefi cial nutritional or physiological effect, as established by generally accepted 
scientifi c evidence;
the nutrient or other substance for which the claim is made:(b) 
is contained in the fi nal product in a signifi cant quantity as defi ned in Community (i) 
legislation or, where such rules do not exist, in a quantity that will produce the 
nutritional or physiological effect claimed as established by generally accepted 
scientifi c evidence; or
is not present or is present in a reduced quantity that will produce the nutritional (ii) 
or physiological effect claimed as established by generally accepted scientifi c 
evidence;
where applicable, the nutrient or other substance for which the claim is made is in a (c) 
form that is available to be used by the body;
the quantity of the product that can reasonably be expected to be consumed provides (d) 
a signifi cant quantity of the nutrient or other substance to which the claim relates, 
as defi ned in Community legislation or, where such rules do not exist, a signifi cant 
quantity that will produce the nutritional or physiological effect claimed as established 
by generally accepted scientifi c evidence;
compliance with the specifi c conditions set out in Chapter III Nutrition Claims or (e) 
Chapter IV Health Claims as the case may be.
The use of nutrition and health claims shall only be permitted if the average consumer1137 can 
be expected to understand the benefi cial effects as expressed in the claim. Nutrition and health 
1136  There are nutrients, for which suffi cient quantities cannot be provided by a balanced and varied diet. 
Derogations for these cases, including the conditions for their application, may be adopted in accordance 
with the procedure referred to in Article 25(2), taking into account the special conditions present in Member 
States. 
1137  According to preamble 16 of the Regulation, the average consumer test is not a statistical test.: “National 
courts and authorities will have to exercise their own faculty of judgment, having regard to the case-law of 
the Court of Justice, to determine the typical reaction of the average consumer in a given case.” The average 
consumer means a person, who is reasonably well-informed and reasonably observant and circumspect. If 
a claim is specifi cally aimed at children, the claim should be assessed from the perspective of an average 
child. 
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claims shall refer to the food ready for consumption in accordance with the manufacturer’s 
instructions.
Article 6 concerns scientifi c substantiation of claims: Nutrition and health claims shall be 
based on and substantiated by generally accepted scientifi c evidence. A food business operator 
making a nutrition or health claim shall justify the use of the claim. The competent authorities 
of the Member States may request a food business operator or a person placing a product 
on the market to produce all relevant elements and data establishing compliance with this 
Regulation.
Article 7 clarifi es the rule on mandatory nutrition information. As described above1138, 
Directive 90/496/EEC has previously required nutrition information to be given in cases where 
a nutrition claim is made. The same rule applies to health claims. With health claims, the 
information to be provided shall consist of information in Group 2 as defi ned in Article 4(1) of 
Directive 90/496/EEC. In addition and as the case may be, the amount(s) of the substance(s) 
to which a nutrition or health claim relates that does not appear in the nutrition labelling shall 
also be stated in the same fi eld of vision as the nutrition information and be expressed in 
accordance with Article 6 of Directive 90/496/EEC.1139
Claims on alcoholic drinks are restricted1140. Later the Commission may determine other 
foods or food categories, for which nutrition or health claims are to be restricted or prohibited. 
This shall be done in the light of scientifi c evidence.1141
The Commission, more particularly its Scientifi c Committee on Food Safety and Animal 
Healthgave a guidance document1142 where the relationship between the Regulation and other 
Community law is clarifi ed in December 2007. On dietetic foods, it is stated that they can bear 
claims authorised on the basis of Regulation 1924/2006/EC. However, this does not apply to 
infant formula: the only permitted claims on these products are listed in Annex IV of Directive 
2006/141/EC.1143
5.3.3.3 Nutrient Profi les
5.3.3.3.1 The Nutrient Profi le as a Condition for Claim Use
The new regulation includes the principle that the use of claims is conditional on respecting 
the overall nutrient profi le of the food. This means perhaps the most controversial 
thing about the new regulation that only “good foods” are allowed to have claims. The 
application of nutrient profi les as a criterion for nutrition and health claims aims to avoid 
a situation where nutrition or health claims mask the overall nutritional status of a food 
product. Nutrient profi les should be based on generally accepted scientifi c evidence on 
1138  Chapter 5.2.1.3.
1139  In the case of food supplements, the nutrition information shall be provided in accordance with Article 
8 of Directive 2002/46/EC.
1140  Only nutrition claims referring to low alcohol levels or low energy levels are allowed. Health claims on 
alcohols are prohibited. Article 4(3).
1141  Regulation 1924/2006/EC, Article 4(5).
1142  Guidance on the Implementation of Regulation N° 1924/2006 on Nutrition and Health Claims Made on 
Foods. Conclusions of the Standing Committee on the Food Chain and Animal Health. 14 December 2007.
1143  Scientifi c Committee Claim Guidance 2007, 4.
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the relationship between diet and health. At the same time, profi les should also allow for 
product innovation, and take into account various dietary habits and traditions.1144
Nutrient profi les will be based on the content of different nutrients and substances with 
a nutritional or physiological effect. This means calculating the amounts of fat, saturated 
fat, trans-fatty acids, poly- and mono-unsaturated fats, salt/sodium, sugars, available 
carbohydrates other than sugars, vitamins, minerals, protein and fi bre. Some of these 
nutrients and substances are avoidable; some are benefi cial. It is not merely the nutritional 
content that resolves the issue of claims. When setting the nutrient profi les, the different 
categories of foods and the place and role of these foods in the overall diet should be taken 
into account. Due regard should be given to the various dietary habits and consumption 
patterns existing in the Member States.1145
EFSA has given its scientifi c opinion on nutrient profi les in January 2008 and has consulted 
stakeholders. Scientists and governments have developed different nutrition profi ling models. 
The Commission was to establish nutrient profi les for different foods and food categories by 
19 January 2009. This work has been delayed. With the nutrient profi les, the Commission 
shall establish all the conditions for the use of claims and also the exemptions. The nutrient 
profi les for food and/or certain categories of food shall be established taking into account in 
particular:
the quantities of certain nutrients and other substances contained in the food, such as (a) 
fat, saturated fatty acids, trans-fatty acids, sugars and salt/sodium;
the role and importance of the food (or of categories of food) and the contribution to (b) 
the diet of the population in general or, as appropriate, of certain risk groups including 
children;
the overall nutritional composition of the food and the presence of nutrients that have (c) 
been scientifi cally recognised as having an effect on health.1146
The nutrient profi les shall be based on scientifi c knowledge about diet and nutrition, and 
their relation to health. In setting the nutrient profi les, the Commission shall request EFSA to 
provide scientifi c advice, focusing in particular on:
whether profi les should be set for food in general and/or categories of food; –
the choice and balance of nutrients to be taken into account; –
the choice of reference quantity/basis for profi les; –
the approach to the calculation of the profi les; and –
the feasibility and testing of a proposed system. – 1147
After setting up the profi les, the Commission shall continue to carry out consultations with 
interested parties, in particular food business operators and consumer groups. Nutrient 
profi les and their conditions of use shall be updated to take into account relevant scientifi c 
1144  Regulation 1924/2006/EC, preamble 11.
1145  Regulation 1924/2006/EC, preamble 12.
1146  Regulation 1924/2006/EC, Article 4(1).
1147  Regulation 1924/2006/EC, Article 4(1).
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developments, after consultation with interested parties, in particular food business operators 
and consumer groups.1148
It is not yet clear how many different nutrition profi les will be created. According to a 
DG Sanco representative, a single set of profi les may be too rigid but on the other hand, 
an excessive number of food categories could be rather unmanageable. A solution might lie 
in combining an overall nutrient profi le with derogations, adjustments and exemptions for a 
limited number of categories of foods or individual foods. These could be identifi ed by taking 
account of Article 4(1): “(b) the role and importance of the food […] and the contribution 
to the diet […] (c) […] the presence of nutrients that have been scientifi cally recognised as 
having an effect on health.”1149
According to a German government agency, there is no need to elaborate nutrient profi les 
for food categories that only include primary agricultural products (e.g. fi sh, meat, fruit or 
vegetables)1150. The Commission seems to share this view, as a Commission representative 
suggests setting profi les for the following food categories:
Vegetab le oils1) 
Spreadable fats2) 
Dairy products3) 
Cereal products (bread, breakfast cereals)4) 
Fruit products5) 
Other foods6) 1151.
It might be necessary to set up separate categories also for ready meals (including soups, pizza 
etc.), beverages (non-alcoholic), and desserts, snacks and sweets.1152
Nutrient profi les include several diffi cult questions: The balance of nutrients in the whole 
diet must be taken into account. A benefi cial nutrient such as calcium or fi bre might balance the 
effect of a fat or a sugar. There is a lack in uniformity regarding portion sizes, and diets vary 
among European food cultures. Grouping nutrients as ‘good’ or ‘bad’ is too straightforward. 
1148  Regulation 1924/2006/EC, Article 4(1).
1149  Didion 2007. 
1150  Bundesinstitut für Risikobewertung: Nutrient Profi les. The Precondition for Health Claims. Updated 
Position Paper 12 March 2007. 
1151  Didion 2007.
1152  The Finnish “Report on health claims used in marketing of foodstuffs in Finland”, page 22, classifi es food 
products into the following 12 categories:
Milk and milk products1) 
Cheese and cheese-like products2) 
Meat, poultry, eggs, charcuterie products3) 
Fish and fi sh products4) 
Cereal products5) 
Vegetables, fruits and berries6) 
Ready meals7) 
Vegetable oils8) 
Spreadable oils9) 
Beverages10) 
Desserts, snacks and sweets11) 
Others.12) 
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For example all trans-fatty acids are not harmful. The nutrient profi les established by the 
Commission will undoubtedly be controversial and raise criticism. Nutrient profi les and their 
conditions of use shall be updated to take into account relevant scientifi c developments in 
accordance with the Committee procedure and after consultation of interested parties, in 
particular food business operators and consumer groups1153.
Previously, claims have been allowed if they are true. Now the food must additionally 
be healthy as a whole. Evaluating the food as a whole takes the prohibition of misleading 
advertising to a new level. Now the consumer does not have to weigh the benefi t of the claim 
to some unhealthy features of the food. Conversely, the consumer cannot use health claims 
as guidance on which unhealthy product to choose. The nutrient profi le approach is more 
paternalistic than the previous system, but is justifi ed because of the diffi culties in evaluating 
the issues of nutrition.
In making up the profi les, some products will end up being ‘bad’ in a sense that nothing good 
can be said about them. The prohibition to make claims might sound unfair to producers of various 
products, such as producers of functional confectionary. It seems that public health concerns 
overweigh freedom of speech. Unhealthy food producers are becoming legally equated with 
tobacco and alcohol producers. Tobacco and alcohol are legal products. Still, marketers have very 
limited space: there are restrictions, limitations, and obligations. Tobacco and alcohol companies 
have no real right to freely sell their products, which is no longer questioned.
5.3.3.3.2 The Derogation
By way of derogation from the rule described above, nutrition claims (it is important to notice 
that the exception does not apply to health claims):
referring to “(a) the reduction of fat, saturated fatty acids, trans-fatty acids, sugars and salt/
sodium shall be allowed without reference to a profi le for the specifi c nutrient/s for 
which the claim is made, ... 
 shall be allowed, where (b) a single nutrient exceeds the nutrient profi le provided that a 
statement about the specifi c nutrient appears in close proximity to, on the same side and 
with the same prominence as the claim. This statement shall read as follows: “High [the 
name of the nutrient exceeding the nutrient profi le] content”1154.
Point (a) means that one can claim ‘reduced amount of harmful nutrient’ even if the product 
does not fi t the profi le.
Point (b) is more controversial. It means that if a nutrient profi le, for example, includes 
limits for fat, salt, and sugar, and the product exceeds one of the three limits, it can still bear 
nutrition claims, for example, “low-fat” or “high in fi bre”.
Prior to Parliament’s second reading vote in May 2006, “a slight amendment to Article 4 
was agreed between Council and Parliament, whereby a nutrition claim will still be permitted 
if only one nutrient (e.g. salt, sugar or fat) exceeds the limit of the nutritional profi le”1155. This 
1153  Regulation 1924/2006/EC, Article 4(1).
1154  Regulation 1924/2006/EC, Article 4(2).
1155  European Commission Press release IP/06/625, 16/05/2006.
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“slight amendment” is a political compromise and the requirement for a healthy nutritional 
profi le is not fully realised. The preambles of the Regulation do not explain the derogation. 
The derogation would sound strange to a nutritional scientist, as it seems to dilute the whole 
idea of only healthy products having claims. Why draw up a nutritional profi le, if the product 
does not have to fi t that profi le? The amendment saved a lot of products: for instance, a ready-
made meal that has a lot of saturated fats but no salt or sugar might be able to bear claims 
relating to the low amounts of salt and sugar. Of course, the derogation was created precisely 
for this reason: to allow important product groups to derogate. For a scientist, legislation 
creates artifi cial boundaries. For a politician, legislation creates necessary compromises.
The derogation led to the need to indicate the remaining unhealthy ingredient. According 
to the agreed rule, the high level of the substance exceeding the nutritional profi le limit must 
be clearly marked on the label, close to and with the same prominence as the claim. This leads 
to unclear messages on labels, for example, a product might have a claim “low fat” next to 
the text “high in sugar”. How will a consumer react? After reading the regulation carefully, he 
would be able to determine that the product is high in sugar but low in fat and also low in other 
harmful nutrients. But the consumer will not be able to determine whether the excess amount 
of sugar makes the product unhealthy as a whole.
In practice, the derogation creates a situation where there are in practice alternative 
nutritional profi les which the product must fulfi ll. These alternatives are certainly not 
equivalent according to nutritional science. For example, popcorn with salt and popcorn with 
sugar are not equivalent although they both have one ingredient that is not healthy. On the 
other hand, this simplistic and unscientifi c thinking is close to the procedures that a consumer 
may consider: “today I avoid sugar, tomorrow I avoid salt”. The consumer does not know 
exactly how each dietary change effects her health, but she might want to take steps in the 
right direction by purchasing a product that “does something right”.
Concerning nutrition claims, the message given to the food industry is that as long as they 
put something good in the food products, products are OK. It would have been a lot stricter - 
and clearer - if they had to make the products healthy as a whole before they could attach any 
nutrition claims to them.
5.3.3.4 Nutrition Claims
According to European defi nition,” nutrition claim” means any claim, which states, suggests 
or implies that a food has particular benefi cial nutritional properties due to:
the energy (calorifi c value) it(a) 
provides;(i) 
provides at a reduced or increased rate; or(ii) 
does not provide; and/or(iii) 
the nutrients or other substances it(b) 
contains;(i) 
contains in reduced or increased proportions; or(ii) 
does not contain(iii) 1156.
1156  Regulation 1924/2006/EC, Article 2(2)(4).
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The new Regulation 1924/2006/EC lays down strict conditions for the use of nutritional claims 
such as “low fat”, “high fi bre” or “reduced sugar”. Nutrition claims shall only be permitted if 
they are listed in the Annex and are in conformity with the conditions set out in the Regulation. 
Amendments to the Annex shall be adopted in accordance with the committee procedure and, 
where appropriate, after consulting the EFSA.1157
The following nutrition claims and the conditions for their use are listed in the Annex:
“low calorie” – 1158,
“ reduced calorie” – 1159,
“calorie-free” – 1160,
“low fat” – 1161,
“fat-free” – 1162,
“low saturated fat” – 1163,
“saturated fat-free” – 1164,
“low sugars” – 1165,
“sugar-free” – 1166,
1157  Regulation 1924/2006/EC, Article 8.
1158  “A claim that a food is low in calorie, and any claim likely to have the same meaning for the consumer, 
may only be made where the product does not contain more than 40 kcal (170 kJ)/100 g for solids or more 
than 20 kcal (80 kJ)/100 ml for liquids. For table-top sweeteners the limit of 4 kcal (17 kJ)/portion, with 
equivalent sweetening properties to 6 g of sucrose (approximately 1 teaspoon of sucrose), applies.”
1159  A claim that a food is reduced-calorie, and any claim likely to have the same meaning for the consumer, 
may only be made where the caloric value is reduced by at least 30 %, with an indication of the characteristic(s) 
which make(s) the food reduced in its total caloric value.
1160  A claim that a food is calorie free, and any claim likely to have the same meaning for the consumer, may 
only be made where the product does not contain more than 4 kcal (17 kJ)/100 ml. For table-top sweeteners 
the limit of 0.4 kcal (1.7 kJ)/portion, with equivalent sweetening properties to 6 g of sucrose (approximately 
1 teaspoon of sucrose), applies.
1161  A claim that a food is low in fat, and any claim likely to have the same meaning for the consumer, may 
only be made where the product contains no more than 3 g of fat per 100 g for solids or 1.5 g of fat per 100 
ml for liquids (1.8 g of fat per 100 ml for semi-skimmed milk).
1162  A claim that a food is fat-free, and any claim likely to have the same meaning for the consumer, may only 
be made where the product contains no more than 0.5 g of fat per 100 g or 100 ml. However, claims expressed 
as “X % fat-free” shall be prohibited.
1163  A claim that a food is low in saturated fat, and any claim likely to have the same meaning for the 
consumer, may only be made if the sum of saturated fatty acids and trans-fatty acids in the product does not 
exceed 1.5 g per 100 g for solids or 0.75 g/100 ml for liquids and in either case the sum of saturated fatty acids 
and trans-fatty acids must not provide more than 10 % of energy.
1164  A claim that a food does not contain saturated fat, and any claim likely to have the same meaning for the 
consumer, may only be made where the sum of saturated fat and trans-fatty acids does not exceed 0.1 g of 
saturated fat per 100 g or 100 ml.
1165  A claim that a food is low in sugars, and any claim likely to have the same meaning for the consumer, may 
only be made where the product contains no more than 5 g of sugars per 100 g for solids or 2.5 g of sugars 
per 100 ml for liquids.
1166  A claim that a food is sugar-free, and any claim likely to have the same meaning for the consumer, may 
only be made where the product contains no more than 0.5 g of sugars per 100 g or 100 ml.
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“with no added sugars” – 1167,
“low sodium/salt” – 1168,
“very low sodium/salt” – 1169,
“sodium-free or salt-free” – 1170,
“source of fi bre” – 1171,
“high fi bre” – 1172,
“source of protein” – 1173,
“high protein” – 1174,
“source of [name of vitamin/s] and/or [name of mineral/s]” – 1175, 
“high [name of vitamin/s] and/or [name of minerals]” – 1176,
“contains [name of the nutrient or other substance]” – 1177,
1167  A claim stating that sugars have not been added to a food, and any claim likely to have the same meaning 
for the consumer, may only be made where the product does not contain any added mono- or disaccharides 
or any other food used for its sweetening properties. If sugars are naturally present in the food, the following 
indication should also appear on the label: “CONTAINS NATURALLY OCCURRING SUGARS”.
1168  A claim that a food is low in sodium/salt, and any claim likely to have the same meaning for the consumer, 
may only be made where the product contains no more than 0.12 g of sodium, or the equivalent value for salt, 
per 100 g or per 100 ml. For waters, other than natural mineral waters falling within the scope of Directive 
80/777/EEC, this value should not exceed 2 mg of sodium per 100 ml.
1169  A claim that a food is very low in sodium/salt, and any claim likely to have the same meaning for the consumer, 
may only be made where the product contains no more than 0.04 g of sodium, or the equivalent value for salt, per 
100 g or per 100 ml. This claim shall not be used for natural mineral waters and other waters.
1170  A claim that a food is sodium-free or salt-free, and any claim likely to have the same meaning for the 
consumer, may only be made where the product contains no more than 0.005 g of sodium, or the equivalent 
value for salt, per 100 g.
1171  A claim that a food is a source of fi bre, and any claim likely to have the same meaning for the consumer, may 
only be made where the product contains at least 3 g of fi bre per 100 g or at least 1.5 g of fi bre per 100 kcal.
1172  A claim that a food is high in fi bre, and any claim likely to have the same meaning for the consumer, may 
only be made where the product contains at least 6 g of fi bre per 100 g or at least 3 g of fi bre per 100 kcal.
1173  A claim that a food is a source of protein, and any claim likely to have the same meaning for the consumer, 
may only be made where at least 12% of the energy value of the food is provided by protein.
1174  A claim that a food is high in protein, and any claim likely to have the same meaning for the consumer, 
may only be made where at least 20% of the energy value of the food is provided by protein.
1175  A claim that a food is a source of vitamins and/or minerals, and any claim likely to have the same meaning 
for the consumer, may only be made where the product contains at least a signifi cant amount as defi ned in the 
Annex to Directive 90/496/EEC or an amount provided for by derogations granted according to Article 6 of 
Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the 
addition of vitamins and minerals and of certain other substances to foods.
1176  A claim that a food is high in vitamins and/or minerals, and any claim likely to have the same meaning 
for the consumer, may only be made where the product contains at least twice the value of “source of [name 
of vitamin/s] and/or [name of mineral/s]”.
1177  A claim that a food contains a nutrient or another substance, for which specifi c conditions are not laid 
down in this Regulation, or any claim likely to have the same meaning for the consumer, may only be made 
where the product complies with all the applicable provisions of this Regulation, and in particular Article 5. 
This means there must be suffi cient quantities of the nutrient present to make a benefi cial effect. For vitamins 
and minerals the conditions of the claim “source of” shall apply.
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“increased [name of the nutrient]” – 1178, 
“reduced [name of the nutrient]” – 1179,
“light/lite” – 1180, 
“naturally/natural” – 1181.
The claim “as much as” is not in the Annex of the Regulation and is consequently not allowed. 
Neither is the claim “super light”.1182
The comparative nutrition claims listed in the annex are the following: “increased [name 
of the nutrient]”, “reduced [name of the nutrient]”, “ reduce calorie” and “light”. With regard 
to comparative nutrition claims, a comparison may only be made between foods of the same 
category, taking into consideration a range of foods of that category1183. The food shall be 
compared to foods that do not have a composition, which allows them to bear a claim, including 
foods of other brands. The difference in the quantity of a nutrient and/or the energy value shall 
be stated, and the comparison shall relate to the same quantity of food. 1184
The Scientifi c Committee on Food Safety and Animal Health has in its Guidance Document 
of December 2007 defi ned more precise rules for comparative nutrition claims. “Same 
category” means that products are similar in terms of nutritional content1185. “Dairy products” 
is too wide a category as milk and cheese cannot be compared but “Milks” can be compared 
with other milks, and “cheeses” with other cheeses.1186
It should be noted that the claim “contains” could also be interpreted as a health claim. 
The Committee Guidance states that while the claim “contains” is normally a nutrition claim, 
in some cases the use of the term “contains” refers to “groups of substances with a specifi c 
functional effect”. In such cases, the “contains” claim is a health claim and must be authorised 
accordingly.1187 Regardless of whether “contains” claims are judged as nutrition claims or 
health claims, the general requirements on claims apply. This means that the substance subject 
to the claim is present in a signifi cant quantity and has been shown to have a benefi cial 
1178  A claim stating that the content in one or more nutrients, other than vitamins and minerals, has been 
increased, and any claim likely to have the same meaning for the consumer, may only be made where the 
product meets the conditions for the claim “source of” and the increase in content is at least 30% compared 
to a similar product.
1179  A claim stating that the content in one or more nutrients has been reduced, and any claim likely to 
have the same meaning for the consumer, may only be made where the reduction in content is at least 30% 
compared to a similar product, except for micronutrients, where a 10% difference in the reference values as 
set in Directive 90/496/EEC shall be acceptable, and for sodium, or the equivalent value for salt, where a 25 
% difference shall be acceptable.
1180  A claim stating that a product is “light” or “lite”, and any claim likely to have the same meaning for 
the consumer, shall follow the same conditions as those set for the term “reduced”; the claim shall also be 
accompanied by an indication of the characteristic(s) which make(s) the food “light” or “lite”.
1181  Where a food naturally meets the condition(s) laid down in this Annex for the use of a nutritional claim, 
the term “naturally/natural” may be used as a prefi x to the claim.
1182  This guidance for given in the December 2007 Guidance by the Scientifi c Committee on Food Health 
and Animal Health, page 7.
1183  This means the marketer cannot choose a suitable product against which to make the comparison.
1184  Regulation 1924/2006 EC, Article 9.
1185  Scientifi c Committee Claim Guidance 2007, 7.
1186  Scientifi c Committee Claim Guidance 2007, 8.
1187  Scientifi c Committee Claim Guidance 2007, 11.
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nutritional or physiological effect. One also has to keep in mind that the use of any claim 
triggers the nutrition labelling requirement discussed above in chapter 5.2.1.3.1188
The Guidance gives examples of “contains” claims that are interpreted as nutrition claims 
and “contains” claims that are interpreted as health claims. A claim is a nutrition claim if in 
the naming of the substance or category of substances, there is only factual information, for 
example: “contains lycopene”, and “contains lutein”.1189
A claim is a health claim if in the naming of the substance or category of substances, there 
is a description or indication of functionality or an implied effect on health. For example 
“contains antioxidants” will be interpreted as a health claim, because the function is an 
antioxidant effect. “Contains probiotics/prebiotics” will be interpreted as a health claim, 
because the reference to probiotic/prebiotic implies a health benefi t. “With prebiotic fi bres” or 
“contains prebiotic fi bres” will be interpreted as health claims, because by using an adjective, 
they describe a nutrient or a substance and thus refer to functionality.1190
The distinction between a nutrition claim and a health claim does not seem clear after 
all. It is diffi cult to separate between substances the mentioning of which does not imply any 
function, and the mentioning of which does. After all, many nutrients and substances have 
necessary and thus benefi cial functions in the body, and the advances in nutritional science 
keep providing us with more and more information on these diet-health connections. This 
might lead to a situation where mentioning any nutrient will be considered a health claim and 
the need for a legal concept such as ‘nutrition claim’ will cease to exist.
5.3.3.5 Health Claims
5.3.3.5.1 General Requirements for the Use of Health Claims
“Health claim” means any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health1191. “Reduction of disease 
risk claim” is a subcategory of “health claim”. It means any health claim that states, suggests or 
implies that the consumption of a food category, a food or one of its constituents signifi cantly 
reduces a risk factor in the development of a human disease1192.
Health claims are prohibited unless they A) comply with the general requirements for 
claims (for example the nutrition profi le), B) comply with the specifi c requirements for health 
claims, C) are authorised in accordance with the Regulation, and D) are included in the lists 
of authorised claims.1193 There are two authorisation routes and lists for claims. The list of 
established claims will be created according to Article 13, and a list of novel claims pursuant 
to Article 14. The authorisation procedures for including claims on the lists are stipulated by 
1188  Scientifi c Committee Claim Guidance 2007, 11.
1189  Scientifi c Committee Claim Guidance 2007, 11.
1190  Scientifi c Committee Claim Guidance 2007, 11.
1191  Regulation 1924/2006/EC, Article 2(2)(5).
1192  Regulation 1924/2006/EC, Article 2(2)(6).
1193  Regulation 1924/2006/EC, Article 10(1).
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Articles 15, 16, 17 and 18. These procedures will be discussed above in detail. Article 19 
concerns modifi cation, suspension and revocation of authorisations1194.
When using health claims, one must always provide the consumer with additional 
information. Health claims shall only be permitted if the following information is included in 
the labelling, or if no such labelling exists, in the presentation and advertising:
a statement indicating the importance of a varied and balanced diet and a healthy (a) 
lifestyle;
the quantity of the food and pattern of consumption required to obtain the claimed (b) 
benefi cial effect;
where appropriate, a statement addressed to persons who should avoid using the food; (c) 
and
an appropriate warning for products that are likely to present a health risk if consumed (d) 
to excess.1195
It is prohibited to use health claims suggesting that health could be affected by not consuming 
the food1196. Reference to general, non-specifi c benefi ts of the nutrient or food for overall good 
health or health-related well-being may only be made if accompanied by a specifi c health 
claim included in the Community lists.1197
National rules on recommendations of national associations of medical, nutrition or dietetic 
professionals and health-related charities may apply in the absence of specifi c Community 
rules1198. It is prohibited to use claims making reference to other associations, and claims 
making reference to recommendations of individual doctors or health professionals1199.
There is also one particular claim type that is prohibited: claims that make reference to 
the rate or amount of weight loss1200. Commission Directive 96/8/EC on dietetic foods for 
weight reduction had previously prohibited this type of claims. It was considered appropriate 
to extend this restriction to all foods. See chapter 5.2.1.4. on marketing of dietetic products.
Other controversial claim types such as psychological and behavioural claims were not 
prohibited but it was clearly stated that scientifi c substantiation is required to back up these 
1194  The applicant or a user of a claim included in the lists may apply for a modifi cation of the relevant 
list. The regular procedures for claim approval apply. Modifi cation, suspension and revocation of authorised 
claims can be initiated by the EFSA, a Member State of the Commission. The EFSA shall issue an opinion 
on whether a health claim included in the lists still meets the conditions laid down in the Regulation. It shall 
transmit its opinion to the Commission, the Member States and, where relevant, to the original applicant of the 
claim in question. The Authority shall make its opinion public. The applicant/user or a member of the public 
may make comments to the Commission within 30 days of such publication. The Commission shall examine 
the opinion of the Authority and any comments received as soon as possible. If appropriate, the authorisation 
shall be modifi ed, suspended or revoked in accordance with the Committee procedure.
1195  Regulation 1924/2006/EC, Article 10(2).
1196  Regulation 1924/2006/EC, Article 12(a).
1197  Regulation 1924/2006/EC, Article 10(3).
1198  Regulation 1924/2006/EC, Article 11.
1199  Regulation 1924/2006/EC, Article 12(c).
1200  Regulation 1924/2006/EC, Article 12(b).
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claims1201. This means for example that claims stating “refreshing”, “helps you concentrate”, 
“helps you sleep” cannot be used without fulfi lling all the requirements for health claims. 
Claims related to children were also not prohibited. This was another controversial issue. 
Instead, claims were subject to a more stringent Article 14 procedure.
5.3.3.5.2 ‘Function’ Claims
Article 13 of the Regulation creates the authorisation procedure for health claims other than 
those referring to the reduction of disease risk and to children’s development and health. 
These are health claims describing or referring to:
the role of a nutrient or other substance in growth, development and the functions of (a) 
the body; or
psychological and behavioural functions; or(b) 
slimming (c) or weight-control or a reduction in the sense of hunger or an increase in the 
sense of satiety or the reduction of the available energy from the diet1202.
The European scientifi c community has started to call these health claims “function” claims1203. 
These claims are legal without product-specifi c authorisation, if they are on the Community 
list of established claims. Claims can only be included in the list if they are:
based on generally accepted scientifi c evidence; and(i) 
well understood by the average consumer.(ii) 1204
These types of claims can be such as: ‘ingredient A of this product promotes bowel movement’, 
‘compound B reinforces bones’, ‘raw material C refreshes’ and ‘raw material D of the product 
increases the sense of satiety and supports weight control’1205.
The Commission shall adopt, in accordance with the Committee procedure, a positive 
Community list of well-established claims by 31 January 2010 at the latest.1206 This list of 
permitted claims will include all the necessary conditions for the use of these claims. Before 
the adoption of the list by the Commission, the EFSA will evaluate the scientifi c evidence of 
the claims. The claims on the list may be used on a label as long as they are proven to apply 
to the food in question.
It is not an easy task to produce the list of established claims. By 31 January 2008, Member 
States had to submit to the Commission a list of claims approved at national level. This 
1201  Regulation 1924/2006/EC, preamble 24. “There are many factors, other than dietary ones, that can 
infl uence psychological and behavioural functions. Communication on these functions is thus very complex 
and it is diffi cult to convey a comprehensive, truthful and meaningful message in a short claim to be used in 
the labelling and advertising of foods.”
1202  Without prejudice to Directive 96/8/EC.
1203  See presentations at NHClaims Congress in Naantali, Finland 7 – 9 November 2007, http://congress.
utu.fi /NHC2007/presentations.php.
1204  Regulation 1924/2006/EC, Article 13(1).
1205  Report on health claims used in marketing of foodstuffs in Finland. Page 4.
1206  Regulation 1924/2006/EC, Article 13(3).
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means claims that are based on generally accepted scientifi c evidence and well understood 
by consumers, and thus deemed acceptable by national authorities. The national list of claims 
shall be accompanied by the conditions applying to the claims and by reference to the relevant 
scientifi c justifi cation.1207 The Commission received similar proposals from all the 27 EU 
Member States by the beginning of 2008. This means the EFSA and the Commission will have 
2 years, beginning in 2008 when the national reports arrive, to compile the EU list.
To predict what the Community list will look like, we now take a look at the contents of the 
Finnish list. The Food Safety Authority1208 and the Ministry of Trade and Industry produced 
the Finnish list. Health claims are widely used in Finland, but previously there has not been 
a national list of accepted claims. The Authority collected information on health claims by 
using a questionnaire on its web page1209. Disease risk reduction claims were not included; 
as they are a separate issue, see below. A total of 625 questionnaires were returned by the 
deadline. Preliminary results of the replies were presented and discussed in a seminar held in 
December 2006. The fi nal report of the study was presented to the Finnish Ministry of Trade 
and Industry in January 2007. The Finnish proposal for acceptable claims and the relevant 
scientifi c justifi cation will be sent to the Commission by the Ministry of Trade and Industry at 
the beginning of 2008. 1210
The Finnish report, a 316-page document of applicable health claims1211 is based on the 
information received from entrepreneurs, and includes numerous scientifi c references. Based 
on this data, the Finnish authorities prepared their list and sent it to the Commission. If we look 
at the Finnish report, we can understand the challenge faced by the EFSA and the Commission. 
We can also fi nd out the most popular claims and the products that typically generate these 
claims.
Consequently, half of the foodstuffs declared were food supplements and about half were 
conventional foodstuffs1212. This means that from a marketing point of view, health claims are 
equally important to functional food and food supplement businesses. There were altogether 
269 substances or combinations of substances, pertaining to which claims were presented1213.
Of the different categories of Article 13 claims, claims describing the role of a nutrient in growth, 
development and/or the functions of the body represented 88% of the claims. Psychological and 
behavioural claims made up 5% and weight-loss claims 7% of the total. The last group includes 
1207  Regulation 1924/2006/EC, Article 13(2).
1208  In Finnish: Elintarviketurvallisuusvirasto, Evira.
1209  The internet questionnaire was on the Evira web page from March 2006 until August 2006, and again in 
October 2006 because of several inquiries. 
1210  Food Safety Agency web page at: http://www.evira.fi /portal/en/food/current_issues/?id=349.
1211  Information on what types of product are used in the claims, and on the scientifi c justifi cation on which 
the claims are based according to the respondents, can be found in the detailed Finnish report (Vaihia K. 
- Sarlio-Lähteenkorva S.: Selvitys Suomen elintarvikemarkkinoilla käytettävistä terveysväitteistä. Eviran 
julkaisuja 8/2007, 316 pages, available at: http://www.palvelu.fi /evi/fi les/55_519_486.pdf. Report on health 
claims used in marketing of foodstuffs in Finland. (English summary, 146 pages) available at: http://www.
palvelu.fi /evi/fi les/55_519_492.pdf.
1212  Report on health claims used in marketing of foodstuffs in Finland, 10.
1213  We need to remember that this fi gure includes only health claims that are not related to reduction of 
disease risk or children’s development. Nutrition claims and medicinal claims are naturally also excluded 
from this fi gure.
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claims that relate to slimming, weight control, a reduction in the sense of hunger, an increase in the 
sense of satiety, or a reduction of the available energy from the diet.1214
The claims are typically used at least in labelling and advertising. Health claims were used 
on labels in 96% of the cases, and in brochures or advertising in 99.7% of the cases. Claims 
are also frequently used in expert material (86% of the cases), and also with other marketing 
channels such as fairs or product presentations (54%).1215
Health claims were made in relation to a total of 269 different compounds, foodstuffs 
and ingredient combinations. Almost every product had some kind of scientifi c evidence to 
back up the claim. Only 4 of 625 claims were not based on any kind of science. The scientifi c 
evidence backing the claims varied in type. Evidence ranged from clinical trials of the product 
itself (22%) to clinical trials of a corresponding product (53%) to research of the ingredient 
(65%). Half of the claims were also backed up by general textbook information.1216 All in all, 
the Finnish claims seem to have a fairly sound scientifi c basis. This information could predict 
that most of the Finnish claims will be accepted and established by the Community list.
The Finnish claims were classifi ed using the PASSCLAIM project classifi cation1217. 
However, there were also claims, which did not fi t into any of the Passclaim categories. The 
Passclaim categories are the following:
Diet-related cardiovascular disease1. 
Bone health and osteoporosis2. 
Physical performance and fi tness3. 
Body weight regulation, insulin sensitivity and diabetes risk4. 
Diet-related cancer5. 
Mental state and performance6. 
Gut health and immunity.7. 1218
The greatest number of claims was related to cardiovascular health, especially to cholesterol 
and blood pressure. There were also claims on other fat values in the blood, the circulation, 
the vascular system and blood clotting, homocysteine metabolism, as well as general 
cardiovascular health. For example, cholesterol control claims are used on pectin in natural 
berries, and cholesterol reduction claims on blackcurrant seed oil combined with vitamin E, 
soluble plant and berry fi bre, and linolenic acid in sea buckthorn berries.1219 Blood pressure 
claims were made on sodium in natural berries1220. General cardiovascular claims were made 
on sea buckthorn berry oil, hawthorn, and blackcurrant seed oil combined with vitamin E1221.
1214  Report on health claims used in marketing of foodstuffs in Finland 2007, 10.
1215  Report on health claims used in marketing of foodstuffs in Finland 2007, 10.
1216  Report on health claims used in marketing of foodstuffs in Finland 2007, 10.
1217  PASSCLAIM was a European Commission Concerted Action Programme in the years 2001-2005 carried 
out by the International Life Science Institute (ILSI) Europe. The fi nal reports of the project are available at 
Passclaim website http://europe.ilsi.org/activities/ecprojects/PASSCLAIM/. 
1218  Report on health claims used in marketing of foodstuffs in Finland, page 10.
1219  There are basically two types of cholesterol claims: claims which refer to the control of cholesterol and 
claims which refer to the reduction of cholesterol or the LDL/HDL ratio. Report on health claims used in 
marketing of foodstuffs in Finland 2007, 11-12.
1220  Report on health claims used in marketing of foodstuffs in Finland 2007, 13.
1221  Report on health claims used in marketing of foodstuffs in Finland 2007, 13-14.
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Many claims were also linked to carbohydrate metabolism and weight control, gut health 
and immunity, and general immunity. Claims on carbohydrate metabolism and/or insulin 
sensitivity were made for example on soluble plant and berry fi bre. Gut health claims were 
made on sea buckthorn berry oil, fruit and berry juice fi bre, and natural berry fi bre.1222 Claims 
on general immunity were made on blackcurrant seed oil and sea buckthorn berry oil1223.
Other important claim categories were claims related to the musculoskeletal system and 
mental health, and claims related to antioxidation. Other claims were on physical performance, 
oral and dental health, skin, hair and nail health, and eye health. Claims related to antioxidation 
were presented as only one factor among other principal claims. For example, a claim linked 
to cardiovascular health may be made, and in addition it is stated that the substance in question 
is also an antioxidant. Antioxidant claims were made on berry and fruit juices, berry seed oils, 
bilberry, forest bilberry, cranberry extract, fl avonoids extracted from sea buckthorn oil and sea 
buckthorn berry, and phenolic compounds of cranberry and lingonberry.1224
When deciding the claims to be put on the list of established claims, the most important 
question is the level of scientifi c evidence needed. The Finnish food industry is of the view 
that with Article 13 claims, textbook data and nutrition references should suffi ce, and no new 
scientifi c studies on the product itself should be required. The food supplement industry wishes 
that studies carried out with ingredients should suffi ce. The entrepreneurs acknowledge the 
need for product-specifi c proof on Article 14 claims, i.e. claims pertaining to the reduction of 
the risk of disease and the health and development of children.1225 The Finnish list was based 
on fairly strict scientifi c criteria, as Finnish scientists share the view that claims must not be 
approved without convincing evidence. However, the Commission seems to be even stricter 
and in autumn 2008 it seems that few Finnish claims will be accepted. It remains to be seen 
whether the fi nished Community list will be very short and abolish many of the health claims 
that are currently used.
After discussing the process for establishing the Community list, we now turn to legal 
issues related to adding claims to the list after 2010. An application is needed for these claims, 
which are: 
based on newly developed scientifi c evidence and/or a) 
which include a request for the protection of proprietary data.b) 
Any Article 13 claims submitted to the EU list after the publication of the fi rst list in 2010 will 
have to be examined by the EFSA and approved by the Commission and Member States1226. 
A food business operator intending to use a health claim not included in the Article 13 list 
may apply for the inclusion of the claim in that list1227 according to the procedure stipulated in 
Article 18 of the Regulation. Article 18 applies to claims that are based on newly developed 
scientifi c evidence and/or include a request for the protection of proprietary data1228.
1222  Report on health claims used in marketing of foodstuffs in Finland 2007, 17.
1223  Report on health claims used in marketing of foodstuffs in Finland 2007, 20.
1224  Report on health claims used in marketing of foodstuffs in Finland 2007, 20.
1225  Report on health claims used in marketing of foodstuffs in Finland 2007, 24.
1226  Through the Committee procedure according to Article 25 of the Regulation.
1227  Regulation 1924/2006/EC, Article 18(1).
1228  Article 13(5) of the Regulation.
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The application for the inclusion shall be submitted to the national competent authority 
of a Member State. The application shall include the reasons for the request, along with the 
following data:
the name and address of the applicant;(a) 
the nutrient or other substance, or the food or the category of food, in respect of which (b) 
the health claim is to be made and its particular characteristics;
a copy of the studies, including, where available, independent, peer-reviewed studies, (c) 
which have been carried out with regard to the health claim and any other material which 
is available to demonstrate that the health claim complies with the criteria provided for 
in this Regulation;
where appropriate, an indication of the information which should be regarded as (d) 
proprietary accompanied by verifi able justifi cation;
a copy of other scientifi c studies which are relevant to that health claim;(e) 
a proposal for the wording of the health claim for which authorisation is sought (f) 
including, as the case may be, specifi c conditions for use;
a summary of the application.(g) 1229
The Member State will send the application to the EFSA to be assessed, and to the Commission 
and the Member States for information. The EFSA shall perform scientifi c assessment of 
the claim (within fi ve months) and subsequently issue its opinion to the applicant, to the 
Commission and to the Member States, and publish it.1230
If the EFSA opinion is in favour of the applicant, the Commission shall take a decision on 
the application (within two months), taking into account:
the EFSA opinion, –
any relevant provisions of Community law, –
other legitimate factors –  relevant to the matter under consideration, and
results of consultation with the Member States. – 1231
According to the EFSA pre-submission guidance of March 2007 (revised August 2007), Article 
18 procedure is not applicable before the aforementioned Community list of permitted health 
claims is adopted.1232 This would have meant January 2010. However, the EFSA seems to have 
changed their mind and started to take in Article 18 applications already in February 2008. This 
is confi rmed by the December 2007 Guidance from the Scientifi c Committee on Food Safety and 
Animal Health of the European Commission1233: “From 1 February 2008 Member States can send 
valid applications to the EFSA for the scientifi c assessment in accordance with Article 18(3)”. 
However, the EFSA has not yet given guidance on how to draft Article 18 claims.
1229  Regulation 1924/2006/EC, Article 15(3).
1230  Regulation 1924/2006/EC, Article 18(3).
1231  Regulation 1924/2006/EC, Article 18(4).
1232  EFSA Pre-submission Guidance for Applicants Intending to Submit Application for 
Authorisation of Health Claims made on Foods. Publication Date: 14 March 2007 Last updated 
(Rev.): 8 August 2007, page 4.
1233  Scientifi c Committee Claim Guidance 2007, 12.
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Article 18 is similar to Article 13, with the exception that the evidence submitted is “newly 
developed scientifi c evidence.” The legislation does not defi ne “new”, but it is understood as 
scientifi c evidence developed after January 31, 2008 (the deadline for Article 13 submissions). 
Because the EFSA started to grant applications via the Article 18 route from the beginning of 
February 2008, some companies might consider withdrawing under Article 13 and resubmitting 
under Article 18. This is because the Article 18 procedure is faster than the Article 13 procedure 
as the EFSA and the Commission will have to abide by the time limits of fi ve and two months. 
However, if the data was published by either an applicant or a third party before January 31, 
2008, the data is not ‘new’ and therefore belongs under Article 13.1234 If the claim is based on 
proprietary data, Article 18 applies regardless of the time when the data was established.
Like the borderline between nutrition claims and function claims, the borderline between 
function claims and disease risk reduction claims has also already shown to be problematic. 
The Commission Scientifi c Committee Guidance of December 20071235 clarifi es the issue: 
If a risk factor of a disease is merely mentioned, without stating, suggesting or implying its 
reduction, the claim should be considered a function claim (Article 13 claim). An example of a 
function claim is given: maintains [naming normal vital function of the body]. If reduction of 
a disease risk factor is claimed, the claim should be considered an Article 14 claim regardless 
of whether the name of the disease itself is mentioned. An example is given: lowers [naming 
risk factor].1236
5.3.3.5.3 Article 14: Disease Risk Reduction Claims and Claims Related to Children’s Health
As stated above, two Community lists of authorised claims will be created. The list based 
on Article 14 will include reduction of disease risk claims and claims relating to children’s 
development and health. These claims are evaluated by EFSA according to the procedure laid 
down in Articles 15, 16, 17 and 19 of the Regulation. These claims may be made only if they 
have been authorised according to the relevant procedure and included in the Community list 
for such claims. The list of claims will include the conditions for the use of the claims.1237 The 
claims are of the type ‘compound A reduces the risk of heart disease’.
In addition to the general requirements for claims and general requirements for health 
claims, reduction of disease risk claims must be joined with another additional piece of 
information: The labelling, presentation or advertising shall bear a statement indicating that 
the disease to which the claim is referring has multiple risk factors and that altering one of 
these risk factors may or may not have a benefi cial effect.1238
Article 15 of the Regulation stipulates the details of the application for authorisation. The 
application shall be sent to the national competent authority of a Member State. The national 
competent authority shall send the application as a whole to EFSA. EFSA shall send the application 
to other Member States and the Commission, and publish the summary of the application.
1234  Tallon 2008. 
1235  Guidance on the Implementation of Regulation N° 1924/2006 on Nutrition and Health Claims Made on 
Foods. Conclusions of the Standing Committee on the Food Chain and Animal Health. 14 December 2007.
1236 Scientifi c Committee Claim Guidance 2007, page 13.
1237  Regulation 1924/2006/EC, Article 14(2).
1238  Regulation 1924/2006/EC, Article 14(2).
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The EFSA has provided guidance on the details of the application. The EFSA published 
its much-anticipated guidelines on disease risk reduction claims in July 20071239. The 44-page 
document, prepared by the Scientifi c Panel on Dietetic Products, Nutrition, and Allergies, 
can be accessed via EFSA’s website1240. Based on EFSA guidelines, food companies have 
put systems in place to ensure they are in as strong a position as possible. Companies want to 
ensure that existing claims can still be made, and to prepare for future disease risk reduction 
claims1241.
The EFSA guidance applies to health claims related to the consumption of a food category, 
a food, or its constituents, including a nutrient or other substance, or a combination of 
nutrients/other substances. The purpose of the guidance is to assist applicants in preparing 
and presenting their applications for authorisation of health claims which fall under Article 
14 of the Regulation, i.e. reduction of disease risk claims and claims referring to children’s 
development and health.
The EFSA Guidance “presents a common format for the organisation of the information to 
assist the applicant in the preparation of a well-structured application”. According to EFSA, 
adherence to the format will facilitate them to do its work in an effective and consistent 
way. EFSA “strongly advises” the applicant to adhere to the Guidance for preparing their 
application. A ready-to-use word-format of the application is also provided1242.1243
The application for an Article 14 claim shall include the following data1244:
the name and address of the applicant;(a) 
the nutrient or other substance, or the food or the category of food, in respect of which (b) 
the health claim is to be made and its particular characteristics;
a copy of the studies, including, where available, independent, peer-reviewed studies, (c) 
which have been carried out with regard to the health claim and any other material 
which is available to demonstrate that the health claim complies with the criteria 
provided for in the Regulation;
where appropriate, an indication of the information which should be regarded as (d) 
proprietary accompanied by verifi able justifi cation;
a copy of other scientifi c studies which are relevant to that health claim;(e) 
a proposal for the wording of the health claim for which authorisation is sought (f) 
including, as the case may be, specifi c conditions for use;
a summary of the application.(g) 1245
1239  Opinion of the Panel on dietetic products, nutrition and allergies (NDA) on a request from the 
Commission related to scientifi c and technical guidance for the preparation and presentation of the application 
for authorisation of a health claim. Adopted 06/07/2007. The draft opinion was published in May 2007, after 
which stakeholders had a chance to give their comments before adoption of the fi nal version.
1240  EFSA web page at: http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1178623592448.
htm.
1241  Nutraingredients.com. Europe. http://www.nutraingredients.com/news/ng.asp?n=76579-efsa-health-
claims.
1242 Available at: http://www.efsa.europa.eu/en/science/nda/Pre_submission_guidance/nda_technical_
guidance.html.
1243  EFSA pre-submission health claim guidance for applicants 2007, 5.
1244  The same data as required when adding claims to Article 13 list.
1245  Regulation 1924/2006/EC, Article 15(3).
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EFSA shall make the Summary of the Application available to the public. The Summary of 
the Application should be presented in a standardized form. Therefore it is mandatory to use 
the form provided in the Appendix B of the EFSA Guidance. The summary The Summary 
shall be preferably presented in English and shall not contain parts which are considered to be 
confi dential as summaries are published on the EFSA website. 1246
Now we turn to what happens after the applicant has done his share. After receiving an 
application, EFSA has fi ve months to give its opinion1247. In order to prepare its opinion, the 
Authority shall verify:
that the health claim is substantiated by scientifi c evidence;(a) 
that the wording of the health claim complies with the criteria laid down in the (b) 
Regulation.1248
EFSA shall forward its opinion to the Commission, the Member States and the applicant. 
The opinion shall include a report describing assessment of the health claim and stating the 
reasons and grounds for EFSA opinion. Article 16(4) particularly1249 must be listed in an 
opinion in favour of authorising the health claim. EFSA shall make its opinion public, and the 
applicant and the public may make comments to the Commission within 30 days from such 
publication.
After receiving the EFSA opinion, the Commission has two months to submit a draft 
decision1250 to its Standing Committee on the Food Chain and Animal Health. When drafting 
the decision, the Commission shall take into account:
EFSA opinion, –
any relevant provisions of Community law, and –
other legitimate factors relevant to the matter under consideration. –
Where the draft decision is not in accordance with the EFSA opinion, the Commission shall 
provide an explanation for the differences. Use of the term “other legitimate factors” grants 
the Commission wide discretionary powers to include other than scientifi c factors in their 
decision-making. A draft decision to amend the lists of permitted health claims shall include 
1246  EFSA pre-submission health claim guidelines to applicants 2007, 5-6.
1247  Regulation 1924/2006/EC, Article 16(1).
1248  Regulation 1924/2006/EC, Article 16(3).
1249  (a) the name and address of the applicant;
(b) the nutrient or other substance, or the food or the category of food, in respect of which a claim is to be made 
and its particular characteristics;
(c) a proposal for the wording of the health claim, including, as the case may be, the specifi c conditions of 
use;
(d) where applicable, conditions or restrictions of use of the food and/or an additional statement or warning 
that should accompany the health claim on the label and in advertising.
1250  The decision on whether or not to include the claim on the Community list.
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the particulars referred to in Article 16(4)1251. The Standing Committee of the Food Chain and 
Animal Health shall adopt a fi nal decision in accordance with the Committee procedure. The 
Commission shall without delay inform the applicant of the decision taken and publish details 
of the decision in the Offi cial Journal of the European Union.
Above, we have discussed the borderline between nutrition claims and health claims, and 
the borderline between function claims and disease risk reduction claims. Also the distinction 
between claims referring to children’s development and health and other health claims has 
required further clarifi cation by the Commission. As stated above, Article 14 covers claims 
that refer to “children’s development and health”. The term “children”, however, is not defi ned 
in the Regulation. Commission Guidance states that it “should be understood as reaching the 
end of the growth period”, and that “an indicative age limit of 18 years can be mentioned, but 
this indication does not intend to defi ne children in the frame of the Regulation”. “Infants” and 
“young children”, as defi ned in Directives on dietetic foods, are subgroups of “children”.1252
According to Commission Guidance, the following health claims should be considered as 
claims referring to children’s development and health (and as such, Article 14 claims):
“Health claims  – solely referring to the development and health of children, and where the 
scientifi c substantiation is only valid for children. In this case, the scientifi c substantiation 
consists of data obtained on studies conducted with children.” An example of this kind 
of claim is given: “calcium is good for children’s growth”.
Health claims used on  – products intended exclusively to children, like follow- on formula, 
processed cereal-based foods and baby foods for young children1253.1254
The following health claims should be considered function claims (Article 13 claims): “Claims 
referring to the role of a nutrient or other substance in growth, development and to the functions 
of the body where the scientifi c substantiation covers the entire life span, or more than the 
children population group.” An example is given: “for children and pregnant women”. In this 
case, the scientifi c substantiation must cover the children population group and the pregnant 
women population group.1255
1251  The same information that must be included in a favourable EFSA opinion: (a) the name and address of 
the applicant; (b) the nutrient or other substance, or the food or the category of food, in respect of which a claim 
is to be made and its particular characteristics; (c) a proposal for the wording of the health claim, including, 
as the case may be, the specifi c conditions of use; and (d) where applicable, conditions or restrictions of use 
of the food and/or an additional statement or warning that should accompany the health claim on the label 
and in advertising.
1252  Scientifi c Committee Claim Guidance 2007, 13-14.
1253  These are dietetic foods under Directive 89/398/EEC. It was stated above that the Nutrition and Health 
Claim Regulation does apply to follow-on-formulae and baby foods, but not to infant formulae. 
1254  Scientifi c Committee Claim Guidance 2007, 14.
1255  Scientifi c Committee Claim Guidance 2007, 14.
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5.3.3.5.4 Data Exclusivity of Health Claims
Health claims included in the Community lists may be used, in conformity with the conditions 
applying to them, by any food business operator1256. An important limitation to this rule is the 
fi ve-year exclusivity of proprietary data: scientifi c data and other information in the application 
may not be used for the benefi t of a subsequent applicant for a period of fi ve years from the 
date of authorisation. This applies both to function claims authorised through Article 18 and 
disease risk reduction claims authorised through Article 14. The conditions for this exclusivity 
of data are:
the scientifi c data and other information (a) has been designated as proprietary by the prior 
applicant at the time the prior application was made; and
the prior applicant (b) had exclusive right of reference to the proprietary data at the time 
the prior application was made; and
the health claim could not have been authorised without the submission of the proprietary (c) 
data by the prior applicant.1257
The subsequent applicant may use proprietary data as grounds for his application, if he has 
agreed with the prior applicant that such data and information may be used. The subsequent 
applicant can always obtain authorisation for the same claim, if he can do it without reference 
to the proprietary data of the original applicant. Exclusivity of data might also be ended before 
the fi ve-year period, if the Commission takes a decision that a claim could be or could have 
been included in the lists without the proprietary data1258. This means that data protection only 
blocks competitors in cases where the scientifi c evidence never was and still isn’t anywhere 
else to be found.
The fi ve-year exclusivity is regarded as a balance between A) promoting research in health 
foods and B) avoiding unnecessary repetition of research efforts. Preamble 32 of the Regulation 
states: “In order to stimulate research and development within the agri-food industry, it is 
appropriate to protect the investment made by innovators in gathering the information and 
data supporting an application.” The explanation continues: “This protection should however 
be limited in time in order to avoid the unnecessary repetition of studies and trials, and to 
facilitate access to claims by small and medium-sized enterprises (SMEs), which rarely have 
the fi nancial capacity to carry out research activities.”
Exclusivity of data to support a health claim is similar to an intellectual property right. 
Similar limited exclusivity of data has been proposed for the novel foods application process. 
A functional food sometimes has both novel ingredient(s) and novel health claim(s). It would 
often be practical to evaluate the safety element (novel food regulation) and the effi cacy 
element (health claim regulation) in a single procedure. If this kind of evaluation procedure is 
not created, at least the two procedures will in the future apply the same principles regarding 
data protection.
1256  Regulation 1924/2006/EC, Article 17(5).
1257  Regulation 1924/2006/EC, Article 21(1).
1258  Regulation 1924/2006/EC, Article 21(2).
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5.3.3.5.5 Transitional Measures for Nutrition and Health Claims
All new products with new claims must be approved according to Articles 13 and 14 of the 
Regulations and added to Community lists before use. There are transitional measures for 
products already on the market and for claims already in use. Non-complying foods placed on 
the market or labelled prior to 1st July 2007 may be marketed until their expiry date, but not 
later than 31 July 2009.1259 This means no illegal labels can be printed after 1st July 2007, but 
the old ones can be used for two years.
With regard to nutrient profi les, foods may be marketed until twenty-four months following 
adoption of the relevant nutrient profi les and their conditions of use.1260 As the Commission has 
until 19 January 2009 to complete the profi les, they will not come into full effect until 2011.
Nutrition claims which have been used in a Member State before 1 January 2006 in 
compliance with national provisions applicable to them and which are not included in the 
Annex, may continue to be used until 19 January 2010. Single Member States can do this 
under the responsibility of food business operators and without prejudice to the adoption of 
safeguard measures.1261 An additional authorisation procedure is created for nutrition claims in 
the form of pictorial, graphic or symbolic representation, used according to criteria elaborated 
by national rules. Member States shall communicate such nutrition claims with the applicable 
national rules and scientifi c data in support of such rules to the Commission by 31 January 
2008. The Commission shall, in accordance with the Committee procedure, adopt a Decision 
concerning the use of such claims. Nutrition claims not authorised under this procedure may 
continue to be used for twelve months following the adoption of the Decision.1262
Health claims other than those referring to the reduction of disease risk and to children’s 
development and health can be made until the adoption of the list, under the responsibility 
of food business operators and without prejudice to the adoption of safeguard measures by 
single Member States. The Commission will establish the list by 31 January 2010. This means 
old function claims can be still be used while all claims referring to disease risk reduction or 
children’s health must be authorised by the Commission.
There is an additional authorisation procedure for old health claims. These are health claims 
that have been used in compliance with national provisions, and been the subject of evaluation 
and authorisation in a Member State. Member States were to communicate these claims1263 
with a report evaluating the scientifi c data in support of the claim to the Commission. After 
consulting the EFSA, the Commission shall, in accordance with the Committee procedure, 
adopt a Decision concerning the health claims authorised in the aforesaid manner. Health 
claims not authorised under this procedure may continue to be used for six months following the 
adoption of the Decision.1264 Thus the marketers that have already undergone one authorisation 
procedure will not have to repeat it The Member State will do it on their behalf.
Different rules apply to health claims which have been in use but which have not been the 
subject of evaluation and authorisation in a Member State. Such claims may continue to be 
1259  Regulation 1924/2006/EC, Article 28(1).
1260  Regulation 1924/2006/EC, Article 28(1).
1261  Regulation 1924/2006/EC, Article 28(3).
1262  Regulation 1924/2006/EC, Article 28(4).
1263  By 31 January 2008.
1264  Regulation 1924/2006/EC, Article 28(6).
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used provided an application was made pursuant to the Regulation before 19 January 2008. 
Health claims evaluated pursuant to this procedure may continue to be used for six months 
after a negative decision is given. Marketers saw this as an opportunity to buy extra time if 
deemed necessary, as it takes time for the EFSA and the Commission to come up with fi nal 
decisions. Therefore, in reality, old health claims may exist in 2009.
The nutrition and health claim Regulation also applies to trade marks and other brand names 
which may be construed as nutrition or health claims1265. For trade marks, the transitional period is 
the longest, 15 years. Products bearing trade marks or brand names existing before 1 January 2005 
may continue to be marketed until 19 January 20221266. Existing brand names suggesting health 
benefi ts (such as promises of weight loss) that do not meet the requirements of the Regulation must 
be phased out and removed from the market.
5.3.3.6 Implications of the European Claim Legislation
The claim legislation means, at least in principle, less trouble for those marketers that use 
established function claims. The Member States, the EFSA and the Commission will draw up 
the list, after which any marketer can use the claims, provided that the product corresponds to 
the claim. This means the marketer is still responsible for evaluating whether the established 
claim applies to a single product.
Use of new function claims or disease reduction claims will require specifi c authorisation 
by the Commission, following scientifi c assessment and verifi cation of the claim by the 
EFSA. After a claim has been added to the list, other entrepreneurs can use the claim 
in marketing, unless the claim is based on proprietary data. The 5-year data protection 
rules might open new market opportunities for the ‘claim-owners’. Health claims could 
be licensed as intellectual property. This means a claim-owner might agree that another 
marketer can use the claim in return for payment of a fi xed sum or royalties.
It will be interesting to see what will be on the fi rst Article 13 list of established claims. 
Will there, for example, be claims that are verifi ed by long-time Chinese use? According to 
the European Botanical Forum (EBF), botanicals that rely on evidence of traditional use for 
health claim substantiation face an uncertain future. This is because the EFSA guidelines fail 
to acknowledge the traditional use criteria. The EFSA guidance document makes no reference 
whatsoever to “traditional use” or “history of use” for botanical products in food and food 
supplements.
The question of established claims is rather similar to the question of safety of novel foods, 
because both pieces of regulation can be discriminatory based on their basic presumptions. Foods 
are not novel and thus presumed safe, if they have been used in Europe. It might be that health 
claims are more easily considered established, if European scientists and consumers in a European 
country have accepted them. Coming from China or America, for example, might cast an extra 
burden of proof onto the marketer. An ‘exotic’ product is probably considered novel, and the health 
claim might also more likely be considered unestablished. In principal, the legal requirements 
for safety and effi cacy are the same for all the products, and the food business operator is always 
1265  Regulation 1924/2006/EC, preamble 4.
1266  Regulation 1924/2006/EC, Article 28(2).
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responsible for the product complying with the law. However, if you are European, you have the 
advantage of European legislators undertaking some of the work.
In the comparison of (functional) foods with herbal medicinal products, European 
information is considered more valuable than, for example, Asian and American 
information. A product can be registered as a traditional herbal medicinal product, if it 
fulfi ls certain other conditions and has been used for 30 years, at least 15 of which were 
in Europe. Safety and effi cacy of these traditional products are considered adequately 
proven and they are allowed to access the market. The legislation seems to be based on a 
basic psychological premise; trust the familiar and be wary of the unfamiliar.
Boal suspects that the expense and administration involved in the pre-market assessment 
process of health claims may prevent some companies from presenting novel claims. But given 
the great potential of the market, several companies may judge the investment worthwhile. 
Either way, the new regulation makes the situation much clearer.1267 There is only one route in 
Europe for presenting health claims; all other health claims are illegal.
The CIAA demanded EU-wide interpretative guidelines on the regulation. This is to ensure 
a level playing fi eld of enforcement authorities and operators and thus guarantee the proper 
functioning of the internal market.1268 The EFSA has already given its guidance on Article 14 
applications. They will also provide guidelines on inclusion of health claims in the Article 13 
list which will include claims that are based upon newly developed scientifi c evidence and/
or which include a request for the protection of proprietary data. Guidelines are also expected 
on nutrition profi les.
The Regulation as such is not enough: several guidance documents and opinions are needed 
to resolve how the Regulation is implemented. The role of EFSA soft law and Commission 
soft law is thus extremely important. The EFSA “strongly advises” the applicants to adhere 
to their guidelines. In practice, it is the EFSA who decides on the health claim procedures. 
The Commission will have to rely on the EFSA on scientifi c issues, thus the EFSA has an 
important role as a non-partial scientifi c assessment body. The Commission can, however, 
base their decision on “other legitimate factors”, not merely the scientifi c opinion from the 
EFSA. This means there is room for political considerations. This is typical of European food 
law: it is based on science, but not merely on science. European operators seem to have more 
faith on the EFSA than on the Commission as regards impartiality.
The Regulation poses challenges to post-market supervisory authorities in the Member 
States. Even though local food control authorities do not need to evaluate the adequacy of 
the claims (as it is done pre-market at the EU level), they must still be able to ensure that the 
preconditions for use of the claims are fulfi lled. This refers to the additional information that 
must accompany the claim and verifi cation of adherence to nutrition profi les that must be 
fulfi lled.1269 There will still also be illegal nutrition claims, health claims, and also medicinal 
claims on foods, which the authorities must eradicate
1267  Boal 2006. 
1268  Review of CIAA Priorities and Objectives for Better Regulation
In light of the Commission proposals to simplify EU legislation. CPT/003/07E-Final Brussels, 28 February 
2007 Page 5.
1269  Report on health claims used in marketing of foodstuffs in Finland 2007, 25.
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5.3.4 Chinese Rules on Nutrition and Health Claims
5.3.4.1 Names of Health Related products
China has new legislation that is common to all health related products, including food among 
other products.1270 This legislation includes:
Working Procedure of Examination and Approval on Health Related Products of  –
Ministry of Public Health;
Rule of Evaluation and Examination Committee of Health Related Products of Ministry  –
of Public Health; and
Regulation on  – Nomenclature1271 of Health Related Products.
Articles of the Procedure discuss the tasks of different authorities1272. The Rule of the 
Committee also contains procedural rules. The Nomenclature Regulation stipulates substantial 
rules on names. ‘Health related products’ refers to food, cosmetics, products related to hygiene 
and safety of drinking water, disinfectant and disinfecting tools and other products related to 
human health; which are examined and approved by the Ministry of Public Health according 
to the following legislation:
Food Hygiene Law of the People’s republic of China – 1273,
Regulation on Hygiene Supervision of Cosmetics, –
Regulation on Health Food Administration, –
Regulation on Hygiene Administration and Supervision of Drinking Water, –
Regulation Administration of Disinfecting, and –
Other laws, decrees and regulations. – 1274
The Nomenclature Regulation has been enacted to protect the consumer’s right to accurate 
information and is applied to, among other things, health food. . The Committee examines the 
names of the health related products. The nomenclature of a health related product must meet 
the following requirements1275:
1270  In EU law, there is no legal product safety category between general product safety and food safety. 
Chinese law on health-related products is here presented in between general product safety and general 
food safety. In Germany, foodstuffs and cosmetics are governed by the same law. Also in the United States, 
foodstuffs, cosmetics, and drugs are governed by the same law.
1271  This means names.
1272  All health related products are evaluated and examined by a committee under the Ministry of Public 
Health, the composition of which is regulated in the Rule on the Committee. The Ministry also has a Health 
Related Products Inspection Institute, which undertakes inspections of samples sent by applicants. The basic 
principle manifested in the rules on the authorities is that openness and impartiality are guaranteed in the 
application procedure and the acceptation of health related products.
1273  Now replaced by the Food Safety Law.
1274  Article 2 of the Working Procedure.
1275  Nomenclature on health related products, article 4.
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It must conform to related laws, regulations, decrees and standards,1. 
It must refl ect the property of product; it must be concise, easily understood, and 2. 
conform to Chinese convention,
The name consists of trademark, model3. 1276, general name, and name of property, in this 
order.
The trademark, model, general name and name of property must meet the following 
requirements1277:
The name must conform to related regulations and adopt a registered trademark. A 1. 
health related product cannot use a trademark which exaggerates functions or misleads 
consumers.
The model should indicate the characteristics of products, such as material, volume, 2. 
capacity and advancement.
The general name should be accurate and scientifi c, and indicate major materials, major 3. 
effective components or have words of function, but not indicate or hint of a curing effect.
The name of property should indicate the objective form of product and should not use 4. 
the abstract name. For those products which consumers are familiar with, the name of 
property can be omitted, such as lipstick etc.
Article 7 lists additional requirements: if the product has the same trademark, same general 
name, and same name of property but different taste or it is produced for special groups of 
people, the difference should be indicated after the name of property.
It is forbidden to use the following contents in nomenclature of a health related product1278:
professional terms not easily understood, and dialects,1. 
false, exaggerating and extreme terms such as highly effective, universal and “xx” 2. 
generation,
vulgar or superstitious terms,3. 
the name of approved medicines4. ,
letters of foreign language, Pinyin of Chinese and symbols. If it is a trademark or letters 5. 
and symbols of a foreign language that have to be used, it should be mentioned in 
specifi cation in Chinese.
The Chinese name of an imported health related product should correspond to the foreign 
name as much as possible. The name can be translated according to meaning, pronunciation, 
or both. Generally, the foreign name is translated according to its meaning.1279
1276  Name of a tool should include the model of the product. This is related to disinfecting tools that are also 
included in the concept of health related products.
1277  The list is given in Article 5 of the Regulation on Nomenclature of Health Related Products, but not in 
this order.
1278  Article 8.
1279  Article 9.
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5.3.4.2 Nutrition Claims
Until recently, nutrition claims have not been regulated in China. In November 2007, the 
Chinese Ministry of Health issued Administrative Measures on Food Nutrition Labelling1280. 
The Measures are applicable from 1st May 2008. Nutrition labelling and nutrition claims are 
regulated by one single instrument.
The new regulation stipulates the defi nition of food nutrition labelling and its scope, nutrition 
declaration and nutrition claim. The three technical annexes stipulate defi nition of nutrition 
ingredients, rounding rules, nutrients reference values, the conditions and terms of nutrition 
claims.1281 Companies are not allowed to state their products are high in calcium, iron or low in 
fat unless they meet certain strict criteria. They must not make false claims nor exaggerate the 
nutritional benefi ts of the product. The prohibition of medicinal claims is also repeated: labels must 
also not make direct or indirect claims of curing illness.1282
5.3.4.3 Health Food Effi cacy: the 27 Claims
The Health Food Regulation was discussed above in chapter 4 with regard to the safety aspect. 
Here we focus on marketing, and particularly on what can be claimed. Health food is defi ned 
as a food that has a specifi c health function, is suitable for certain groups of people, but is 
not for curing a disease. 1283 In Article 23 of the Food Hygiene Law, misleading advertising 
of health foods was prohibited: The content of the product description shall be accurate. The 
functions and ingredients of the product shall be identical with the information given in the 
product description and there shall be no false information. Article 51 of the new Food Safety 
Law states the same rules in new words. Claims that refer to prevention or treatment of disease 
(medicinal claims) are prohibited on health foods. Suitable and unsuitable user groups of the 
health food must be given, as also the functional ingredients and their content.
As stated above, the Health Food Regulation establishes minimum safety and effi cacy 
requirements for health foods as follows:
raw materials and fi nal products must comply with food hygiene requirements and shall  –
not cause any acute, sub chronic, or chronic harm to human body,
necessary animal and/or human tests must have confi rmed a clear and stable health effect, –
formulation and dosage must be based on scientifi c evidence (the functional ingredient  –
should be identifi ed but when that is impossible, at least the raw materials that cause 
the effect shall be listed),
therapeutic effects shall not be claimed –  in labelling or advertising.1284
1280  22 pages, in Chinese.
1281  WTO TBT/SPS notifi cation. http://www.tbt-sps.gov.cn/sites/English/News/Lists/news/DispForm.aspx?ID=60.
1282  Reuters Beijing January 11 2008.
1283  Article 2.
1284  Health Food Regulation, Article 4. Huang – Lapsley 2005, 266.
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There is certain mandatory information that must be given to consumers on health foods. 
According to the Health Food Regulation1285, the label and specifi cation of health food must 
contain the following details: role of the product in health protection, suitable user groups, 
optimal dosage, storage method, name and quantity of effective components1286, order number 
of health food certifi cate, and the health food symbol. Names of health foods should be accurate, 
scientifi c and should not use names of peoples, names of places, names that are misleading 
or exaggerating, or names of minor effective components1287. Labels and advertisements of 
health foods must be accurate and compatible with the nature and quality of the products. 
There shall be no referrals to therapeutic effects. It is also forbidden to use superstition in 
health food advertisement.1288
It is important to notice that in China, only health foods can bear health claims. Regular 
foods cannot bear health claims. On the other hand, health foods cannot bear medicinal claims. 
This way the health food regulation separates normal foods from health foods, foodstuffs from 
medicines, and food advertising from medicine advertising. To make the separate functions 
clear, health foods must bear the advice: ‘this product cannot substitute any medicine’1289.
There are currently 27 possible functions and claims for health foods, with other functions 
not accepted:
Enhancing immune function1. 
Assisting in blood lipids reduction2. 
Assisting on blood sugar reduction3. 
Anti-oxidation (delay of aging)4. 
Assisting in memory improvement5. 
Reducing eye fatigue6. 
Facilitating lead excretion7. 
Thinning throat mucus (moistening of throat)8. 
Assisting in hypertension (blood pressure) reduction9. 
Enhancing sleep10. 
Promoting lactation11. 
Alleviating physical fatigue12. 
Enhancing anoxia endurance13. 
Assisting protection against irradiation hazard14. 
Weight reduction15. 
Enhancing child growth and development16. 
Increasing bone density17. 
Alleviating nutritional anaemia18. 
Assisting in protection against liver chemical injury19. 
Alleviating acne20. 
Eliminating skin pigmentation21. 
1285  Article 21.
1286  If components of effective function cannot be determined under present conditions, names of major raw 
materials having a health protection function should be listed.
1287  Health Food Regulation, Article 22.
1288  Health Food Regulation, Article 23.
1289  Functional Ingredients December 2005 China News. Available at www.functionalingredientsmag.com.
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Improving skin moisture22. 
Improving skin oil content23. 
Regulating gastrointestinal fl ora24. 
Facilitating digestion25. 
Alleviating constipation26. 
Assisting in protection against gastric mucosa injury.27. 1290
The Chinese health claim categories cover all the important claims that are most interesting to 
Western functional food developers. The Ministry of Health revised the procedures for effi cacy 
evaluation in 2003, when the current list of 27 functions/claims came into force. Cosmetic claims 
were separated into four different claims instead of just one (claims 20-23 above). Similarly, 
stomach health claims were separated into four different claims (claims 24-27 above).1291
It is not possible to market an all-purpose health food: a health food with the same recipe 
is not allowed to be used for the application of more than two functions. Applications for 
supplementary functions are not accepted.1292 Most of the important claims interesting to 
Western developers of functional foods are included in the list. Two important claim types 
are missing: claims related to cancer, and claims related to sexual functions. Some of the 
listed health issues are not familiar to the European people as they are not a part of European 
health policies. It is therefore not likely that a Western company will focus research and 
product development efforts particularly on these issues. Companies often build on their own 
experience and competencies and are best at what is familiar to them.
In 2002, 60 percent of authorised health foods focused on three functions: immune regulation, 
regulating blood pressure, and anti-fatigue. Health foods were not often in regular food form; 
instead they were primarily in the form of liquid, capsule, tablet, or powder. It is noteworthy, that in 
about 90 percent of health foods, the active ingredients of the products were related to Traditional 
Chinese Medicine.1293 Today, other types of health foods are also emerging. For example, probiotic 
products are gaining interest. In 2002, 90 percent of health foods were marketed by Chinese 
companies, 10 percent were imported1294.
It is noteworthy that many of the claims are currently formulated in a way that considers 
other factors than diet in improving one’s health. The verb “assist” is now used in 6 claims. 
For example, one cannot say that a product lowers hypertension; instead it is allowed to say 
that it assists in hypertension alleviation. This approach is similar to the European rules on 
health claims reminding the consumer of lifestyle factors.
The list of allowed claims would not give much guidance without rules on scientifi c 
substantiation of the claims. According to the current rules on health food effi cacy, animal 
trials are required for 22 of the 27 claims. Animal trials are not required for claims on:
1290  Ministry of Health Notifi cation 2003, point A.
1291  Huang – Lapsley 2005, 264.
1292  Ministry of Health Notifi cation 2003, points B and C.
1293  Wang et al. 2003. 
1294  Huang – Lapsley 2005, 263.
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alleviating eye fatigue, –
cosmetic claims: alleviating acne, eliminating skin pigmentation, improving skin  –
moisture, and improving skin oil content.1295
Human feeding trials are now required for 20 claim categories. Human trials are not required 
for claims on:
enhancing immune function, –
enhancing sleep, –
alleviating physical fatigue, –
enhancing anoxia endurance, –
assisting in protection against irradiative hazard, –
increasing bone density, –
assisting in protection against liver chemical injury. – 1296
If both animal and human tests are required, human tests are done after getting a positive result 
with animal tests. Before a human feeding trial can be started, it must receive approval from an 
ethical committee. The samples submitted for functional evaluation must have already passed 
safety evaluation.1297
The testing parameters and trial designs are precisely regulated for each claim. Here we 
mention as an example a product, which claims to assist in hypertension alleviation. Both 
animal experiments and human feeding trials are required. Animals to be used are 10-12 
week old rats with hypertension. The duration of a feeding experiment is 30-45 days. Testing 
parameters are body weight, blood pressure, and heart rate. Human trials must be done with 
18-65 year-old hypertension patients. Systolic heart pressure should be at least 140 and 
diastolic at least 90. Testing parameters are the clinical syndrome & signs, blood pressure, 
and heart rate.1298
The regulations do not give precise requirements on how effective a product must be. 
Similarly to the European rules on claims, the regulations only give the scientifi c criteria that 
are used in the evaluation of the application. Whether the product is effective enough is a 
question that the SFDA will have to evaluate on a case-by-case basis.
5.4 General Rules on Medicine Marketing1299
5.4.1 EU
Next we will discuss the general rules on medicine marketing, including rules on labelling 
and advertising, without yet going to regulations on medicinal claims. In the EU, labelling 
1295  Huang – Lapsley 2005, 277-281.
1296  Huang – Lapsley 2005, 277-281.
1297  Huang – Lapsley 2005, 276.
1298  Huang – Lapsley 2005, 278. For information on trial designs and testing parameters of other claims, see 
Huang – Lapsley 2005, 277-281.
1299  This means rules other than those applicable to claims.
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is regulated in Title V and advertising in Title VIII of the Medicinal Products Directive 
2001/83/EC1300. Advertising is “any form of door-to-door information, canvassing activity or 
inducement designed to promote the prescription, supply, sale or consumption of medicinal 
products”1301.
Like foodstuffs, there is certain information that a marketer must give to the consumer. 
These are to be given in the label and in the package leafl et of a medicinal product. Certain 
information must appear on the outer packaging of medicinal products or, where there is 
no outer packaging, the immediate packaging. These are: name of the medicinal product, 
qualitative and quantitative composition in respect of active substances, pharmaceutical form 
and contents by weight, route of administration, list of ingredients, expiry date, special storage 
precautions, disposal of unused medicinal products or waste materials, authorisation number 
and manufacturing batch number, and special warnings.1302 These particulars must be legible 
and clearly comprehensible1303.
Member States may require the use of certain forms of labelling of the medicinal 
product making it possible to ascertain: the price, the reimbursement conditions of social 
security organisations, the legal status for supply, identifi cation and authenticity.1304 
In Finland for example, the Nordic number is required on the label of all medicinal 
products, except radio pharmaceuticals and herbal remedies. It is written as “Vnr XX 
XX XX”. Products containing infl ammable material must contain the international 
warning symbol (fl ame), and products that may reduce the ability to drive or operate 
machines must have a warning triangle.1305
The packaging of all medicinal products must contain a package leafl et, unless all the 
information required features directly on the outer packaging or on the immediate packaging. 
The package leafl et must include certain particulars. These are: name of the medicinal product, 
therapeutic indications, information necessary before taking the medicinal product, the 
1300  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the 
Community code relating to medicinal products for human use.
1301  It includes in particular: “the advertising of medicinal products to the general public, advertising of 
medicinal products to persons qualifi ed to prescribe or supply them, visits by medical sales representatives 
to persons qualifi ed to prescribe medicinal products, the supply of samples, the provision of inducements to 
prescribe or supply medicinal products by the gift, offer or promise of any benefi t or bonus, whether in money 
or in kind, except when their intrinsic value is minimal, sponsorship of promotional meetings attended by 
persons qualifi ed to prescribe or supply medicinal products, sponsorship of scientifi c congresses attended by 
persons qualifi ed to prescribe or supply medicinal products and in particular payment of their travelling and 
accommodation expenses in connection therewith”. Article 86(1) of the Directive.
1302  Article 54 of the Directive.
1303  Article 56 of the Directive.
1304  Article 57 of the Directive.
1305  Notice to Applicants. Guideline on the packaging information of medicinal products for human use 
authorised by the Community. March 2007. Included in The Rules governing Medicinal Products in the 
European Community. Page 18.
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necessary and usual instructions for proper use, description of the adverse reactions, reference 
to the expiry date and date on which the package leafl et was last updated.1306.
Now we turn to actual advertising, voluntary messages of the marketer. First of all, 
advertising of a medicinal product must encourage rational use of the product and may not 
be misleading.1307 All advertising to the general public of a medicinal product must be clearly 
identifi able as such and must include the following minimum information: a) name of the 
medicinal product, b) the information necessary for correct use of the medicinal product; c) an 
express, legible invitation to carefully read the instructions on the package leafl et.1308
The Medicinal Products Directive 2001/83/EC distinguishes between advertising to doctors 
and pharmacists, and advertising to the general public. Advertising a medicinal product to 
persons qualifi ed to prescribe or supply such products “shall include essential information 
compatible with the summary of product characteristics”1309. Advertising of medicines to 
the general public is more restricted and more precisely regulated. It may not include any 
information which:
“gives the impression that a medical consultation or surgical operation is unnecessary; –
compares the medicinal product with other treatments or products; –
suggests that the health of the subject can be enhanced by taking the medicine or  –
affected by not taking it;
is directed exclusively or principally at children; –
refers to a recommendation by scientists, health professionals or persons who, because  –
of their celebrity, could encourage the consumption of medicinal products;
suggests that the medicinal product is a foodstuff – , cosmetic or other consumer product;
suggests that the safety or effi cacy of the product is due to the fact that it is natural; –
could, by a description or detailed representation of the case history, lead to erroneous  –
self-diagnosis;
refers, in improper, alarming or misleading terms, to claims of recovery; uses, in  –
improper, alarming or misleading terms, pictorial representations of changes in the 
human body caused by disease or injury, or of the action of a medicinal product on the 
human body;
mentions that the medicinal product has been granted a marketing authorisation”. – 1310
1306  Article 59 of the Directive. Specifi c provisions apply to the packaging and container of medicinal products 
containing radionuclides (Article 66), and to the labelling and package leafl ets of homeopathic medicinal 
products (Article 69).
1307  Article 87 of the Directive.
1308  Article 89 of the Directive.
1309  Article 91 of the Directive.
1310  Article 90 of the Directive.
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Prescription medicines1311 cannot be advertised directly to consumers. Neither can medicines 
that contain psychotropic or narcotic substances. 1312 Further, the following therapeutic 
indications may not be mentioned in advertising to the general public: tuberculosis, sexually 
transmitted diseases, other serious infectious diseases, cancer and other tumoral diseases, 
chronic insomnia, diabetes and other metabolic illnesses1313. Direct distribution of medicinal 
products to the public for promotional purposes is totally prohibited1314.
The prohibition of direct marketing of prescription medicines does not apply in certain 
cases. First of all, it does not apply to vaccination campaigns carried out by the industry and 
approved by the competent authorities of the Member States1315.
In 2001, the Commission proposed to allow a fi ve-year trial period for advertising of 
prescription medicines for three chronic conditions: HIV/AIDS, diabetes and asthma. The 
proposed experimentation provoked a debate on the benefi ts and disadvantages of allowing 
pharmaceutical companies to communicate directly with the public1316, and was rejected by 
the Parliament and the Council. Stakeholders thought the experiment would be a step towards 
direct-to-consumer advertising of medicines, which is only allowed in the United States and 
New Zealand, and against which there are good grounds1317. In Europe, the debate goes on. 
There are plans on public-private partnerships on patient information, on which consumer 
organisations have expressed their concerns1318.
The rules prohibiting advertisements on prescription medicines still leave the door open for 
advertising that does not endorse a certain product, but rather gives information on a certain 
medical condition. Such “consumer guidance” has been carried out by medicine companies, 
for example, concerningerection disorders1319. In Finland, the National Agency of Medicines 
has given guidance on what is considered advertising: if the information for instance in a 
leafl et is intended to support proper use of the product, it is not considered advertising. In 
this case, also the name of the product can be mentioned. The materials can be considered 
advertising, if they promote the use of the product or praise benefi ts of the treatment compared 
to other treatments.1320
1311  When granting a marketing authorisation, the competent authorities must determine whether the medicinal 
product is subject to medical prescription or not. Article 70 of the Directive. This is done based on the criteria 
set in Article 71 of the Directive: “Medicinal products shall be subject to medical prescription where they: are 
likely to present a danger either directly or indirectly, even when used correctly, if utilized without medical 
supervision, or are frequently and to a very wide extent used incorrectly, and as a result are likely to present 
a direct or indirect danger to human health, or contain substances or preparations thereof, the activity and/
or adverse reactions of which require further investigation, or are normally prescribed by a doctor to be 
administered parenterally.”
1312  Article 88(1) of the Directive.
1313  Article 88(2) of the Directive.
1314  Article 88(6) of the Directive.
1315  Article 88(4) of the Directive.
1316  Meek 2002. 
1317  Mintzes 2001, 1. Reasons to ban DTC medicine advertising include: it raises medicine costs, is not 
impartial enough, favours new medicines that might not be as safe as the old ones, and promotes the 
medicalisation of normal life. 
1318  Mintzes 2006, 29. 
1319  See for example http://www.miesjanainen.info/.
1320  National Agency for Medicines web page at: http://www.nam.fi /laaketeollisuus/ukk/ukk_lt_
markkinointi.html.
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To facilitate access to information about medicines available in the EU and to complement 
the commercial information, the EMEA has launched a public database called EudraPharm. 
It includes information about the formulation, the strength, and the therapeutic area of the 
medicine. The EPHA (European Public Health Alliance) criticises this database for not being 
complete and not covering all the information patients would require, such as full details of 
clinical trials or the effi ciency of the medicine, side effects assessments, etc.1321
A particular problem with medicine marketing is medicinal product information on the 
Internet. Material on the Internet is not excluded from the defi nition of an ‘advertisement’. 
Internet material must fulfi l all the normal requirements for medicinal products advertising. 
According to UK guidelines, if a site has links to another site where additional information on 
the medicinal product is presented, this other site will also be included in determining whether 
the marketing is lawful1322.
5.4.2 China
The labelling and advertising rules of medicines are fairly similar in China as in Europe. 
Packages of pharmaceuticals must be labelled and include directions for use in accordance 
with the regulations. The label or directions must indicate certain mandatory information:
the generic name of the medicine,
components,
specifi cations,
the producer,
registration number,
batch number of the product,
production date,
expiry date,
indications or major functions,
directions for use,
dosage,
restrictions,
adverse reactions, and
precautions.1323
The label must coincide with the approved indications and directions for use, and must be in 
standard Chinese characters1324. Labels cannot be misleading or use unscientifi c promotional 
phrases.
1321  European Publish Health Alliance web page at http://www.epha.org/a/2492.
1322  MHRA: The Medicines Borderline Section and the Internet. Medicines Borderline Section March 2006.
1323  Medicine Administration Law, Article 54.
1324  Tsoi 2007.
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Advertising can be described as giving voluntary information in order to sell the product. 
In China, medicinal product advertising is regulated both by the Advertisement law1325 and 
the Medicine Administration Law. There is a pre-clearance system for medicinal products 
advertising, discussed above in chapter 2.
According to Advertisement law, advertisements relating to pharmaceuticals (and medical 
apparatus and instruments) cannot contain the following:
Unscientifi c assertions or guarantees of effi cacy;1. 
The rate of treatment effi cacy;2. 
Comparisons with other medicines or medical apparatuses in effi cacy or safety;3. 
Titles or images of medical research institutes, academic institutions, medical 4. 
organisations or experts, doctors or patients; and
Other content prohibited by laws and administrative decrees.5. 1326
The content of an advertisement for a medicine should be based on the indications approved by the 
medicine control authorities.1327 According to the Medicine Administration Law, the contents of 
pharmaceutical advertisement must be true, legitimate and free of false claims. The advertisements of 
non-pharmaceuticals shall not be involved in the publicising of pharmaceuticals. Points 1) and 4) above 
are repeated by the Medicine Administration Law.1328
Several experts are of the view that Chinese law on medicinal products advertising is not 
functioning properly as misleading medicine advertising has become a real problem in China. 
Ads on hospitals and medicinal products are very common in China, but according to the State 
Administration of Industry and Commerce, medicine advertising is the least trusted of all advertising 
by consumers in 20061329. A government fi gure says that about 2.5 million Chinese took the wrong 
medication because of misleading advertising1330. The SFDA conducted a national survey of 466 
newspapers and 55 local TV channels from January to November in 2006, discovering 48,990 
illegal advertisements on medicines1331.
To counter-attack the described problems, China is tightening control over medicine 
advertising. The State Administration of Industry and Commerce and the State Food and Drug 
Administration (SFDA) promulgated:
the Standards for the Examination and Publication of Medicine Advertisements, and1) 
the Measures for the Examination of Medicine Advertisements.2) 
1325  Advertising Law of the People’s Republic of China. Adopted at the Standing Committee of the Eighth 
National People’s Congress of the People’s Republic of China on October 27, 1994 to be put Into Effect on 
February 1, 1995.
1326  Advertisement law, Article 14.
1327  Advertising Law, Article 15. Medicine Administration Law, Article 61.
1328  Medicine Administration Law, Article 61.
1329  Hong Kong Trade Development Council. www.tdctrade.com. Business Alert – China. Issue 05, 2007 (1 May). 
1330  People’s Daily Online: http://english.people.com.cn/200603/22/eng20060322_252583.html. March 22, 2006.
1331  Tsoi 2007.
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These both took effect on 1st May 2007.1332In addition to these, a new law called “Advertising 
Law on Public Interest” has been proposed. This law would add the amount of useful medicine 
advertising on TV in the form of “public service ads”.1333
According to the new Standards and Measures, the following fi ve categories of drugs are 
banned from advertising:
narcotic drugs, psychotropic drugs, toxic drugs for medical use and radioactive drugs; –
medicinal preparations made by medical institutions; –
medicines specially needed by the army; –
medicines which have been specifi cally banned or prohibited from production, sale and  –
use by SFDA; and
medicines which have been granted approval for trial production. – 1334
Use of exaggerated expressions and unethical promotional phrases is also banned. In order to 
ensure the safety of drugs, proper guidance should be given to their reasonable use. Medicine 
advertisements may not encourage excessive use of medicines. They may not contain the 
following content:
sales promotion offering free medical treatment, free gifts, premiums, gifts or prizes in  –
the form of medicines;
“essential for every household” or similar expressions; –
“money back if ineffective”, “insured by insurance company” and other guarantees; –
information such as comparison with other drugs, ranking, recommendation and awards  –
received.1335
Further restrictions set by the new Standards to medicine advertising include the following:
advertisements may not contain the name or image of army units or individual military  –
personnel, or use military equipment or facilities for promotion purposes;
advertisements may not target children or promote the medicine in the name of  –
children;
advertisements may not contain the name, address, contact information, and treatment  –
methods of medical institutions; or information regarding free medical consultation, 
medical (hotline) inquiry, special outpatient service and other medical services offered 
by medical institutions.1336
1332  Hong Kong Trade Development Council. www.tdctrade.com. Business Alert – China. Issue 05, 2007 
(1 May). 
1333  People’s Daily Online: http://english.people.com.cn/200603/22/eng20060322_252583.html. March 22, 
2006.
1334  Hong Kong Trade Development Council. Key to Economy and Trade. Issue 05, 2007 (01 May) 
1335  Hong Kong Trade Development Council. Key to Economy and Trade. Issue 05, 2007 (01 May) 
1336  Hong Kong Trade Development Council. Key to Economy and Trade. Issue 05, 2007 (01 May) 
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In addition to banning certain types of medicine advertising, the new rules also created 
additional information requirements for both prescription medicines and over- the- counter 
medicines. Medicine advertisements must bear:
the generic name of the medicine, –
warning statement, –
medicine advertising approval number, –
medicine production approval number, and –
name of the company producing or selling the medicine, and may not show the  –
“helpline” or “helpline number” separately.
Since 2000, OTC and prescription medicines have been regulated separately. Encouraging 
patients to purchase OTC medicines for less serious diseases is considered benefi cial as it 
reduces government medication expenditures and hospital visits.1337 The warning statement for 
prescription medicine advertisements is: “This advertisement is intended only for medical and 
pharmaceutical professionals”. The warning statement for over-the-counter (OTC) medicine 
advertisements is: “To be purchased and used according to the specifi cations of the drug or as 
recommended by pharmacist.” Prescription medicines may not be advertised directly to the 
public. Like in Europe, they may only be advertised in designated medical and pharmaceutical 
journals. Non-prescription drug advertisements must bear the OTC label.1338
Advertisements of medicines that claim to improve or boost sexual performance must be 
completely in line with the symptoms or indications shown in the approved drug specifi cations. 
Advertisements with this kind of content are banned from broadcast on TV or radio between 
7 am and 10 pm.1339
5.5 Claims in Medicine Marketing
Above (chapter 5.4.) we have discussed the general rules on medicinal advertising. Here we 
focus on effi cacy and the rules on presenting the medicinal claim.
5.5.1 EU Rules on Medicinal Claims
5.5.1.1 Modern medicines1340
A modern medicine (pharmaceutical, chemical medicine, synthetic medicine) must have 
a therapeutic (medical) indication. The therapeutic indication is mandatory information 
that must be included in an application for authorisation, more precisely in the Summary 
of Product Characteristics (SPC). This means that medicines always bear a claim stating 
a medical indication. The Summary of Product Characteristics sets out the scientifi cally 
agreed position of the medicinal product, which is distilled during the course of the 
1337  Wikipedia. Article on pharmaceutical industry in China. 
1338  Hong Kong Trade Development Council. Key to Economy and Trade. Issue 05, 2007 (01 May) 
1339  Hong Kong Trade Development Council. Key to Economy and Trade. Issue 05, 2007 (01 May) 
1340  Here we mean medicines that are not herbal or homeopathic medicines.
–242–
pre-market assessment process. The Summary of Product Characteristics, including the 
approved therapeutic indication(s), is the basis of information for health professionals on 
how to use the medicinal product safely and effectively, and it cannot be changed except 
with the approval of the originating competent authority. The label and the package leafl et 
are drawn up in accordance with the SPC.1341
The therapeutic indication(s) should be stated clearly and concisely and should defi ne the 
target disease or condition distinguishing between: 
treatment A) (symptomatic, curative or modifying the evolution or progression of the 
disease) indication, 
preventionB)  (primary or secondary1342) indication, and 
diagnosticC)  indication.
When appropriate, the indication should defi ne the target population especially when 
restrictions to the patient populations apply.1343
The basic principle is that by the information in the label and the package leafl et, patients 
should be fully and correctly informed about the medicine they are using. There is only 
one case where the therapeutic indication is not allowed. According to Directive 2001/83/
EC1344, “the competent authorities may decide that certain therapeutic indications shall not 
be mentioned in the package leafl et, where the dissemination of such information might have 
serious disadvantages for the patient”. This clause was introduced to avoid circumstances 
where a patient might not have been informed of the diagnosis (cancer, for instance) and 
would learn about it when reading the package leafl et of the medicine. This derogation from 
general principles should only be used in exceptional circumstances.1345
5.5.1.2 Herbal Medicines
When discussing the effi cacy of herbal medicines, we should briefl y go back to the separation 
of foodstuffs and medicines discussed in chapter 3. Some herbal marketers intentionally blur 
the line between foodstuffs and medicines. Food supplements have a nutritional, not a medical 
use. They must not contain medicinal substances, medicinal plants or vitamins with medicinal 
effect. Many herbals classifi ed as food supplements are in practice used if not to prevent a 
1341  Notice to Applicants. A guideline on summary of product characteristics. October 2005. Included in The 
Rules Governing Medicinal Products in the European Union. Volume 2C. Page 1.
1342  We discussed different types of prevention in chapter 3.3. The difference between prevention and risk 
reduction separates foods from medicines. According to Wikipedia, primary prevention avoids the development 
of a disease, and secondary prevention prevents progression of a disease or the emergence of symptoms. For 
example, if a person has already had a heart attack, (s)he needs secondary prevention to prevent it happening 
again. Also the term ‘tertiary prevention’ is in use, but apparently activities that reduce the negative impact of 
the disease are in Europe classifi ed as ‘treatment’.
1343  Notice to Applicants. A guideline on summary of product characteristics. October 2005. Included in The 
Rules Governing Medicinal Products in the European Union Volume 2C Notice to Applicants. Page 4.
1344  Article 59 (2).
1345  Notice to Applicants. Guideline on the packaging information of medicinal products for human use 
authorised by the Community. March 2007. Included in The Rules governing Medicinal Products in the 
European Community. Page 9.
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certain disease but at least to enhance health. The producers want to sell their products as 
foods because of the much simpler import, sales and marketing rules. But simultaneously, they 
want in their marketing to give the impression that the product acts like a medicinal product. 
Therefore, there are herbal products on the market that are sold as foods but still illegally 
marketed as medicines.1346
As regards effi cacy, herbal medicines are totally different from synthetic drugs. The quality 
of the medicinal plant is decisive to the quality of the products. Preparing herbal medicines 
is a bit like preparing wine: every year it is a bit different even if the plants are grown in the 
same place. Herbs grown in different countries have even bigger differences. In the package 
of the herbal medicinal product, the amount of the plant extract is given. This is called the 
therapeutic ingredient. Therapeutic ingredient does not, therefore, mean any single chemical 
substance like with synthetic medicines. The plant extract can contain hundreds of chemical 
compounds, and the amount of each chemical is not usually known.1347
Medicinal plants can be used as such either fresh or dried. For some plants, all above 
ground parts can be used. For others, only leaves, seeds, fl owers or roots are used. Plants or 
plant parts can be used to produce:
herbal tea, –
simple extracts (tincturae) or –
extracts produced with more complex procedures (extracta). – 1348
Herbal tea is produced like ordinary tea by infusing a dried medicinal plant in boiling water. 
Extracts are produced by using solvents that dissolve ingredients of the plant into the liquid, 
which is usually a mixture of water and alcohol. The goal is to dissolve as many medicinal 
ingredients as possible. The extract can be used either as such (tincture) or it can be concentrated 
by evaporating the solvent (extract). Extract reminds synthetic medicines because it is usually 
in form of pills, capsules or tablets. These are signifi cantly stronger than tinctures. Some 
plant ingredients can also be removed in the process. 1349 The producers often standardise 
the product in relation to one chemical substance in the product, usually the most important 
therapeutic ingredient. This way the fi nal product always contains the same amount of this 
one ingredient.1350
In practise, herbal medicinal products are tablets, capsules, mixtures or enemas. They must 
contain only medicinal plants, not pharmaceuticals or synthetic vitamins.1351 Herbal medicines 
must apply for a Product License. The principal application procedure is the same as for 
chemical medicines. When marketing herbal medicinal products, the marketer must adhere 
to the therapeutic use accepted by the authorities and the product information presented in 
the Summary of Product Characteristics. The general rules of medicine marketing apply: 
marketing must not lure into excess use of herbs or be otherwise improper.1352
1346  Enkovaara 2002, 21.
1347  Enkovaara 2002, 33.
1348  Enkovaara 2002, 33.
1349  Enkovaara 2002, 36.
1350  Enkovaara 2002, 37.
1351  Enkovaara 2002, 22.
1352  Enkovaara 2002, 31.
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Since 1986, established medicinal products do not have to go through new clinical tests. 
This means that a product license can be admitted based on scientifi c literature published on 
the substance. The literature must show that the substance has established medical use and 
that it has acknowledged effi ciency and acceptable safety.1353 According to directive 1999/83/
EC1354, a medicinal product, also a herbal medicinal product, has a record of well-established 
medicinal use if it has been used as a medicine in the EU territory for at least 10 years. In 
practice, applications for authorisation of herbal medicines are often based on established 
medicinal use, not clinical tests and trials1355.
If someone wants to market an herbal medicine that does not have established medicinal 
use in Europe, he must complete clinical trials similar to those for synthetic medicines. Under 
the European Medicines Agency (EMEA), there is a Committee on Herbal Medicines. The 
Committee was established in 2004, and it gives scientifi c opinions on herbal medicines. One 
of the basic guidelines concerning herbal medicines drafted by the EMEA committees is the 
2006 Guideline on Quality of Herbal Medicinal Products and Traditional Herbal Medicinal 
Products1356.
5.5.1.3 Traditional Herbal Medicines
Traditional herbal medicines are a new European regulatory category created by Directive 
2004/24/EC. It is a tailor-made category for products on which there is not enough scientifi c 
literature to make them well established in a sense that they could be authorised in the primary 
procedure for medicines. Traditional herbal medicines can be registered in a simplifi ed 
procedure called ‘traditional-use registration’.
According to preamble 5) of the Directive 2004/24/EC, “the long tradition of the medicinal 
product makes it possible to reduce the need for clinical trials, in so far as the effi cacy of the 
medicinal product is plausible on the basis of long-standing use and experience”. According 
to Article 16(a)(e), the data on the traditional use of the medicinal product must be suffi cient, 
in particular:
the product must prove not to be harmful in the specifi ed conditions of use, and –
the  – pharmacological effects or effi cacy of the medicinal product must be plausible on 
the basis of long-standing use and experience.
This means that products categorised as traditional herbal medicines, require no clinical data to 
show proof of effi cacy. The difference between a literature-based herbal medicine application 
and a traditional herbal medicine registration is that in the primary procedure, 10 years of 
established medicinal use is enough, and in the simplifi ed procedure, 30 years of traditional 
use is enough. Established use means scientifi cally established through adequate published 
1353  Enkovaara 2002, 20.
1354  Commission Directive 1999/83/EC of 8 September 1999 amending the Annex to Council Directive 75/318/
EEC on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and 
clinical standards and protocols in respect of the testing of medicinal products.
1355  National Agency for Medicines web page at: http://www.nam.fi /laaketeollisuus/rohdosvalmiste/
kasvirohdosvalmiste/index.html.
1356  Available on EMEA web page at: http://www.emea.europa.eu/pdfs/human/qwp/281900en.pdf.
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data. The borderline between established use and traditional use still remains unclear, and 
EMEA guidelines are expected on the subject.
Because effi cacy of traditional herbal medicines is not based on scientifi c trials, there is 
certain mandatory information that must be given to the consumer. There is an obligation to 
include in the labelling, the package leafl et and in any advertising the information that the 
product is a traditional herbal medicinal product and that the effi cacy has not been clinically 
proven but relies exclusively on long-term use and experience; and that the user should consult 
a doctor or a qualifi ed medical practitioner if the symptoms persist during the use of the 
medicinal product.
Compared to chemical medicines, there is still a relative lack of rigorous clinical trials 
on herbals. The effi cacy of herbal medicines has been tested in hundreds of clinical trials, but 
this volume of data is still small considering the thousands of plants that are used as medicines. 
Studies have shown that herbal medicines might often have fewer serious side effects compared 
to pharmaceuticals. They might also offer just as effective remedies with lower cost. However, the 
evidence on these benefi ts is incomplete.1357 This is why the legislator has had to settle with the 
above- described approach, where the product can be marketed based on history of use, but the 
consumer has to be informed of the lack of evidence. The decision on whether to trust a traditional 
herbal medicinal product is on the consumer.
The lack of trials is mostly due to the fact that the herbal industry is small and can rarely 
afford the considerable expense of a clinical trial. Public funds are not often dedicated to 
research of herbal medicines. The EU directive harmonising the registration of herbal 
medicines did not offer any incentives for companies to invest further into research. Research 
is needed to enable knowledge-based use of herbal medicine.1358 At the moment, a consumer 
must rely more on faith and less on facts when using herbals. The lack of complete evidence 
is possibly holding back the optimal use of herbals. There are arguments against ‘history of 
use’ as a ground for authorisation. Historically, there have been long-standing traditions of 
treatments later proven to be ineffective.
5.5.1.4 Homeopathic Medicines
Homeopathic products can be approved either in the primary authorisation procedure for medicines 
according to Article 16(1) or their own simplifi ed registration procedure according to Article 
14(1) of the Medicinal Products Directive 2001/83/EC. In practice, the simplifi ed registration 
scheme “appears to be applicable to the majority of homeopathic medicinal products”1359. The 
primary procedure is problematic as regards Mutual Recognition. In case of disagreement between 
Member States, referrals to the EMEA Committee on Human Medicinal Products do not apply to 
homeopathic medicinal products.1360
According to Article 14(3) of the Medicinal Products Directive, proof of therapeutic effi cacy 
is not required of the homeopathic products registered according to the simplifi ed procedure. 
Correspondingly, the labelling of those products shall bear the following information: 
1357  Ernst 2003.
1358  Ernst 2003. 
1359  Report on EMEA Workshop on Homeopathic Medicinal Products. London, 27th October 2006. Page 6.
1360  Report on EMEA Workshop on Homeopathic Medicinal Products. London, 27th October 2006. Page 7.
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“homeopathic medicinal product without approved therapeutic indications”.1361 Article 15 lists 
the information needed in the simplifi ed procedure. This information includes bibliographical 
data concerning the product’s homeopathic nature1362. This means homeopathic use of the 
product must be presented, for instance, on the basis of the literature.1363
The rules of the simplifi ed procedure indicate that a consumer must get the product (s)
he orders, but effi cacy is not guaranteed. A consumer may or may not believe that because 
the product has been used in homeopathy for condition X, it is effective for condition 
X. As discussed above in chapter 4, the Member States may or may not establish the 
simplifi ed procedure. This had led to an unharmonised state, which creates obstacles to 
practitioners of homeopathy. The dispute on whether homeopathy is actually effective 
goes on worldwide. The Lancet attacked homeopathy in 2005 stating that a review of 110 
trials found no convincing evidence the treatment worked any better than a placebo1364.
5.5.2 Chinese Rules on Medicinal Claims
The rules on effi cacy and marketing are basically the same for modern and traditional 
medicines in China. Traditional Chinese Medicine (TCM) remains a recognised and valued 
source of treatment1365. The Chinese government has supported the development of both 
traditional Chinese medicine and Western medicine in China. As described above in chapter 
4, the Chinese intend to be a global leader in bringing herbal medicine into the 21st century 
by establishing modern standards.
1361  If homeopathic medicinal products are placed on the market with therapeutic indications or in a form, 
which may present risks that must be balanced against the desired therapeutic effect, the usual rules governing 
the authorisation to market medicinal products are applied. This means that in these cases, the same market 
authorisation and labelling rules apply as to immunological medicinal products.
1362  Article 15: “An application for special, simplifi ed registration may cover a series of medicinal products 
derived from the same homeopathic stock or stocks. The following documents shall be included with 
the application in order to demonstrate, in particular, the pharmaceutical quality and the batch-to-batch 
homogeneity of the products concerned:
  –  scientifi c name or other name given in a pharmacopoeia of the homeopathic stock or stocks, together 
with a statement of the various routes of administration, pharmaceutical forms and degree of dilution 
to be registered,
  –  dossier describing how the homeopathic stock or stocks is/are obtained and controlled, and justifying 
its/their homeopathic nature, on the basis of an adequate bibliography,
  –  manufacture and control fi le for each pharmaceutical form and a description of the method of dilution 
and potentisation,
  –  manufacturing authorisation for the medicinal product concerned,
  –  copies of any registrations or authorisations obtained for the same medicinal product in other Member 
States,
  –  one or more specimens or mock-ups of the outer packaging and the immediate packaging of the 
medicinal products to be registered,
  –  data concerning the stability of the medicinal product.”
1363  National Agency for Medicines web page at: http://www.nam.fi /english/pharma_industry/herbal_
remedy/homeopathic/index.html.
1364  BBC News 26 August 2005.
1365  China-Britain Business Council. China-Britain Business Review Archive. 
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According to the new Chinese Standards and Measures on medicine advertising (2007), 
claims on the curative effects of medicines in advertisements must be scientifi c and accurate 
and may not contain any of the following content:
unscientifi c assertion or guarantee of effi cacy; –
claims of curative rate or effi ciency; –
comparison of effects and safety with other medicines; –
explicit or implicit suggestion that the drug can heal all diseases and is good for all  –
symptoms in contravention of the rules of science;
suggestion that the medicine is “safe with no toxic side effect” or has “very little toxic  –
side effect”;
for proprietary Chinese medicine, explicit or implicit suggestion that it is “natural” and  –
guaranteed safe;
explicit or implicit suggestion that the medicine is essential for normal daily life and  –
for the treatment of diseases;
explicit or implicit suggestion that the medicine can help one cope with the tension of  –
modern life, studies or examination, and can help boost academic performance, energy, 
competitiveness, height and intelligence;
other unscientifi c terms or suggestions such as “the latest technology”, “state-of-the-art  –
science” and “the most advanced methods of preparation”.
The rules on therapeutic claims are thus the same for modern and traditional medicines, with no 
special categories for medicines without proven therapeutic effi cacy. However, the scientifi c 
criteria for effi cacy are not yet established.
5.6 Food and Medicine Marketing: Conclusions
As with safety, there are no particular rules on the marketing of functional foods. Again, this 
is because there is no legal category of functional foods. General marketing rules apply to 
the marketing of functional foods. Marketing must be decent and truthful. In addition, food 
marketing or medicine marketing rules apply. As with safety, marketing rules of foodstuffs 
vs. medicines vary considerably. The main difference is that foods are allowed to bear health 
claims, and medicines are to have medicinal claims.
General rules on food marketing are largely the same within the EU and in China. The 
mandatory ingredient list will advise the consumer on what is in the product, and misleading 
advertising is prohibited. China has recently introduced legislation on nutrition labelling and 
nutrition claims, which is comparable to its European counterpart. Guideline daily amounts 
(GDA) are used as a guide for consumer.
Health claims are allowed both in the EU and in China. In China, a category of health foods 
has been created. Health foods are the only foods that can bear health claims, and no foods 
can bear medicinal claims. The category of health foods is suitable for all foods with health 
effects, including normal foods, fortifi ed foods and food supplements. In Europe, normal foods, 
dietetic foods and food supplements can bear health claims. The EFSA and the Commission 
have defi ned the borderlines of nutrition claims and the two separate types of health claims: 
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function claims and disease risk reduction claims. The separation between disease risk 
reduction and disease prevention is the separation between foodstuffs and medicines.
The general rules on medicine marketing are also largely the same in the EU and China. The 
basic law guarantees that consumers receive enough information on the use of the medicine, on 
its therapeutic effects, side effects, precautions etc. The law also prohibits typically unethical 
marketing methods such as targeting children. The Chinese government has recently improved 
laws on medicine marketing to tackle the serious problems that have occurred.
With regard to effi cacy, which is closely related to the medicinal claim, the required 
scientifi c proof varies according to the type of medicinal product. In Europe, legislators have 
created separate categories of traditional herbal medicines and homeopathic medicines, for 
which no scientifi c proof of effi cacy needs to be presented. On the other hand, no therapeutic 
claims can be presented for these products. This means the legislator has left it up to the 
consumer to decide whether to trust the product based on tradition only. For regular medicines, 
the requirements for scientifi c tests and clinical trials are very strict, and the EMEA evaluates 
the evidence on behalf of the consumer.
In China, foods have always been used for medicinal purposes. Medicinal products are 
divided into two: traditional Chinese medicines and modern medicines. Compared to Europe, 
China is putting more emphasis on traditional medicines and developing them side-by-side 
with modern medicines. China is building a science-based approach and modern legislation 
on traditional medicines. In the future, effi cacy of traditional medicines will be evaluated 
according to special legislation.
The laws on marketing of foodstuffs and medicines are often disobeyed both in China and 
in Europe. Illegal marketing practices are common regarding health foods, dietetic foods and 
food supplements. These are often marketed as medicines. In China, there have been serious 
cases of fake medicines. With health-related products, certain factors lead to misleading 
marketing: Consumers are ignorant compared to businesses, consumers cannot immediately 
determine if the product is effective or not, and health is so important to consumers that they 
are willing to pay for it even if the result is uncertain. This means there are lucrative earnings 
available for swindlers. It is a challenging job for legislators to make deception unprofi table.
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6 CASE: THREE CHINESE BERRIES
6.1 Case Introduction
In this chapter, we draw conclusions on the European and Chinese legal systems from an 
entrepreneur’s perspective. For this purpose, a case concerning fi ctional health-enhancing 
products and their legal status is presented. This means investigating how the legislation works 
in the situation of three Chinese plants aimed at fi ghting the metabolic syndrome.
The chosen plants are:
Hawthorn fruit (1) Crataegus pinnatifi da, Chinese hawthorn)
Emblic leaffl ower fruit (2) Phyllanthus emblica), and
Chinese wolfberry fruit (3) Lycium barbarum L.).
1)   2)   3) 
These berries have qualities that make them promising raw materials for functional foods. 
We are interested in how these plants are/would be legally evaluated in EU and in China. Our 
hypothetical goal is to produce functional foods utilising the health-enhancing properties of 
these three berries, and to legally sell the products to consumers.
The important legal questions are:
Which are the applicable rules?A) 
Is it possible to sell the products as foods and/or medicines?B) 
If foods, will the products be classifi ed as novel foods?C) 
If novel foods, which are the requirements for authorisation?D) 
Which will be the marketing claims available?E) 
Exotic fruits and berries have shot to popularity in the last couple of years, particularly 
because of their antioxidants and vitamin C. The food industry calls this the ‘superfruit’ trend. 
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Food and beverage manufacturers are developing products to reply to consumer demand for 
wolfberries, cranberries, noni, and blackberries for example.1366 
6.2 Scientifi c Background
6.2.1 Target Diseases
The metabolic syndrome is a condition where a person is overweight and in risk of getting 
cardiovascular disease and diabetes. This means the person has high blood pressure, low 
level of (good) HDL cholesterol, high level of (bad) LDL cholesterol, insulin resistance 
and/or glucose intolerance. The condition is called metabolic syndrome, because the risk of 
contracting heart trouble and the risk of getting diabetes are often associated with the same 
persons. The lipid (fat) metabolism and the glucose (sugar) metabolism are closely connected, 
and both are connected to obesity. By treating metabolic syndrome it is possible to prevent type 
2 diabetes and cardiovascular disease.
Researchers link the rise in metabolic syndrome to growing affl uence, changing lifestyles 
and growing urbanisation1367. The syndrome is common in middle-aged and older persons. 
According to Hu et al., the overall prevalence of the metabolic syndrome in non-diabetic adult 
Europeans is 15%1368. The WHO estimates that metabolic syndrome is present in 7–36% of 
European men and 5–22% of women aged 40–55 years1369. According to a 2005 study, 13.7 
% of Chinese adults has metabolic syndrome1370. According to He et al., the prevalence of 
metabolic syndrome is 46% in Beijing elderly people1371, 35% in men, 54 in women1372.1373
These fi gures are important as they point out that the syndrome causes a lot of human suffering 
and huge economic losses. What is interesting to us is that obesity, cardiovascular disease, and 
diabetes are largely nutrition problems.1374 The metabolic syndrome can often be prevented and/or 
treated by diet, where functional foods can be one part of dietary therapy.
Obesity is the basic culprit for many health problems. Obesity increases the risk of 
cardiovascular disease and type 2 diabetes.1375 In Europe, around half of the adult population 
1366  Nutraingredients.com Europe. News Headlines 18/06/2007. 
1367  Functional Ingredients September 2005 China News. 
1368  Prevalence of the Metabolic Syndrome and Its Relation to All-Cause and Cardiovascular Mortality in 
Nondiabetic European Men and Women. Gang et al. 2004. 
1369  Tonkin 2004. 
1370  Functional Ingredients September 2005 China News. 
1371  60 to 95 years.
1372  These fi gures are based on the International Diabetes Foundation defi nition of metabolic syndrome. Yao 
et al. 2006. 
1373  Apparently the situation is worse in the U.S. Around 25 % of Americans have the metabolic syndrome. 
Over 40 % of Americans over 60 have it. Metabolic Syndrome Institute web page at: http://www.metabolic-
syndrome-institute.org/medical_information/mets_epidemic
1374  Chai 2004.
1375  In Europe, a person is considered overweight, if BMI (body mass index) is at least 25, and obese, if BMI 
is at least 30. The Chinese use different cut-off points for overweight and obesity. A person is considered 
overweight, if BMI is at least 24, and obese if BMI reaches 28.
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is overweight1376. China faces the dual problem of malnutrition and obesity. Chronic diseases 
associated to obesity are increasing rapidly in China.1377 20.7 % of Chinese were overweight 
in 19971378. According to a 2005 study, some 18 million adults in China were obese, and 137 
million were overweight1379. Abdominal fat is particularly dangerous.1380 Abdominal obesity is 
associated with insulin resistance and predicts the onset of type 2 diabetes. Abdominal obesity 
also predicts coronary artery disease, more directly than BMI (body mass index).1381
Diabetes is a condition where the body cannot handle glucose (sugar). Hyperglycaemia 
(too much sugar in the blood) appears when pancreatic beta cells can no longer compensate 
insulin-resistance by increasing insulin release.1382 Type 1 and type 2 diabetes have different 
causes and population distributions.1383 Type 1 diabetes cannot be prevented. Type 1 diabetes 
was traditionally called juvenile diabetes, as most children’s diabetes is type 1. Here we only 
discuss type 2 diabetes, as it is most interesting regarding functional foods. Changes in lifestyle 
can delay or prevent onset of type 2 diabetes. Risk factors for type 2 diabetes include, among 
others, obesity, low level of HDL, and high level of triglycerides in the blood.
A worldwide diabetes epidemic is occurring. Around 8% of Europeans and adult Americans 
have diabetes1384. The cause of death for diabetics is often cardiovascular disease, for example 
a stroke.1385 There is no cure for diabetes. Type 1 diabetes is always treated with insulin 
injections, plus diet. Some people with type 2 diabetes can manage their disease with diet and 
exercise alone, others require medicinal treatment. Diet is important for both prevention and 
treatment of type 2 diabetes. Goals of nutritional therapy are: control of blood sugar and blood 
lipid levels, control of hypertension, weight loss, and improving general health. Nutritional 
therapy is thus similar in cases of diabetes and heart disease.
In nutritional therapy, the terms glycemic index and glycemic load are important. Glycemic 
index ranks foods on how they affect our blood glucose levels.1386 Different carbohydrates have 
different glycemic responses, i.e., they have different effects on blood sugar levels. Glycemic 
load of a serving of food is glycemic index (%) multiplied by grams of carbohydrate per 
1376  International Obesity Task Force web page at: http://www.iotf.org/database/documents/
EUPresentationGraphNov06_004.ppt#1.
1377  Chai 2004.
1378  Chai 2004. 
1379  Functional Ingredients September 2005 China News. 
1380  To avoid risks associated with excess body fat, waist circumvention should not exceed 80 cm for female 
and 85 cm for male population.
1381  Metabolic syndrome institute web page at: http://www.metabolic-syndrome-institute.org/medical_
information/defi nition.
1382  Metabolic syndrome institute web page at: http://www.metabolic-syndrome-institute.org/medical_
information/defi nition.
1383  In addition, there is gestational diabetes, which occurs during pregnancy and typically resolves when 
the baby is born. Metabolic syndrome institute web page at: http://www.diabetes.org/gestational-diabetes.
jsp.
1384  British Heart Foundation Statistics Website at: http://www.heartstats.org/datapage.asp?id=4529.
1385  Metabolic syndrome institute web page at: http://www.metabolic-syndrome-institute.org/medical_
information/defi nition.
1386  Glycemic index is the area under the curve of blood glucose produced by an amount of carbohydrate in a 
food, relative to the area produced by the same amount of carbohydrate from a standard source (usually white 
bread or glucose). This means products containing carbohydrates are compared to a product that affects the 
blood sugar levels the most.
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serving. Epidemiological studies suggest that glycemic index and glycemic load are associated 
with increased risk of type 2 diabetes and cardiovascular disease. High-glycemic-load diets 
could increase risk of type 2 diabetes by increasing insulin demand, which could lead to beta 
cell exhaustion and glucose intolerance. These diets can also make the body produce counter-
regulatory hormones which would increase insulin resistance, insulin demand and glucose 
intolerance. These mechanisms would create diabetes.
Oral medicines used to treat type 2 diabetes function by increasing insulin production, 
decreasing blood glucose or enhancing the body’s ability to use its own insulin more effectively. 
A drug called metmorfi n enhances insulin sensitivity.1387 Thiazolidinediones are also insulin 
sensitising, and may improve insulin resistance.1388
Cardiovascular diseases represent today the principal cause of mortality in developed 
countries. Heart disease is the leading cause of death for American, European, and Chinese 
adults1389. The WHO presumes that CVD will become the primary cause of death worldwide 
by the year 2020. Prevalence of hypertension among Beijing residents aged 15–69 was 24.8% 
in 2001, and prevalence of coronary heart disease 7.22%. Of Beijing residents, 2.14% had had 
a stroke. In Shanghai, the pattern is similar. 1390 Consumption of animal-based products per 
capita has increased rapidly in China. It has tripled since the 60’s.1391 Consumption of fat and 
meat continues to increase among Chinese urban citizens.1392
The cardiovascular system is made up of the heart and blood vessels. Cardiovascular 
diseases (CVD) include coronary heart disease (coronary artery disease, ischemic heart disease), 
stroke (angina pectoris, heart attack), hypertension, and rheumatic heart disease (arrhythmia). 
Causes of cardiovascular disease are multiple and many lifestyle factors are related to the 
risk of CVD. Risk factors for cardiovascular disease are, among other things, hyperlipidemia, 
hypertension1393, obesity and diabetes. Hyperlipidemia means excess of certain unbenefi cial 
fats in the blood: LDL cholesterol1394, triglycerides and phospholipids. Hypertension is defi ned 
as high blood pressure.
Several cardiovascular disease risk factors can be affected with diet. Goals of 
cardiovascular disease nutritional therapy are: to prevent obesity and type 2 diabetes, and to 
1387  Metabolic syndrome institute web page at: http://www.metabolic-syndrome-institute.org/medical_
information/prevention_and_treatment.
1388  Metabolic syndrome institute web page at: http://www.metabolic-syndrome-institute.org/medical_
information/prevention_and_treatment.
1389  Functional Ingredients September 2005 China News. 
1390  Chai 2004.
1391  Chai 2004.
1392  Chinese disease patterns show different characteristics in urban vs. rural areas. The transition 
in urban areas from communicable to non-communicable diseases is almost complete. Heart and 
brain vascular diseases, cancer and diabetes are increasing rapidly. In rural areas, communicable, 
endemic diseases such as tuberculosis are still not under control. Chai 2004.
1393  Blood pressure is high if systolic pressure is at least 140 mmHg and diastolic pressure at least 90 
mmHg.
1394  Excess of blood cholesterol is called hypercholesterolemia. There are two main types of blood cholesterol: 
LDL and HDL. LDL (low density lipoprotein) is ‘bad cholesterol’ and related to CVD risk. HDL (high density 
lipoprotein is ‘good cholesterol’ and inversely related to CVD risk. Reducing serum LDL cholesterol and 
increasing HDL cholesterol decreases risk of CVD. This is widely established.
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maintain optimal levels of lipid profi les and blood pressure.1395 Medicinal products to tackle 
dyslipidaemia (wrong kind of fat in the blood) include statins and fi brates. Statins act on LDL 
cholesterol, and fi brates act on HDL cholesterol and triglycerides1396. Hypertension is treated 
with medicines such as diuretics, alpha blockers, beta blockers, calcium channel blockers, 
angiotensin receptor blockers, ACE inhibitors, sympatholytics, and vasodilators1397.
6.2.2 Use of the Berries in Traditional Chinese Medicine
The medicinal use of hawthorn has a long history.1398 In ancient times, the Chinese herbalists 
mainly used dried fruits of hawthorn to improve digestion. For the past thirty years, the use of 
hawthorn as a strengthener of the cardiovascular system has been noted and adopted by Chinese 
herbalists. Western applications of hawthorn have been verifi ed by Chinese researchers and 
added to lists of hawthorn applications in Chinese medicine. There are now several hawthorn 
products on the market for strengthening heart function, lowering blood lipids, and dilating 
blood vessels to promote blood circulation.1399
According to “The Essentials of Traditional Chinese Herbal Medicine”, hawthorn fruit 
(Fructus Crataegi, Shanzha) can promote blood circulation and release blood stasis1400. 
Active components include organic acids such as crataegic acid, citric acid, and caffeic acid, 
fl avonoids such as vitexin and quercitin, and vitamins such as vitamin C, ribofl avin, and carotenes. 
Hawthorn fl avonoids can increase blood fl ow in coronary blood vessels and lower blood pressure. 
Hawthorn fruit can also increase serum HDL cholesterol and reduce LDL cholesterol, and prevent 
atherosclerosis. For cardiovascular diseases such as hypertension, hyperlipidemia and coronary 
heart disease, hawthorn fruit is used as syrup, tablet, instant power and tincture. Average dosage is 
10-15grams of raw or fried fruit; a large dosage is 30grams. A warning goes as follows: “Intake of 
an extra-large dosage of hawthorn may produce a sedative effect and inhibit respiration, although 
the drug is of low toxicity.”1401
Chinese wolfberries, also known as Goji berries, come from the Lycium barbarum plant, 
a vine that grows in China, Tibet and other areas of Asia. Wolfberry fruit (Fructus Lycii, 
Gouqizi) can, according to “The Essentials of Traditional Chinese Herbal Medicine”, treat 
1395  This means LDL 3.5-5 mmol /l with no specifi c goal on HDL cholesterol. Systolic blood pressure should 
be under 120 mmHg and diastolic blood pressure under 80 mmHg.
1396  According to Taskinen, fi brates seem to be the optimal drug for correcting dyslipidaemia in patients with 
the metabolic syndrome who have low LDL-cholesterol. According to her, the management of these subjects 
is in clinical practice commonly neglected despite their increased risk of cardiovascular disease. Metabolic 
syndrome institute web page at: http://www.metabolic-syndrome-institute.org/medical_information/expert_
point_of_view/taskinen.
1397  Messmer 2006. 
1398  Food use of hawthorn is also important. Hawthorn fruits are in China used as a food to make 
many kinds of snacks, for example haw fl akes, which are sold also in all the large cities in the U.S. 
The fruits, which are called shānzhā in Chinese, are also used to produce jams, jellies, juices, tea, 
wine, etc. Wikipedia. Article on hawthorn. http://en.wikipedia.org/wiki/Crataegus.
1399  Dharmananda. 
1400  The Essentials of Traditional Chinese Herbal Medicine 2003, 126. Another important indication is 
digestion trouble. Hawthorn can promote digestion and release stagnation of food. 
1401  The Essentials of Traditional Chinese Herbal Medicine 2003, 126-127.
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“diabetes mellitus with endogenous heat due to defi ciency of yin”. For this purpose, wolfberry 
fruit is combined with rehmannia, fi gwort root (Radix Scrophulariae, Xuanshen), Chinese 
yam, milkvetch root and magnoliavine fruit (Fructus Schisandrae, Wuweizi). It is stated that 
wolfberry fruit can apparently and persistently reduce blood sugar and lower blood pressure. 
Normal dosage is 5-10 grams of berries. A warning goes as follows: “Wolfberry fruit should 
not be prescribed for patients with diarrhoea due to defi ciency of the spleen, because it can 
replenish yin and moisten dryness.”1402
Hawthorn and Chinese wolfberry are mentioned in every common book on traditional Chinese 
medicine. According to Cai, hawthorn is used to lower blood pressure and blood cholesterol1403, 
wolfberry fruit to lower blood pressure and blood sugar1404, and wolfberry root to treat high cholesterol1405. 
According to Zhao, hawthorn fruit is used to lower blood pressure1406, and wolfberry fruit to treat 
diabetes1407. According to Hou et al., hawthorn fruit is used “to promote blood circulation and disperse 
blood stasis, lower blood pressure and the level of blood lipids1408”, and wolfberry to treat diabetes1409. 
Hawthorn is also used to treat obesity1410.
Emblic leaffl ower is apparently not among the most commonly used medicinal plants, as 
the general Chinese books on traditional Chinese medicine do not recognise the plant. This is 
probably because roots of its medical use are in ancient India, where it was respected as “Saint 
fruit”1411 and because it was typically used by the Tibetan minority of China. Even today the 
fruit is most popular in India. The plant is, however, recorded in the Chinese pharmacopoeia. 
It is used, among other things, to cure “internal heat”, “blood heat”, “blood disease”, and high 
blood pressure.1412
6.2.3 Scientifi c Evidence on the Berries
It was stated above that hawthorn, emblic leaffl ower, and barbary wolfberry have potential 
for use in functional foods. This is not just because they are part of the above-mentioned 
superfruit trend, but because they actually have scientifi cally proven benefi cial effects on risk 
factors of cardiovascular diseases, type 2 diabetes, and the metabolic syndrome. The effects 
are mainly due to fl avonoids and triterpene acids in hawthorn, polysaccharides and alkaloids 
in barbary wolfberry, and vitamin C and tannoids in emblic leaffl ower. We will not list all the 
available scientifi c research on the berries, but refer to some of the latest studies that might be 
relevant in supporting health claims on our functional foods.
Hawthorn fruit has been found to have:
1402  The Essentials of Traditional Chinese Herbal Medicine 2003, 254-255.
1403  Cai 1993, 107.
1404  Cai 1993, 102.
1405  Cai 1993, 71. 
1406  Zhao 1996, 85.
1407  Zhao 1996, 79. 
1408  Hou 1994, 61. 
1409  Hou 1994, 71.
1410  Hou 1994, 142.
1411  Yalin Health company web page at: http://www.yalin-health.com/en/info/index.asp?id=5.
1412  Yalin Health company web page at: http://www.yalin-health.com/en/info/index.asp?id=5.
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hypolipidemic activity – 1413,
positive effects on arteries and coronary fl ow – 1414,
positive effects on blood pressure – 1415, and
antioxidant activity – 1416.
Emblic leaffl ower fruit has been found to have:
hypoglycemic activity – 1417,
hypolipidemic activity – 1418,
cardioprotective effects – 1419, and
antioxidant activity – 1420.
Chinese wolfberry fruit has been found to have:
hypoglycemic activity – 1421,
hypolipidemic activity – 1422, and
antioxidant activity – 1423.1424
Hypoglycaemic is something that lowers the level of sugars in the blood. Something that is 
hypolipidemic lowers the level of lipids. Antioxidants protect cells from damage. The berries 
could be used in functional foods as such (dried), or their active ingredients could be captured. 
Some of the more technological options for functional foods are:
oils, –
“phenolic fractions”, and –
glycoconjugates (barbary wolfberry). –
6.3 Which Rules to Follow?
In chapter 2, we have discussed the European and Chinese legal systems on foodstuffs and 
medicines from regulators to implementing agencies. Norms on several levels and of several 
types are relevant to legal evaluation of our functional food products.
1413  Xiong et al. 2004. Chen et al. 2002.
1414  Pittler et al. 2008. See also Cai et al. 1999, which was on leaf extract, not berries.
1415  Walker et al. 2006.
1416  Gong – Wang 2005. Zhang et al. 2001.
1417  Suryanarayana et al. 2007.
1418  Anila – Vijayalakshmi 2002. Anila – Vijayalakshmi 2003. Augusti et al. 2001.
1419  Liu et al. 2003. Liu et al. 2005.
1420  Kaur – Kapoor 2002. Bajpai et al. 2005.
1421  Tian – Wang 2005.
1422  Jiang et al. 2007. Ma et al. 2005. 
1423  Xin et al. 2007. Wu et al. 2004.
1424  Luo et al. 2004. relates to all of these actions.
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6.3.1 International Agreements and Cases
Usually, global agreements and standards like Codex Alimentarus agreements have their 
effects on private parties through the member states by their legislative organs and enforcement 
organs. The European Court of Justice has stated that WTO agreements are not intended 
to confer rights on individuals. It has still found some situations where private parties are 
allowed to rely on WTO agreements as interpreted by the WTO Dispute Settlement Body. 
According to Pere, these situations are limited in applicability and leave important gaps to 
rights of private persons. Although WTO law is binding, it seems to lack effective remedies. A 
company cannot necessarily receive any compensation for damage suffered due to a Member 
State not complying with their WTO obligations or as a result of countermeasures to such 
WTO-illegal action.1425
The relationship between WTO law and Chinese law is similar: if China has failed to meet 
a WTO obligation, a private company can probably not resort to WTO law against the Chinese 
government. When China adjoined the WTO, there was academic debate on whether PRC 
courts should directly apply WTO agreements1426. According to Jie, there are no clear rules 
on the hierarchy between Chinese laws and treaties. The ambiguous hierarchy is deliberate, 
leaving room for discretion for Chinese legislators and courts.1427
6.3.2 EU
When in Europe, one must fi rst look into the Community level Regulations and Directives. With 
foodstuffs, the General Food Regulation gives general principles on producer responsibilities. 
Concerning functional foods, the Novel Food Regulation and the Regulation on Nutrition 
and Health Claims are often relevant. With medicines, the Medicinal Products Directive is 
the most important one. The directive was recently amended with regard to traditional herbal 
medicinal products.
Secondly, there are laws by Member State parliaments, and lower level decrees and 
decisions by Member State ministries. In Finland for example, the Food Act is very similar to 
the European General Food Regulation. The EU principles such as the precautionary principle 
are transferred into Member State laws with little room for discretion. The European and 
national laws may be defi ned as ‘hard law’, as they have their base in EU Treaties and Member 
State constitutions. Hard law is enforceable by European and Member State courts. If rules are 
not followed, the functional food product can be taken off the market or have its marketing 
claim prohibited. Also civil liability and criminal sanctions might follow.
So-called ‘soft law’ is important in connection with foodstuffs and medicines. With 
foodstuffs, one must follow guidelines by the European Commission, the EFSA, and national 
food authorities. Concerning novel foods, the Commission Recommendation includes 
detailed requirements of the application procedure. On health claims, the EFSA has produced 
1425  Pere 2005, 85. We will not go further into analysing the direct effect of WTO law to private persons. See 
Pere 2005 on European case law thereof.
1426  Hu 2000, 104.
1427  Jie 2008, 108.
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guidelines for example on how to draft applications1428. Of national soft law, the Finnish 
guides on health claims and food supplements by the Finnish Food Safety Agency might be 
relevant for our purposes. With medicines, the “Notice to Applicants” by the Commission and 
scientifi c guidelines by the EMEA are important sources of law.
Legally, guidelines are not binding. However, if an applicant chooses not to follow a 
guideline, this decision must be explained and justifi ed in the dossier. The courts might give 
administrative soft law the weight similar to hard law norms. The problem of reliability of soft 
law is relevant also to a lawyer’s responsibility towards his client. Normally, a lawyer cannot 
be sued for negligence if he bases his advice on soft law. If the soft law cannot ultimately be 
enforced, the client cannot sue the maker of the soft law, either. This is because the producer 
of soft law can revert to the fact that soft law is non-binding guidance only.
Scholars of legal theory have listed attributes of soft law that add weight to it. The evaluation 
depends on:
how the regulation is created (quasi-democracy, stakeholder involvement), –
formal recognition of the regulation (referral to soft law in hard law), –
degree of utilisation of the regulation (the more used, the more binding), and –
moral acceptability (the more compatible with current values, the more binding). – 1429
Based on these criteria, typical European soft law (such as EFSA and EMEA advice on how 
to draft applications) can be regarded as fairly binding.
To keep up the good reputation of the industry, and to be respectable among other industry 
players, one should also have a look at self-regulation guidelines. There are guidelines 
by the European food industry association (CIAA) and the European Health Product 
Manufacturers.
One could also decide not to follow the rules. All EU Member States foresee fi nes and/or 
imprisonment as criminal penalties for the sale of unsafe products, for example unhygienic 
foods or counterfeit medicines. Also misleading advertising, for example presenting fake 
health claims, is a crime. In civil proceedings, damages may be imposed on consumers, 
business partners, and sometimes also to competitors.
6.3.3 China
In China, the food and medicine law consists of certain basic laws given by the National 
People’s Congress or the State Council, and several supplementing pieces of regulation given 
by the Ministry of Health or the State Food and Drug Administration (SFDA). Compared to 
the European system, Chinese laws are more fragmented, each law covering one aspect of the 
foodstuff and medicine business. These separate pieces of regulation must be read together.
If we decide to sell our berry products as foodstuffs, the general Food Safety Law and 
particularly the Health Food Regulation are most relevant to us. The original Health Food 
Regulation of 1996 has been supplemented by over 20 Notifi cations by the Ministry of Health 
1428  See EFSA pre-submission health claim guidance for applicants 2007, and EFSA scientifi c and technical 
health claim guidance for applicants 2007.
1429  Koulu 2009, 132.
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and the State Food and Drug Administration. These govern good manufacturing practice, the 
application procedure, labelling, and advertising of health foods. In the future, health food 
regulations will be consolidated in a single piece of law.
The Chinese Regulation on Novel Foods will possibly be relevant if we use a raw material 
that has not traditionally been used in China. The new Novel Food Regulation came into force 
in December 2007, replacing the original regulation dating from 1991. However, health foods 
and novel foods are separate legal categories in China, and novel foods cannot bear health 
claims. As we probably want to market our functional foods as health-enhancing, we will have 
to register them as health foods. In this case, both the safety and effi cacy of the product will be 
examined in the health food procedure, and the novel food procedure does not apply.
If we decide to sell berry products as traditional medicines, the rules of the general Medicine 
Administration Law apply. New legislation particularly on traditional medicines is impending. 
It will include precise rules on safety and effi cacy of traditional medicines.
Besides national rules, there are also local rules by cities and provinces. In Hong Kong for 
example, foodstuffs and medicines are mainly regulated together in Part V (Food and Drugs) 
of the Public Health and Municipal Services Ordinance (Cap. 132)1430. Sometimes local rules 
contradict with national rules in hygiene issues, for example. In this case, it might be advisable 
to abide by the stricter rules.
6.4 Foodstuffs or Medicines?
Based on the evidence above, we assume the three berries (or their fragments) to have a 
scientifi c base for use in health-enhancing products in EU and China. These products would 
be aimed at fi ghting the metabolic syndrome. First, we must consider whether these products 
would legally be treated as foods or medicines. In chapter 3, we have discussed the European 
and Chinese rules on categorisation.
6.4.1 EU
6.4.1.1 The Choice between the Two Categories
In EU law, there is no defi nition or category for functional foods. The categories of foodstuffs 
and medicines have traditionally been distinct. Whether the product is a food or a medicine 
is an important question as there are two different sets of law: one for foods and another for 
medicines. The most important difference between foodstuffs and medicines is that a risk/
benefi t ratio is applied to medicines: safety and effi cacy are assessed simultaneously and side 
effects are only allowed if the benefi ts exceed the risks.
For foods, the safety requirement is more absolute. Foods must not provoke any health 
hazards. The notion of food side effects would not be acceptable to consumers. There is one 
important exception to this: allergens in foods are allowed, and allergens can even be added to 
foods as additives. This means foods are basically safe for people without allergies. A further 
1430  The Government of Hong Kong Special Administrative Region. Food and Environmental Hygiene 
Department web page at: http://www.fehd.gov.hk/safefood/foodlaw1.html.
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limit to absolute safety is that various harmful chemicals and contaminants are allowed in 
foods, as long as their amounts do not exceed the set maximum limits, see chapter 4. With 
regards to marketing claims, medicinal claims are prohibited from foods, but disease risk 
reduction claims are allowed if substantiated.
Businesses and consumers normally see functional foods as foods, not medicines This can 
be derived from the term itself: the producers and marketers call their products functional 
foods. Consumers don’t normally see functional foods as medicines, either. Functional foods 
are not taken to treat some acute condition; they are instead consumed to gain a future benefi t. 
As opposed to foods, medicines are consumed to gain an immediate effect.
In EU law, the separation of foodstuffs and medicines is derived from their defi nitions. A 
functional food could be regarded as a medicinal product based on either its functions or its 
presentation. The defi nition of medicines says: products are medicines if they:
function as medicines and/or A) 
are presented as medicines.B) 
According to the defi nition of food, those that are medicines are not foods. A product cannot 
be both. An important clarifi cation was recently added to the defi nition of medicines: unclear 
cases are regarded as medicines. Classifi cation as medicine is legally possible for functional 
foods, because the previously mentioned defi nition of medicinal products does not exclude 
food-form products. A functional food could thus, according to EU law through pre-market 
authorisation or registration, receive the status of a medicinal product.
Basically, the marketer must himself know and decide whether the product belongs under 
food law or medicine law. The form of the product does not determine classifi cation. The 
decision is based on product composition, the known effects of the product ingredients in 
human body, and the presented therapeutic use. When making the decision on which legal 
category to pursue, the benefi ts and costs of each option need to be weighed:
Firstly, the pre-market procedures are separate for foodstuffs and medicines. The possible 
novel food and health claim procedures for foods are demanding, but still not as burdensome 
as the herbal medicine authorisation procedure. The new registration procedure for traditional 
herbal medicines is available to some products.
Secondly, available claims differ between foodstuffs and medicines. For foodstuffs, health 
claims are allowed, but medicinal claims prohibited. A food cannot have medicinal functions 
or medicinal claims. Even if the product has signifi cant health effects, we might be willing to 
settle for food status. This is because the consumer impact of a disease risk reduction claim 
might be almost as strong as that of a medicinal claim.
Thirdly, we must keep in mind that for medicinal products, there are limitations on available 
marketing channels1431. These marketing channels for herbals vary in different EU Member 
States. In Finland, around half of the authorised herbals authorised according to the old law 
can be sold in food stores, and the other half can only be sold in pharmacies. None of these 
herbals require prescription.1432 According to the new legislation, herbal medicinal products 
1431  National Agency for Medicines web page at: http://www.laakelaitos.fi /laaketeollisuus/luokittelu/
luokittelun_jalkeen/index.html
1432  National Agency for Medicines web page at: http://www.laakelaitos.fi /uploads/Laaketeollisuus/
Rohdokset/Rohdosluettelo_2006_2_28.pdf.
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can only be sold in pharmacies, but traditional herbal medicinal products can also be sold in 
food stores.
Even if we consciously decided to go with the medicine option, it might not be viable in 
practice. It might prove to be diffi cult or impossible to get a medicinal product license for 
something that looks, tastes, and feels like food. This is because the authorities seem to want 
to keep medicines and foods separate, regardless of their legal defi nitions. For example, the 
Finnish practice is “margarine cannot be medicine”.
We must also remember that the categorisation decision does not include authorisation. 
If a product is classifi ed as a medicine, this decision does not entail that the product will be 
authorised as a medicine. It merely means that without appropriate pre-market procedures, the 
product is illegal. If the product is categorised as food, this decision does not amount to an 
approval that the product may legally be sold under food law. It merely means that the product 
must comply with food law requirements.
6.4.1.2 Grounds for the Classifi cation Decision
At times we are unsure whether the functions of our product are medicinal. This typically 
means that our product contains healthy or medicinal ingredients but we still want to sell it as 
a food, for the aforesaid reasons. In this case, we either need to ask for a classifi cation decision 
before we market the product, or just sell the product as food and wait for the authorities to 
possibly react.
Ultimately, national authorities resolve whether a product is a food or a medicine. This 
enables every EU Member State to divide functional foods into foodstuffs and medicines 
based on their own criteria. For example, according to Finnish law1433, the National Agency 
of Medicines will, if needed, decide whether a substance or a preparation is to be regarded 
as a medicinal product. In unclear cases it is “recommended” that the producer apply for a 
classifi cation decision.1434
Categorisation in Finland is based on the pharmacopoeia drafted according to the 
Medicines Act1435. The pharmacopoeia is a list of substances regarded as medicines, and it 
includes quality requirements for each medicinal substance. According to the Decision on the 
Pharmacopoeia, substances in Annex 1 of the Decision are medicines. Herbals in annex 2 and 
vitamins and minerals exceeding the daily dose in Annex 3 can be regarded as medicines1436. 
Also other substances and herbals equivalent to substances and herbals in Annexes 1 and 2 
and corresponding to the defi nition of medicines can be regarded as medicines. 1437 Basically, a 
product will be classifi ed as a medicine, if it contains functional ingredients in quantities that 
possess a pharmacological effect. The defi nition of ‘pharmacological’ does not exist in law.
1433  Section 6 of the Medicinal Products Act.
1434  Food supplement guide, updated 2006. Page 19.
1435  Section 83 of the Medicines Act states that the National Agency of Medicines must every third year, of 
more often if necessary, regulate on a pharmacopoeia (lääkeluettelo, list of medicines) that takes into account 
the defi nition of medicinal product etc.
1436  A new pharmacopoeia (1179/2006) came into force in the beginning of 2007. Compared to the previous 
pharmacopoeia given three years earlier, no new herbs were added to Annex 2.
1437  National Agency for medicines web page at: http://www.laakelaitos.fi /laaketeollisuus/luokittelu/
luokittelun_perusteet/index.html.
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If medicines, our functional berry products would be regarded as herbal medicines. An 
herbal medicinal product is a medicinal product exclusively containing as active ingredients 
one or more herbal substances or one or more herbal preparations. Herbal substances are, 
among others, either dried or fresh plant parts. Herbal preparations are herbal substances 
subjected to treatments such as extraction, distillation, expression, fractionation, purifi cation, 
concentration or fermentation. Herbal preparations include comminuted or powdered herbal 
substances, tinctures, extracts, essential oils, expressed juices and processed exudates. This 
means subjecting our berries to a technological procedure will not change their legal category. 
Dried or fresh berries would legally be herbal substances, and fractions and oils would legally 
be herbal preparations.
However, plant parts and plant extracts can of course also be used as foods. What resolves 
the issue of foodstuff vs. medicine is whether the product is either presented as a medicine or 
functions as a medicine. It is fairly easy to avoid our product being classifi ed as a medicine 
by presentation. We simply must not mention that it will cure, treat or prevent a disease. For 
example, we cannot use claims like “for heart disease” or “to prevent diabetes”.
The medicinal function is more complicated. The new European defi nition of medicinal 
product addresses the issue of what kind of functions are to be considered medicinal functions. 
Substances which “may be used in or administered to human beings either with a view to 
restoring, correcting or modifying physiological functions by exerting a pharmacological, 
immunological or metabolic action” are medicinal products. It is also stated in the directive 
that any unclear borderline cases are to be treated as medicines, not foods. This new rule will 
also affect our situation: if we want to avoid our products being classifi ed as medicines, we 
need to be certain that our products do not constitute unclear cases but are clearly foods.
What makes the categorisation decision more diffi cult is that the same plant raw material 
can be used in products categorised as foodstuffs and other products that will be categorised as 
medicines. Garlic is an example of a plant that can be used both as a food and as a drug. Garlic 
products are marketed in the European Union both as foodstuffs and as herbal medicinal 
products. All EU countries have garlic foodstuffs on their markets, and garlic medicinal 
products are available in some EU Member States.1438 Likewise, the Finnish Food Agency 
has interpreted that a commonly known medicinal plant Echinacea purpurea can also be sold 
as food. In this case, the use of the medicinal plant must be based on something else than 
the medicinal effect of the substance or herb. It is clear that there may be two products on 
the market that contain the same substances or herbs but to which different rules apply. It is 
unclear what these, other than medicinal uses might be, in the case of Echinacea.
Because of different traditions in different EU countries, a product can be classifi ed as a 
medicinal product in one EU Member State and as a foodstuff in another. Often the marketer 
would prefer the product being classifi ed as food. For example, many products containing 
medicinal plants are in Germany classifi ed as herbal medicinal products requiring a Product 
License, but are in Great Britain sold as foods without any pre-market approval. Some of 
the vitamin preparations that are classifi ed as medicines in Finland are classifi ed as foods in 
several Member States. Preparations that contain the hormone melatonine are classifi ed as 
medicines in most European countries, but not all.1439
1438  Kroes 2006. 
1439  Enkovaara 2002, 22.
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If we applied for a classifi cation decision, and it resulted in our products being classifi ed as 
medicines because of medicinal functions, we would have three alternatives:
Withdraw from all plans of marketing. –
Apply for authorisation as herbal medicine. –
Change the product so that it no longer has medicinal functions, and then sell it as food. –
6.4.1.3 Finnish Categorisation Cases
To predict the outcome of the categorisation decision, we might want to look at how similar 
cases have previously been treated. The Finnish Agency of Medicines has an online record of 
classifi cation cases, classifi cation decisions resulting in verdict ’non-medicine’ since the beginning 
of 1995 and decisions resulting in verdict ‘medicine’ since the beginning of 20011440. The category 
of ‘non-medicines’ in practice includes foods and cosmetics.
The classifi cation is in each case based on:
the information given to the Agency by the applicant of the classifi cation decision, –
the information given in product marketing, and –
scientifi c literature on the effects of product ingredients. – 1441
Again, the two important elements of the classifi cation decision appear. These are product 
functions and the marketing claims.
In 2006 (published by 11 December 2006), there were 16 classifi cations as medicines, and 
13 as non-medicines.
The non-medicines were:
tiger balsam for sore shoulders, containing menthol, mint, eucalyptus etc. –
antiseptic mouth wash –
sport nutrition (recovery and fat-free muscle building) –
various food supplements containing vitamins (A,B,C,D,E), minerals, fi sh oils and  –
omega three fatty acids
Aloe Vera extract and vitamin C, food supplement –
salt for horses, for constipation –
clam etc. for dogs’ joints –
Psyllium Ispaghula bark powder for horses, for problems related to eating sand. –
Of these, only Aloe Vera and Psyllium Ispaghula were plant-based products.
If medicinal marketing claims, i.e. a therapeutic indication, had appeared on the 
Aloe Vera label, it would no doubt have been considered a medicine. Aloe Vera (in 
Finnish, medicinal Aloe) is on the Pharmacopoeia Annex 2 list on herbals that can be 
1440  They have also a third category, which covers health care appliances and devices.
1441  National Agency for Medicines web page at: http://www.laakelaitos.fi /laaketeollisuus/luokittelu/
luokittelupaatoksia/index.html.
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regarded as medicines. Apparently, the medicinal function was in this case not strong 
enough for the product to be regarded as a medicine.
Psyllium Ispaghula is used for stomach troubles because of its fi bre content1442. 
The plant is not listed in the pharmacopoeia, and has no pharmacological effect and 
therefore it is regarded as food, not medicine.
The medicines in 2006 were:
Melon extract etc. for vitiligo – 1443
Glucosaminesulfate for joints –
Benzoyleperokside for acne –
Antibacterial mouth wash –
Spirulina platensis –  (algae) for malnutrition and lack of nutrients
Citrus aurantium – , green tee extract, guarana extract etc. for weight management
‘Amino acid enzymes’, hawthorn berry extract, vitamins etc. for digestion (two products) –
Colostrum – 1444, Echinacea purpurea, eucalyptus, menthol and vitamins for sore throat
Cranberry extract for urinary tract infections – 1445
Saw palmetto ( – Sabal serrulata) 1446 extract, nettle1447 extract, lycopene for prostate 
problems and impotence1448
Boswellia – 1449 extract etc. for arthrosis1450
Vaccinium myrtillus –  (blueberry) and Tagetes erecta1451 etc. for night vision and eye 
diseases1452
Soy, vitamins etc. for eye health – 1453
Symphtytum offi cinalis –  (blackwort)1454 extract etc. for joints, muscles, bruises, cuts etc.
Annona muricata – 1455 powder for health enhancement and immunity.
1442  “Psyllium is a soluble fi bre used primarily as a gentle bulk-forming laxative. It comes from a shrub-like 
herb called plantain that grows worldwide.” Atlanta Journal-Constitution web page at: http://www.ajc.com/
health/altmed/shared/health/alt_medicine/ConsSupplements/Psylliumcs.html.
1443  Also known as leukoderma, in Finnish: valkopälvi.
1444  In Finnish: ternimaito. The milk that a cow produces after giving birth.
1445  The applicant had classifi ed the product as a food supplement, but medicinal claims had been presented 
in advertising.
1446  In Finnish: sahapalmu.
1447  In Finnish: nokkonen.
1448  The applicant had classifi ed the product as a food supplement, but medicinal claims relating to prostate 
problems and impotence had been presented in advertising.
1449  Boswellia is a genus of trees that have pharmacological uses particularly as anti-infl ammatories. 
Wikipedia. 
1450  The applicant had classifi ed the product as a food supplement, but medicinal claims relating to arthrosis 
(In Finnish: nivelrikko) had been presented in advertising.
1451  In Finnish: isosamettikukka.
1452  The applicant had classifi ed the product as a food supplement, but medicinal claims had been presented 
in advertising.
1453  The applicant had classifi ed the product as a food supplement, but medicinal claims had been presented 
in advertising.
1454  In Finnish: rohtoraunioyrtti.
1455  Other names: Graviola, soursop, Brazilian paw paw, guanábana. Raintree Nutrition company web page 
at: http://www.rain-tree.com/graviola.htm.
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In this list, there are several plant-based products. In 2006 the Agency had not specifi ed whether 
the classifi cation was based on medicinal claims or product function. It is clear that almost all 
of the above-listed products would have been classifi ed as medicines just because of the claim 
used. If a product is marketed for prevention or treatment of a disease, it is always considered 
a medicinal product. One cannot claim, for example, “for vitiligo” or “for arthrosis” if one 
wants to sell the product as food.
Some of the above could also have been classifi ed as medicinal products by function, 
even without medicinal marketing claims. For example Echinacea, Symphytum offi cinalis 
and Sabal serrulata are well-known medicinal plants that are listed in the pharmacopoeias. 
Products containing these plants are classifi ed as medicines, if they are present in quantities 
that have a pharmacological effect on the body.
Cranberry and blueberry of the berries in the above list are not listed in the pharmacopoeia, 
even though they do have scientifi cally proven health functions. Hawthorn, on the other hand, 
is listed in the pharmacopoeia. We will return to the three chosen berries (hawthorn, emblic 
leaffl ower, and barbary wolfberry) in the next chapter.
The non-medicines of the year 2005, consist of, for example:
pastille containing 17 % Aloe Vera juice –
artichoke ginseng tea, 99 % artichoke, 1 % ginseng –
herbal tea containing: 90 % Mulberry, 10 %  – Chrysanthemum fl ower
refreshing drink containing  – Angelica archangelica1456 leaf extract
muscle relaxing massage cream containing  – Angelica archangelica etc.
food supplement containing:  – Kaempferia pafi fl ora 75 mg, Butea superba 50 mg, 
Zingiber offi cinale 50 mg, Anamitra Cocculus W & A-leaf 25 mg, Nelumbo nucifera 
Gaertner-leaf 25 mg, Piper nigrum, linnseed 25 mg
herbal tea containing:  – Polygonum multifl orum 15 %, Tinaspora sinensis mer 50 %, 
Piper lolot C 10 %, Glychyrrhiza uralensis 5 %, Cortex acantho panasis 10 %, Rhizoma 
imperatae 10 %.
The refreshing drink product contained Angelica archangelica 1.09mg/l. The massage 
cream contained Angelica archangelica 0.6 %. Angelica archangelica is a commonly known 
medicinal plant, and the decisions to categorise these two products as foods were based on the 
low quantities of the medicinal plant.
The non-medicines from 1995 to the end of June 2004 consist of:
Aloe Vera use (1996) –
Ecoway Noni (2001) –
Ginseng Tea (Special) (2003) –
Guarana brasil (1996) –
Maui Noni (1 tablet every 3rd day) (2004) –
Green Echinacea tea (2003) –
This information from before 2005 is not very useful as the compositions of the products are 
not given and it is not explained why the product was classifi ed as a non-medicine.
1456  In Finnish: väinönputki.
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Medicines from 2001 to 20051457 consist of, for example:
Ginseng tablet, containing ginsenosides 8.3 mg/tablet –
Ginseng extract, corresponding to 340mg ginseng root/tablet –
Ginseng root 100mg –
Ginseng extract 100mg, ginsenosides 24mg/tablet –
Ginseng extract 100mg, 80mg ginsenosides –
Ginseng radix 70% –
Ginseng (ginsenosides 8mg) –
Echinacea radix –  400mg
Echinacea  – extract 33.6% (168.7mg /tablet)
Silybum marianum –  (milk thistle, holy thistle)1458 extract
Cordyseps sinensis  – (Cordyseps mushroom, caterpillar fungus)1459 75%
Cordyseps sinensis –  1000μg. Chrome 200μg. sport nutrition
Cordyceps sinensis –  (part of powder mix) 2.61g/11.8g, Gingko biloba1460 (part of powder 
mix) 1.15g/11.8g
Gingko biloba –  tea 15% (0.3g/tea bag)
Valeriana offi cinalis –  (valerian)1461 44g fresh root/ 100g powder
Valeriana offi cinalis –  600mg
Sennae folium –  (senna leaf)1462 tea 30%
Frangulae cortex – 1463 tea 30%
Eleutherococcus senticosus  – (Acanthopanax senticosus, green ginseng)1464 15% (0.3g/
tea bag)
Nappy rash cream,  – Hypericum perforatum (St. John’s Wort)1465 14.5%, Arnica Montana 
(mountain arnica)1466 1.9%
Liquorice containing  – Hypericum perforatum 0.1%, Valeriana offi cinalis 0.1%, 
Cimicifuga rasemosa (black cohosh, black snakeroot)1467 0.1%
The list of products classifi ed as medicines in 2001 to 2005 is useful, as the Agency has provided 
grounds for each classifi cation decision. All of the above were categorised as medicines based 
on their function. If a product is categorised as a medicine by function, it means the product has 
physiological or pharmacological effects on the body. In these cases this was due to the presence 
1457  National Agency for Medicines web page at: http://www.laakelaitos.fi /uploads/Laaketeollisuus/
luokittelu/laakkeet2001-2005.pdf.
1458  In Finnish: maarianohdake. This plant is used in liver diseases because it enhances liver tissue renewal. 
Yrttitarha project web page at: http://www.yrttitarha.com/kanta/maarianohdake/.
1459  In Finnish: kiinanloisikka. This is a mushroom used in traditional Chinese medicine for general well-being as 
it helps the liver, kidneys, etc. Sahelian, Ray: web page at: http://www.raysahelian.com/cordyceps.html.
1460  In Finnish: neidonhiuspuu.
1461  In Finnish: rohtovirmajuuri.
1462  In Finnish: sennan lehti.
1463  In Finnish: paatsaman kuori.
1464  In Finnish: venäjänjuuri.
1465  In Finnish: mäkikuisma.
1466  In Finnish. etelänarnikki.
1467  In Finnish: tähkäkimikki.
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of high quantities of the medicinal plant. The Agency must base their decision on scientifi c facts, 
particularly on the effective doses of each plant.
In 2001 – 2005 there were numerous products categorised as medicines based on the 
marketing claim. These were products marketed for menopause and female hormonal changes, 
impotence and male performance, psoriasis, urinary tract infections and prevention of kidney 
stones, impotence, and depression or anxiety, for example. In these cases, the Agency did not 
even have to look at the function of the product, as the claims were medicinal. The Agency 
probably considered these as relatively simple cases.
When investigating the above lists of categorisation decisions, we must keep in mind 
that legislation changed in November 2005. That is when the implementation legislation of 
directive 2004/24/EC came into force in Finland. This directive included a change in the 
defi nition of a medicinal product, and created the new category of traditional herbal medicinal 
products. Based on the Finnish legislation1468 implementing directives 2004/24 and 2004/27, 
the new legislation in fact shifted the borderline between medicines and foods, so that former 
foods may now be considered medicinal products. This can be inferred from the transitional 
regulations:
If a product has received product authorisation according to old legislation, and the  –
product corresponds to the defi nition of traditional herbal medicinal product according 
to new legislation, the National Agency of Medicines will change the product license 
into product registration, when renewed.
If a product has received product authorisation according to old legislation, and does  –
not correspond to the defi nition of traditional herbal medicinal product according to 
new legislation, product authorisation according to new legislation must be applied for, 
when renewed.
If a product has been classifi ed as a foodstuff according to old legislation, and the  –
product corresponds to the defi nition of traditional herbal medicinal product according 
to new legislation, registration as a traditional herbal medicinal product must be 
applied for by the end of 2007.
Here we see that ‘traditional herbal medicinal product’ is by Finnish legislators seen as a legal 
category consisting of both former medicines and of former foods. This means that some of the 
products previously categorised as foodstuffs could now be regarded as medicines.
The change in the defi nition of medicinal product in the Finnish law of November 2005 
corresponds to the change of the directive 2004/24/EC. In the new defi nition1469, the medicinal 
action is more precisely defi ned as “pharmacological, immunological and metabolic action”. 
This clarifi cation as such does not shift the borderline between foodstuffs and medicines, and 
the Finnish lawmakers agree on this.
How is it then possible that some of the products previously classifi ed as foods might 
according to the new legislation be classifi ed as traditional herbal medicinal products? This 
outcome must be based on the notion that according to new legislation, unclear cases are to be 
1468  Laki lääkelain muuttamisesta. 4.11.2005/853.
1469  Finnish Medicines Act section 3.
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categorised as medicines. The Finnish law now includes the same rule1470 as the directive1471: 
unclear cases are to be treated as medicines, in cases where a product corresponds to the 
defi nition of a medicinal product and also the defi nition of some other product (for example 
food but also medical devices and cosmetics).
Before the selection rule existed, unclear cases were apparently sometimes treated as 
foods, sometimes medicines. We might presume that all EU Member States have understood 
the new rule in a similar manner, and that the borderline has in fact somewhat shifted towards 
medicines. This means we cannot rely on any ‘non-medicine’ categorisation decisions by any 
EU Member States from before 2005 for comparison to our products.
6.4.1.4 Probable Categorisation of the Three Berries
Hawthorn is used as herbal medicine in Europe. In Western herbalism, hawthorn fruit, leaf, 
and fl ower have all had a long history of use for treating cardiac weakness, and this has 
become a focus of modern research.1472 For example, in the Finnish Pharmacopoeia, hawthorn 
(Crataegus) is listed in Annex 2: herbals that could be considered as medicines. This does 
not mean that products made of hawthorn are automatically regarded as medicinal products. 
Instead, it means that products containing hawthorn in quantities that have pharmacological 
effects on the body, are considered as herbal medicines.
At the moment (end of 2006), there are two authorised herbals based on hawthorn on the 
Finnish market: both in the form of tincture and both used for mild heart conditions. It has 
to be noted, that these products have been authorised under the old law on herbal medicines. 
Both can be sold in the Finnish food stores1473. In the future, these products will have to be 
authorised as herbal medicinal products or registered as traditional herbal medicinal products 
according to the new legislation.
Emblic leaffl ower and barbary wolfberry are not listed in the European Pharmacopoeias. The 
classifi cation decisions of products would have to be based on evaluation of the pharmacological 
properties of the product. Products would not automatically be classifi ed as herbal medicinal 
products just because emblic leaffl ower and barbary wolfberry are known medicinal plants. Again, 
the dosage is important. If medicinal plants are present in quantities possessing ‘pharmacological 
effects’, products will likely be considered as medicines.
Besides through medicinal function, presenting medicinal claims is the other route for our 
products to achieve medicinal status. As stated above, medicinal claims are of the type “for 
prevention of diabetes” and “for heart conditions”. Mention of the metabolic syndrome would 
also constitute a medicinal claim.
1470  Finnish Medicines Act section 3(3).
1471  Medicinal products directive, Article 2(2).
1472  Crataegus laevigata, Crataegus monogyna and Crataegus oxycantha are the species used in Europe 
and they are different from the Chinese hawthorn (Crataegus pinnatifi da). Dharmananda. 
1473  National Agency for Medicines web page at: http://www.laakelaitos.fi /uploads/Laaketeollisuus/
Rohdokset/Rohdosluettelo_2006_2_28.pdf.
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6.4.2 China
In China, foodstuffs and medicines are traditionally seen as substances from the same source. 
Many herbs can be sold either as health foods or traditional Chinese Medicines. This is the 
case for our berries: all three berries are on the market both as food and as herbal medicines. 
If we want to develop functional food products to the Chinese market, there is legally room 
for different types of products made of the three berries. The two basic legal alternatives are 
health foods and traditional Chinese medicine.
Chinese legislation separates foodstuffs and medicines based on product functions. Health 
foods form the relatively clearly defi ned borderline category between regular foods and 
medicines.
‘Health foods’ category is suitable for products that:
possess the general nature of food, –
can regulate bodily functions of certain consumer groups, but –
are not intended for therapeutic purposes. –
The Health Food Regulation establishes 27 possible health-related functions for health foods, 
including regulation of blood pressure, regulation of blood lipids, and regulation of blood sugars. 
These are the health claims also available to marketers. The health foods category is suitable for us 
as we are functional food developers fi ghting the metabolic syndrome. If we were interested, for 
example, in cancer risk reduction, the health food category would not be available. The application 
for health food registration is sent to the SFDA, and several different research reports on safety, 
effi cacy and quality of the product are required.
Traditional medicines, on the other hand, are plant-based medicines, sold for a therapeutic 
purpose, to prevent or treat a disease. For these, an application to the SFDA is necessary. Traditional 
medicines are evaluated according to the Medicine Administration Law.
6.5 General Safety Requirements
General safety requirements for consumer products, and foodstuffs and medicines in particular, 
were discussed above in chapter 4.
6.5.1 EU
According to general rules on product safety, it is illegal to sell unsafe products to consumers 
including products that are hazardous and products on which the consumer is not given enough 
information to enable safe use.
European food safety requirements are strict. Foods must not be dangerous to a person’s 
health. Besides short-term health effects, also long-term health effects, cumulative health 
effects and effects on subsequent generations are taken into account when determining safety 
criteria. The precautionary principle guides the risk analysis.
General requirements applicable to all foods include biological safety and chemical safety. 
Biological safety is guaranteed by hygiene rules. In Europe, the separate hygiene rules for 
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different types of products, for example meat, eggs and milk, were recently codifi ed into one 
single Regulation. Chemical safety of foods is guaranteed by regulating residues, contaminants, 
additives, and food contact materials. GMO foods have their own authorisation procedure.
Functional foods are sometimes fortifi ed by vitamins and minerals. Here one must follow 
the EU Regulation on food fortifi cation. With regard to substances other than vitamins and 
minerals, national rules on fortifi cation apply. The Regulation on food supplements gives the 
rules on allowed vitamins and minerals in these products. In the future, the Regulation on 
food supplements will probably also cover other substances than vitamins and minerals, for 
example herbals. Until that time, national rules on food supplements apply. If one wants to 
sell the product as a dietetic food, particular compositional and quality criteria are given in 
specifi c directives.
Medicine safety is evaluated concurrently with effi cacy. Potential risks must be outweighed 
by therapeutic effi cacy. Safety of medicines is guaranteed by procedural requirements relating 
to tests and trials that have to be performed and documented before authorisation is granted. 
There are simplifi ed procedures for certain medicines that are considered safe and effective 
without a need to provide a complete dossier of documents.
With new chemical and herbal medicines, the application must include a complete dossier 
of documents. This dossier contains information on the results of physico-chemical, biological 
or microbiological, pharmacological and toxicological tests.
Applications can also be based on:
essential similarity to existing medicines, or –
scientifi c literature to prove a  – well-established medicinal use with recognised effi cacy 
and an acceptable level of safety.
Applications on traditional herbal medicines can also be based on a history of safe use. 
The required ‘history’ is defi ned as 30 years of use, of which 15 years within the European 
Community area.
Homeopathic medicines can be authorised via the primary procedure just like other 
medicines. There is also a simplifi ed procedure for homeopathic medicines that bear no 
therapeutic indication and are suffi ciently diluted to make them harmless. With herbal 
medicines, lowering the dose will make the product a food; in homeopathy it will make the 
product eligible for simple registration as a medicinal product. Because of different cultural 
traditions, the simplifi ed procedure does not exist in all the EU Member States.
6.5.2 China
The Chinese food safety legislation consists of similar pieces of law as its European 
counterpart. Both biological and chemical safety is regulated. Food hygiene is regulated 
nationally through the Food Safety Law. In addition, there are separate decrees giving specifi c 
hygiene rules on food irradiation, meat and meat products, milk and milk products, eggs and 
egg products, aquatic products, condiments, sugar, alcohol, grain, edible vegetable oil, tea, 
edible mushrooms, street food, student food etc.1474. Local authorities issue the food hygiene 
1474  Kan – Zhang 2002.
–270–
licenses to manufacturers and sellers1475. Also day-to-day control of food hygiene is under the 
competence of local authorities. This is why hygiene rules in practice vary in different parts 
of China.
Chemical safety is the goal of regulations on food additives, environmental contaminants, 
pesticide residues, hormones and antibiotics residues, food contact materials etc1476. GMO 
legislation is also in place. The Chinese Ministry of Agriculture has established the pollution-
free-program and the green program to produce food without harmful chemicals. However, 
these programs are not yet commonly followed.
According to general rules on medicine safety, the sale of fake medicines and medicines 
of inferior quality is prohibited. With modern medicines, safety is based on pre-clinical and 
clinical trials. With traditional medicines, safety evaluation is often based on long tradition 
of use. However, the safety approach to traditional medicines is similar to that of modern 
medicines: all medicines are recognised to have side effects, a risk-benefi t ratio is applied, and 
appropriate dosage is an integral part of treatment.
6.6 Particular Safety Criteria of Novel Foods
Functional foods often have new ingredients the use of which might involve new types of 
health hazards. The safety of a functional food will in these cases have to be evaluated pre-
market according to novel food legislation. We need to consider whether our berry products 
(if considered foods, not medicines); 
would be considered novel foods, and if so,  –
what would be the procedure to determine their safety, and  –
whether they would be authorised as legal novel foods. –
These questions are evaluated based on novel food regulations and literature1477, and in 
comparison to existing novel food products.
6.6.1 Current EU Novel Food Regulation
6.6.1.1 Would berries be considered novel?
In the EU, a food that has not been marketed to a signifi cant degree before May 1997 is considered 
novel. Novel foods must go through the pre-market authorisation procedure, where an application 
is fi rst sent to a Member State, and where all EU Member States thereafter have their say on 
whether the food should be authorised. A simplifi ed procedure (notifi cation) is available to those 
novel foods that are substantially equivalent to existing foods.
1475  Food safety authorities in provinces, autonomous areas, and municipalities directly under the central 
government.
1476  Kan – Zhang 2002.
1477  Discussed above in chapter 4.2.
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It is evident that hawthorn berries are not novel foods as the plant has been commonly 
used as food in Europe for decades. It is now used as a food supplement1478 and as regular 
food1479.
We have a recent opinion on the novelty of barbary wolfberry by the UK’s Food Standard 
Agency (FSA). According to the FSA, consumption of Lycium barbarum (Chinese wolfberry, 
goji berry) has been signifi cant for many years, and more importantly, before May 1997. 
Therefore the berry does not need to be authorised as a novel food. The FSA started seeking 
evidence of goji consumption in February 2007. According to initial reports, no signifi cant 
history of consumption before 1997 was evident. This would have resulted in the requirement 
of the fruit to be authorised as a novel food. Products containing wolfberries are at the moment 
being sold on the UK market.1480
With emblic leaffl ower fruit, the situation is more diffi cult. We can fi rst take a look at other 
plant-based foods that have been considered novel. The three plant-based novel foods that 
have gone through the authorisation procedure are: Stevia rebaudiana Bertoni, Nangai nuts, 
and Noni fruit1481. Among the notifi ed novel foods, there are for example prune kernel oil 
and argan oil. All of these were not novel foods as such, as they had signifi cant history of food 
use outside Europe, but apparently no history of food use in Europe was found.
Basically, the marketer must know whether his product is novel. It is illegal to market 
novel foods without authorisation. If the marketer is not sure of novelty, they can search the 
European market themselves, and ask for guidance from the national food safety authority of 
their EU Member State. If a novel food application is made, the food safety authorities will 
perform a literature search and a fi eld study to determine whether the food is in fact novel.
We have superfi cially searched through literature and the Internet and not found European 
food use of emblic leaffl ower. We thus predict that emblic leaffl ower fruit as a functional food 
ingredient would indeed be considered a novel food in Europe.
6.6.1.2 Would the berries be eligible for the simplifi ed procedure?
According to the current novel food regulation, certain novel foods or novel food ingredients 
may follow a simplifi ed procedure, which only requires notifi cation from the company. This 
is when the foods are considered (by a national food assessment body) as “substantially 
equivalent” to existing foods or food ingredients. This assessment of substantial equivalence 
is based on the composition, nutritional value, metabolism, intended use, and the level of 
undesirable substances contained in the food. If considered novel, we must consider whether 
the three berries would be eligible for the simplifi ed procedure, or whether they would need 
authorisation according to the principal procedure.
So far (September 2006), around 70 notifi cations on novel foods have been made. This 
means that these 70 products were regarded as novel, but essentially similar to existing foods. 
1478  For example the Finnish herbal company Frantsila and the Swedish herbal company Örtagubben use 
hawthorn in food supplements: http://www.frantsila.com/m-tuotteet-yrttiuutteet.htm, http://ortagubben.
jetshop.se/default.aspx.
1479  This can be inferred from various marmalade recipes on European homepages, for example http://
kerkka.vuodatus.net/blog/archive?m=09&y=2006, http://www.recepthjalpen.se/hagtorn.html.
1480  Nutraingredient.com Europe News Headlines 18/06/2007. 
1481  The details of the authorisation processes for these three foods will be discussed below.
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Of these, around 30 concerned noni fruit. In addition, there were notifi cations on prune kernel 
oil and argan oil. Prune kernel oil, huile d’amandon de pruneau, was notifi ed in July 2000. 
Argan oil (Argania spinosa L.) was notifi ed fi rst in July 2002 and subsequently in 2005 
and 2006. Other novel foods notifi ed were a vitamin, a fungus, a couple algae, and around 
30 products with added phytosterols or phytostanols often by companies extending their 
cholesterol-lowering product lines.1482
Noni juice was already mentioned above. After it received authorisation in 2002, 
several people and companies have notifi ed it. A German fi rst notifi ed it in November 2003. 
Subsequently, several German, French, Danish, and Dutch actors have notifi ed it. All of the 
notifi cations were based on an assessment by national food agency that the product in question 
is similar to the original noni juice authorised as novel food.1483
In the previous chapter, we concluded that hawthorn and barbary wolfberry would not be 
considered novel in Europe. To be eligible for the simplifi ed procedure, emblic leaffl ower fruit 
would need to be considered substantially equivalent to some other berry. So far, notifi cation 
process has been used only to bring to market the same fruit (noni) that has already been 
authorised through the primary procedure. We thus predict that emblic leaffl ower fruit would 
not be considered equivalent to any other berry.
6.6.1.3 Would the berries be authorised?
If considered novel and not eligible for the simplifi ed procedure, we must predict whether our 
functional food products would be authorised in the primary procedure for novel food safety 
evaluation. According to the law, a novel food can be authorised if it is safe for consumers to use. 
Novel food assessment integrates nutritional and toxicological aspects: nutritional properties 
of the food and the predicted dietary exposure affect the toxicological testing programme. 
Besides science, novel food evaluation is in practice also affected by different cultures and 
different political interests of EU Member States. According to exotic food producers, the 
safety requirements for novel foods are so strict that for example wheat, potatoes and green 
leafy vegetables would not be accepted if now introduced in Europe.
Based on the current legislation, only one novel food product that even resembles berry-
based products has been authorised: the noni juice. Two plant-based novel foods have been 
rejected. These are Stevia rebaudiana Bertoni1484 and Nangai nuts (Canaria indicum L.)1485 
It is noteworthy, that of the three novel foods rejected since 1997, two were plant products. 
All the products containing stanols or sterols have been authorised. Currently novel food 
safety requirements concerning so-called exotic plants are strictly interpreted in Europe, and 
producers of these plants are demanding some relief to these requirements.
1482  European Commission web page at: http://ec.europa.eu/food/food/biotechnology/novelfood/notif_list_en.pdf.
1483  European Commission web page at: http://ec.europa.eu/food/food/biotechnology/novelfood/notif_list_en.pdf.
1484  Commission Decision 2000/196/EC.
1485  Commission Decision 2001/17/EC.
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Stevia case
The Commission’s Scientifi c Committee on Food gave its opinion1486 on Stevia rebaudiana 
Bertoni in June 1999. Information on the chemical composition of the plant leaves was 
available to the Committee. The leaves contain a complex mixture of natural sweet chemicals, 
the main sweet principle being stevioside.1487 There was data showing stevioside is not toxic. 
The Committee also knew the plant in question is a traditional American natural sweetener 
used for centuries. It has been added to herbal teas and other beverages.1488 They also knew 
that the plant was cultivated in several American and Asian countries, as well as in Europe1489. 
Botanically, the plant was well identifi ed1490. There were no particular technological processes 
involved, only drying1491 and thus it is safe to say that using the plant in foods was not a 
discovery of any kind.
In Paraguay, the plant had since the 50s been administered to diabetics to reduce blood 
sugar levels. The applicant had also provided results of one animal test proving this kind of 
benefi ts to diabetics. According to the applicant, a signifi cant decrease in liver glycogen after 
2 weeks and a signifi cant decrease in blood glucose levels after 4 weeks were showing in the 
rat test. The Committee did not consider this animal test convincing, as they did not have 
the details of the study.1492 The dry powder was intended to replace some of the sucrose in 
drinks, jams and sweets to reduce the caloric intake. Besides diabetics, the product was also 
considered good for obese individuals.
The Committee would have wanted more information, though. They would have liked 
the product to be carefully analysed, and the composition standardised, preferably with 
regard to stevioside. The producer should have known where the plants are cultivated, which 
variety of the species will be used, and what the composition of commercial products is. 
Also toxicological tests on the fi nal products should have been helpful, even though nothing 
inherently toxic is present in the plant. Also microbiological issues should have been addressed 
in the application.1493 The appropriate intake was also unclear to the Committee. There were 
also no studies to show the physiological and pharmacological effects of substituting sugar with 
Stevia rebaudiana in diabetic or obese individuals.1494 There were also no studies on how the 
use of the plant might affect absorption of other food.1495 The list continuing, no investigations 
on the allergenic potential of the leaves and the powdered leaves were submitted.1496
1486  Opinion on Stevia Rebaudiana Bertoni plants and dried leaves. Expressed on 17 June 1999 Scientifi c 
Committee on Food. SCF/CS/NF/STEV/3 Final 17/6/1999
1487  Opinion on Stevia rebaudiana Bertoni as a novel food, page 3.
1488  Opinion on Stevia rebaudiana Bertoni as a novel food, page 2.
1489  Stevia Rebaudiana Beroni was cultivated in Paraguay, Mexico, Central America, Japan, China, Malaysia, 
and South Korea. Opinion on Stevia rebaudiana Bertoni as a novel food, page 2. In Europe it was reported to 
be cultivated in Spain, Belgium and the UK. In Europe, the plant was cultivated in greenhouse conditions, as 
it does not survive winter climate. Opinion on Stevia rebaudiana Bertoni as a novel food, page 3.
1490  Opinion on Stevia rebaudiana Bertoni as a novel food, page 3.
1491  Opinion on Stevia rebaudiana Bertoni as a novel food, page 3.
1492  Opinion on Stevia rebaudiana Bertoni as a novel food, page 4.
1493  Opinion on Stevia rebaudiana Bertoni as a novel food, page 3.
1494  Opinion on Stevia rebaudiana Bertoni as a novel food, page 4.
1495  Opinion on Stevia rebaudiana Bertoni as a novel food, page 4.
1496  Opinion on Stevia rebaudiana Bertoni as a novel food, page 5.
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The list of missing information includes issues that should not be relevant in novel food 
assessment. Microbiological issues are under general European food law, and hygiene rules 
apply similarly to non-novel and novel products. Novel food assessment is not about whether 
hygiene rules are obeyed. Similarly, it does not prevent a food from being authorised if it has 
allergenic potential. Many common foods have allergenic potential, and labelling allergens is 
another issue from novel food assessment.
The conclusion of the Scientifi c Committee was that there was not enough information available 
to evaluate the safety of the plant. There was no data to support safe use of it as food ingredients or 
as sucrose substitute for diabetics and obese individuals.1497 On the same date (17 June 1999), the 
Committee also gave its negative opinion on the use of it as a food additive1498. The additive process 
is legally separate from the novel food process, but the decisions were intertwined. The outcome of 
the process is that Stevia plants and stevioside as a sweetener are banned in Europe. Nevertheless, 
they have appeared on the market1499.
If we look at the opinion on stevioside as a food additive, we can better understand why 
the application on Stevia as novel food was rejected. There have been several studies on 
stevioside and its metabolite steviol. Particularly steviol seems to be problematic, as it has 
been shown to decrease fertility in male rats and to include developmental toxicity. It has been 
reported to cause cancer when fed at very high doses to rodents.1500
Nangai nuts case
Nangai nuts1501 (Canarium indicum Linné, kenari nuts1502, ngali nuts, galip nuts, java almonds) are 
the other example of a plant product that has been rejected as novel food in EU.
The request to market nangai nuts was made on behalf of a Vanuatu company called Pacifi c 
Nuts Ltd. The request was submitted to the French authorities in December 1998. The initial 
assessment report by the French competent authorities concluded that the product is safe for 
human consumption and could therefore be authorised. The French decision was subject to certain 
recommendations regarding microbiological controls, regular monitoring of afl atoxin levels and 
labelling requirements similar to those for nuts in general because of potential allergenic risks.1503 
This meant the French were willing to treat nangai nuts as quite harmless products, and considered 
normal precautions adequate.
However, objections were raised by four other Member States. Therefore, the Scientifi c 
Committee for Food had to assess the product. They gave their opinion in March 2000, stating 
that data necessary for the assessment of the safety of the product is lacking. They said the 
product should not be authorised. 1504
It was at this stage of the procedure when the applicant claimed that nangai nuts are in fact 
not a novel food at all. The applicant claimed that these nuts were consumed in the Netherlands 
1497  Opinion on Stevia rebaudiana Bertoni as a novel food, page 5.
1498  Opinion on stevioside as a sweetener, adopted on 17/6/1999. SCF/CS/ADD/EDUL/167 fi nal.
1499  http://www.food.gov.uk/news/pressreleases/2000/jun/stevioside.
1500  Opinion on stevioside as a sweetener.
1501  This is what the nuts are called in Vanuatu.
1502  This is what the nuts are called in Indonesia.
1503  Opinion on nangai nuts as novel food, page 2.
1504  2001/17/EC: Commission Decision of 19 December 2000 on refusing the placing on the market of 
“Nangai nuts” (notifi ed under document number C(2000) 3888).
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to a signifi cant degree. This claim was examined by the Dutch authorities who could not fi nd 
such nuts. Nangai nuts were considered novel foods. The decision prohibiting nangai nuts was 
issued in December 2000.1505 This means it took two years to assess the safety of these nuts.
The opinion of the Scientifi c Committee1506 was based on similar facts as it was in the 
Stevia Rebaudiana Bertoni case described above. Again, not enough tests had been completed 
on the plant.
The Committee knew that the almonds were widely used in the Pacifi c region. The estimated 
consumption of ngali nuts in Western Melanesia was about 60 tonnes of almonds or about 70 
g/day/person1507. No particular technology was involved, besides drying, fl oating, soaking and 
drying again. The Committee also knew that Ngali nuts are listed in the Australian tables 
of composition of Pacifi c Island Foods and that the nutrient content of the kernels had been 
analysed. From nutritional point of view, the Committee stated that nangai nuts are practically 
the same as nuts eaten in Europe. 1508
The applicant had performed various tests on the nuts. They had for example tested the 
nuts for heavy metals and mycotoxins. The Committee would have wanted more information, 
though. They said not all the relevant mycotoxins were present in the studies performed. The 
applicant had tested the product for four different afl atoxins, but not for other mycotoxins. 
According to the Committee, the information on the analytical methods employed when 
determining the nutritional composition of the nuts was not adequate. Information on the 
storage conditions of the samples was insuffi cient. The Committee said that the product does 
not comply with the EU hygiene standards. They were also missing toxicological assessment 
of the nuts and wanted information on potential genotoxicity of the nuts.1509 Also the allergy 
issue was mentioned: the possible allergenicity of the nuts had not been investigated.
It is interesting how the Committee ends its Opinion: “no conclusions can be drawn 
on the safety … , if the assessment procedures … have to be followed strictly.1510 Even the 
Scientifi c Committee of Food, the drafter of the legal texts, did not seem to know whether the 
procedures, laid down in the Regulation and in the Recommendation, were meant to be strictly 
followed. They left the door open for the Commission to make the ultimate decision. The 
Commission then decided that the nuts should be prohibited based on insuffi cient information. 
This suggests that the Commission answered ‘yes’ to the question of whether the procedures 
have to be strictly followed.
Noni case
The application to put Noni (Morinda citrifolia L., Indian mulberry) juice on the market 
was made by a U.S. company, Morinda Inc., in April 2000.1511 The request to market the 
1505  Commission Decision 2001/17/EC.
1506  Scientifi c Committee on Food. Opinion on the safety assessment of the nuts of the Ngali tree
(expressed on 8 March 2000). SCF/CS/NF/DOS/5 ADD 1 REV 3 fi nal 14/03/00.
1507  Opinion on nangai nuts as novel food, page 2.
1508  Opinion on nangai nuts as novel food, page 3.
1509  Opinion on nangai nuts as novel food, page 3.
1510  Opinion on nangai nuts as novel food, page 4.
1511  The product in question was not exactly Noni fruit itself, but “Tahitian Noni” juice, a fruit juice mixture 
of 89 % Noni fruit (Morinda citrifolia L.) and 11 % common grape and blueberry juice concentrates and 
natural fl avours. 
–276–
product was addressed to the Belgian authorities. In the initial assessment report, the Belgians 
rejected the application and concluded that additional assessment was required. The Scientifi c 
Committee gave its Opinion in December 20021512, and Commission’s decision authorising 
the product followed in June 2003.1513 This time the procedure took over three years.
The Belgian authority had rejected the application based on inadequate toxicological tests: 
the doses used in the original tests were too low. They would also have liked to know the 
place of noni in the diet.1514 Member States objected noni juice for various reasons: besides 
toxicological and allergy studies, they focused on health claims and the medicinal nature of 
the product.1515
Here we can see that the purpose of the novel food regulation was not clear: is it just for 
determining safety as such? Or should it include assessment of the functional food properties 
of the food? The fact is that often the novel ingredient in a food is added because of its health 
effects. This is also the case with our berries: we want to use them in novel functional foods 
because they have health effects. The question of whether marketing claims are a separate 
issue from safety assessment is now getting clearer: the new regulation on nutritional and 
health claims creates a framework for all food claims. The claims are thus not evaluated in the 
novel food procedure.
In this case, the applicant had closely followed the Recommendation on how to structure the 
novel food application. He had provided the required information of a non-GMO novel food. 
Concerning the compositional data, the applicant gave a typical compositional profi le of the 
juice. He also had a Quality Assurance Policy and Procedure Manual to ensure the consistency 
of products. The samples used for toxicological tests were shown to be representative of 
commercial products.1516 The applicant had paid particular attention to fi nding possible toxic 
chemicals, and found nothing.1517 The production process did not give rise to any concerns: 
it was similar to all fruit juices1518. Nutritional facts were also not particularly interesting: the 
juice is similar to other fruit juices1519. The microbiological issues were also the same as with 
other fruit1520.
The extent of toxicological and allergy-related data is what separated the Noni application from 
Stevia and Nangai applications. There was ample data available on Noni.
1512  Opinion of the Scientifi c Committee on Food on Tahitian Noni® juice (expressed on 4 December 2002). 
SCF/CS/NF/DOS/18 ADD 2 Final 11 December 2002.
1513  Commission Decision 2003/426/EC of 5 June 2003 authorising the placing on the market of ‘noni juice’ 
(juice of the fruit of Morinda citrifolia L.) as a novel food ingredient (notifi ed under document number 
C(2003) 1789).
1514  Opinion on noni fruit as novel food, page 2.
1515  Opinion on noni fruit as novel food, page 3.
1516  Opinion on noni fruit as novel food, page 3.
1517  Plants such as Morinda Citrifolia were known to have chemicals called anthraquinones in their roots, and 
these chemicals were known to be genotoxic. It had been stated in a previous study that these chemicals did 
not exist in the fruit of the plant. Still, the applicant had analyzed the juice for these chemicals. Opinion on 
noni fruit as novel food, page 3.
1518  Opinion on noni fruit as novel food, page 4.
1519  Opinion on noni fruit as novel food, page 5.
1520  By applying Good Agricultural Practices (GAP), Good Hygienic Practices (GHP), Good
Manufacturing Practices (GMP) and pasteurisation (87.7 °C for three seconds) the product was
to be regarded as microbiologically safe. Opinion on noni fruit as novel food, page 5.
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The history of use for Noni is interesting. The plant occurs from India through South-East 
Asia to Eastern Polynesia. It has a long tradition as dye plant1521, as medicinal plant and as 
food. Virtually all parts of the plant (fruit, leaf, bark, root, fl ower and seed) have been used for 
medicinal purposes such as to treat cuts, infl ammations, fungal infections, constipation and 
diarrhoea. Food use also has a long history: several studies refer to raw or cooked Noni fruit 
as part of the diet of aboriginal populations of Polynesia and Australia. Some studies suggest 
that it was eaten only in times of famine, as it tastes and smells bad.1522 “Tahitian Noni” juice 
was at the time of the application already produced on a commercial scale. The applicant had 
marketed its “Tahitian Noni” juice in USA, Canada, Japan, Australia, Mexico, Norway and 
Hong Kong.1523
Lessons of the Noni, Stevia, and Nangai cases
Based on the information on two prohibited products, particularly Nangai nuts, it is not enough 
that the products seem to be safe, based on thousands of years of use. You also have to prove it 
by various tests. The list of required information in the Commission Recommendation should 
be considered mandatory. As all of the above-mentioned tests are required before you can 
bring a food on the market, it is fairly demanding particularly for a small company.
It is also noteworthy that in the noni case the Member State would have been stricter, 
and in the nangai case, the Member State would have been more fl exible than the Scientifi c 
Committee of the European Commission. In the current system, Member State opinion is thus 
not a good predictor of the fi nal outcome of the procedure.
Based on the above cases, we predict that emblic leaffl ower or products made thereof 
could probably receive novel food authorisation, provided that we performed all the required 
tests on toxicology and nutritional values.
6.6.2 Future EU Novel Food Regulation
To get a better picture of the novel status of our potential products, we must look into the proposed 
changes in the EU novel food regulation. In the future, the producers will hopefully not have to 
avoid the novel food category. The Commission has proposed changes to the defi nition of novel 
food, to the novel food process, and to the nature of novel food decisions as to whom they apply. 
We cannot be sure whether the Commission proposal will be accepted as such, but we have chosen 
to discuss some of the likely issues that might affect our types of product.
It is very probable that the European Food Safety Authority (EFSA) will evaluate novel food 
applications in the future. This has also been supported by the majority of stakeholders. EFSA 
will have all the best experts to evaluate the safety. The Commission has proposed novel foods 
to be evaluated in the Common Procedure that is also applicable to additives, fl avourings, and 
enzymes. In this procedure, the application for authorisation is sent to the Commission, which 
hears EFSA, and publishes a Community list of authorised foods. Timelines are set for each 
stage of the process.
1521  Its root and bark have been used for colouring purposes. Opinion on noni fruit as novel food, page 4.
1522  Opinion on noni fruit as novel food, page 4.
1523  Opinion on noni fruit as novel food, page 2.
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We have previously predicted that emblic leaffl ower fruit would currently be regarded as 
novel food in Europe. This would also apply to some other Chinese berries and plant-based 
products. The novel food defi nition is not about to be changed. As a result, in the future the 
so-called exotic plants will still be considered novel in the EU.
Instead, the authorisation procedure will be made less stringent and more affordable for 
plant-based products than for those more technological novel foods. It has been proposed 
that a simplifi ed procedure will be applied to traditional foods from third countries. This 
change is welcome by several actors, and will make the situation a bit more convenient for 
importers of foreign berries, fruit, vegetables etc. The primary procedure has been considered 
too burdensome, and also as a restriction of trade for exotic fruits.
In the future a notifi cation procedure shall apply to our products, more particularly functional 
foods made of emblic leaffl ower fruits. According to the proposed Novel Food Regulation, 
“traditional food from a third country” means “novel food with a history of food use in a third 
country, meaning that the food in question has been and continues to be part of the normal diet for 
at least one generation in a large part of the population of the country”.
A marketer of a traditional food will still have to provide some evidence on safety. The 
notifi cation shall be accompanied by documented data demonstrating the history
of safe food use in the third country1524. We will need a certifi cate of the foreign, in this case 
Chinese, food safety authorities stating that the product has been used for a long time without 
any safety issues arising. “History of safe food use” indicates that “the safety of the food in 
question is confi rmed with compositional data and from experience of use and continued use 
in the normal diet of a large part of the population of a country”1525.
In the future novel processes leading to a signifi cant change in food composition or structure 
will still be evaluated according to the EU novel food regulation.
6.6.3 Chinese Novel Food Legislation
In China, a functional food ingredient might have to go through novel food legislation. A novel 
food might be for example a foreign plant, a newly developed raw material, or an innovative 
processing technology. The novel food procedure does not have anything to do with health 
claims. One must always go through the health food procedure if one wishes to present health 
claims on the fi nal product.
The Chinese novel food legislation will not affect our business because the three berries 
have established food uses in China. This makes them non-novel. For example, wolfberries 
are added to congee soup1526, and hawthorn is used in haw fl akes1527. Emblic leaffl ower is not 
as common in China as in India, and is mainly used in China as a health food supplement, 
which still accounts as food use and makes the berry non-novel.
1524  Article 8(1) of the Novel food proposal 2007.
1525  Article 3(2)(c) of the Novel food proposal 2007.
1526  Wolfberry is also added to tonic soups, and used for as herbal tea. Even wolfberry beer is available. 
Wikipedia. Article on wolfberry. 
1527  Haw fl akes are a Chinese sweet made of hawthorn. Hawthorn is also used in jams, jellies, juices, alcoholic 
drinks etc. Wikipedia. Article on Crataegus.
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6.7 General Rules on Marketing
6.7.1 EU
A functional food marketer must keep in mind the general rules on advertising and comparative 
advertising: giving false or misleading information to consumers is prohibited, and applies 
both to foodstuffs and medicines.
Foods must be labelled so the consumer is provided with all the information required by 
the labelling rules. The newest labelling requirements relate to common allergens. Nutrition 
labelling is currently mandatory if a nutrition claim is made, and otherwise voluntary. Novel 
foods and GMO foods have their own labelling requirements. European consumers are hesitant 
to purchase GMO foods.
For food supplements consisting of vitamins or minerals, the EU regulation of 2002 applies. 
The regulation includes specifi c labelling requirements. Consistently with the food supplement 
legislation, rules on foods fortifi ed with vitamins or minerals are harmonised in Europe (since 
2004. Also for fortifi ed foods, there are specifi c labelling requirements. For other supplements and 
other kind of fortifi cation, such as products with fi bre, amino acids or herbal extracts, national rules 
apply. We predict that European harmonisation of supplements and fortifi ed foods will continue in 
the future to cover these other types of common products.
We are mainly interested in functional foods, referring to foods that are in food form and 
possess some health effects. Some of these might be fortifi ed as discussed above. One marketing 
alternative is to sell the product as a dietetic food. For dietetic foods, (foodstuffs for particular 
nutritional purpose), the word ‘dietetic’ or ‘dietary’ can be used. Dietetic foods are always aimed 
for specifi c groups of people with specifi c dietary needs. Some dietetic foods involve pre-market 
notifi cation. For dietetic foods, nutrition labelling is mandatory.
A nutrition claim on a food is basically a claim where the amount of a certain nutrient 
is claimed to be high or low. For example, ‘low fat’ and ‘high fi bre’ are nutrition claims. 
Nutrition claims are legally a fairly simple question as all allowed nutrition claims are listed in 
the Annex of the nutrition and health claim regulation of 2007. One just needs to be aware (to 
measure) the content of the substance, for example fat, in the product. Health claims on foods 
will be separately discussed in the next chapter.
At least in theory, functional foods could also be sold and marketed as medicines, as discussed 
above. In this case, the product must comply with rules on medicine labelling and advertising, 
and restrictions to marketing channels. All medicinal products must include a package leafl et in 
their packaging, and the information to be given on this package leafl et is precisely regulated. 
For example instructions for proper use and information on medicine’s side effects are important 
for consumers. All medicine marketing must encourage rational use of medicines. Medicine 
advertising must not be directed at children. Prescription medicines cannot normally be advertised. 
Medicinal claims will be separately discussed in the next chapter.
6.7.2 China
The Chinese general rules on marketing are largely the same as in Europe. The aim is to provide 
the consumer with all the relevant information of the product. Misleading advertising is prohibited. 
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Foods must be labelled. Particular requirements on allergy labelling are still missing. Medicines 
must have a product leafl et containing all the relevant information on the product.
In China, it is not so much the marketing legislation but its implementation that is lacking. 
Because of severe scandals related to counterfeit and fake medicines, the Chinese are now 
focusing on control and supervision of the rules on medicine advertising.
6.8 Legislation on Health Claims and Medicinal Claims
Above we have discussed whether our fi ctional functional food products would be regarded as 
foodstuffs or medicinal products. Here we assume that some of our fi nal products are legally 
medicines, and some are foods. We have developed products in different legal categories and 
we want to make marketing claims that are as convincing as possible.1528 Thus, we are willing 
to present health claims for food products, and medicinal claims for medicinal products.
The viable legal categories within the EU are1529:
(traditional) herbal medicinal product, –  
dietetic food (foodstuff for particular nutritional purposes) and, –  
as the most interesting alternative,  – a ‘normal’ food with health claims
A dietetic food could be sold as a food suitable for diabetics or a food suitable for people 
with high cholesterol or hypertension. The normal food with health claims could be aimed for 
example at people with a risk of diabetes or cardiovascular disease.
The viable legal categories in China are:
traditional Chinese medicine, and –
as the more interesting alternative,  – health food.
6.8.1 EU
The fi rst rule concerning claims is that medicinal claims on foods are prohibited. This applies 
to all foods including normal foods, dietetic foods and food supplements. Medicinal claim 
means a statement where a product is said to prevent, treat or cure a disease.
Health claims on foods are legal but subject to stringent requirements. There are two types 
of health claims, so called ‘function’ claims and disease risk reduction claims. The Commission 
will publish EU wide lists on both types of accepted health claims.
1528  In reality, we would consider the claim issue simultaneously with the safety issue and all the other aspects of 
product development. In this study, the marketing issue is discussed separately for readability reasons only.
1529  Here we have left out the option of developing a ‘normal’ medicinal product. This would mean fi nding and 
capturing the active chemicals in the plants, and selling them as (prescription) drugs. It is not certain that this kind 
of medicinal product could ever be developed and authorised, and it would take years if it were possible. In this 
study, we are interested in the mass consumer market, and primarily products sold by the food industry. Herbal 
medicines (in Europe: herbal medicinal products, in China: traditional Chinese medicines) are included, because 
the legal division between herbal medicines and functional foods is important, and some food-form products might 
be legally categorised as herbal medicines, regardless of whether intended as such.
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The EU Member States are currently preparing their lists on established ‘function’ type 
health claims. These lists are to be submitted to the EFSA by January 2008. Industry consultant 
Richardson advised companies to fi nd out what is on the Member State lists. Accordingly, if a 
food is not on the positive list by 2010 hard work will be required for a claim to be made in the 
future1530. At this stage, we cannot be sure what claims will be on the ‘established claim’ list. 
It is unlikely that claims particularly on emblic leaffl ower, barbary wolfberry or even the more 
familiar hawthorn will appear. The fi nal list will most likely include antioxidant claims such 
as claims on fl avonoids and phenolic compounds1531. These substances are present also in our 
berries, which will make claims similar to “contains antioxidants” available to us.
Novel health claims (claims not on the list) and disease risk reduction claims must be 
authorised separately. We would be interested in claims that maintain: “For sufferers of 
metabolic syndrome”, “Lowers cholesterol”, “Lowers blood sugar”, etc. We could either 
state that “Hawthorn lowers cholesterol”, or that “Functional food product Hawthorn lowers 
cholesterol”. The rules are the same. The claim must not be misleading: the active ingredient 
must be present in quantities that produce a health effect in normal use. The scientifi c assessment 
of a disease risk reduction claim is made by EFSA, and the fi nal decision by the Commission. 
With disease risk reduction claims, one has to keep in mind that the risk factor itself might 
not be established. In this case, initially it needs to be proved that a certain condition is a risk 
factor, and then that the product affects the risk factor.1532
The EU Regulation on nutrition and health claims came into force in 2007. It is interesting 
that Commission claimed to create liberal legislation:
“The proposal covers nutrition claims (e.g. “rich in vitamin C” or “low in fat”) 
and health claims (i.e. claims of a positive relationship between a specifi c food and 
improved health). It sets rules for making such claims and also allows health claims 
(including “reduction of disease risk” claims) that were previously prohibited. In the 
interest of consumer protection, it also includes certain restrictions. The Regulation will 
protect consumers, improve the free movement of goods, increase the legal security of 
operators and prevent abusive claims, thus ensuring fair competition. The proposal will 
result in a more liberal environment for claims in labelling and advertising. Disease-
related messages, which were until now totally prohibited by EU legislation, will now 
be allowed if they can be scientifi cally substantiated and authorised at EU level.”1533
The Commission seems to state that health claims were previously prohibited and that now they 
have been freed. In fact health claims were not prohibited before the regulation. In several countries 
they were allowed, including disease risk reduction claims. The food industry does not see the new 
regulation as making the situation more liberal; in fact they see the Regulation as one of the strictest 
possible alternatives of the various systems available.
1530  Nutraingredients.com news at: http://www.nutraingredients.com/news/ng.asp?n=76579-efsa-health-
claims.
1531  See for example the Finnish list of ‘function’ claims, and particularly the list of antioxidant claims 
Ministry of Trade and Industry web page at: http://www.ktm.fi /fi les/18357/Antioksidatiivisuus2.pdf.
1532  Heiskanen 2001, 26.
1533  Commission DG SANCO Food Safety web page 21st September 2006.
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What is positive to a functional foods developer is that legal uncertainties around the claim 
issue seem to be resolving, at last. The lists of established claims are impending and there is 
plenty of guidance available on how to use claims. Nutrition and health claims are factual 
claims that have to be substantiated, which is not too much to ask from every responsible 
business. There are procedural costs with new claims, but they affect the competitor similarly. 
The choice by an entrepreneur of a nutrition or health claim will depend on the costs and 
benefi ts of the claim.
Companies view health claims as a means of recouping some of the fi nancial outlay for 
testing of effi cacy and toxicity of the products. The possibility of making claims encourages 
investment in product development and introduction and export of new innovative products.1534 
Claims are useful to the company if they are useful to the consumer. Incidentally for some, 
claims on labels may be the only way to obtain knowledge of healthy products. 1535 The 
consumers will decide on their own if they want the product, based on many other factors 
besides the claim1536.
It is not necessarily always clever to make a health claim just because it is legally possible. 
Costs in making claims relate to chemical analysis1537, human studies1538, and submission of 
the evidence to the regulatory authorities. The new regulation rewards these efforts by granting 
fi ve-year exclusivity to proprietary materials that support a health claim. After this period, 
competitors can use the proprietary data without compensation to the originator.
1534  For example Suontama 1999, 26, and Tainio 1997, 40.
1535 For example through the Kellogg’s All Bran campaign in the USA, knowledge of the relationship 
between fi bre and cancer increased, with the greatest change in those socio-economic groups that 
do not read educational material. There may, therefore, be an advantage to claims of packaging for 
those sectors. Stephen 1998, 432. Even in Finland, there are people who never read a magazine on 
health. Those that are still in school may have up-to-date information on nutrition, but others do 
not go to lectures on newest nutritional research. 
1536  For example the sensory properties of the product, the price of the product, personality, age and social 
class of the consumer, etc. 
1537  Analytical procedures appropriate for determining concentrations of chemical entities within products 
include gas chromatography, high-pressure liquid chromatography or thin-layer chromatography. Many of 
the methods are time-consuming and hence costly, but it is unlikely that once the method is developed and 
validated, the results would be ambiguous. Stephen 1998, 429.
1538  With human studies, a considerable fi nancial commitment can be incurred in a study for which the 
results are not even useful. All efforts should be made to determine that results would be meaningful and 
unambiguous before substantial costs are incurred. According to Stephen, embarking on the production of 
new products without recognising the requirement of scientifi c proof of effect as a component of the overall 
development of a product is a recipe for failure. There are many who believe that a little rapid research 
is suffi cient to confi rm the reputation of a plant, and then attempt to proceed from there toward lucrative 
industrial production. Stephen 1998, 429.
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Scientifi cally, it is not always easy to manufacture a product that justifi es a claim1539. Some 
studies show1540 that some consumers do not want health claims, as they do not have faith in 
them. In spite of strict legislation, these consumers might still exist. Sometimes consumers 
fi rst resist a claim, but then learn to accept it1541. In some countries, functional foods are sold 
where claims are not permitted, or outside the health food categories. This means health claims 
are not the only way to success.1542
It is also noteworthy that the new regulation on health claims only allows health claims on 
foods where the nutrition profi le of the food is in certain limits. These nutrition profi les will 
be established for different foods, such as breakfast cereal and yogurt. This will be done by 
the EFSA by January 2009. The profi les will include limits for different types of harmful fats, 
salt/sodium, and sugar. This means that a barbary wolfberry yogurt or an emblic leaffl ower 
muesli with a health claim cannot contain much sugar or fat. The functional food product must 
be healthy as a whole.
There is one exception to the nutrient profi le rule. If the product only exceeds one single 
limit in the nutrient profi le, it can still be presented in a nutrition claim of the product that 
another nutrient is present in low quantities. For example, a yogurt can be claimed to be ‘low-
fat’ even if it has lots of sugar. In this case, a statement ‘high in sugar’ must be included along 
with the ‘low-fat’ statement. As we are interested in health claims, and not so much in nutrition 
claims, this loophole does not aid our case.
Medicines always bear a medicinal claim, as they must have a therapeutic indication. 
The therapeutic indication is the key of the whole product, and also the key of consumer 
marketing. The therapeutic effect of a herbal medicine is typically verifi ed by literature 
instead of scientifi cally verifying it in animal tests and human trials. With traditional herbal 
medicines, not even literature evidence is required. However, traditional herbal medicines are 
1539  Bioavailability and performance of the active ingredients is not always a simple thing. For example, 
vitamin supplementation often fails, and many vitamin-enriched prototypes contain too little vitamin compared 
to planned claims. Vitamins C, thiamine and ribofl avin are particularly unstable and diffi cult to work with. A 
food company might need to partner with someone with medical insight and ability to do clinical trials. For 
this reason, specialist research companies and the pharmaceutical giants are partnering with food ingredient 
supplier and food companies. Food Engineering & Ingredients, October 2001, 18.
1540  There has been consumer research showing that consumers want strong claims, and research that shows 
they don’t. Niva and Jauho (1999) found a connection between a consumer’s perception of research on diet-
health relationship and his perception of health claims. If the consumer generally is suspicious of health 
effects of single products, he does not want health claims – because he thinks they are misleading. Those 
consumers that have faith on scientifi c research behind functional foods are in favour of the use of health 
claims in marketing. Niva – Jauho 1999, 46-47. This means that if you do not already have the trust of the 
consumer, claims will only create adverse reactions.
1541  Young 1998, 173.
1542  For example in Japan, the population accepts the functional benefi ts and is knowledgeable about them, 
and thus they will buy the products independent of the claims. While a considerable number of products 
have been licensed FOSHU (food for special health use) in Japan, this is a small number in comparison to 
the hundreds of functional products being successfully marketed in Japan. Stephen 1998, 431. With olive oil 
(particularly in the United States), the fi ndings on its healthiness were reported at scientifi c meetings, in the 
literature, and from there to the popular press and media. The result was a huge increase in sales of olive oil. 
Without the ability to make a claim, the olive oil industry is benefi ting through good research in the form of 
controlled human studies. The fi ndings are sound, unambiguous and have been confi rmed by a number of 
investigators worldwide. Stephen 1998, 432. This implies that if the scientifi c proof is widely known and 
trusted, claims are not necessarily needed.
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not allowed to contain mention of a therapeutic indication. These products are allowed to be 
sold as medicines, but without medicinal claims.
All of the three berries have potential for developing herbal medicinal products. With 
adequate evidence, these products could be authorised through the primary procedure for 
medicines. Hawthorn has established use as herbal medicine in Europe, but the traditional 
herbal medicine option is probably still not available. Only those products that cannot be 
registered as herbal medicines are allowed to be registered as traditional herbal medicines. The 
category of traditional herbal medicines is for plants on which information is not available, and 
on hawthorn there is both literature on traditional use and data from newer scientifi c studies. 
We would not be interested in the traditional herbal medicine category anyway, because we 
want to present strong claims.
6.8.2 China
Health foods and drinks became big business in China during the 1990’s. The market 
grew chaotic which led to government intervention. With the enactment of the health food 
regulation in 1996, the number of producers of health foods decreased to less than a third in 
less than a year. The rigid regulatory environment allows genuine manufacturers to recoup 
market share and gain a certain critical mass. Simultaneously to promoting domestic research 
and development, the Chinese laws have also gradually opened the market to foreign health 
products and ingredients.1543
According to Chinese legislation on health-related products, the name of a product must 
not be misleading or confuse foodstuffs with medicines. Medicinal claims are allowed for 
medicinal products only, including traditional Chinese medicines. Medicinal claims are 
prohibited on foods. For health foods, and only for health foods, health claims are allowed. 
Among the 27 listed possible health food functions, at least 3 are quite suitable for our 
purposes. These are:
assisting in blood lipids reduction, –
assisting in blood sugars reduction, and –
alleviating hypertension. –
If we have the required scientifi c evidence on our products, we can apply for health food status 
for our functional food products. The claims on health foods must be truthful, and substantiated 
through animal tests and/or human trials. The SFDA is responsible for pre-market approval of 
health foods. Only the listed 27 claims are available. Other health claims are prohibited.
There are important restrictions to health food raw materials. There are three categories of 
raw materials with three lists.
List I includes materials that can be used either as foods or medicines (around 90  –
substances).
List II includes materials that can be used as health food materials (around 110  –
substances).
1543  Giract China News February 2006. Extract in Functional Ingredients.
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List III includes materials that are prohibited as health food materials (around 60  –
substances).
First of all, one can use only 14 different raw materials in one product. This fi gure includes 
health-promoting materials and not basic food raw materials such as water or sugar. 
Furthermore, if one uses materials outside list I, one can only use 4 materials altogether. If one 
uses materials outside lists I and II, one can only use 1 raw material.
Hawthorn and barbary wolfberry are on the fi rst list. This means that if we use hawthorn 
and barbary wolfberry, we can also use 12 other raw materials (that are not on lists 2 or 3). For 
example, if we want to use hawthorn with one material on the list II, for instance Ginseng fruit, 
we can use 4 materials altogether. Emblic leaffl ower is not on any of the lists. This means we 
can use it as health food raw material, but in this case we cannot use other raw materials.
6.9 Other Legal Issues to Consider
When using plants as raw materials in functional foods, food supplements or herbal medicines, 
one has to make sure that it is not a question of endangered species. CITES (the Convention on 
International Trade in Endangered Species of Wild Fauna and Flora) applies here. Practically 
all countries are parties to CITES. The EU has even stricter rules than CITES on international 
trade of endangered species.
Intellectual property issues are obvious to pharmaceutical companies but they also apply to 
herbal medicines and functional foods. It is often advisable to protect the functional ingredient by a 
patent or a utility model, and the names and logos with trademarks. Trademarks have to be registered 
for every country separately. The cost of trademarks rises with the number countries, the number of 
product categories, and the time of exclusivity. Sometimes the protection for geographical origin of 
the food might be relevant. Poor enforcement on intellectual property rights remains a top concern 
for companies operating in China. It might infl uence research and development plans, and the 
products or technologies that companies are willing to sell, license, or manufacture in China1544.
Contracts form the framework for business. Confi dentiality agreements with international 
business partners are needed. Sometimes keeping the information secret is a better alternative 
to disclosing the information in a patent application. Patented ingredients or other property 
material or knowledge may be commercialized by licensing agreements. With international 
contracts, the choice of law and the venue for dispute settlement are things to consider.
6.10 Final Conclusions for a Functional Food Marketer
When developing functional foods, legal issues including marketing rules must be considered 
in early stages of product development. Legislation is not necessarily something that hampers 
good products from achieving the market but a reminder of issues that a responsible producer 
would have to consider anyway. A good product is something a consumer can trust. It 
delivers what it promises. It is up to the manufacturers to know and decide which regulatory 
category their functional food will fall into. The choice of legal category should be compatible 
1544  See US-China Business Council 2008, 12.
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to the scientifi c proof of effect, and a claim requires a complete and integrated marketing 
communications plan around it.
A product will be classifi ed as medicine in Europe, if one uses medicinal claims such 
as “prevents heart disease and diabetes”. A product will also be classifi ed as medicine, if 
functional ingredients are present in quantities that cause a pharmacological effect. With 
plant-based products, one possibility is to consciously sell the product as herbal medicine. 
Traditional herbal medicines can be sold based on history of use only, without having to prove 
effi cacy. If sold as food, an innovative product must probably be authorised through novel 
food procedures. This requires explicit microbiological, nutritional, and toxicological data to 
be joined in the application. The European defi nition of novel food includes all the plants that 
are unfamiliar to Europeans, even if used for centuries for example in China or America.
As regards marketing in Europe, foods are allowed to bear health claims but not medicinal 
claims. Functional foods could be sold as dietetic foods, foods that are suitable for certain 
groups of people, such as for people with celiac disease. Concerning foods with a more general 
target group, nutrition claims and health claims can be used according to the new European 
Regulation. A list of established ‘function’ claims will be published in 2010, after which all 
new ‘function’ claims must be authorised separately. Disease risk reduction claims will always 
have to be authorised separately.
According to Seppänen, the false orientalist picture of China as a lawless Confucian 
society has led to foreign companies neglecting legal planning in China1545. We do not want 
to do this mistake. In China, foodstuffs and medicines are separated by their functions and 
claims just as in Europe. Medicines have therapeutic effects, and only medicines are allowed 
to bear medicinal claims. The health food category is often suitable for a functional food, if it 
has one of 27 listed functions. Only health foods can bear health claims in China. The health 
food regulation also covers foods fortifi ed by vitamins and minerals, and vitamin and mineral 
supplements. The novel food category and the health food category are separate in China: a 
food cannot be both. This means that if health claims are wanted, both safety and effi cacy of 
the food are evaluated through the health food procedure. 
1545  Seppänen 2005, 584.
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7 TASKS OF FUTURE LAW
In this chapter, we draw conclusions on the European and Chinese legal systems from a 
regulator’s perspective. The laws on foodstuffs and medicines will constantly have to be re-
evaluated and further developed in both the EU and China.
7.1 Foodstuffs vs. Medicines
In China, the foodstuff vs. medicine -issue is actually not an issue. The same product, often 
a herb, can be sold as food for healthy people and as medicine for sick people. Health foods 
often comprise of materials that are used in traditional Chinese medicine. The legal difference 
between health foods and medicines is that health foods have a special health function, but 
are not for curing a disease.
The European legal defi nition of food encompasses products ingested by humans, excluding 
medicines. This means the food law does not give any clarifi cation to whether a borderline 
product should be treated as a medicine. We have to look at the defi nition of medicine. The 
Medicinal Products Directive gives two parts to the defi nition of a medicinal product, by 
virtue of its presentation and by virtue of its functions. Consequently, a product is legally 
a medicinal product if it falls within either or both of these parts. This principle has been 
consistently held and confi rmed by the European Court of Justice. The defi nition of medicinal 
product was recently changed. It was clarifi ed that medicinal function means pharmacological, 
physiological or metabolic action1546, whereas according to the Nutrition and Health Claim 
Regulation, foods might have “benefi cial nutritional or physiological effects”1547. It was also 
added into the Medicinal Products Directive that all unclear cases are to be regarded as 
medicines.
From the EU defi nitions of food and medicine, it is still not clear whether a functional 
food could in practice be authorised as a medicine. As described above, the defi nition of 
medicines is fulfi lled if the product either A) has a medicinal effect or B) uses medicinal 
claims. There are no other parts to the defi nition. There is no exclusion of foods. It is clear that 
a according to law, a functional food (as defi ned in chapter 1.3.) could be considered a legal 
medicinal product or an illegal medicinal product either by its functions or by its presentation. 
In practice, food-form products are rather classifi ed as foods.
1546  Directive 83/2001/EC, Article 1(2).
1547  Regulation 1924/2004/EC, preamble 14.
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The borderline between foodstuffs and medicines remains a problem, as the European 
Court of Justice has accepted that there can be different interpretations of the defi nition 
of medicinal products among the Member States. A product can be a food in one Member 
State and a medicine in another. Herbs in particular are often used both as foodstuffs (food 
supplements, natural sources of food fl avourings) and as herbal medicines1548. This is one 
remaining obstacle to free movement of foodstuffs and medicines.
In the future, it is possible that:
there will be a European law on how to divide products into foodstuffs and medicines, –
the categorisation decision will be done by the EFSA, and it will be applicable to the  –
whole Community.
The UK experience with guidelines and procedures for borderline products could be used as 
guidance in establishing a similar categorisation system at the European level1549. The function 
and the claim of the product would be evaluated together to determine whether a product is 
a medicine. If a product contained therapeutic doses of ingredients generally regarded as 
medicinal and indicative of a medicinal purpose, it would likely be considered a medicine. 
With regard to presentation, a UK-style list of phrases forbidden in food marketing could 
be useful to marketers1550. If the division between foodstuffs and medicines is considered 
necessary, the European defi nitions should be unambiguous.
Even if we create effi cient categorisation rules, it will take a lot of the entrepreneurs’ 
and the agencies’ energy to determine whether a product is a food or a medicine. The 
European legislators tried in 2004 to make categorisation easier by establishing the unoffi cial 
borderline category for “unclear cases”, and directing these products under medicine law1551. 
The diffi culty of defi ning medicines in manner that would clearly exclude foods could also 
have lead legislators to the conclusion that the categorisation decision should not be decisive. 
Nutrition and health are closely connected, and science reveals new connections all the time. 
We might just as well classify all foods as medicines. Our science-based understanding on 
the relationship between diet and health seems to make it impossible to defi ne medicines in a 
manner that would clearly exclude foods.
Instead of focusing on what is food and what is medicine, legislators should focus on 
safety and effi cacy of all products. If borderline products do not fi t to the two sets of rules (one 
for foodstuffs and one for medicines), there are basically two alternatives. Either we create 
a borderline category or we bring regulation of foodstuffs and medicines closer together. 
If similar principles are used with foodstuffs and medicines, similar products are treated in 
similar manner, regardless of the classifi cation decision. This way the classifi cation decision 
could no longer lead to great injustice.
We can already see the regulation of foodstuffs and medicines coming closer together. The 
novel food legislation and the health claim legislation together are creating a kind of authorisation 
1548  Silano et al. 2004, 108.
1549  The UK rules on borderline products were discussed above in chapter 3.
1550  Including marketing terms like “alleviates”, “avoids”, “clears”, “combats”, “controls”, “counteracts”, 
“eliminates”, “fi ghts”, “heals”, “help”, “protects against”, “remedies”, “removes”, “repairs”, “restores”, 
“stops”, and “traditionally used for”.
1551  See Directive 2004/27/EC, Article 2(2), and explanations in preamble 7 of the Directive.
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procedure for functional foods. Both evaluations (safety and effi cacy) are in the future done by the 
EFSA. This evaluation is similar to what the EMEA is doing with medicines. Similar principles are 
used in evaluating plant-based novel foods and herbal medicines.
From consumer point of view, the purpose of use of a product is decisive. It is not important 
whether a product is a food or a medicine but whether it has a health-enhancing function 
or a medicinal function. There will be products with health effects (weight-loss products, 
lactose-free, gluten-free products, products for diabetics, products with added or concentrated 
vitamins, minerals, prebiotic or probiotic acids, fi bre, herbs, sterols and stanols, xylitol, etc.), 
and products with medicinal effects (herbal and chemical medicines). The claim will inform 
the consumer on the purpose of use, and the use of a health claim or a medicinal claim will 
depend on scientifi cally proven effects of the product. The product form (food vs. pill) should 
not be legally relevant.
Food supplements seem to be a somewhat obscure, suspicious and problematic category 
for everyone involved: some marketers try to sell the products as medicines, some consumers 
use food supplements for medicinal purposes, and authorities take the product form as a 
medicinal message. The legal concept of food in concentrated form does not seem to reach the 
audience. We suspect this is due to the fact that food supplements in practice always do have 
special health effects, separating these products from common foods (foods in food form) 
and bringing them closer to medicines. Instead of what the product is (food vs. medicine), it 
is interesting what the product does. Some products have health effects and some products 
medicinal effects.
This brings us back to making the distinction between disease risk reduction and disease 
prevention. It might be impossible to reach a situation where all the stakeholders, including 
the consumers, understand and agree on these two concepts. Regardless of all the legal 
determinations, classifi cation rules, and scientifi c criteria, European and Chinese consumers 
can still use foods for medicinal purposes. This is something the law cannot affect. Consumers 
can also use spells, rocks, crystals, scents, fl owers, etc. for medicinal purposes. The legislator 
can give precise criteria for authorising products, but cannot force consumers to trust them, or 
to distrust something else.
7.2 Law on Product Safety
7.2.1 Food Safety
Food safety law is complicated with several different factors of safety to consider. Biological 
hazards like animal diseases must be rigorously fought against. Minimising the amount of 
harmful chemicals in food is also an important goal. Here we have mainly discussed the 
particular safety issues of functional foods, which are often related to novelty of the 
ingredients.
The aim of novel food legislation is that previously unknown substances cannot be put to 
consumers’ dinner plates before pre-market scrutiny. Novel food legislation has existed in the 
EU since 1997 and in China since 1990. China revised its Novel Food Regulation in 2007. 
Also in Europe, novel food legislation is under reconstruction in order to deal with problems 
with the current law. In 2008, the Commission has proposed a new Novel Food Regulation. 
Currently, many companies wish for their products not to be considered novel. They might 
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even be deterred from product development that might result in something considered novel. 
This is because the novel food process in seen as excessively burdensome and unpredictable. 
Even if the product is clearly novel, illegal marketing of the novel food is often preferred to 
making an application.
The European food industry has called for a more innovation-friendly regulatory 
environment. The uncertainty of the legal status of novel products and possible delays in 
the novel food procedure exacerbate risks and add costs. The current novel food regulation 
rewards for being the follower to the market rather than the innovator1552. According to 
Brookes, the time taken for novel food authorisations should be reduced and uncertainties 
should be minimised. It is fairly easy to agree on these notions. Brookes is also of the view that 
incentives to encourage innovation should be considered either in form of exclusive access to 
market or compensation for data provision.1553
With reference to the European defi nition of novel food, the issue of plant-based products 
raised controversy. The defi nition says all food not used in the Community before May 1997 is 
novel. This means that not only foods that are novel in the sense that they are newly developed 
are considered novel. Also foods, which have been used for perhaps thousands of years but 
which have not been used in Europe, are considered novel. The defi nition of novel food is 
clearly discriminatory and not based on science but instead on practical reasons. It is diffi cult 
to be aware of all the foods used in the world, so it was considered the most feasible to require 
documentation on all third country foods.
Novel foods must go through the pre-market authorisation procedure, where the marketer 
must present scientifi c tests and trials, indicating product safety. Foods that are equivalent to 
previous foods are exempted. This means old foods are presumed safe, and the novel food 
evaluation is mainly a comparative test. This comparative approach has been chosen because 
it is fairly diffi cult to prove absolute safety of a novel food, because a novel food often replaces 
something else in the diet and consists of multiple substances the effects of which are diffi cult 
to show in animal tests.
Third country food producers are understandably not so impressed on the justifi cation 
behind the defi nition, or the rule that equivalent products are exempted. There have been 
continuous arguments at the WTO on the European novel food regulation, particularly 
regarding plant-based products from third countries. With plants, the Commission will have to 
decide whether ‘history of safe food use’ in the country of origin could be enough to presume 
the food safe. This decision will affect farmers in developing countries, and companies willing 
to introduce plant based products, such as functional foods made of Chinese berries.
Also, the Chinese defi nition of novel food is based on local novelty, not global novelty. 
Everything not traditionally eaten in China is considered novel according to Chinese food law. 
Each legislator has as its primary task to protect its own citizens. This should not, however, be 
used as an excuse to create artifi cial barriers to trade. The producers of exotic food products 
have strong arguments supporting their view that either at least some of their products should 
1552  Brookes 2007, 6. Under the current Novel Food Regulation, other companies can obtain 
authorisation to market similar novel products almost immediately after the original applicant. 
Companies second to market companies avoid some of the costs associated with seeking 
authorisation. Companies ‘second to market’ are also not subject to the same time delays as 
original applicants in terms of planning market entry. Brookes 2007, 4.
1553  Brookes 2007, 6.
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not be considered novel, or, alternatively, that the safety requirements including scientifi c 
evidence and the authorisation processes should be less burdensome for these products.
To respond to the criticism, the European Commission has indeed proposed a simplifi ed novel 
food procedure for traditional foods from third countries. Traditional foods are still defi ned as 
novel, but they need not show all the evidence on safety that is required in the primary procedure. 
The marketer is still required to provide the proof on history of safe food use. This means he will 
have to provide the Commission with compositional data in addition to evidence on long-time food 
use that still continues in the third country in question.
Novel production processes will continue to be evaluated under novel food law, if they 
lead to ‘signifi cant changes’ in the food product. Despite criticism, the Commission has not in 
its 2008 proposal clarifi ed the concept of ‘signifi cant change’. This leaves room for soft law 
guidance. According to the current and the proposed Regulation, a novel process is evaluated 
under novel food legislation, if that production process “gives rise to signifi cant changes in 
the composition or structure of the food which affect its nutritional value, metabolism or level 
of undesirable substances”. According to Chinese novel food law, food ingredients are novel 
if their original composition has changed by the adoption of new production techniques. This 
newly introduced legal phrase will also require clarifi cation on what is considered a signifi cant 
change.
The issue of food ingredients with multiple purposes will be partly settled by the 
Commission’s proposal. A novel substance could be used as an additive or as an ingredient in 
other foods. A producer will in the future be able to apply for authorisation in one procedure 
instead of two procedures. In 2006, the Commission has proposed a Common Procedure for 
additives, fl avourings, and enzymes. In 2008, the Commission proposed to include novel 
foods in this Common Procedure. If used both as an additive and an ingredient, the food can 
be authorised through one safety evaluation procedure. However, additives and ingredients 
have their own criteria according to which they are evaluated1554, and if authorised, they are 
included in two separate Community lists. The Common Procedure does not apply to food 
supplements: they are still to be authorised in their separate procedure. Also in China, additives 
are regulated in a separate mechanism to novel foods. Food supplements are in China regulated 
either as common foods of health foods. If health foods, they must be registered as such.
The property nature of novel food authorisations is another important question to be 
answered. In addition to patents1555, originator medicine companies enjoy data exclusivity, 
which is another type of intellectual property. The 10-year of exclusivity1556 starts when an 
originator drug receives its license. During the exclusivity period, originator data cannot be 
used to authorise generic copies.
For novel foods, a similar type of intellectual property has been suggested in Europe. The 
suggested period of data exclusivity is 5 years. Novel food authorisations could be given as 
regulations that apply to all producers instead of decisions that apply just to the applicant. 
1554  The Additive Regulation vs. the Novel Food Regulation.
1555  Patent protection is available for 20 years from the application. For medicines, this period can be 
increased by up to 5 years through a Supplementary Protection Certifi cate. Patents are also granted for new 
uses, indications, dosages, and changes in formulation. Producers or generics naturally think intellectual 
property protection for medicines is too strong. European Generic Medicines Association web page at: http://
www.egagenerics.com/gen-patents.htm.
1556  After 8 years, a generic producer may apply for authorisation. After 2 more years, the generic can be 
marketed.
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Duplicating efforts will be avoided, and data exclusivity will be the reward for being fi rst to 
market and completing all the necessary safety tests. The regulations authorising novel foods 
could apply to all different uses of the new ingredient. This relates to the above-mentioned 
question of possibly combining the additive, supplement, and ingredient procedures.
The benefi t of the data exclusivity period would be simplicity. There are problems, though. 
If the defi nition of novel food would not simultaneously be changed, also data on third country 
vegetables and berries would be granted exclusivity. This would sound unreasonable. One 
could also argue that patent protection, or in some countries utility model, is enough intellectual 
property for food developers. For unpatentable foods, this approach presumes that trademarks 
are enough protection, and being the fi rst to market is enough incentive.
In China, decisions on novel food authorisation apply to all, and there is no data exclusivity. 
Due to history and economic reasons, the Chinese are generally not in favour of strong 
intellectual property or granting private monopolies. Also in Europe, there is a strong movement 
against creating more property rights. In the future, new types of intellectual property will at 
least have to be considered in many fi elds of economy. They are suggested because old types 
of intellectual property are not deemed to serve their goals properly. Reorganisation might 
include making some property rights stronger and others weaker.
7.2.2. Medicine Safety
With regard to medicine safety, there are considerable gaps in knowledge as regards plant-
based medicines. The utilisation of herbal medicine in the prevention and treatment of diseases 
and the maintenance of health is currently not fully realised, partly due to lack of rules. 
Herbal medicines are completely legal and increasingly popular also in Europe. However, the 
legislation is not based on any detailed knowledge on safety, effi cacy or cost-effectiveness. 
Neither do European governments have clear strategies on how to develop the herbals industry 
and how to best guarantee consumers’ rights. The European legislators’ attitude towards herbal 
medicine is rather uninterested, even though the use of herbal medicine might often be an 
effective alternative with fewer serious side effects and lower cost.
With the creation of the category of traditional herbal medicine by Directive 24/2004/EC, 
the EU decided to step away from the evidence based approach and justify marketing based on 
use only. According to the rules, it is legal to sell a product as a traditional herbal medicine if 
it has been used for such purpose without side effects for at least 30 years, of which 15 years 
in the Community area. The EMEA Committee for Herbal Medicinal Products is currently 
drafting a list of plants that have established use as traditional herbal medicines. National 
registrations will be granted based on this list.
The decisive date with traditional herbal medicines is when the new law came into force. 
In Finland this was November 2005. The authorities look 30 years back from this date to 
determine the products that have been in use for at least 30 years. Any new products cannot 
after this require the status of traditional herbal medicines. This means that if the product 
has been used for thousands of years for example in China, it is not possible to acquire the 
European status of traditional herbal medicine. Traditional medicines of countries outside 
Europe must go through the primary procedure for herbal medicines.
China has in recent years considerably strengthened its medicine legislation. This process 
was related to China’s entry to the WTO in 2001. Requiring GMP (good manufacturing 
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practice) certifi cates of all medicine manufacturers has signifi cantly reduced the number of 
medicine manufacturers, thereby cleaning up the market. Counterfeiting medicines has been 
attacked with stricter legal consequences. However, more resources on medicine control are 
still needed.
The Chinese have a long tradition in using plant-based medicines, and traditional medicine 
is strong in China. The Chinese are researching medicinal plants and developing this industry 
side-by-side with modern medicines. After thousands of years of practice, the Chinese are 
also putting legislative effort into further developing traditional medicine. The Regulations 
on traditional Chinese medicine were given in 2003. In 2007, the Ministry of Health drafted a 
law that will specify the requirements on traditional medicine. The Chinese have strategies in 
place to integrate traditional medicine with modern medicine and ambitious goals in creating 
research protocols and post-marketing surveillance systems for traditional medicine. They see 
traditional medicine as globally integral in bringing health for all.
The Europeans might have something to learn from the Chinese approach where herbal 
medicine is taken seriously. The Chinese efforts will probably show in future global market 
shares of plant-based medicines. The potential of herbal medicine cannot be fully realised by 
settling for unscientifi c not to mention discriminatory regulatory solutions.
7.3 Law on Health Claims and Medicinal Claims1557
Consumers are often ignorant of the nutritional basis underlying functional foods, and thus 
susceptible to betrayal. Marketing of functional foods must thus be regulated. With marketing 
of functional foods, the legislator’s tasks are to guarantee adequate information to consumers 
and to protect them from misleading claims. At the same time, the industry must not be 
burdened with overly heavy obligations. With no regulation, functional foods backed by 
considerable research efforts and investment could be undermined by less effective products. 
This would be frustrating to legitimate businesses.
The European Regulation on nutrition and health claims1558 is a huge step in regulating 
functional foods and hopefully cleaning up the industry. Before the Regulation, companies had 
too much space to confuse consumers with impressive but imprecise claims. Consumers were 
confused by all kinds of health claims, which were more or less scientifi cally substantiated, and the 
role of traditional foodstuffs became unclear. The Regulation was preceded by years of discussion, 
frustration, and national rules. According to Commissioner Kyprianou, each side would have liked 
to go further with the nutritional claim and health claim regulation, but the decided outcome is a 
good compromise that takes account of all positions in a balanced way.1559
In the future, only foods that comply with a certain nutrient profi le can bear claims. The 
EFSA will publish nutritional profi les for each product type by 19 January 2009. The nutritional 
profi le requirement means that if a food is high in fat, saturated fatty acids, trans-fatty acids, 
salt/sodium, and sugar, it cannot be promoted by nutrition or health claims. This means that 
1557  Nutrition claims are not discussed here as they are considered a rather simple issue where few controversies 
exist.
1558  Regulation 1924/2006/EC of the European Parliament and of the Council of 20 December2006 on 
nutrition and health claims made on foods.
1559  European Commission Press release IP/06/625, 16/05/2006.
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health-related messages are available only to foods that are healthy as a whole. Without this 
rule, consumers would themselves have to calculate the health benefi t of the claim and relate 
it to other nutritional information on the product.
However, in the fi nal compromise version of the Regulation, it was agreed that if one nutrient 
exceeds the nutrient profi le, the product could still bear a claim stating that another ‘evil’ is 
present in low quantities. In addition, the claim must be accompanied by a statement ‘High 
[… (*)] content’. This one-nutrient exception rule has been criticised for being completely 
unscientifi c, as the effect of adding one of the three evils varies greatly in different products. 
The loophole might lead to a situation where claims will be on products that nutritionists 
would not consider healthy. The original plan was that the product would always have to 
comply with the nutrient profi le as a whole to make a nutrition claim or a health claim. The 
industry was opposed to this total ban, and a compromise was reached. Politics surpassed 
science, which sometimes happens in food law matters.
The implementation of the new Regulation is a huge job. The EFSA has the most important 
role as the scientifi c advisor. Health claims are separated in two categories:
Health claims other than those referring to the reduction of disease risk and to children’s  –
development and health (Article 13), so called ‘function’ claims1560;
Reduction of disease risk claims and claims referring to children’s development and  –
health (Article 14).
The national food safety agencies will gather their lists of established ‘function’ claims by 
end of January 2008, based on which the EFSA will publish the community list of established 
function claims by end of January 2010. In the future, all new function claims will be 
scientifi cally evaluated by the EFSA. Disease risk reduction claims and claims related to 
children’s development and health will always have to be separately evaluated, and the EFSA 
has received applications for these claims since July 2007.
With hindsight, the chosen approach seems like the only reasonable way to deal with 
scientifi c substantiation of claims. A horizontal approach to claims1561 was established instead 
of creating additional product categories. The lists of already accepted claims benefi t the 
whole business and duplicative work in substantiating claims is avoided. It is inevitable that 
innovative products, on which there is no scientifi c consensus yet, will have to go through 
complicated procedures.
For example Winkler has been in favour of an even simpler approach where there are only 
two types of claims: content claims, about what is in the food, and effect claims, about what 
the food does to the consumer. The operating principle for this system would be to authorise 
1560  Function claims are health claims describing or referring to:
“(a) the role of a nutrient or other substance in growth, development
and the functions of the body; or
(b) psychological and behavioural functions; or
(c) without prejudice to Directive 96/8/EC, slimming or weight control or a reduction in the sense of hunger or 
an increase in the sense of satiety or to the reduction of the available energy from the diet”. Article 13(1).
1561  The claim regulation applies to all foods irrespective of whether they are foods in food form, foods in 
pill form, foods for the general public, foods for certain groups of people, novel foods or GMO foods. For 
example, Kwak-Jukes was in favour of this approach. Kwak – Jukes 2000b, 116.
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whatever claims science already substantiates and establish effective controls over the rest.1562 
The European system is quite close to this ‘simple’ approach. Nutrition claims are the content 
claims, and health claims are the effect claims. It is just health claims that are separated into 
‘function’ claims and disease risk reduction claims.
It was discussed above that data protection for novel food applications has been suggested 
in Europe. A data protection rule already applies to applications for health claim authorisation. 
Any food business operator may use health claims included in the Community lists, if they are 
not restricted for use in accordance with the provisions of Article 21 of the Regulation. Article 
21 grants 5-year exclusivity to an applicant that has provided his proprietary data to support 
the claim.
Concerning medicines and medicinal claims, the creation of the category ‘traditional herbal 
medicinal product’ in 2004 manifests the European legislators’ powerless attitude as regards 
plant-based products. A herbal medicinal product may be sold based on ‘history of use’, 
where ‘history’ is defi ned as 30 years, 15 of which in the Community area. In the marketing 
of traditional herbal medicinal products, the marketer must mention that the effi cacy of the 
product is not based on any clinical trials but instead on history of use only. Instead of an 
evidence-based approach, the EU decided to let the consumer decide whether to trust the 
product.
The category of traditional herbal medicinal products was created because there simply is 
no scientifi c proof of effi cacy on several herbs that are sold in Europe. The alternatives were 
to require scientifi c proof or let the products be sold based on history of use only. The taken 
solution can only be temporary. The goal of foodstuffs and medicines legislation must be that 
there are scientifi c facts behind products that are used to promote health. To let herbal medicines 
be sold without proof of effi cacy is going to harm the business in the long run. The only way 
to properly utilise the potential of herbal medicines is to take the scientifi c approach and to 
get rid of categories not based on clinical evidence. The Chinese are developing traditional 
medicine side by side with modern medicine, but Europeans certainly are not.
The same lack of science applies to homeopathic medicines. They are a similar category 
with traditional herbal medicines. Homeopathic medicines can be sold if homeopathic literature 
shows they have been used for a certain purpose. In addition, they must be diluted enough to 
make them safe. The marketer must mention that there is no proof of effi cacy.
This situation means that herbal medicines and homeopathic medicinal products can be 
sold as medicines without proof of effi cacy, when at the same time functional foods must have 
solid proof to back up their claims. Homeopathic medicines are often promoted by saying 
that they “are under medicines regulation”, which gives the impression that they are regulated 
similarly to modern medicines. Food legislation is in fact stricter science-based than medicines 
legislation.
In China, marketing of foods and medicines is under tightening regulatory control. The 
Health Food Regulation of 1996 has proven helpful in cleaning up the industry and guiding 
the health food market towards scientifi c research and development. Only health foods can 
bear health claims in China. The Health Food Regulation establishes 27 different functions/
claims that a health food may have. Each claim has its substantiation rules listing the required 
animal tests and human trials to support the claim. Data protection for applicants is not granted: 
1562  Winkler 1997, 192.
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an applicant may refer to data provided by another applicant. The Chinese intend to further 
improve the health food registration and inspection system.
The Chinese rules on medicine marketing of 2007 aim to clean up medicine advertising 
mainly by two means:
specifying the legislation: defi ning the prohibited marketing methods more precisely, and –
hardening punishments. –
Health claim legislation was created because it was scientifi cally established that foods in fact 
have health effects. The distinction between foods and medicines is now set between disease 
risk reduction and disease prevention. We concluded above that in the future, the categorisation 
decision on whether a product is a food or a medicine might lose its signifi cance, and that 
legislators should focus on safety and effi cacy of all products. Effi cacy would be relative to 
marketing, and would mean truthfulness of the marketing claims used.
It is, for example, not interesting whether lemon juice is a medicine but more interesting 
that it prevents scurvy or reduces the risk of scurvy. We predict that new innovations and new 
scientifi c information on health effects of foods will lead to a situation where the distinction 
between foodstuffs and medicines will lose its relevance, and medicinal claims will be 
acceptable for foods. For example, if buckthorn oil can be used to prevent the episodes of 
atopic eczema, it will not be relevant whether the oil is categorised as a cosmetic, a food, or a 
medicine. A claim will be possible if the evidence supports it. This will mean we have come 
full circle and the ancient adage “let your food be your medicine” is valid again.
7.4 About the Roles of Pre-Market and Post-Market Control
It is easy to agree that foodstuffs and medicines must be regulated to avoid potentially high risks 
to consumers. Without regulating safety, effi cacy, and marketing, markets would not function 
properly as the consumers would not know what they were buying. Legislation is not effective 
unless implemented properly. This can be seen with medicine advertising in China, or marketing 
of weight-loss products in Europe. There are two basic alternatives on how the rules can be 
implemented: through pre-market control or through post-market control.
There are important differences between medicines and foodstuffs. Medicines can be 
precisely regulated and evaluated before they access the market, and pre-market control is thus 
the dominant regulatory mechanism for medicines. Pre-market control is made possible by the 
fact that pharmaceuticals are relatively homogenous products produced by big companies.1563 
In contrast to the case of medicines, strong pre-market control is usually not possible for 
foodstuffs. This is because the food market is much more fragmented, in China even more so 
than in Europe.
Before discussing offi cial pre-market and post-market control, we must mention the control 
done by entrepreneurs themselves. Both in the EU and in China, the producers themselves 
are responsible for the safety and effi cacy of their products. This means that offi cial control 
does not free the entrepreneur from responsibility for faulty products. This applies both to 
foodstuffs and medicines. Implementation of self-control mechanisms is fundamentally a 
1563  Krapohl 2004, 519.
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question of trust, supplemented by GMP1564 documents and reports drafted by the entrepreneurs 
themselves. The self-monitoring system will save money if authorities can divide operators 
in separate risk categories and focus on the more risky operations, according to scientifi c risk 
assessment principles.
Pre-market control means that offi cials in an application must authorise a product authorised 
or notifi cation procedure before it can be sold to consumers. By means of pre-market control, 
authorities have a chance to make sure that the product as a whole complies with the laws. 
A lighter version of authorisation procedure is the notifi cation procedure, where a producer 
or marketer informs the authorities before bringing a new product onto the market, enabling 
authorities to react if deemed necessary.
There are problems to pre-clearance: gathering the necessary information into a dossier 
takes time and delays the placing of a product on the market. The time taken by the authorities 
in reviewing the product further delays market access, sometimes unpredictably. There are 
possible confi dentiality and intellectual property issues. Pre-market control also demands 
public resources, unless totally funded by the regulated industry.
On the other hand, pre-market control enables broad review of products accessing the 
market, and will block some products that would have caused serious health incidents if used 
by patients or consumers. Pre-market control is also more predictable from the applicant’s 
point of view. For this reason, entrepreneurs sometimes voluntarily discuss their product and 
it’s marketing with authorities already in the product development phase, even if there is 
no legislative requirement of pre-market control. The authorities sometimes take charges for 
these services.
At the moment, authorisation procedures are in Europe and China applied to all medicines, 
GMO foods, novel foods, and additives. Authorisation procedures apply also to health foods in 
China and novel health claims in Europe1565. In Europe, notifi cation procedures apply to food 
supplements and some of dietetic foods. The regulatory agencies of foodstuffs and medicines 
do not just implement the laws; they also create the law. In the pre-market procedures, the 
authorities often take the negotiation and counselling strategy and discuss with the applicant 
on how to make the product legal. Due to this practice, lawyers are not often needed to settle 
issues between companies and the control authorities1566. The limits of the discussion and 
persuasion approach are further discussed below in chapter 7.6.3.
In Europe, safety and effi cacy of functional foods will possibly in the future be evaluated 
simultaneously in one EFSA procedure. The separation of the two evaluations in food law 
is not due to any practical or scientifi c reasons but the two separate roots of novel food and 
health claim regulations. First, in the 70s, appeared foods that had previously unresolved 
safety issues to be dealt with. The European novel food legislation followed this technological 
development in 1997. Later, in the 90s, appeared functional foods where also effi cacy issues 
had to be resolved. Legislation on health claims followed in 2007. With medicines, safety and 
effi cacy have always been evaluated simultaneously, and now often by the EMEA. In China, 
safety and effi cacy of health foods is evaluated in one procedure by the SFDA.
1564  Good Manufacturing Practice.
1565  Regulation on nutrition and health claims widened the area of pre-market control so that all new marketing 
claims must be authorised by the EFSA before appearance on labels and advertisements.
1566  On the contrary, lawyers are often needed to settle issues between states protecting their own industries.
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Functional foods have forced regulators to create new pre-market control mechanisms. 
When deciding on how to regulate functional foods, governments must weigh the benefi ts 
and costs of pre-market control. The pre-market system might be considered adequate as to 
safety issues, but disproportional to the possible problems of health claims. In the spirit of 
freedom of speech, marketing is not usually disposed under pre-market control. By misleading 
marketing communication, the severity of health risks caused is usually not as great as with 
products that are unsafe. However, it seems that regulators ended up with total pre-market 
control of functional foods, including their marketing. When creating new pre-market 
procedures, precise time limits should be given in law. This has already been done regarding 
pharmaceutical legislation and should also be done in the fi eld of food law.
Today there seems to be a need for three different pre-market procedures for foods:
Innovative foods without health claims (novelty relates to other feature than health 1) 
effect).
Innovative foods with health claims (functional foods).2) 
Natural materials (mainly plants) that have not previously been used as foods.3) 
These procedures would apply to foods in food form and foods in pill form. Procedure 1) 
would include additives, fl avourings, and enzymes. Procedure 2) would include dietetic foods, 
fortifi ed foods and GMO foods.
There is also a continuous need for two different pre-market procedures for medicines:
Herbal medicines.1) 
Chemical medicines.2) 
With herbal medicines, applications can be based on literature or on preclinical and clinical 
trials. It is questionable whether it is suitable to uphold medicine categories for products 
without any proof of therapeutic effect and without referral to therapeutic effi cacy. Instead of 
creating legal categories for products on which information is not available, we could focus 
on scientifi c research to produce this information.
All of the above-mentioned fi ve procedures would also have to include simpler versions 
for products that are novel but essentially similar to previously authorised products. At the 
moment, there are already simplifi ed procedures to generic medicines and novel foods that are 
similar to previously authorised ones.
Even when a pre-market procedure exists, someone will always dismiss the authorisation 
procedure and put unauthorised products where only post-market control applies. Post-market 
control means controlling products already on the market. This means the authorities use 
various means to verify that product safety; effi cacy and marketing are according to the law. If 
this is not the case, the product can be withdrawn from the market and penalties imposed.
If governments were to rely on post-market control only, the marketer of a medicine or 
foodstuff could basically do as he pleases but the authorities could forbid the product or 
marketing action afterwards. The health risks caused to consumers are the most obvious 
problem with this approach. This would also lead to uncertainty and waste of resources. To 
avoid the waste of product development and marketing efforts, companies would ask the 
authorities for pre-market advice on how the product would be treated. With complex issues, 
pre-market control is thus the only practical solution.
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It is generally agreed that better post-clearance systems are needed. There are numerous 
problems related to post-market control of foodstuffs and medicines. ‘Wonder drugs’ are one 
of them. These are products claiming to cure just about everything are marketed throughout 
the world. Internet complicates the issue further. Responsible producers are of course against 
these wonder drugs, because it affects the reputation and consumer confi dence in the whole 
business of health foods, functional foods, and herbal medicines. These ‘wonder drugs’ are 
not legally registered as medicines, but still marketed with medicinal claims. It is diffi cult to 
control this activity because:
it is sometimes diffi cult for authorities to fi nd the company or person that is legally  –
responsible for marketing of the product,
enforcement of penalties is a slow procedure because the accused can always appeal, so  –
the marketer has plenty of time to collect cash before he can be stopped,
the penalties for illegal marketing are not economically signifi cant. – 1567
With post-market control, legislators should focus on increasing transparencies in the food chain 
and the medicine industry, entrepreneur responsibility, effective implementation, and effective 
penalties. The issue of burden of proof is also important with post-market control. The burden of 
proof should be on the producer and marketer of a product. The entrepreneur should be able to 
prove the safety of his product and to substantiate the marketing claims used.
7.5 Central vs. Local Legislation
In this chapter, we discuss the competences between Central and Local legislators. In the EU, 
this means EU vs. its Member States. In China, this means national vs. provincial legislation. 
Before discussing these issues, we must discuss the relationship between global rules and 
the rules of EU and China. Global agreements are in a sense above both EU and China. 
According to the Agreement Establishing the World Trade Organization, a Member shall 
ensure the conformity of its laws, regulations and administrative procedures with its WTO 
obligations1568.
The WTO is about negotiations, agreements, and dispute resolution. International trade rules 
are created through negotiations, currently the Doha round. The Dispute Settlement Body can 
resolve whether certain trade-related legislation passed in a national democracy is against the WTO 
rules. This means a WTO member state cannot legislate freely regarding protectionist purposes. 
WTO member states can set their own environmental or health rules, but they cannot discriminate 
between domestic and foreign companies. The principles of most-favoured-nation and national 
treatment are the cornerstones of free trade.
The WTO settles trade disputes based on trade agreements. It is not an environmental 
or public health organisation.1569 However, the WTO Dispute Settlement Body cannot avoid 
natural science when a case is for example on a chemical and its health effects. Decisions 
1567  Enkovaara 2002, 32.
1568  Qingjian 2002, 298.
1569  See Palmujoki 2003, 719-720.
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on such cases are often based on complex and sometimes confl icting scientifi c evidence1570. 
To uphold WTO legitimacy, it is important to openly develop legal and scientifi c principles 
that WTO member states can agree upon. This is diffi cult as the interests of industrialised 
countries and developing countries often differ. Codex Alimentarius rules and other standards 
are referred to in WTO agreements. This referral makes international soft-law standards 
important sources of WTO law.
In Europe and China, similar trends of legal centralisation can be noticed. In Europe, the 
EU, not its Member States, regulates foodstuffs and medicines. In China, several national 
laws have been enacted since the 1990s. Where local legislation still exists, it has led to 
problems. The reasons for harmonisation are the same in the EU and in China: harmonisation 
is considered necessary in order to guarantee consumer rights, and for the proper functioning 
of the internal market.
Most of the important European food law has been harmonised by the EU Commission. 
This harmonised legislation includes hygiene rules, restrictions on additive use, pesticides 
and maximum levels of pesticide residues, novel food and GMO food authorisation, food 
supplements, food labelling and nutrition information, nutrition claims and marketing claims, 
etc. Food law is now frequently given in the form of Regulations instead of Directives. This is 
because differing interpretations are deemed to undermine the ideas of the internal market and 
equal consumer rights. With medicines, there is even less room for national interpretations. 
Medicine quality, safety, and effi cacy are stipulated in exact manner by European level hard 
law and soft law.
European harmonisation of health-promoting foods has come a long way through regulations 
on food supplements, fortifi ed products and nutrition and health claims. Areas where variations still 
exist between Member States are probable targets for future harmonisation. However, European 
national food agencies still have their various guidelines on how they interpret the European law 
and implement it in practice. Different practices in different states are seen as obstacles to trade. 
Increasing harmonisation of European food law decreases the need for both national legislation 
and national soft law. We predict the next issues to be harmonised in European foodstuffs and 
medicines law to be:
The foodstuff vs. medicine -issue.1) 
Food supplements containing other ingredients than vitamins or minerals.2) 
Food fortifi cation with other substances than vitamins or minerals.3) 
The decision on whether a product is a foodstuff or a medicine is at the moment made by EU 
Member States, the categorisation decisions being based on national soft law materials. This 
central scientifi c and political question is often related to functional foods, where disease 
risk reduction has to be compared to disease prevention. In the future, a European law on 
how to separate foodstuffs and medicines might be considered necessary. Simultaneously, the 
categorisation decision might be shifted onto the EFSA or the EMEA.
European rules on food supplements and fortifi ed foods using for example fi bre, phytosterols, 
or lactic acid bacteria, might be harmonised in the future. At the moment, these products 
are regulated by national rules. Some are also scrutinised as novel foods. Harmonisation of 
fortifi cation rules would make the rules clearer for some functional food businesses.
1570  See Kulovesi 2003, 65-66.
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The size and diversity of China has led the government to use a system of local autonomy. In 
environmental issues, the resistance of local and provincial governments is a serious obstacle to 
sustainable development policy. Similar problems relate to regulation of foodstuffs and medicines. 
The Chinese Food Hygiene Law of 1995 declared that precise food safety standards are to be 
decided locally. The new Food Safety Law upholds this principle. Standards vary, and national 
and local standards contradict one another. Implementation and control of the rules differs among 
provinces and cities. The national Food Safety Standard will solve some of the problems. However, 
it is not possible for the central government to be aware of all the day-to-day decisions and actions 
of localities. Local offi cials might see national laws as obstacles to their cities’ growth and personal 
promotion, and hence readily defy them. Promotions are often based on meeting economic targets, 
and cooperation with other provinces or cities is not rewarded. This enhances local protectionism.1571 
Distrust in food and medicine marketing describes consumer attitudes in China.
An important step towards centralisation in China is that currently all food and medicine 
pre-market authorisations are under the competence of the SFDA. This has eliminated the 
confl icting standards that previously prevailed among provincial government agencies. The 
Health Food Regulation was important in setting common national rules for functional food 
products. The proposed national law on traditional herbal medicines will strengthen patient 
confi dence in China, and also promote acceptance of herbal medicine and related business 
opportunities in foreign countries. In the future, China will probably have to harmonise all 
important food and medicine standards nationally in a similar manner that is being done with 
exported foods. Chinese laws as such already guarantee that foodstuffs and medicines are safe 
and effective. As stated above, China can build confi dence in the food and medicine industries 
by strengthening implementation and control of laws, and particularly at the local level.
In Europe, there have been complaints that it is diffi cult to understand the totality of 
Community and national laws. For example, the Finnish Ministry of Agriculture and Forestry 
has stated that “the totality of foodstuff legislation will inevitably be unclear”, because 
European regulations are not repeated in the Finnish law1572. European law both adds volume 
and complicates structure. Hallberg states this from a court’s perspective1573. Likewise in 
China, the relationship of national laws and local laws is not clear. Laws are often broad and 
hard to understand as such. In China, national and local laws at times contradict one another, 
and national government agencies have to take action to revoke local laws1574.
There are solutions to complexity stemming from central vs. local laws. The obvious 
solution is abolishing local laws. The European approach is not in fact far from this situation. 
Central regulation would guarantee equal consumer and patient rights, and also free movement 
of goods. However, there are also positive sides to local legislation. The most persuasive 
argument in favour of local legislation is that it is easier for citizens and local experts to get 
their voice heard. It does not serve any purpose to enact the same laws both on central and 
local level. The local laws must serve local needs and be based on genuine local differences 
in these needs.1575
1571  Lam 2006. 
1572  Maa- ja metsätalousministeriö. Selvitys lainsäädännön muutostekijöistä 2005. Page 13.
1573  Hallberg 1997, 69. 
1574  Lam 2006.
1575  See Tala 2005b on the role of national legal policies. 
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If both central and local legislation are considered necessary, regulation targets can be served 
by using a referral technique, where local laws refer to central laws. In China, implementation 
and control of central laws must be enhanced. This will require a culture where pursuing 
national aims is awarded instead of pursuing local aims. Also in Europe, national and local 
favouritism can sometimes be detected behind food and medicine law. European laws are still 
often compromises between national interests rather than instruments based on scientifi c risk 
analysis and common economical goals.
As opposed to minimum harmonisation, maximum harmonisation is today preferred 
in EU consumer protection. Simultaneously, it seems that the focus has shifted from the 
consumer onto the entrepreneur. First, consumer protection was primarily about protecting 
the consumer. Now the goal rather seems to be to keep the protection at a reasonable level to 
facilitate trade. For example, the UCP directive tries to make the rules on consumer marketing 
clear, as national rules cease to exist. Simultaneously, positive aspects of diversity might be 
missed. Nehf suspects1576 that at least in the short term, the UCP Directive might increase legal 
complexity rather than simplify the rules. According to him, simple solutions often fail to fi x 
complex problems.
MacMaoláin (2007) is of the view that national regulators would, more likely than the 
EU Commission, pay attention to food quality such as nutritional properties (for example 
to fi ght obesity) and ethical questions. He thinks that in order to promote free trade, the EU 
sets unnecessarily low requirements on foods. According to the industry on the other hand, 
food safety and food quality should be strictly separated into area of law (safety) and area of 
markets (quality). This would mean leaving the quality dimension of foods for the consumers 
to decide: consumers will pay for the quality they want. We are of the view that consumers 
need encouragement by legislators. Products should be legally favoured if they are healthy for 
people and the environment and also ethically sustainable.
7.6 About the Role of Soft Law
7.6.1 Types of Soft Law
In Europe, there are at least four different types of soft law concerning food and medicine 
industries:
Administrative regulations and so called normative and scientifi c guidelines by the 1) 
Commission, the EFSA1577, the EMEA1578 and national food and medicine agencies.
Standards by governmental organisations such as Codex or Council of Europe.2) 
Standards of non-governmental organisations, for example the International Life 3) 
Science Institute and consumer organisations.
Self-regulation guidelines.4) 
1576  Nehf 2007.
1577  European Food Safety Authority.
1578  European Medicines Agency.
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In China, it is diffi cult to separate between hard law and soft law. First of all, there are laws 
enacted by the National People’s Congress. Then there are regulations and directives given by 
the State Council, which is the highest administrative body in the nation. In reality, it is the 
State Council that decides on important law. In addition, there are regulations and directives 
given by various departments under the State Council. These departments include the Ministry 
of Health and the State Food and Drug Administration.1579
7.6.2 Administrative Soft Law and the Role of Regulatory Agencies
Various administrative guideline-type documents are particularly important in regulating 
foodstuffs and medicines. There are several reasons for this:
There is a need for  – scientifi c expertise. Several issues are resolved by scientists alone.
There is a need for great regulatory  – detail. Requirements on product safety and effi cacy 
cannot be defi ned in fl exible terms because these may become a matter of life and death or 
serious impact on health. This applies most of all to the pre-market authorisation procedures. 
The large amount of detailed rules means large volumes of guidance texts.
There is a need for  – constant changes, due to the scientifi c and detailed nature of the 
laws.
Administrative soft law is considered a necessary and a natural part of medicine law. In a 2002 
WTO publication, it is stated that medicine laws provide the basis for medicine regulation, but 
standards and guidelines equip regulatory authorities with the practical means of implementing 
the laws. The absence of soft law guidelines “may lead to variations in the implementation 
of the law, or even lead to questions about the transparency of law enforcement”. Therefore, 
“standards and guidelines should be established in a written form for all medicine regulatory 
functions”. Administrative soft law should be publicly available to all the parties involved, 
and be used to guide regulatory practice.1580 For the same reasons, soft law guidelines are 
needed in the food industry: besides the applicants, guidelines tell the authorities themselves 
how to lead the application procedures.
Senden recommends that European soft law instruments should be rationalised and used 
consistently, and that their legal effect should be clarifi ed1581. The Commission has worked 
to clarify the role of guidelines in the fi eld of medicines law1582. The main conclusion is that 
although not binding, guidelines should be followed unless there is good reason to deviate 
from them. European soft law on medicines is given mostly at the Community level. The 
‘Notice to Applicants’ by the Commission is an important source of law defi ning the details of 
the pre-market authorisation process of medicines. The Notice includes regulatory guidelines. 
Scientifi c guidelines by the EMEA specify the requirements for tests and trials on medicines. 
These documents are not legally binding but are, in practice, followed like laws.
1579  Lists of Chinese food, drug and cosmetics laws in 2007 at: http://www.chinafdc-law.com/laws/index_1.html.
1580  Ratanaqijitrasin – Wondemagegnebu 2002, 2.
1581  See Recommendations by Senden 2004, 498-502.
1582  Procedure for European Union guidelines and related documents within the pharmaceutical legislative 
framework. London, 20 June 2005. EMEA/P/24143/2004.
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Efforts to clarify the role of soft law would be welcome also in the food sector. Namely, soft 
law is also important in European regulation of foodstuffs. With novel foods, the Commission 
Recommendation is particularly important. The Recommendation defi nes the requirements 
and details of the European pre-market procedure that applies to novel foods1583. A pre-
market procedure applies also to GMO1584 foods. In this case detailed rules were given by the 
Regulations themselves1585, not by a Notice or a Recommendation. This might have implied 
that a preference for legally binding instruments was emerging. However, with the Health 
Claim Regulation, the application procedure is again based on guidelines by the EFSA.
Large volumes of soft law materials regulating foodstuffs are given also by EU Member 
States. For example, the Finnish food agency has their guidelines on practically every issue 
where legal uncertainty might arise. These guidelines not just explain the law but create it. The 
Finnish regulatory guidelines include, for instance, a guideline on food supplements, where 
detailed information on separation of herbal medicines, food supplements and dietetic foods is 
included. It is stated that to be classifi ed as a food supplement, a product can provide at most 
200 kJ energy per day. This information is nowhere else to be found. The UK Food Agency 
has created a complete regulatory package on so-called borderline products that are either 
medicines or foods. A particular problem with European national guidelines is that they are 
not always translated to any other European languages. It is thus diffi cult for entrepreneurs in 
other European countries or third countries to be aware of their contents. Crucial information 
could be missed that might even affect the decision on whether to bring the product to the 
market in the fi rst place.
A general problem with international and national guidelines is that the procedure for 
drafting them is not always democratic or transparent. Guidelines are often discussed among 
the stakeholders, but there are no rules on who will be asked for opinion and whose opinion 
weighs the most. When factually delegating legislative power to food or medicine agencies, 
one must carefully consider who actually makes the decisions and whether common good will 
be pursued. The capacity and expertise of the agencies must be such that the industries cannot 
overweigh them.
Another basic legal problem with these guidelines is that entrepreneurs and consumers 
cannot appeal these guidelines as such. Guidelines are something between legislation and 
administrative decisions implementing the law. Guidelines do not possess the democratic 
element of legislation, and neither are they subject to control by courts. Legally, the binding 
nature of guidelines is diffi cult to grasp. Soft law guidelines tell regulation objects how the 
legislation will be interpreted when decisions in individual cases are made. The makers of soft 
law guidance documents are not assuming any responsibility on whether they are interpreting 
the laws correctly. If an entrepreneur decides to follow a guideline, he still cannot be sure of 
1583  With novel foods, companies that want to place a novel food on the EU market need to submit their 
application in accordance with Commission Recommendation 97/618/EC that concerns the scientifi c 
information and the safety assessment report required. 
1584  Genetically modifi ed organism.
1585  Regulation (EC) 1829/2003 of the European Parliament and of the Council of 22 September 2003 on 
genetically modifi ed food and feed, supplemented by Commission Regulation (EC) 641/2004 of 6 April 2004 
on detailed rules for the implementation of Regulation (EC) 1829/2003 of the European Parliament and of 
the Council as regards the application for the authorisation of new genetically modifi ed food and feed, the 
notifi cation of existing products and adventitious or technically unavoidable presence of genetically modifi ed 
material which has benefi ted from a favourable risk evaluation.
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doing everything correctly. However, following guidelines will probably be seen at least as 
a bona fi de attempt to follow the law. Not following guidelines will be seen as something an 
entrepreneur will have to explain. This way, guidelines can be seen as a starting point for 
discussion.
If we want to create law that can be trusted, and rights and obligations that can be enforced, 
soft law should not be created. In this case, the Commission, the EFSA, the EMEA, and 
all the national agencies should be given the legal competence to do what they are already 
doing: giving more detailed regulations on general food and medicine laws. In this case, they 
would not have to use phrases like “this is not a complete or defi nitive statement of the law”. 
This extensive delegation of hard legislative power does not seem acceptable. In spite of the 
ambiguity, we might be more comfortable with non-binding soft law.
Non-binding guidelines are in fact a part of an implementation strategy where agencies 
have a lot of power and implementation is based on co-operation, fl exibility, and negotiation. 
Guidance by guidelines is supplemented by individual guidance given by agencies to targets 
of regulation. Implementation happens through constant interaction between entrepreneurs 
and the implementing agencies. Business operators often ask the foodstuff and medicine 
agencies for information on how to fulfi l their legal requirements, and the agencies explain - 
and create - the law as best they can. Persuading the regulation targets to follow the rules is 
often cheaper and faster than forcing them to follow the rules. Using sanctions might spoil the 
cooperation spirit.
The cooperation strategy has its limits, though. First, this kind of implementation strategy can 
only work when regulation targets are motivated to follow the rules1586. Getting caught selling 
products that are hazardous to health will have a strong impact on company image for years. For 
this reason, most food and medicine companies are completely willing to try their best to avoid 
this. ‘Normal’ food industry operators and pharmaceutical companies are responsible, or at least 
interested in their responsible image.
However, sometimes business operators will not listen to any non-binding guidance or 
persuasion. All kinds of ‘magic’ foods and food supplements marketed for weight loss both in 
Europe and China can be mentioned as examples. These products are continuously marketed 
with false and misleading claims, and the agencies must use sanctions to get them off the 
markets. For these companies, short-term fi nancial gains are more important than long-term 
credibility.
Secondly, there is the risk of so-called regulatory capture, where the objects of regulation 
push their demands so far that they actually get to decide how they are regulated. Agencies 
must be careful of not giving too much weight on the industry opinion only. Cooperation 
and mutual understanding does not mean that the agencies must always please the industry. 
It merely means that, if possible, industry efforts are recognised, and overly burdensome 
measures are avoided.
The third important challenge of the strategy is treating entrepreneurs equally. The use of 
non-binding guidelines and case-by-case information guidance means that implementation 
is fl exible in a certain meaning. This brings the negotiation element into the picture. The 
entire information and negotiation strategy is based on trust, and it will lose its foundation if 
implementation takes place on unequal terms. Flexibility cannot mean that companies with 
similar risks are treated in a different manner. Equal treatment is the responsibility of the 
1586  Tala 2001, s. 271. 
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agencies. Ethical rules and implementation principles must be discussed among agency staff. 
In the supranational context, the decision-making rules are even more important.
Scientifi c risk assessments and scientifi c guidelines are the most suitable tasks for foodstuff 
and medicine agencies. Independent agencies are valuable in resolving scientifi c issues based on 
science, not politics. If we want the EMEA and the EFSA in Europe and the SFDA in China 
to perform impartial risk assessments based on science, we must guarantee independence from 
political actors. This is because it is often tempting to pursue local short-term interests instead of 
common good, particularly if everybody else is doing the same. Trust in other European nations is 
needed for the Europeans to allow the agencies to act independently. Likewise in China, the SFDA 
needs its independence to be credible.
Creating total independence of the agency (EMEA, EFSA, of SFDA) creates a control 
problem, as the agency might develop a will of its own. The control problem can be avoided 
by setting substantive decision-making criteria by law, in which case it is possible to subject 
decisions of regulatory agencies to review by courts. This is what Krapohl suggests1587. This 
means the political actors must set the legal principles under which the agency acts. Only after 
this can implementation be trusted within a regulatory agency.
7.6.3 Standards
Standards are seen as playing a supporting role to legislation. The European Commission 
sees standards as “technical specifi cations which allow compliance with legal requirements”. 
Standards are seen as innovation-friendly, as they are developed by the interested parties 
themselves and updated according to state of the art.1588 The European Commission sees 
standards as the New Approach to legislation that allows public and private interests to 
merge, at the same time fulfi lling the goals of Better Regulation. The Commission has in 
2008 re-asserted its commitment to market-led standardisation and to the voluntary use of 
standards1589.
Even though standardisation is presumed as private action, governments are involved. 
Standardisation is thus something between public and private. The European Commission 
says “A stronger role for standardisation ... is important for the ... effort to address economic, 
environmental and social challenges.” If we look at these goals, it sounds like standards are 
the new law. Standards, particularly global standards, are seen as the new approach saving 
governance from its oblivion created by the fall of the nation-state. Standards are seen as 
a “better-regulation” alternative to legislation, and an answer to many of the problems in 
modern societies.
Using standards does not free us from questions of regulation quality, critical evaluation, 
and further development. How regulation is done is more important than who does it. Standard 
setting is a procedure: what is important to regulation targets is the outcome of this procedure, 
the content of the regulation. Regulators need to let stakeholder voices be heard, balance 
interests, be just.
1587  Krapohl 2004.
1588  Commission Communication on Standards 2008, 4.
1589  Commission Communication on Standards 2008, 6.
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4.6.4 Self-Regulation
As an alternative to legislation, regulators should consider the viability of self-regulation or 
industry codes of best practice. Some of food and medicine law issues might be better resolved 
by the industries themselves. Reliance on self-regulation should always be the result of a 
conscious process by the government, where the benefi ts and downsides of self-regulation 
have been weighed. Self-regulation should not exist just because the legislator is too busy to 
react on some issue, the legislator wants to get the easy way out, or just because the industry 
claims that legislation is not welcome.
There is more space for self-regulation in the foodstuffs sector than with medicines. The 
pre-market authorisation process for medicines is globally harmonised and very strictly defi ned 
by law without much room for interpretation. In Europe, the Commission and the EMEA 
have drafted all the necessary explanatory documents. Self-regulation is mainly related to 
advertising of medicines. Likewise in China, self-regulation does not have a great role in 
regulating medicines.
Regulation of foods is heading for the same direction: the food industry is getting more 
and more regulated. New food legislation covers new areas and is also stricter than before. 
This development is due to serious health problems that have received wide attention and 
created consumer distrust. Legislators see their job as building confi dence in new products 
such as functional foods. They have, for example, created pre-market authorisation processes 
for novel foods and precise criteria for presenting health claims.
The food industry is not content with tightening regulatory control. They demand that the 
area of self-regulation is expanded. They claim to be responsible and willing to guarantee 
consumer rights themselves. However, they have not in practice addressed the issue of high-
energy food marketing to children, for example. Advertising restrictions imposed in Britain 
were considered too demanding because “they might affect sales”. It is not likely that business 
operators will pass rules on themselves if there is a fi nancial cost to it. Even if the majority of 
food industry actors were to agree on the rules, there would always be some players breaking 
the codes and destroying the system.
The Chinese government has in food hygiene issues promoted self-regulation and 
regulation by consumer organisations. The Chinese are also campaigning to make consumers 
more responsible with regard to food safety issues. Although important, these approaches will 
not suffi ce. In China it is an enormous task to offi cially control the whole food chain, so the 
government wishes that food business operators and consumers could manage by themselves. 
In our opinion, the laissez-faire attitude will not work in China or in Europe. Foodstuffs and 
medicines are too important for the government to step aside. Self-regulation has proven useful 
in certain minor questions where the industry as a whole is motivated in following common 
rules that often supplement hard-law norms.
Consumers often prefer legislation to self-regulation, based on experience. Consumer 
demands in product safety and marketing information are in practice always opposite to the 
industry propositions. Perhaps consumers are trying to get more than they actually want in 
order to get at least something. Consumers often ask for things that they don’t actually need, 
and certainly don’t want if there is a cost to it. They also ask for things that are certainly not 
good for them. Consumers are often ignorant, indifferent, or even self-destructive. Just like 
the industry opinion, the consumer opinion cannot be the only decisive one when deciding on 
food and medicine law.
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If we decide to keep creating soft law, we need to discuss the legal weight of this material. 
There will be no simple answer to the question. Different parts of soft law should have different 
weight. If a document comes from “a regulatory agency”, an average citizen will understand 
it being the law. There are legal certainty reasons that support giving weight to regulatory 
agency guidelines. Self-regulation is different, as an entrepreneur knows he is here not dealing 
with law. The courts do not have to consider that abiding by the industry norms is always 
adequate. The industry norms might not be strict enough, as businesses are not often the fi rst 
to impose norms upon themselves. There might be important considerations that have been 
totally left out of the industry norms. However, following the industry norms can still be used 
as evidence of bona fi de efforts to act legally, especially where ‘hard law’ norms are missing.
7.7 Final Conclusions
The main tasks of legislators regarding foodstuffs, medicines, and functional foods are in our 
opinion:
To ensure that products on the market are safe and effective.A)  This requires focus on 
implementation and control. There have to be standards on required scientifi c studies 
to prove safety. Hoax products should be taken off the market in order to build trust in 
products that actually work.
To create a favourable environment for research and development.B)  This includes 
providing proper education in natural sciences, offering support to R&D fi rms in their 
research projects, strengthening cooperation between universities and companies, and 
establishing adequate intellectual property protection.
To guarantee adequate C) information on foodstuffs, medicines, and functional foods by 
raising public awareness on diet-health issues by means of health education, and by 
ensuring that only understandable and useful marketing claims are used.
Possibly to D) further encourage healthy consumer behaviour such as giving tax benefi ts 
for healthy products, or restricting advertising, or even sales, of foods that are high in 
calorifi c value, fat, salt and sugar. Financial rewards for healthy lifestyles have been 
suggested as an even more extreme incentive.
With foodstuffs, medicines, functional foods as we defi ned them, and functional foods as 
others defi ne them, the primary task of regulators is to promote health. Regulation will have an 
effect on the dietary and medical choices of consumers. Functional foods have to be judged by 
their merits. The ultimate aim of regulation on functional foods should be to make consumer 
diets better and the amount of patients smaller. European and Chinese regulators cannot work 
alone to achieve this. As members of the WTO, they cannot decide to promote their industries 
and protect their citizens simply by dismissing foreign products. Food law and medicine law 
issues are better solved globally and international cooperation is integral.
When regulating functional foods, the restrictive approach of protecting consumers is 
not enough. The governments must look at functional foods as a positive development. New 
healthy products coming to market and a wide selection of choices benefi t consumers. Besides 
health effects, functional foods can be valuable in offering business possibilities also for 
smaller companies and creating jobs. The governments must thus aim at regulatory solutions 
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that promote innovation and do not stifl e competition. The appropriate level of intellectual 
property protection needs to be carefully considered. The legislators must set clear, enforceable 
requirements and predictable, transparent procedures. Many governments have promoted food 
development also by allocating public research funds into food development.
The concepts of ‘food security’ and ‘right to food’ have changed over time1590. Food 
security means that food is available and that it is safe. Law can potentially play an important 
role in both1591. Today food security is not just understood as a right to suffi cient food, but 
as a right to safe, nutritious, and healthy food1592. Functional foods might further widen the 
concept of food security. A person might, for example, be considered to have a right to use 
cholesterol-lowering foods. Here the task of governments and other governance regimes 
would be to ensure consumer access to safe and effective products. The WHO Nutrition report 
of 2003 recommends the creation of “health-supporting environments”. It is not a question of 
communities vs. governments or local initiatives vs. legislation. Both are needed. Consumers 
and food chain operators need to be involved.1593 Administrative regulations, standards, and 
self-regulation are new modes of governance that have profound implications on how law and 
democracy are perceived.
A lot of energy is currently being used to settle whether a product is a food or a medicine. 
This is particularly with plant-based products such as berries and herbs. The governments 
must look at the use of foodstuffs and medicines from a new perspective. Foods and medicines 
may well be used for similar purposes. This means food law and medicine law should be 
considered as a whole. The division of foodstuffs and medicines would lose its signifi cance if 
food law and medicine law were to be merged with each other. According to Howe, it is time 
to break down the somewhat arbitrary regulatory barriers that discriminate between foods 
used for sustenance alone, functional foods, food supplements, traditional or herbal medicines, 
other over-the-counter products and prescription medicines. Manufacturers, health providers 
and consumers would be better served by establishing a unifi ed approach for evaluating the 
health potential – and limitations – of all these products1594.
We could aim at developing a range of integrated diet and lifestyle options for achieving 
and maintaining optimal health. If treatment was necessary, we could use the most effi cacious 
combinations of active nutrients with medication. Obvious examples are the use of low-fat diets 
with cholesterol-lowering drugs and low salt foods with blood pressure medication. However, 
medicine companies are not currently encouraged by the regulatory environment to evaluate 
the potential benefi ts of nutrient/medicine combinations. Adoption of such a combination 
approach will require an unprecedented level of cooperation between the regulatory authorities 
and all stakeholders.1595
In addition to international fora, more discussion on food and medicine law is needed on 
national, local, and consumer level. An average consumer would probably want food and 
medicine law to promote health but also to guarantee information and freedom of choice. 
Part of consumers might want the law to promote sustainable development. In a democracy, 
1590  Mechlem 2004, 647-648. 
1591  Snyder 2004, 496. 
1592  Mechlem 2004, 648.
1593  WHO Nutrition Report 2003, 144.
1594  See Howe 2000, S111.
1595  See Howe 2000, S111.
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citizens can vote representatives to change the laws if they wish. However, food and medicine 
law is not often familiar to consumers, and the issues are not debated before elections. If 
questioned, European consumers and citizens might have differing opinions, for example, on 
the following European legal solutions that currently exist:
generic copies of originator medicines can be sold after 10 years has passed since  –
authorisation of the originator medicine,
herbal medicines can be sold without proof of effi cacy, even if they have a relatively  –
short history of use in Europe,
even thousands of year history of use in third countries does not allow a herbal medicine  –
to be sold in Europe,
homeopathic medicines can be sold without proof of effi cacy, –
old foods are presumed safe, and new foods are presumed safe if they are similar to old  –
foods,
third country old foods such as vegetables and berries are presumed unsafe and it is thus  –
diffi cult to bring them onto the EU market,
innovative foods are presumed unsafe and it is thus diffi cult to bring them onto the EU  –
market.
What is relevant regarding consumer law is what the consumers expect of the law. The culture 
of trust in a regulated market affects expectations on how cautiously one needs to act on the 
consumer market. European consumers appear to expect the state to safeguard their position 
in the marketplace. However, even the legal cultures in Northern and Southern parts of Europe 
differ in this respect.1596 American consumers tend to trust collective consumer activism rather 
than consumer law1597.
Even though Chinese legal rules and institutions are increasingly similar to their Western 
counterparts, legal culture will change slowly1598. The Chinese tend to trust neither the law 
nor the companies. In China, the difference between legal system surface and legal reality is a 
wider cultural phenomenon. It is related to the notion of ‘rule by man’, the reliance to family 
and friends in the fi rst place, and the Confucian principle of confl ict avoidance. In the Chinese 
legal culture, the administrator long had all the (imperial) power. The ‘rule by man’ tradition 
runs counter to rule of law. The separation of powers is new to the Chinese and reliance to 
social connections, guanxi, is deeply rooted and also runs counter to the establishment of rule 
of law1599.
1596  Consumers in Northern Europe expect to be protected at the level of institutions and programs, 
whereas consumers in Southern Europe rely on personal contact with the seller, Howells et al. 2006, 257.
1597  Business ethics as science, as corporate culture, and as brand strategy developed in the U.S. because 
legislation was too slow and ineffective in reacting to clear ethical problems in corporate behaviour. Regulation 
is in the U.S. often used only when absolutely necessary, freedom being a core value. This relates to the 
history of the U.S. as a British colony and the federal government as a representative of this colonial power. 
See Tolonen 2007.
1598  According to Jones, Chinese legal system may some day be what it now is on paper. He suspects this will 
not happen soon, if ever. He thinks the surface will be similar to Western legal systems, but the legal culture 
will continue to be infl uenced by history. Jones 2003, 40.
1599  Kubayashi 2008, 6.
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Legal culture, including consumer trust in regulation, is not a stable phenomenon but 
changes through time. The roles of governments and other governance regimes are constantly 
in fl ux. Consumers will have to learn the most basic assumptions on a given legal culture:
what can be expected of regulators, –
what can be expected of companies, and –
what is under their own responsibility. –
From a consumer viewpoint, there is not a substantial difference between who regulates the 
companies: whether it is governmental bodies or non-governmental bodies. From business 
viewpoint, there is a difference between law, co-regulation and self-regulation. As the scope 
of business law widens, the room for business ethics becomes narrower, and vice versa: if 
business ethics are highly developed, law is supposedly not needed.
Confucius relied on moral rather than legal rules. Currently rule of law is gaining importance 
in China. Reverting to legal proceedings is new in China and something that Confucius 
wholeheartedly avoided. Legal institutions are needed because of the transition from planned 
economy to market economy. This transition is not complete, which makes it diffi cult for 
the Chinese and others to know the roles of state vs. markets in China1600. According to 
Qingjiang, there is no turning back China's progress into a market-oriented economy and rule-
based society1601. At the same time, rule of law is being discussed in Europe, as legislation is 
increasingly replaced by co-regulation, standards, and self-regulation. A new understanding 
of law is emerging. When China accepts rule of law, rule of law as we know it may no longer 
be the same.
1600  See Lichtenstein 2003, 288, about corruption and the unclear role of the state.
1601  Qingjiang 2002, 62.
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